




From Gene Function and
Cellular Interaction to Morphology
Toshio Nakanishi · Roger R. Markwald
H. Scott Baldwin · Bradley B. Keller
Deepak Srivastava · Hiroyuki Yamagishi
Editors
Etiology and Morphogenesis of Congenital
Heart Disease
Toshio Nakanishi • Roger R. Markwald
H. Scott Baldwin • Bradley B. Keller









Department of Pediatric Cardiology









Department of Pediatrics (Cardiology)
Vanderbilt University
Nashville, TN, USA









Gladstone Institute of Cardiovascular Disease
San Francisco, CA, USA
Department of Pediatrics and Department of
Biochemistry and Biophysics
University of California
San Francisco, San Francisco, CA, USA
Hiroyuki Yamagishi
Pediatrics, Division of Pediatric
Cardiology
Keio University School of Medicine
Tokyo, Japan
ISBN 978-4-431-54627-6 ISBN 978-4-431-54628-3 (eBook)
DOI 10.1007/978-4-431-54628-3
Library of Congress Control Number: 2015960929
# The Editor(s) (if applicable) and The Author(s) 2016, corrected publication March 2018. The book is
published with open access at SpringerLink.com.
Open Access This book is distributed under the terms of the Creative Commons Attribution-
Noncommercial 2.5 License (http://creativecommons.org/licenses/by-nc/2.5/) which permits any
noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and
source are credited.
The images or other third party material in this book are included in the work’s Creative Commons
license, unless indicated otherwise in the credit line; if such material is not included in the work’s
Creative Commons license and the respective action is not permitted by statutory regulation, users will
need to obtain permission from the license holder to duplicate, adapt or reproduce the material.
This work is subject to copyright. All commercial rights are reserved by the Publisher, whether the whole
or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations,
recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or
information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar
methodology now known or hereafter developed.
The use of general descriptive names, registered names, trademarks, service marks, etc. in this
publication does not imply, even in the absence of a specific statement, that such names are exempt
from the relevant protective laws and regulations and therefore free for general use.
The publisher, the authors and the editors are safe to assume that the advice and information in this book
are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the
editors give a warranty, express or implied, with respect to the material contained herein or for any errors
or omissions that may have been made.
Printed on acid-free paper
This Springer imprint is published by Springer Nature
The registered company is Springer Japan KK
Preface
This book is based on the 7th Takao International Symposium on the Etiology and
Morphogenesis of Congenital Heart Disease held in August 2013 in Tokyo, Japan.
The Takao symposium was first held in 1978 by Dr. Atsuyoshi Takao. At that time,
Dr. Takao wanted to organize an international conference to stimulate and integrate
research on the morphogenesis of the heart because not many conferences were
focused on this aspect in those days. Dr. Takao did not want to use his name in the
title of the symposium and the conference was simply called “Symposium on the
Etiology and Morphogenesis of Congenital Heart Disease.” Since the first sympo-
sium, the Takao symposium has been held every 5 years, and proceedings were
published after each symposium, in 1980, 1984, 1990, 1995, 2000, and 2005. This
book, published in 2016, is the first one to be officially named the “Takao” book. I
would like to note that the Takao symposium and its publications have been
supported by the Akemi fund from The Sankei Newspaper since its inception.
The Akemi fund is based on donations from many persons from all over Japan to
save children with congenital heart disease.
For those who are not familiar with Dr. Takao, he was a professor and the chief
of pediatric cardiology at The Heart Institute of Japan at Tokyo Women’s Medical
University from 1972 to 1990. He passed away on August 8, 2006, at the age of 81.
Dr. Takao was very interested in the research of cardiac morphogenesis. In the
1970s, research in his laboratory was aimed at inducing heart disease by centrifu-
gation, radiation, and various drugs such as retinoic acid. Some of those studies
found that maternal administration of retinoic acid caused heterotaxy syndrome and
transposition of the great arteries in mice. Thymic abnormalities and interruption of
the aortic arch (type B) were also noted. However, Dr. Takao began to see the
limitations of the methodologies in experimental teratology in clarifying the
mechanisms underlying heart malformation.
In 1965, DiGeorge reported on an infant with hypoparathyroidism and recurrent
infections along with three necropsy cases with absent thymus and parathyroid
glands. From the early 1980s, deletion of chromosome 22q11 was recognized as a
cause of DiGeorge syndrome and microdeletion of this region was confirmed in
1991 and 1992.
v
Conotruncal anomaly face syndrome was first reported by Kinouchi and Takao
in 1976. In the early 1970s, Dr. Takao began to recognize a characteristic facial
appearance with a flat nasal bridge, small mouth, nasal voice, high arched palate,
and ear lobe abnormalities, along with mental retardation among patients with
conotruncal anomalies, mainly tetralogy of Fallot. He named this combination
“conotruncal anomaly face syndrome.” Soon, he recognized the importance of
molecular biology in clarifying the etiology and mechanisms of this syndrome. In
the early 1980s, the molecular biology laboratory was established in his depart-
ment. Microdeletion of chromosome 22q11.2 was confirmed also in conotruncal
anomaly face syndrome.
Although Dr. Takao realized the importance of molecular biology in the late
1970s, it was not until after he retired in 1990, that he began to study molecular
biology techniques. In 1990, he set up the International Molecular Cellular Immu-
nological Research Center. He worked as the director of the Institute until 2006. In
2003, investigators of the Institute, including Atsuyoshi Takao and Rumiko
Matsuoka, published a paper suggesting that the TBX1 mutation was responsible
for conotruncal anomaly face syndrome.
It is amazing that so much progress has been accomplished since the first Takao
symposium, with path-breaking changes occurring in fields ranging from experi-
mental teratology to regenerative medicine. As we understand more about the
detailed molecular mechanisms underlying cardiac malformation, we begin to see
some hope of manipulating these mechanisms to treat congenital heart disease, as
noted by Dr. Markwald in his chapter in this book. Recent progress in cardiac
regenerative medicine by using progenitor cells is largely based on the knowledge
obtained from research on the etiology and morphogenesis of congenital heart
disease. Basic researchers and cardiologists who have been working in this field
should be proud that they have contributed so significantly, in the past nearly
40 years, to this valuable progress.
I hope this book sheds light on the direction in which we should proceed in the
research field in the next 5 years, to ultimately save the lives of those who suffer
from congenital and acquired heart diseases.
Shinjuku-ku, Tokyo, Japan Toshio Nakanishi
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Srivastava and his team have long since been consistently contributing to research
on the molecular mechanisms underlying early heart development, especially on
the signaling and transcriptional cascades that regulate cell fate in the heart tissue of
the embryo. Early on, Srivastava recognized the importance of microRNA in
regulating gene transcripts in the developing heart. Through their research, they
were successful in directly converting fibroblasts into cardiomyocytes, a process in
which microRNA may play an important role. Srivastava emphasizes the impor-
tance of the molecular biology of cardiac morphogenesis for the development of
regenerative medicine. He also emphasizes the importance of cardiac fibroblasts as
a source of cells for restoring damaged cardiac cells. There seems to be great
difficulty in the conversion of fibroblasts to cardiac cells noninvasively in humans.
It will be a while before the clinical use of these technologies becomes a reality in
saving the lives of pediatric and adult patients with heart failure due to congenital
heart disease.
Gittenberger-de Groot and her team emphasize the potential importance of
epicardium in repairing damaged myocardium. They report that epicardial-derived
cells can differentiate into various cell types such as fibroblasts, arterial smooth
muscle cells, endothelial cells, and cardiomyocytes. Epicardial-derived cells con-
tribute to the formation of the coronary arteries, semilunar valves, atrioventricular
valves, and myocardium. It is thought that since epicardial-derived cells have the
T. Nakanishi (*)
Department of Pediatric Cardiology, Heart Institute, Tokyo Women’s Medical University,
Tokyo, Japan
International Molecular Cellular Immunological Research Center, Tokyo, Japan
e-mail: pnakanis@hij.twmu.ac.jp
potential to develop into various types of cells, it may be possible to use them for
the repair of ischemic myocardium. The methodology of using the epicardium or
epicardial-derived cells to rescue the damaged heart tissue remains to be
investigated.
Sekine, Shimizu, and Okano report a technology to generate a cell sheet effi-
ciently by using a temperature-responsive culture dish. The cell sheet can then be
layered to form the cardiac tissue. Clinical trials using this cardiac tissue to repair
the damage caused by myocardial infarction or cardiomyopathy are ongoing. Long-
term results of this technology will need to be studied in order to apply it to
pediatric patients with dilated cardiomyopathy and severely reduced contractile
function.
Tohyama and Fukuda report a technology to efficiently purify cardiomyocytes
differentiated from induced pluripotent stem (iPS) cells derived from human
T lymphocytes. They were able to transplant these cardiomyocytes into the heart.
They have also made disease models, including that of long QT syndrome, using
these cardiomyocytes. iPS technology has great potential because it can synthesize
the cardiac tissue from a patient’s own blood cells. However, even for diagnostic
purposes, the establishment of stable techniques to generate cardiomyocytes repro-
ducibly from iPS cells is difficult, at least at this moment. For clinical use, safety
issues of iPS cells remain to be clarified.
Markwald and his team emphasize that central signaling pathways (or hubs) in
which mutations disrupt fundamental cell functions play a key role in the develop-
ment of congenital heart disease. More specifically, they note two signaling
pathways as “hubs”: the nodal kinase activated by extracellular ligands (such as
periostin) and the cytoskeletal regulatory protein, filamin A. They report that
disruption of nodal kinase pathways causes septal defects and malformation of
atrioventricular valves. However, if we can manipulate these pathways after birth,
we may be able to rescue these defects. Fibroblasts, which may be derived from the
bone marrow, play an important role in forming the ventricular septum and atrio-
ventricular valves, and their activity may be regulated by periostin and filamin
A. Manipulation of periostin or filamin A may modify fibroblast activity and may
be able to rescue septal and valve malformation.
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Reprogramming Approaches
to Cardiovascular Disease: From





Heart disease is a leading cause of death in adults and children. We, and others,
have described complex signaling, transcriptional, and translational networks
that guide early differentiation of cardiac progenitors and later morphogenetic
events during cardiogenesis. We found that networks of transcription factors and
miRNAs function through intersecting positive and negative feedback loops to
reinforce differentiation and proliferation decisions. We have utilized a combi-
nation of major cardiac regulatory factors to induce direct reprogramming of
cardiac fibroblasts into cardiomyocyte-like cells with global gene expression and
electrical activity similar to cardiomyocytes. The in vivo efficiency of
reprogramming into cells that are more fully reprogrammed was greater than
in vitro and resulted in improved cardiac function after injury. We have also
identified a unique cocktail of transcription factors and small molecules that
reprogram human fibroblasts into cardiomyocyte-like cells and are testing these
in large animals. Knowledge regarding the early steps of cardiac differentiation
in vivo has led to effective strategies to generate necessary cardiac cell types for
regenerative approaches and may lead to new strategies for human heart disease.
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Heart disease remains the leading cause of death worldwide, despite improved
treatments that have decreased death rates from cardiovascular diseases. Congenital
heart malformations, the most common of all human birth defects, occur in nearly
1 % of the population worldwide, regardless of race. With more than one million
survivors of congenital heart disease (CHD) in the United States, it is becoming
apparent that genetic disruptions that predispose to developmental defects can have
ongoing consequences in maintenance of specific cell types and cellular processes
over decades. A more precise understanding of the causes of CHD is imperative for
the recognition and potential intervention of progressive degenerative conditions
among survivors of CHD.
Because cardiomyocytes (CMs) rarely regenerate in postnatal hearts, survivors
of congenital and acquired heart disease often develop chronic heart failure.
Unfortunately, end-stage heart failure can only be addressed by heart transplanta-
tion, which is limited by the number of donor organs available, particularly in
children. Alternative solutions include cellular therapy that replaces lost CMs either
by transplanting CMs or inducing new CMs in situ at areas affected by the
infarction.
In recent years it has become apparent that adult somatic cells can be converted
into other types of cells through epigenetic reprogramming. With this technology,
for example, somatic cells, such as fibroblasts, can be dedifferentiated into pluripo-
tent stem cells by nuclear transfer [1] or with defined transcription factors [2]. Direct
reprogramming of fibroblasts into the chief functional cells of different organs,
including CMs, neurons, hepatocytes, hematopoietic cells, and endothelial cells,
has been accomplished and holds great promise for regenerative medicine [3]. In
particular, cardiac fibroblasts represent a large pool of cells in the adult heart [4] and
thus may provide a reservoir of cells from which to generate new CMs through
epigenetic reprogramming.
In 2010, we reported that mouse cardiac and dermal fibroblasts could be directly
reprogrammed into induced CM-like cells (iCMs) in vitro by a combination of three
developmental cardiac transcription factors, Gata4, Mef2c, and Tbx5 (GMT)
[5]. Since then, other labs around the world have reported success in
reprogramming mouse fibroblasts into iCMs with similar cocktails of
reprogramming factors [6–10]. We and others have also directly converted
human cardiac and dermal fibroblasts into cardiac cells [11–13]. Several review
papers published from different labs illustrate the potential and challenges of this
new avenue for cardiac regenerative medicine [14–19].
Here, we discuss the cardiac developmental biology discoveries that underpin
direct reprogramming approaches and consider the opportunities and challenges of
this technology for addressing cardiac regeneration.
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1.2 Molecular Networks Regulate Cardiac Cell Fate
In vertebrate embryos, the heart is the first functional organ to form. The morphologi-
cal development of the heart has been summarized in several reviews. During devel-
opment, numerous signaling and transcriptional cascades regulate cell fate decisions
in distinct heart fields. In addition, the Gata, Mef2, Hand, Nkx, and T-box family of
transcription factors control expression of cardiac genes and direct the specification
and differentiation of cardiac myocytes. These transcription factors have been fre-
quently included in studies that directly convert fibroblasts into cardiac cells.
MicroRNAs (miRs)—small single-stranded noncoding RNAs that negatively
regulate the stability of gene transcripts—also regulate cardiac gene expression
[20, 21]. Transcription factors regulate miR expression, and in turn, miRs can
modulate the activities of transcription factors through positive and negative feed-
back loops. One of the major regulators of cardiac lineage determination during
heart development is miR-1. Expression of miR-1 in either mouse or human
embryonic stem cells (ESCs) caused them to favor the muscle cell fate. In contrast,
miR-133 promoted muscle progenitor expansion and prevented terminal differenti-
ation, while another miRNA, miR-499, promoted the ventricular cell fate in human
ESC-differentiated CMs and caused cardiac hypertrophy and enlarged hearts in
miR-499 transgenic mice. These studies demonstrate that miRs cooperate with
transcription factors to form an intertwined network that reinforces specific cell
fate decisions and differentiation during cardiac development.
1.3 Cardiac Fibroblasts in the Normal and Remodeling Heart
Fibroblasts are mesenchymal cells that produce many extracellular matrix
components in organs. Fibroblasts show heterogeneity based on morphology,
glycogen pools, collagen production, cell surface markers, and global gene-
expression profiles. Although the percentage of fibroblasts among the total cells
in the heart varies between species, the large population of fibroblasts is quiescent
and abundantly distributed in the interstitial and perivascular matrix in the normal
heart.
Cardiac fibroblasts synthesize extracellular matrix to provide a 3D network for
myocytes and other cells of the heart; they also regulate the biological and electro-
physiological response of CMs during physiological and pathological development.
In embryonic mouse hearts, cardiac fibroblasts induced proliferation of CMs via
paracrine signals of fibronectin, collagen, and heparin-binding EGF-like growth
factor; however, in adult mouse hearts, cardiac fibroblasts promoted hypertrophic
maturation of CMs via beta1-integrin signaling [22]. Cardiac fibroblasts were also
found to form intracellular electrical coupling and communicate with myocytes
through gap junctions, suggesting that cardiac fibroblasts could conduct electric
signaling between different regions of myocytes that are electrically isolated by
connective tissue in the normal heart.
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1.4 Direct Cardiac Reprogramming In Vitro
To identify the combination of reprogramming factors that could convert a cardiac
fibroblast toward a cardiomyocyte-like state, we generated a transgenic mouse in
which enhanced green fluorescent protein (EGFP) was driven by the alpha myosin
heavy chain (αMHC) promoter [5, 22], providing a tool to screen through many
potential regulators. We ultimately found that a combination of three transcription
factors—Gata4, Mef2c, and Tbx5 (GMT)—could convert ~15 % of cardiac
fibroblasts into αMHC-EGFP-positive cells, which we called induced CM-like
cells (iCMs) [5]. iCMs formed sarcomere structures and displayed whole-
transcriptome expression profiles that were shifted significantly toward the profile
of CMs, even at the single-cell level. Although most in vitro iCMs were only
partially reprogrammed, many of them could generate Ca2+ transients, and some
started beating spontaneously 4–6 weeks after reprogramming. Using a lineage-
tracing strategy in mice (e.g., Isl1-Cre-YFP and Mesp1-Cre-YFP), we did not
observe activation of cardiac progenitor markers during GMT cardiac
reprogramming [5], suggesting that GMT directly converted fibroblasts toward
the cardiac cell fate without dedifferentiation back into a progenitor status. Song
et al. [8] found that a basic helix-loop-helix transcription factor, Hand2, could help
GMT to convert TTFs into functional beating iCMs.
1.5 Direct Cardiac Reprogramming In Vivo
The ultimate goal in generating new iCMs is to improve systolic function of
damaged hearts and restore its normal structure and function. Therefore, we tested
direct cardiac reprogramming in vivo with the hypothesis that the heart’s native
microenvironment would promote direct reprogramming of fibroblasts to CMs. We
expected that direct cardiac reprogramming would be enhanced in the native heart
and could improve the function of the damaged heart.
We delivered GMT into mouse hearts after acute MI via retroviruses. These
viruses can only infect actively dividing cells and, thus, could deliver the
reprogramming factors into non-myocytes (mostly fibroblasts), but not into CMs
that exit the cell cycle after differentiation. Four weeks after introducing GMT, we
found numerous genetically labeled reprogrammed cells within the scar area of
mouse hearts, indicating newly born iCMs reprogrammed from cardiac fibroblasts
(Fig. 1.1). We found that more than 50 % of in vivo-derived iCMs closely
resembled endogenous ventricular CMs, had a rod shape, were binucleate, assem-
bled sarcomeres, generated Ca2+ transients, and elicited ventricular-like action
potentials and beating activity [23]. By microarray analysis, in vivo mouse
GMT-iCMs showed similar global gene-expression profiles with mouse adult
CMs, such that they were clustered as one type of cells [11]. The iCMs
reprogrammed in vivo were electrically coupled with endogenous CMs, and no
arrhythmias were observed in mice that received GMT reprogramming factors.
Most importantly, introducing GMT in vivo reduced scar size and cardiac
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dysfunction up to 12 weeks after coronary ligation [23]. Similarly, Inagawa
et al. [24] successfully reprogrammed cardiac fibroblasts into iCMs in vivo by
introducing GMT into the heart of immunosuppressed mice with single-
polycistronic retrovirus, which contains GMT with self-cleaving 2A peptides.
Furthermore, Song et al. [8] found that introducing GMT and Hand2 in vivo
could directly convert cardiac fibroblasts into iCMs and also improved function
and decreased scar.
1.6 Direct Cardiac Reprogramming in Human Fibroblasts
Establishing the technology of cardiac reprogramming in human cells was a
necessary step toward considering clinical application. However, neither GMT
nor GHMT, which reprogrammed iCMs from mouse fibroblasts, was able to
reprogram human fibroblasts into iCMs in vitro [11–13]; however, inclusion of
additional reprogramming factors resulted in successful reprogramming. Nam
et al. [12] found that GHT, without MEF2C, but with another transcription factor,
myocardin, and two muscle-specific miRNAs, miR-1 and miR-133, could repro-
gram human fibroblasts into iCMs. These reprogrammed iCMs expressed multiple
cardiac genes, developed sarcomere-like structures, and generated Ca2+ transients
with a small subset of the cells exhibiting spontaneous contractility after 11 weeks
in culture. Wada R. et al. [13] reported that GMT with MESP1 and myocardin could
activate cardiac gene expression in human neonatal and adult cardiac fibroblasts. In
our study, pairing GMT with ESRRG and MESP1 induced global expression of
cardiac genes and shifted the phenotype of human fibroblasts toward the CM-like
state. Reprogrammed human iCMs were epigenetically stable and formed sarco-
mere structures, and some could generate Ca2+ transients and action potentials
[11]. By comparing whole-transcriptome expression of 4-week and 12-week
iCMs, we found that reprogramming human cells takes longer than mouse cells
because of their progressive repression of fibroblast genes. Nonetheless, our analy-


















Fig. 1.1 In situ reprogramming of fibroblasts to cardiomyocytes. Representative histologic
sections from mouse hearts treated with dsRed or Gata4/Mef2c/Tbx5 containing retroviral vectors
injected into the myocardium after coronary ligation. Scar area quantification is indicated
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level, human iCMs were reprogrammed at a level similar to mouse iCMs
reprogrammed by GMT in vitro [11].
1.7 Challenges and Future Directions
The studies summarized here demonstrate that forced expression of three or four
developmentally critical transcription factors can directly convert mouse cardiac
fibroblasts into CM-like cells in vitro, although most of these iCMs were partially
reprogrammed. These same factors generated more mature CM-like cells in the
native heart, improved heart function, and reduced scar size in the mouse heart post-
MI. Similarly, expression of five to seven reprogramming factors converted human
fibroblasts into non-perfect iCMs in vitro. By comparing in vitro versus in vivo
iCMs in mice [8, 23] and considering the similarities between human and mouse
iCMs in vitro [11], we speculate that the cocktails recently identified in human
fibroblasts may be sufficient to reprogram adult CM-like cells that are fully
functional in the in vivo environment, such as in the pig or nonhuman primate
heart, as is the case in mice. These studies have been driven by the deep knowledge
of cardiac development gained over the last two decades and represent a valuable
application of this knowledge for potential clinical development postnatally.
Successfully achieving cardiac reprogramming requires high expression and
proper stoichiometry of reprogramming factors, healthy and non-senescent
fibroblasts, and optimal conditions for cell culture. In addition, culture conditions,
such as electric stimulation, might help facilitate and maintain the functional
maturation of iCMs at late stages (i.e., after cardiac cell fate conversion), and the
process may require some small-molecule compounds and growth factors to over-
come epigenetic barriers at the early stages of in vitro reprogramming. The epige-
netic barriers that prevent cardiac reprogramming in vitro remain unknown;
however, the in vivo environment of the heart appears to overcome these epigenetic
blocks. We speculate that secreted factors and direct cell-cell interactions, includ-
ing mechanical and electrical, from myocytes and non-myocytes may work
together to improve direct cardiac reprogramming.
Another elusive concept is the molecular mechanism that underlies direct
cardiac reprogramming. What are the DNA targets of those reprogramming
factors? How are those transcriptional changes epigenetically stabilized during
reprogramming? By combining mechanism assays at whole-population and
single-cell levels, we can gain a more integral and comprehensive understanding
of how core transcription factors establish a self-reinforcing molecular network that
controls cardiac cell fate.
While many challenges and hurdles remain in this blossoming research field, the
high demand for regenerative medicine strategies for the heart emphasizes the
significance of these efforts in discovering new therapeutic strategies. Observing
the functional benefits of in vivo reprogramming in mouse heart and the promising
and similar degree of reprogramming in mouse and human in vitro iCMs, we are
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endeavoring to translate direct cardiac reprogramming for future clinical
applications.
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The Arterial Epicardium: A Developmental
Approach to Cardiac Disease and Repair 2
Adriana C. Gittenberger-de Groot, E.M. Winter, M.J. Goumans,
M.M. Bartelings, and R.E. Poelmann
Abstract
The significance of the epicardium that covers the heart and the roots of the great
arteries should not be underestimated as it is a major component with impact on
development, disease, and repair. The epicardium differentiates from the
proepicardial organ located at the venous pole (vPEO). The differentiation
capacities of the vPEO into epicardium-derived cells (EPDCs) have been exten-
sively described. A hitherto escaped part of the epicardium derives from a second
proepicardial organ located at the arterial pole (aPEO) and covers the intraper-
icardial part of the aorta and pulmonary trunk. In avian and mouse embryos,
disturbance of epicardium differentiation causes a spectrum of cardiac anomalies
including coronary artery abnormalities, deficient annulus fibrosis with rhythm
disturbances, valvemalformations, and non-compaction cardiomyopathies. Late in
prenatal life the epicardium becomes dormant, losing the activity of many genes.
In human cardiac diseases, both arterial and venous epicardium can be activated
again into EPDCs. The epicardial reactivation observed after experimental
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myocardial infarction and during aneurysm formation of the ascending aorta provides
clinical relevance. EPDCs applied for cell therapy demonstrate repair processes
synergistic with the resident cardiac progenitor stem cells that probably share an
embryonic origin with EPDCs. Future therapeutic strategies might be possible
addressing cell autonomous-based and signaling capacities of the adult epicardium.
Keywords
Epicardium • Venous pole • Arterial epicardium • Cardiac disease • Congenital
anomlies
2.1 Origin of the Epicardium
The cardiogenic mesoderm is referred to as first heart field, flanked medially by second
heart field (SHF)mesoderm. The addition of SHF-derived cardiacmesoderm enables the
formation of all cardiac components. A secondary layer will cover the complete
myocardial tube (Fig. 2.1) and the developing roots of the great arteries. At the venous
pole, the vPEO develops fromwhich the epicardium (cEP) spreads over the cardiac tube
up to the ventriculo-arterial junction [1]. Here, the cEP meets the PEO located at the
arterial pole (Fig. 2.2) [2] forming arterial epicardium (aEP) that is continuous with the
pericardium.BothPEOstructures and the spreading cEPand aEPexpressWilms’ tumor-
1 suppressor gene (WT-1) among others and harbor endothelial and mesenchymal cells.
2.2 Epicardium-Derived Cells (EPDCs)
Epicardial cells lose epithelial contacts by epithelial–mesenchymal transition
(EMT) and EPDCs relocate subepicardially [3, 4]. Early EPDCs invade the thin
myocardial wall. Proliferation of the myocardium depends on both endocardial-
and epicardial-derived signals, including Raldh2 [5] with a spatiotemporal differ-
ence between right and left ventricle (Fig. 2.1). The aEP starts EMT slightly later
than cEP, and ensuing EPDCs can be detected in the outer layers of the developing
great arteries and at the myocardial–endocardial cushion interface (Fig. 2.2).
Epicardial heterogeneity with a subset of cells taking part in the initial EMT
wave provides the myocardium with the main number of the future interstitial
fibroblasts. The next wave of EMT correlates with the formation of the fibrous
atrioventricular annulus [6] and contributes to part of the atrioventricular cushion
cells. At the ventriculo-arterial junction aEP migrates into the outflow tract forming
the future arterial annuli and partake in the semilunar valves [7].
12 A.C. Gittenberger-de Groot et al.
2.3 Heterogeneity of Epicardial Cells
2.3.1 The Cardiac Fibroblast
The epicardium is the main source of the interstitial, the fibrous annulus, and the
coronary adventitial fibroblasts [7, 8]. The endocardial cells lining the cushions are







Fig. 2.1 Four-chamber view of a mouse heart (ED12.5) immunostained for WT1. Note brown
cells lining the pericardial cavity (PC), including the epicardium. The AV groove is indicated
(arrows). The left ventricular (LV) wall contains hardly EPDCs, whereas some are present in the
RV and in the interventricular septum (IVS). Note the presence of EPDCs at the border of the AV
cushion and the interatrial septum (short arrows)
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2.3.2 Arterial Smooth Muscle Cell
After ingrowth of the peritruncal coronary capillary plexus into the aorta, EPDCs
surround the main coronary vessels and differentiate into smooth muscle
cells (SMC). Differentiation into SMCs is regulated by many genes including
FGF, VEGF, Notch, SRF, and PDGFRb and their ligands [8]. Quail–chicken





Fig. 2.2 Cross section of aorta (Ao) and right ventricular outflow tract (R-OFT). Aortic epicar-
dium is densely packed and cuboid (arrows), whereas cEP is squamous (short arrows). Note
EPDCs at the border of R-OFT cushions and myocardium and between Ao and R-OFT
14 A.C. Gittenberger-de Groot et al.
2.3.3 Endothelial Cells
The origin of the coronary endothelium is still under debate. Using a quail vPEO
transplanted into the isochronous chick as reviewed in [10] pointed out that
coronary ECs do not derive from the coelomic lining but from endothelial cells
from the sinus venosus sprouting into the stalk of the vPEO. This is also supported
by studies using transgenic mice [11]. We have shown that the sinus venosus-
derived endothelial cells express the “arterial” Notch1, underlining the plasticity of
these cells [9]. The discussion on the origin of the coronary endothelium is kept
alive as specific compartments produce restricted numbers of ECs [12, 13].
2.3.4 Cardiomyocytes
Conditional reporter mice studies, using WT-1 and Tbx18 as epicardial marker,
suggested that a population of EPDCs might differentiate into a myocardial pheno-
type. However, based on interaction between BMP and FGF, some of the
progenitors of cardiomyocytes in the SHF share the same markers with cells in
the underlying mesoderm of the SHF and the epicardial population [14]. Other data,
including quail–chicken chimera, also do not support EPDC–cardiomyocyte
transition [3].
2.3.5 The Purkinje Fiber
The Purkinje fiber is a specialized cardiomyocyte induced by endothelin produced
by endocardium and endothelium. We have postulated an essential interaction
between EPDCs and endocardial-/endothelial-derived factors after vPEO tracing
and inhibition experiments [15].
2.4 Congenital and Adult Cardiac Disease
In a large-screen microarray [16], no epicardium-specific gene has been encoun-
tered. Therefore, it is challenging to attribute specific cardiac malformations and
diseases to epicardial malfunctioning. However, in animal models it is possible to
link the epicardium to certain cardiac defects and diseases. We are dealing with
complex tissues in which epicardial cells are essential.
2.4.1 Non-compaction
The most relevant cardiomyopathy resulting from abnormal EPDC function is the
primary left ventricular non-compaction cardiomyopathy [4] demonstrating a
spongious myocardium usually including the ventricular septum. Differences in
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amount and timing of LV and RV invasion by EPDCs might account for predilec-
tion of the LV. With respect to congenital heart disease, a spongious ventricular
septum can be connected with muscular VSDs.
2.4.2 Conduction System Anomalies
The main components of the conduction system are myocardial in origin. Clini-
cally, it has been hypothesized that the genetically determined long QT syndrome is
linked to abnormal Purkinje fiber function. Indirectly, the abnormal formation of
the fibrous annulus with persisting accessory pathways can result in reentry
tachycardias. PEO inhibition in chick embryos showed defective atrioventricular
isolation, delaying the shift from a base-to-apex to an apex-to-base conduction [17].
2.4.3 Valvulopathies
PEO inhibition can lead to deficient AV valve formation [18, 19]. Furthermore,
abnormal differentiation including defective undermining of the valve leaflet is
similar to Ebstein’s anomaly of the tricuspid valve as observed in combination with
accessory pathways [4]. EPDCs of aEP origin are found in the outflow tract
cushions (Fig. 2.2) probably acting via Notch signaling and hence influencing
bicuspid aortic valve formation.
2.4.4 Coronary Vascular Anomalies
Experimental studies disturbing normal coronary development result in a number of
malformations that associate human congenital pattern variations with abnormal
ventriculo-coronary-arterial communications (fistulae). Fistulae found in avian
models with absent coronary arterial orifices in the aorta [20] resembling coronary
malformations found in pulmonary atresia without VSD are hypothesized to be a
primary coronary vascular disease [21].
2.5 Cardiovascular Repair
Myocardial infarction. Different approaches have focused on the potential of the
adult epicardial cell after myocardial infarction (MI). A c-kit-positive subepicardial
population indicates renewed epicardial activity with acquisition of stem cell
characteristics [22]. Using a retrovirally induced fluorescent Katushka labeling of
dormant epicardium showed EPDCs that migrated into the myocardium and
differentiated into a myofibroblast phenotype. The activated epicardium and
EPDCs reexpressed WT1 not only in the MI border zone but also in remote areas.
Another approach is represented by epicardial cells cocultured with
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cardiomyocytes in which EPDCs change myocardial alignment and contraction
[23]. A direct approach was provided by grafting human adult atrial epicardial cells
[24] cultured in vitro from a cobblestone epithelium into spindle shape, thereby
acquiring characteristics of mesenchymal stem cells. Injection of these adult human
EPDCs into immune-incompetent mice resulted in a marked improvement of
cardiac function [24] indicative of repair. Combined injection with adult human
cardiomyocyte progenitors (CMPCs) aimed at induction of cardiomyocyte regen-
eration [25] which showed an additive effect on remodeling, although no new
cardiac cell types (endothelial cells, fibroblasts, SMCs, or cardiomyocytes) could
be traced to human origin. The capacities, expressed within the normal embryonic
state, seem to be preserved in adult life and in disease states.
2.6 Future Directions and Clinical Applications
Many positive effects of EPDCs either after injection or by stimulation of the
dormant native epicardial covering of the heart are due to a paracrine mechanism
[22, 24, 25]. These findings bear important potential for drug and cell-based
therapeutic approaches to stimulate the native epicardium in repair of the ischemic
cardiac wall. An underdeveloped area is the priming of grafts taken from the
pericardium for use in cardiac or arterial repair.
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Cell Sheet Tissue Engineering for Heart
Failure 3
Hidekazu Sekine, Tatsuya Shimizu, and Teruo Okano
Abstract
In recent years, regenerative medicine using cells for treating tissue defects has
been in the spotlight as a new treatment for severe heart failure. Direct injection of
bone marrow-derived cells and isolated skeletal myoblasts has already been used
clinically as a method to improve cardiac function by regenerating cardiac muscle
cells andbloodvessels. The research on reconstructing functional three-dimensional
(3D) cardiac grafts using tissue engineeringmethods has also nowbeen addressed as
a treatment for the next generation. Our laboratory has proposed an original tissue
engineering technology called “cell sheet engineering” that stacks cell sheets to
reconstruct functional 3D tissues. Transplantation of cell sheets has already shown it
can cure damaged hearts, and it seems clear that the field of cell sheet tissue
engineering can offer realistic treatment for patients with severe cardiac disorders.
Keywords
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3.1 Introduction
Heart transplantation is the last hope for treatment of patients with severe heart failure
due to ischemia-related disease and dilated cardiomyopathy. However, the lack of
donor organs for transplantation continues to be a serious problem around the world.
Although there have been many developments in artificial heart systems such as
mechanical temporary assist devices or left ventricular assist devices (LVADs),
there are also problems in conjunction with thromboembolism, infection, and finite
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durability. Given these challenges with current technologies, regenerative therapies
are being investigated as an alternative approach and present new possibilities for the
repair of a damaged heart. Recently, the direct injection of either autologous skeletal
myoblasts or bone marrow-derived cells has been examined in clinical studies as an
alternative cell source to cardiac muscle cells [1–3]. The direct injection of the
dissociated cells has shown to be slightly effective, but it is often difficult to control
the form, dimensions, or the position of implanted cells. In an attempt to solve these
problems, research on advanced therapies using functional tissue produced by
engineered cardiac grafts has started. Over the past decade, several studies have proved
that bioengineered cardiac tissues could improve cardiac function in animal models of
impaired heart [4]. In this review, we discuss the progress of research on myocardial
regeneration with a focus on our own original approach using cell sheet engineering.
3.2 Cell Sheet Engineering
We have developed our own “cell sheet engineering” method using temperature-
responsive culture dishes created by the covalent grafting of a temperature-responsive
polymer, poly(N-isopropylacrylamide) (PIPAAm), to normal cell culture dishes
[5]. Under normal culture conditions at 37 C, the dish surface is relatively hydropho-
bic, and cells can attach, spread, and proliferate similar to commercially available
tissue culture surfaces. However, when the temperature is reduced to below the
polymer’s lower critical solution temperature of 32 C, the polymer surface becomes
hydrophilic and swells, forming a hydration layer between the dish surface and the
cultured cells. This allows the cells to detach as a single sheet without the need of
enzymatic treatments such as trypsinization. Since the use of proteolysis measures is
unnecessary, critical cell surface proteins and cell-to-cell junction proteins remain
intact, so that the cells can be harvested noninvasively as an intact sheet while
retaining their extracellular matrix (ECM) (Fig. 3.1). Consequently, we can recreate
3D structures such as cardiac tissue by repeated layering of individual cell sheets [6].
3.3 Cardiac Tissue Reconstruction
Harvested cell sheets consist of only confluently cultured cells with their biological
ECMon the basal side of the cell sheets, which acts as an adhesive agent for promoting
an intimate attachment between each layered cardiac cell sheet.Within layered cardiac
constructs, gap junctions are formed which rapidly establish an electrical connection
between the cell sheets, leading to 3D cardiac tissues that synchronously pulsatile
[7]. Additionally, when these tissueswere transplanted onto the subcutaneous tissue of
nude rats, the grafts were macroscopically observed to beat synchronously [8]. Impor-
tantly, these implanted tissues also showed long-term survival up to 1 year and
8 months, and the grafts also contained elongated sarcomeres, gap junctions, and
well-organized vascular networks within the bioengineered cardiac tissues [9].
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3.4 Cell Sheet Transplantation in Small Animal Models
Transplantation of engineered tissue such as cardiac grafts onto infarcted rat hearts
(Fig. 3.2) demonstrated morphological and functional connections via bridging
cardiomyocytes that migrated from the transplanted grafts to the host heart
[10]. Cardiac graft transplantation also improved damaged heart function with
significant improvements in the host ejection fraction [11]. We have also
demonstrated that control of EC densities in engineered cardiac tissues induces
enhanced neovascularization and leads directly to improved function of the ische-
mic myocardium [12]. Moreover, when compared to direct cell injection, the
cardiac graft transplantation exhibited superior cell survival and engraftment
[13]. Similarly, skeletal myoblast grafts were able to improve left ventricular
contraction, reduce fibrosis, and prevent remodeling via the recruitment of
hematopoietic stem cells through the release of various growth factors [14]. The
implantation of myoblast grafts also induced the restoration of left ventricular
dilatation and prolonged life expectancy in dilated cardiomyopathic hamster
[15]. Additionally, mesenchymal stem cell grafts demonstrated improved cardiac
function in impaired rat hearts, with the reversal of cardiac wall thinning and
prolonged survival after myocardial infarction. This recovery after myocardial
infarction suggests that the improvement in cardiac function may be primarily
due to the effects of growth factor-mediated paracrine and/or a decrease in left
ventricle wall stress, which in turn result from the relatively thick mesenchymal
stem cell sheets [16].
Fig. 3.1 Cell sheet engineering. Using temperature-responsive dishes, cultured cells can be
harvested as intact contiguous sheets by simple temperature reduction without proteolytic
treatment
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3.5 Cell Sheet Transplantation in Preclinical and Clinical
Studies
Our latest work has been to transplant engineered tissue in clinically relevant large-
animal models. In a pacing-induced canine dilated cardiomyopathy model, trans-
plantation of skeletal myoblast grafts has shown improved cardiac function with
reduction of fibrosis and apoptosis [17]. In a porcine cardiac infarction model,
skeletal myoblast graft transplantation provided improvement of cardiac function
with attenuation of cardiac remodeling [18]. Transplantation of skeletal myoblast
grafts has also demonstrated that it is an appropriate and safe treatment for chronic
myocardial infarction without increasing the risk of ventricular arrhythmias. Most
recently, the transplantation of cardiac progenitor cell grafts derived from embry-
onic stem cells improved cardiac function without teratoma formation and induced
cardiomyogenic differentiation in a simian impaired heart model. Our latest work
provides evidence of the safety and efficacy of using embryonic stem cells for
myocardial regeneration [19].
Based on the promising results in various animal models, there is a clinical study
using cell sheet transplantation currently underway. Autologous skeletal myoblast
sheet therapy has demonstrated that it is possible to improve cardiac function to
such a degree that LVADs are no longer required for patients with dilated
cardiomyopathy [20].
Fig. 3.2 Transplantation of the cardiac grafts onto infarcted rat hearts
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3.6 Conclusions
The field of tissue engineering presents an exciting approach to regenerative
therapies. The future solutions scaling up give more powerful construct creation,
resulting in the developments of remarkable tissue-engineered cardiac assist
devices or organ replacement. Overall, cell sheet tissue engineering is a novel
approach for cardiac treatment that promises efficient and effective alternative
therapies in regenerative medicine.
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Future Treatment of Heart Failure Using
Human iPSC-Derived Cardiomyocytes 4
Shugo Tohyama and Keiichi Fukuda
Abstract
Heart transplantation can drastically improve survival in patients with a failing
heart; however, the shortage of donor hearts remains a serious problem with this
treatment strategy and the successful clinical application of regenerative medi-
cine is eagerly awaited. To this end, we developed a novel method to generate
human induced pluripotent stem cells (iPSCs) from circulating human T
lymphocytes using Sendai virus containing Yamanaka factors. To establish an
efficient cardiac differentiation protocol, we then screened factors expressed in
the future heart site of early mouse embryos and identified several growth factors
and cytokines that can induce cardiomyocyte differentiation and proliferation.
Subsequent transcriptome and metabolome analysis on undifferentiated stem
cells and cardiomyocytes to devise a specific metabolic environment for
cardiomyocyte selection revealed completely different mechanisms of glucose
and lactate metabolism. Based on these findings, we succeeded in metabolically
selecting cardiomyocytes using glucose-free and lactate-supplemented medium,
with up to 99 % purity and no teratoma formation. Using our aggregation
technique, we also showed that >90 % of the transplanted cardiomyocytes
survived in the heart and showed physiological growth after transplantation.
We expect that combining these techniques will achieve future heart
regeneration.
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Heart disease remains a leading cause of death despite recent medical advances, and
heart transplantation remains the ultimate treatment for severe heart failure. How-
ever, limited donor numbers remain an unsolved problem for transplantation
therapy, and both patients and clinicians hold great hope for the future success of
heart regenerative cell therapies as an alternative strategy [1]. Pluripotent stem cells
(PSCs) including embryonic stem cells (ESCs) and induced pluripotent stem cells
(iPSCs) can self-renew infinitely and are potential mass production sources for
therapeutic cardiomyocytes. In particular, human iPSCs have the huge advantage of
avoiding immunological rejection after cell transplantation.
Human iPSCs were first generated from dermal fibroblasts by Takanashi and
Yamanaka in 2007 [2], using a retroviral transduction system. Subsequently, the
methodology for generating iPSCs has dramatically improved. We previously
reported that integration-free iPSCs could be easily and rapidly generated from
terminally differentiated circulating T lymphocytes in peripheral blood using
Sendai virus [3]. Our method makes it possible to generate iPSCs from any patients
including children, girls, and the very elderly by blood sampling alone.
Such cumulative advances in iPSC generation techniques should accelerate the
development of applications for iPSCs generated from patients. However, many
hurdles remain in realizing such applications in human heart regeneration, due
largely to the assumption that one patient will require at least 1 109
cardiomyocytes to recover cardiac function (Fig. 4.1). The important steps to
overcome are as follows: (1) cardiac differentiation efficiencies should be stably
improved regardless of the source cell lines; (2) large-scale cultivation systems will
be required to obtain the billions of differentiated cells required; (3) approximately
1 109 cardiomyocytes should be efficiently collected and residual undifferenti-
ated stem cells should be eliminated from large-scale, mixed, differentiated cell
populations; (4) purified cardiomyocytes should be functionally and electrophysio-
logically characterized; (5) tissue engineering technologies might need to be used
prior to transplantation because dispersed transplanted cardiomyocytes have not yet
achieved high survival rates [4]; and (6) confirmation of safety and efficiency with
these techniques is essential in large animal models before clinical application. In
this chapter, we discuss these hurdles to realizing heart regenerative therapy in
more detail.
4.2 Cardiac Differentiation from Human iPSCs
Many approaches using ESCs have been investigated to induce cardiac differentia-
tion. In general, the differentiation of ESCs into any cell lineage is based on the
mechanism of normal early development [5]. The visceral endoderm is known to
play a key role in the differentiation of cardiac precursors that are present in the
adjacent mesoderm during development, and Mummery et al. [6] previously
reported that human ESCs effectively differentiate into cardiomyocytes when
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cocultured with mouse visceral endoderm-like (END-2) cells. In an attempt to
improve cardiac differentiation efficiencies inexpensively and easily, Takahashi
et al. [6] screened a chemical compound library approved by the United States Food
and Drug Administration (FDA) and found that ascorbic acid efficiently induced
cardiac differentiation. However, this chemical alone might be not enough to
induce cardiac differentiation from iPSCs.
Several studies have shown that various combinations of heart development-
related proteins including BMP, activin, Wnt, BMP inhibitor, and Wnt inhibitor
induce cardiomyocytes from ESCs [7–10]. We reported that the context-dependent
differential action of BMPs in cardiomyocyte induction is explained by the local
action of Noggin and other BMP inhibitors and, accordingly, developed a protocol
to induce cardiac differentiation of mouse ESCs through transient administration of
Noggin [9]. However, to obtain hundreds of millions of cardiomyocytes, it is
necessary to establish a cardiac differentiation method that is both efficient and
cost-effective due to the many expensive recombinant protein factors used. To
address this problem, Minami et al. [11] screened small-molecule compounds to
identify those that significantly increase cardiac differentiation induction, and they
revealed some inhibitors of canonical Wnt signaling as candidates. In addition,
Fig. 4.1 Overview of steps to overcome for realization of heart regenerative therapy. The critical
hurdles to overcome are as follows: (1) improvement of cardiac differentiation efficiencies,
(2) establishment of large-scale cultivation systems, (3) purification of large-scale
cardiomyocytes, (4) electrophysiological characterization, (5) utilization of appropriate tissue
engineering technologies, and (6) confirmation of safety and efficiency in large animal models
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recently novel efficient protocols using small molecules and/or chemically defined
media have been reported (Lian et al. Nat Protocols 2013;8:162–175, Burridge
et al. Nat Methods. 2014;11:855–60).
Several studies then showed that induction techniques in ESCs could also be
applied to iPSCs, although differentiation efficiencies were suggested to be inferior
compared to ESCs. However, as such differentiation efficiencies vary greatly with
different cell lines [12], further investigation is needed in the future. Furthermore,
to efficiently obtain large quantities of cardiomyocytes inexpensively, it is neces-
sary to continue refining efficient cardiac differentiation systems combined with the
use of small-molecule compounds. However, despite improved cardiac differentia-
tion efficiencies, it is inevitable that human PSC derivatives will contain not only
cardiomyocytes but also undifferentiated stem cells and/or noncardiac cells because
all PSCs cannot differentiate into cardiomyocytes. Therefore, to confirm safety
after transplantation, it is necessary to remove noncardiac cells and undifferentiated
stem cells that could cause tumors.
4.3 Nongenetic Methods for Purifying Cardiomyocytes
One of the biggest risks with in vitro-generated cardiomyocytes for clinical use is
teratoma formation due to residual PSC contamination [13]. Current procedures for
eliminating such contamination and boosting cardiomyocyte enrichment involve
genetic modification [14, 15] and nongenetic methods using a mitochondrial dye
[16] or antibodies to specific cell-surface markers [17]. However, none of these
methods are ideal for the therapeutic application of PSC-derived cardiomyocytes
due to insufficient stability, genotoxicity, and the use of fluorescence-activated cell
sorting (FACS). To address this issue, we sought to purify cardiomyocytes effi-
ciently and inexpensively, based on differences among cell-specific nutrition
sources.
To create a metabolic environment where “residual undifferentiated stem cells
cannot survive and only cardiomyocytes can survive,” we performed metabolome
and transcriptome analysis in neonatal cardiomyocytes and PSCs. We found that
these PSCs mainly depended on activated glycolysis and actively discharged lactate
into the extracellular media. In addition, biomass needed for proliferation such as
amino acids and nucleic acids were actively synthesized in PSCs compared to
cardiomyocytes. On the other hand, cardiomyocytes mainly depended on oxidative
phosphorylation in mitochondria to obtain adenosine triphosphate (ATP) effi-
ciently. We also performed metabolome analysis to demonstrate that other noncar-
diac proliferating cells also depended on glycolysis, like PSCs. Thus,
cardiomyocytes and proliferating noncardiac cells including PSCs showed
differences in metabolism (Fig. 4.2) that we then successfully exploited to select
cardiomyocytes from human PSCs efficiently and inexpensively simply by chang-
ing the cell-specific medium to one that is glucose depleted and lactate
supplemented [18]. The cardiomyocytes selected by metabolism showed normal
electrophysiological properties and did not form teratoma after transplantation.
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Furthermore, we succeeded to establish a practical culture system for generating
substantial numbers of purified cardiomyocytes by combining a massive suspension
culture system with a metabolic selection medium (Hemmi et al. Stem Cells Transl
Med. 2014;3:1473–83).
4.4 Transplantation of Human PSC-Derived Cardiomyocytes
Many studies have been conducted regarding cell transplantation therapies in
animal models using human PSC-derived cardiomyocytes. The survival of dis-
persed transplanted cardiomyocytes is reportedly very low [4], and some ingenuity
is required in the method of transplantation. Our group previously reported that
transplanted cell survival was dramatically improved by transplantation after for-
mation of cardiomyocyte aggregates [16], while Laflamme et al. [9] showed a
similar effect using a prosurvival cocktail that inhibited apoptosis.
With regard to the effectiveness of cell transplantation, Laflamme et al. [9]
also demonstrated that transplanted human ESC-derived cardiomyocytes could
improve cardiac function after 4 weeks in a rat myocardial infarction model. In
addition, Shiba et al. [20] demonstrated that transplanted human ESC-derived
cardiomyocytes electrically coupled to the host cardiomyocytes and suppressed
arrhythmias in a guinea pig myocardial infarction model. Furthermore, with respect
to cell transplantation in large animals, Kawamura et al. [19] recently reported that
cardiac cell sheets comprising purified human iPSC-derived cardiomyocytes
generated using our method [18] improved cardiac function in a pig myocardial
infarction model. Thus, efficacies have been achieved in cell transplantation
Fig. 4.2 Distinct metabolic differences between cardiomyocytes and other proliferating cells
including undifferentiated stem cells. Cardiomyocytes efficiently obtain ATP mainly via oxidative
phosphorylation, while other proliferating cells including PSCs obtain ATP, nucleotide, and amino
acids via activated glycolysis
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therapies using human iPSC-derived cardiomyocytes, although many such studies
showed only short-term effectiveness. Thus, careful evaluation of the efficacy and
safety of human iPSC-derived cardiomyocytes in cell transplantation over the
longer term must be ongoing.
4.5 Future Directions
The discovery and refinement of human iPSCs generation is expected to advance
not only regenerative medicine but also drug discovery and analyses of genetic
disorders using patient-specific iPSCs [19]. The major and common problem
remaining in this quest is securing sufficient numbers of mature and functional
cardiomyocytes with high purity. To solve this problem, it is essential to develop a
stable and efficient mass culture system and to establish a simple system to analyze
the electrophysiological function of the generated cardiomyocytes (Fig. 4.1). Fur-
thermore, the future realization of clinical applications using human iPSCs will
necessitate a better understanding of the cell biology and techniques involved in
tissue engineering generally. Only then will we be able to achieve long-term safety
and efficacy in the heart failure models of large animals and finally realize human
heart regenerative therapies.
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Abstract
In searching for remedial etiologies for congenital heart disease (CHD), we have
focused on identifying interactive signaling pathways or “hubs” in which
mutations disrupt fundamental cell biological functions in cardiac progenitor
cells in a lineage-specific manner. Based on the frequency of heart defects seen
in a clinical setting, we emphasize two signaling hubs – nodal kinases activated
by extracellular ligands (e.g., periostin) and the cytoskeletal regulatory protein,
filamin A (FLNA). We discuss them in the context of valve and septal develop-
ment and the lineages which give origin to their progenitor cells. We also
explore developmental windows that are potentially amenable to remedial
therapy using homeostatic mechanisms like those revealed by a chimeric mice
model, i.e., irradiated animals whose bone marrow had been reconstituted with
GFP+ hematopoietic stem cells, that shows bone marrow-derived cells track to
the heart, engraft, and give rise to bona fide fibroblasts. We propose to use this
model to deliver genetic payloads or protein cargos during the neonatal period to
override biochemical or structural deficits of CHD associated with valve and
septal signaling hubs or fibroblast/myocyte interactions. Preliminary tests of the
model indicate remedial potential for cardiac injuries.
Keywords
Heart defects • Valves • Septa • Matricellular proteins • Periostin • Cell
signaling • Kinases • Filamin A • Hematopoietic stem cells • Fibroblast •
Lineage • Genetic engineering
R.R. Markwald, Ph.D. (*) • S. Ghatak • S. Misra • R.A. Moreno-Rodrı́guez • Y. Sugi •
R.A. Norris
Department of Regenerative Medicine and Cell Biology, Medical University of South Carolina,
173 Ashley Avenue, Room BSB-648B, P.O. Box 250508, Charleston, SC 29425, USA
e-mail: Markwald@musc.edu
# The Author(s) 2016





Etiologies of congenital heart defects have been difficult to identify and explain,
often invoking discussions of genetics and environment or both. After 40+ years of
searching for etiologies, especially ones that might be potentially remedial, a few
conceptual observations are emerging (although by no means is there consensus).
These include suppositions that:
1. Genetics more than environment is responsible for CHD based on the ability to
simulate human heart congenital defects in animal genetic models (see also
Bhattacharya [1]).
2. The evolution of genetic thought is toward trans-heterozygous, multigenetic
interactions vs. single gene hits.
3. Mutations in the downstream intracellular signaling targets of growth factor,
transcription factors, or matricellular proteins are more likely to be the root
cause of heart defects seen in children by pediatric cardiologists (as the loss of
both alleles for upstream early regulatory genes is usually lethal).
4. Intersecting regulatory networks or signaling hubs coordinate fundamental
biological processes in cardiac progenitor cells in a lineage-restricted manner.
5. Based on the frequency of different types of heart defects, the lineages most
likely to be modified by genetic mutations or environmental stressors in CHD
are the non-cardiomyocyte lineages, primarily fibroblasts.
5.1.2 Hub Hypothesis
In trying to provide answers to the questions most often asked by parents of children
born with heart defects – “why did it happen?” and “what can be done about it?” –
we have endeavored to integrate these five emerging concepts around two examples
of central signaling hubs or platforms that intersect with multiple gene regulatory
networks (like the spokes of a wheel) to regulate or “tune” behavioral changes in the
progenitor cells engaged in valvuloseptal morphogenesis (or myocardial
remodeling). In so doing, we propose that intersecting signaling hubs explain
why so many different genes, if mutated or deleted, can engender similar
anatomical dysmorphic phenotypes, e.g., ventricular septal defects. This suggests
that there are only so many ways progenitor cells can respond to normal or
abnormal signaling inputs: e.g., they can proliferate, activate, or suppress apoptotic
pathways; transport ions; secrete, endocytose, adhere/migrate, and generate con-
tractile forces; change polarity or shape; and differentiate. Thus, the conceptual
appeal of common final pathways or intersecting signaling hubs/nodes is that they
provide potential for exploring “shared” remedial therapies for CHD that do not
require an individual approach for correcting each abnormal gene.
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5.2 Searching for Candidate Signaling Hubs in Heart
Development
5.2.1 Nodal Signaling Kinases
In patients with Down, Marfan, or Noonan Syndromes, there is increasing evidence
that genes encoding nodal signaling kinases like FAK/AKTkt/PI3K, RAS, MEKK/
ERK1/2, PTPN11, etc., are likely candidates for CHD if they are mutated or
overexpressed [2–4]. Such genes are not usually lethal (as there exist molecular
or functional redundancies), yet as indicated for syndromic heart defects, they have
potential to change functional behaviors in progenitor cells that normally mold and
remodel the simple tubular heart into a four-chambered organ. As indicated in
Fig. 5.1, intracellular signaling kinases (and small regulatory GTPases) are the
direct and indirect downstream targets of growth factors (e.g., TGFβ and BMP
2&4) that are normally secreted by the embryonic endocardium or myocardium [5],
or in the case of extracellular ligands like matricellular proteins (periostin, the CCN
family), they are secreted by the mesenchymal progenitor cells of valves and
connective septa which are derived from both endocardium and epicardium
[6]. In the case of matricellular and other extracellular proteins (Fig. 5.2), binding
to integrin receptors triggers integrin-dependent, downstream signaling kinases/
GTPases (FAK/AKT/PI3k) which activate effector mechanisms of growth, sur-
vival, and differentiation into the fibrous structures (valves and septa) that assure
coordinated and unidirectional blood flow through the right and left sides of the
developing heart. Epicardial-derived mesenchymal cells also express periostin as
they invade the ventricular myocardium and, like endothelial-derived mesenchyme,
secrete collagen and differentiate into ventricular connective tissue but also con-
tribute to the parietal leaflets of the AV valves [7, 8]. Disruption of these signaling
pathways by either silencing one or more of the kinases shown in Fig. 5.1, inhibiting
β-integrin functions, or deleting the periostin gene itself resulted in septal defects,
abnormal (poorly differentiated, hypertrophic) valves, arrhythmias associated with
a reduction in the AV fibrous connective tissue, and a reduction in ventricular
elastic modulus due to loss of interstitial collagen [9, 10]. These findings are
consistent with the relevance of central or nodal signaling kinases to heart develop-
ment and how different genes, if mutated or inhibited, could produce similar
abnormal anatomical phenotypes as a result of either binding to, activating, or
encoding a kinase or GTPase component of an interactive signaling pathway.
Conceivably, these same interactive signaling pathways could also be used to
explore remedial therapies for CHD. Any one or combination of the signaling
kinases or effector proteins shown in Fig. 5.1 could be a candidate therapeutic
target that could be used to bypass or circumvent a genetic or biochemical block
associated with a particular CHD, if a way could be found to administer drugs or
small molecules that silence, simulate, or activate them. Identifying an in utero
approach using orally administered or injected signaling inhibitors, lithium, or
retinoids is appealing but lacks target specificity (potentially engendering a broad
spectrum of side effects), or it can create a catch-22 in the sense that treatments may
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have to begin too early, i.e., before it can be actually determined that a development
defect is going to happen. Genetic rescues can identify and test candidate target
mechanisms (e.g., breeding Noonan mice into an Erk null background) but have
little practical remedial potential for preventing CHD.
Another plus for interactive signaling hubs is their potential to reveal a new or
unexpected “spoke” whereby genetic, protein, or biochemical connections to sig-
naling pathways are not readily apparent or known, e.g., hyaluronan synthetase
2 (Has2). As shown by Misra et al. [6], Has2 is activated by nodal kinases that are
regulated by periostin-integrin-linked signaling [6]. Phosphorylation of Has2 leads
to secretion of hyaluronan (HA) (Fig. 5.1, right) which, in addition to its osmotic
properties, also binds to CD44, a tyrosine kinase receptor for HA that is expressed
by valvular-septal mesenchymal progenitor cells [11]. Binding of HA to CD44
activates some of the same kinases also activated by periostin-integrin signaling,
thereby triggering positive feedback loops that can amplify or sustain shared
biological effects of periostin including formation, migration, and survival of
progenitor valvuloseptal mesenchyme as well as a positive feedback on the secre-
tion of periostin itself (Fig. 5.1) [6, 11]. CD44 signaling also appears to be part of a
signaling complex revealed by immunoprecipitation that is required for periostin to
activate another candidate signaling hub – filamin A (Fig. 5.2).
Fig. 5.1 (Left): Generalized model proposing the candidate genes for CHD. Based on syndromic
mutations or overexpression, the model proposes that the most likely candidates are genes that
encode components of a signaling hub such as the one shown for an extracellular ligand and
membrane receptors. Their interaction activates a cascade of nodal kinases within valvuloseptal
progenitor cells that regulate biological functions in progenitor cells that are normally associated
with remodeling the primary heart into a four-chambered organ. (Right): Periostin-integrin model
depicting downstream targets activated by periostin binding to specific β-integrin heterodimeric
receptors expressed in valve and septal progenitor cells. Based on published results [6], periostin
binding to integrin induces phosphorylation of p-FAK (a nodal kinase) which, in turn, activates
different signaling pathways, p-AKT/PI3K and/or p-Erk, each with distinct biological activities;
e.g., p-AKT/PI3K promotes hyaluronan (HA) secretion and enhances periostin expression,
whereas Erk activates collagen secretion and survival (anti-apoptotic) mechanisms
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5.2.2 Filamin A
Filamin A (FLNA) is a homo- or heterodimeric Y-shaped cytoplasmic protein in
which each main chain consists of an actin-binding region at the amino terminus, a
core of 24 highly homologous Ig-like repeats followed by a carboxyl integrin-
binding domain. The most widely studied function of FLNA is its ability, upon
activation, to self-assemble into signaling scaffolds or to cross-link cortical actin
filaments into a dynamic three-dimensional structure [12]. In the developing heart,
FLNA can promote or suppress cell processes important for heart development as
evident that when the gene is deleted, lethality ensues. Through its role as an actin-
binding protein that anchors various transmembrane proteins to the cytoskeleton, it
can generate contractile forces to support migration and fusion of the paired midline
AV mesenchymalized “cushions” to form the AV septum [13]. Upon activation, the
scaffolds assembled by FLNA form docking sites for second messengers like smad
2/3 which are critical for transmitting TGFβ signaling in heart development
[14, 15]. While FLNA is also expressed in the brain and other organs, it is
specifically expressed in the heart in valvuloseptal mesenchyme derived from the
endocardium and epicardium [16]. The null phenotype, although lethal at ED15.0,
is consistent with the pattern of FLNA expression in valvuloseptal primordia, i.e.,
there are septal and valve defects at all axial levels: atrial, atrioventricular, ventric-
ular, and outlet [15–17].
FLNA itself responds to many signaling “inputs” that can activate FLNA or
modify its binding to actin [18], including Ras and Rho kinase. Immunoprecipita-
tion studies confirmed that FLNA is also a downstream target of kinases induced by
periostin-integrin signaling that promote the binding of PAK-1 to FLNA, resulting
in its activation (Fig. 5.2). A large primary atrial septal defect is seen in periostin
Fig. 5.2 Coordinated activation of Filamin and p21-activated kinase 1 (PAK1) by periostin/β1-
integrin signaling in E16.5 mouse AV cells. (a) Representative Western blot for periostin (PN),
p-filamin A (ser 2152), and filamin A from lysates prepared from isolated mouse E16.5 AV valve
cells, transfected with vector controls, PN cDNA, PN-siRNA, and CD44 siRNA for 48 h or treated
with 5 μg/ml β1-integrin-antibody for 24 h. (b) Same protocol as A but lysates were immunopre-
cipitated with filamin A and binding proteins in the immunoprecipitate were immunoblotted. The
figure shows that upon activation, phospho-PAK1 (ser144) binds to Filamin (and transfers its
phosphate to activate the FLNA protein). Because silencing CD44 prevented binding of PAK1 to
FLNA, we have suggested that CD44 forms a signaling complex with periostin-integrin-FAK that
is required for activating FLNA through PAK1
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null mice [19] that is also seen in FLNA nulls, suggesting an interaction between
“signaling hubs” that (normally) promote: (1) fusion of paired mesenchymal
primordia (often called “cushions”) to form septal and valvular primordia and
(2) remodeling of the fused cushion primordia during fetal and early postnatal
life into mature leaflets or tendon-like septal structures.
Loss-of-function, point mutations in FLNA have also been found in patients with
mitral valve disease (e.g., prolapse), all of which occurred in the actin-binding
domains of FLNA and similarly effected cell signaling pathways or cytoskeletal
organization [20]. For example, a G288R and P637Q point disrupted a signaling
network that balanced RhoA and Rac1 GTPases activities and correlated directly
with inhibited cell spreading, migration, and contractile force generation [21]. The
G288R and P637Q mutation also interfered with FLNA’s normal capabilities to
promote the expression and transport of beta integrins to the cell surface or bind a
variety of intracellular target proteins including vimentin and transglutaminase
2 (TG2) [16, 22]. We found that TG2 homeostatically functions to covalently link
serotonin to FLNA enhancing its potential to bind cytoskeletal F-actin and generate
contractile forces related to or required for remodeling of valve primordia into
compacted, sculpted leaflets [16].
FLNA expression, like periostin, peaks in the postnatal period but is barely
detectable in adult heart tissues unless there is an injury ([17, 19, 23]). These
findings have three implications: (1) heart development is not over at birth;
(2) the postnatal period may still be an open window to explore remedial therapies
for CHD, particularly for valve and septal defects [24, 41]; and (3) mutations in
genes that cause abnormal structural or functional changes in heart tissues may not
always be immediately visible at birth but progressively appear over time
[25]. Thus, some “adult cardiovascular degenerative diseases” may actually have
an embryonic developmental etiology [26].
5.2.3 Relevance of Signaling Hubs to CHD
Shared (interconnected) protein signaling hubs point to a multiplicity of ways by
which seemingly unrelated genes (including ones yet to be identified) can converge
to engender anatomically similar developmental heart defects [27, 28]. Understand-
ing these mechanistic relationships will be important as they have realistic remedial
potential for identifying candidate approaches for preventing, modifying, or even
reversing some of the clinical consequences of CHD, particularly if they are
recognized early in the neonatal period. For example, AV valves in which there
is diminished function of FLNA are enlarged at birth (and mesenchymal-like) but
have elevated phosphorylation of ERK1/2 (16, unpublished data) which progres-
sively leads to a more pronounced degenerative, myxomatous-like phenotype. A
potential remedial therapy would be to find a way to attenuate ERK signaling and
assess whether progression to a degenerative phenotype could be delayed or even
reversed. A precedent for this would be the fibrillin-1 knockin model of Marfan
syndrome in which the valves become myxomatous or the Loeys-Dietz mice with
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mutated TGFβ receptors in which the aortic root is dilated and prone to aneurysm
[29, 30]. ERK 1/2 pathways are used in both syndromes to transduce elevated,
noncanonical TGFβ signaling. Pharmacological approaches (e.g., Losartan) to
blunt ERK signaling in both syndromes have improved their cardiovascular func-
tion and tissue structural integrity [30]. In a related fashion, understanding that TG2
promotes serotonylation of FLNA (and its binding affinity for actin), altering
serotonin uptake, and/or synthesis could also prove to be new remedial approaches
for treating valve and septal structural defects during the neonatal period when they
normally complete their maturation. The key would be to identify a means or route
for delivering these potential remedial therapies to the “right cell targets” at the
“right time”.
5.3 Lineage Is a Key to Remedial Therapy
Finding the “right cell targets” for remedial therapy is a question of lineage. Any
hope of efficacious remedial treatments would seemingly require that treatments be
directed to those cell populations that are normally involved in valve and septal
formation and, if mutated, result in CHD. In heart development, it is the
non-myocyte – mostly fibroblast – populations of the heart that appear to be the
critical players in valvuloseptal morphogenesis. They are the only heart progenitor
cells to express the extracellular signaling ligands like periostin or the cytoskeletal
regulatory protein like FLNA. The progenitors of fibroblasts, as noted above, are
the mesenchymal stem cells (or “cushion” cells) derived from the transformation of
two epithelia: endocardium and epicardium. Cells derived from either lineage have
the potential to differentiate into fibroblasts by autonomously secreting periostin
[31, 32]. Thus, cardiac fibroblasts are derived from at least two origins which are
carried over from intrauterine to postnatal and adult life [32]. This raises two
questions: (1) Are new fibroblast progenitor cells added to the heart after birth?
(2) If so, are the same signals (e.g., periostin) used to direct their progression into a
cardiac fibroblast lineage during embryonic life also used postnatally? The answers
to both questions appear to be “yes.”
5.3.1 Postnatal Origin of Cardiac Fibroblasts
Recent single cell engraftment experiments indicate that in postnatal and adult life,
cardiac fibroblasts are also derived from bone marrow or from pericytes that
express the hematopoietic stem cell marker – CD45 [33–38]. In these experiments,
adult mice were lethally irradiated and a single (or clone) of a rigorously isolated
wild-type CD45+ hematopoietic stem cell (HSC) carrying a green fluorescent
protein (GFP) marker was injected into their tail vein. Mice which survived clearly
had received a true multipotential stem cell capable of restoring the blood cell
lineages. We then asked if any of the original clones of CD45+/GFP+ HSCs left the
bone marrow and engrafted elsewhere. They did. We found that CD45+/GFP+ cells
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migrate and engraft in several organs including the heart. Specifically they
engrafted into the inlet and outlet valves, ventricular fibrous interstitium, and as
pericytes surrounding coronary microvasculature [36, 37]. In addition to the CD45
marker and GFP, they also expressed fibroblast markers, e.g., collagen-1, HSP47,
vimentin, discoid domain receptor 2 (DDR2), and, importantly, periostin
[33, 37]. This suggested to us that cardiac fibroblasts are a renewable cell popula-
tion that can be replenished homeostatically by circulating progenitor cells of bone
marrow, HSC origin. Based on marker expression, monocytes are probably the
immediate circulating progenitors of the CD45+/collagen I+ cells that engraft into
the heart, probably as “blank” cells that differentiate into fibroblasts [38, 39]. Impor-
tantly, their numbers increase in the valves and ventricular interstitium significantly
if the heart was injured by coronary ligation or cryoablation, indicating that they are
also a population of fibrogenic precursors that can respond dynamically to injury or
inflammatory signals [38, 40]. In quantitative terms, bone marrow-derived cells
accounted for 20–30 % of fibroblasts in normal adult myocardial tissue [36, 37,
39]. In contrast, we found GFP+ label in myocytes at exceedingly low frequency
[36] making this approach suitable for a targeted assessment of non-myocyte
contributions to cardiac structure and function. It is important to recall, in this
context, that not all lineage markers of hematopoietic cell sources (e.g., CD34) are
applicable across species.
5.3.2 A Strategy to Use Fibroblast Progenitors to Carry Genetic
Payloads
The bone marrow origin of postnatal cardiac fibroblasts does not in any way
exclude new fibroblasts arising by proliferation from lineages carried over from
intrauterine life. However, those fibroblasts would be expected to continue to carry
forward any mutations or other functional or biochemical deficits from embryonic
life, whereas those derived from bone marrow provide an opportunity to be isolated
and genetically or pharmacologically manipulated (or reengineered) and then
returned to the marrow. Thus, we propose to use these fibrogenic CD45+
progenitors to carry genetic payloads (or protein cargos) to sites where fibrous
valvuloseptal or interstitial tissues are underdeveloped or hyperplastic or where
maturation (e.g., valves) has been delayed. Genetic reengineering theoretically
could be done to benefit the health of the newborn with a cardiac developmental
defect at any time or age, but given its potential for regeneration, earlier in the
postnatal period would appear to be the “right time” to implement remedial
therapies before “wet cement becomes hardened” [41].
5.3.2.1 This Strategy Calls for a Conceptual Revision in Our Thinking
About Fibroblasts
This strategy calls for a conceptual revision in our thinking about fibroblasts that
recognizes that they are a renewable cell source that can form a community of
active modulators of cell behaviors that can change cardiac function. The full story
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of cardiac fibroblasts is yet to be realized as to their function in health and disease
including CHD. Already much is being learned about their potential for repair
through homotypic interactions or heterotypic interactions with myocytes. Modes
of contact between fibroblasts or fibroblasts and myocytes include connexin-based,
gap junctions through which ions or small molecules (microRNAs) can be trans-
ferred [42], tunneling nanotubes [43] through which mitochondria can be
exchanged, or by paracrine secretions of cytokines, growth factors, or matricellular
proteins that facilitate their engraftment, proliferation, and/or differentiation [44].
5.4 Remedial Therapies: Delivering Genetic “Payloads”
Our basic premise is that bone marrow-derived fibroblasts make homeostatic
contributions to the non-myocyte cells of adult heart valve and septal connective
tissues. We propose to exploit our findings using the single cell engraftment model
to deliver relevant payloads to connective tissues of hearts with visible congenital
malformations, e.g., valves, septa, hypoplastic ventricles, or non-compacted myo-
cardium in which growth has been compromised. We include myocardial growth
malformations because there is emerging evidence that fibroblasts establish hetero-
typic contacts in vivo with myocytes that can affect myocyte growth or electro-
physiology [45]. For example, isolated CD45+ bone marrow cells could be
genetically engineered to secrete growth factors like neuregulin which has been
shown to reactivate cell cycling in mononucleated cardiomyocytes [46]. For hypo-
plastic valve or septal tissues, we have already suggested (see above) several
genetic or small molecule pharmacological remedial approaches that would be
amenable to using CD45 cells for their delivery; for example, viral transduction
of CD45+ cells could be used to overexpress or suppress any of kinase or integrin
genes known to promote or inhibit fibroblast differentiation [47, 48], focusing on
Cre-promoters that allow sharp delineation from myocytes lineages
[49, 50]. Antennapedia internalization sequences could also be used to introduce
a wide range of “cargo” peptides into isolated CD45 cells.
5.4.1 Preliminary Studies
While we have shown using chimeric mice, i.e., irradiated animals whose bone
marrow had been reconstituted with GFP+ hematopoietic stem cells, that it is
possible to track bone marrow-derived cells that give rise to bona fide fibroblasts
in the heart, it remains to be determined whether they can effectively be transduced
to carry a cargo that can have a remedial effect in injured heart tissues. As proof of
concept, we prepared a lentivirus periostin-silencing (shRNA) vector directed
against the 30 end of the periostin transcript that was shown to block periostin
protein expression (>95 %) in vitro [6, 19]. These silencing or empty control
vectors were injected directly into the bone marrow minutes prior to an acute
myocardial “cryoinjury” administered by a liquid nitrogen cooled microprobe
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directly to the left ventricle of anesthetized mice. This procedure allows for a
consistent injury of known size and location within 4 days. As shown in Fig. 5.3,
an externally visible scar (blue-white in color) developed within a week in control
cryoinjured mice, whereas in experimental cryoinjured mice in which periostin-
silencing vectors were injected into the bone marrow, the scar was barely visible
and the tissue appeared healthy and vascularized. Echocardiographic analyses were
performed at weekly intervals. Cryoinjured mice that received bone marrow
injections of the periostin-silencing vector exhibited performance metrics (e.g.,
LV vol., ejection fraction) comparable to normal mouse baseline values, whereas
those that received the empty control vector exhibited significant reduction of all
baseline values. While preliminary, we expect that bone marrow transduction will
target cells that potentially can engraft into the heart and modify connective tissue
or myocardial remodeling to benefit patient health.
Finally, as developmental biologists searching for remedial etiologies and
therapies, we believe the crux of the issue lies in shifting our focus toward
understanding that:
1. The later periods of fetal and neonatal cardiovascular development present a
window to initiate remedial therapies.
2. The interactions between multiple signaling hubs will become a priority rather
than continuing to investigate early events or single genes.
3. The heart is an integrated organ in which lineages can provide insight for
improving therapeutic outcomes for CHD through genetic or pharmacological
manipulation.
Fig. 5.3 Cryoinjured adult hearts treated with lentiviral siRNA vectors to silence periostin
injected into the bone marrow. (a) arrows denote a typical injury site 4 days after cryoablation;
after 8 weeks, a large scar (white color) is visible on the left ventricular surface which when
examined histologically reveals extensive fibrosis (blue in Masson stain, muscle is red). (b) left
panel, empty vector control showing developing scar is turning bluish due to lost vascularity and
fibrosis; right panel is a heart after bone marrow injection with periostin siRNA vector. The injury
site is barely detectable and well vascularized. Performance metrics (bottom) indicate that
silencing periostin gave results similar to those of baseline controls
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4. The complexity and balance of signals that affect processes controlling the
formation of the heart may also come into play after birth or into adult life,
where their engineered re-expression can be used to enhance or awaken the
ability of heart cells to adapt to pathophysiological stimuli engendered during
development.
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Part II
Left-Right Axis and Heterotaxy Syndrome
Perspective
Bradley B. Keller
The generation of a unique left-right patterning is essential to higher organisms with
complex multicellular organs, and errors in patterning represent the origins of some
of the most complex forms of congenital heart disease (CHD). Our understanding of
these heterotaxy-related syndromes has evolved from initial clinicopathologic
correlates over a century ago to the generation and investigation of model
organisms (fly, frog, mouse) and the subsequent identification and validation of
patterning-related genes and pathways critical for normal human development and
responsible for disease states.
Dr. Shiraishi reviews human heterotaxy syndromes associated with CHD,
providing a broad overview of the role of cilia, molecular mechanisms involved
in left-right patterning, and associated clinical features. Early asymmetric expres-
sion of critical morphogens in left-right patterning (Nodal, Lefty2, Pitx2) is
required for normal development, and errors in the expression of these morphogens
result in patterning errors. Heterotaxy-related CHD is often associated with unbal-
anced development of the ventricles, resulting in variations of “single ventricle”
physiology and requiring staged surgical palliation to separate the venous and
systemic circulations. Children and adults with palliated single ventricle physiol-
ogy, including heterotaxy patients, face a range of medical complications related to
cardiac dysfunction and the consequences of increased central venous pressure and
reduced cardiac performance. As highlighted by Dr. Shiraishi, large gaps in our
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understanding of the pathogenesis of heterotaxy syndromes and their optimal
medical and surgical management still exist. Hopefully, readers of these chapters
will be intrigued and encouraged to pursue solutions.
Dr. Hamada provides an update on the investigation of cilia-mediated flow
patterns during early embryogenesis. Motile cilia generate unique extraembryonic
flow patterns that mechanically condition non-motile cilia in the ventral node,
impact subsequent morphogenesis, and can be explored in fly and mouse model
systems. Several key morphoregulatory pathways including agonists and
antagonists of noncanonical Wnt signaling and stretch-sensitive Pkd Ca2+ channels
are clearly involved.
Dr. Shibata and colleagues share some interesting findings on the association of
heterotaxy/polysplenia syndrome, single gene mutations in several patterning
genes, including BMPR2, and pulmonary artery hypertension. These associations
require further investigation in model systems where the consequences of CHD
including heterotaxy syndrome can be explored in aging animals and in adults with
congenital heart diseases.
Thus, the clinical presentation of CHD associated with heterotaxy represents a
spectrum of common final pathways and a range of early errors in embryo pattern-
ing and morphogenesis, modified during fetal life and then palliated using our
current medical and surgical therapies. Investigation of the mechanisms responsible
for normal and aberrant patterning and morphogenesis will continue to reveal
important genes and pathways that can be used to identify the origins of CHD
and may also be important for future targeted therapies, for example, related to
pulmonary artery vascular remodeling and hypertension.
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Heterotaxy syndrome is characterized by a wide variety of cardiac and extra-
cardiac congenital malformations that are primarily induced by disorders of the
left-right axis determination during early embryonic development. Prognosis of
the disease remains unsatisfactory because the syndrome is often associated with
complicated congenital heart diseases. Long-term follow-up of heterotaxy
patients, particularly those who underwent Fontan procedure, is now one of
the most important issues in pediatric and adult congenital heart disease clinics.
Collaborative studies between pediatric cardiologists and basic scientists are
essential for improving the prognosis of heterotaxy syndrome.
Keywords
Heterotaxy • Left-right axis • Signal transduction • Heart surgery
6.1 Introduction
Heterotaxy syndrome is a rare but serious congenital disease that occurs approxi-
mately 1 to 5,000–7,000 of live birth [1]. Patients are generally subdivided into
“bilateral right sided” (right isomerism) or “bilateral left sided” (left isomerism)
according to the characteristic morphology of atrial appendages of the heart.
However, there is a wide spectrum of pathology with considerable overlap of the
anatomical features.
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6.2 Molecular and Cellular Mechanisms of Left-Right
Determination
The left-right axis determination initiates in the primitive node at E7.5 in mice and
develops through the following pathways [2, 3]:
1. Breaking of symmetry as a result of leftward “nodal flow”
2. Transmission of asymmetric signals to the lateral plate mesoderm (LMP)
3. Asymmetric expression of nodal and lefty2 in the LMP
4. Situs-specific morphogenesis mediated by asymmetric expression of Pitx2
6.2.1 Node Cell Monocilia Create Leftward “Nodal Flow”
and Activate Asymmetry Signaling Around the Node
The determination of the left-right asymmetry starts as leftward nodal flow
generated by rotational movement of monocilia in the primitive node [4, 5]. Clock-
wise rotation of motile cilia creates unidirectional leftward flow because the
rotational axes of cilia tilt caudal direction of the embryos [6, 7].
There are two models why nodal flow is perceived by nodal and perinodal cells.
One hypothesis (chemosensory model) is that the nodal flow produces a gradient of
left determinant particles (node vesicular parcels) containing hedgehog proteins
and nodal [8, 9], which activate downstream signaling of nodal in the left-side
perinodal cells.
Alternative hypothesis (mechanosensory model) is that the leftward nodal flow
provokes an asymmetrical increase influx of Ca2þ ion in the sensory cilia cells
through PKD2, a causative gene for human polycystic kidney disease [9, 10]. This
Ca2þ influx is linked to the activation of nodal in the left-side perinodal cells, which
is consequently transferred to the left LPM.
6.2.2 Asymmetry Signaling Transmits to the Left Lateral Plate
Mesoderm
Transmission of nodal to the left LMP followed by lefty2 and Pitx2 activation [11]
and the consequent heart morphogenesis in the normal subjects, right/left isomer-
ism, and situs inversus is summarized in Fig. 6.1a.
6.2.3 Genes Associated with the Human Heterotaxy Syndrome
Recent human and animal model studies have provided insights into the genetic and
developmental etiology of the heterotaxy syndrome. In human, genes that are
associated with heterotaxy syndrome are ZIC3, NODAL, CFC1, ACVR2B,
LEFTY2, CITED2, and GDF1 [12–14].
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6.3 Clinical Manifestation of the Heterotaxy Syndrome
Factors that deteriorate prognosis of the heterotaxy syndrome are complications
with pulmonary venous obstruction, pulmonary arterial distortion, regurgitation of
atrioventricular valve, elevated pulmonary vascular resistance, and impaired ven-
tricular function [15].
6.3.1 Right Isomerism
Neonates with right isomerism typically show single atrium, single right ventricle,
and univentricular atrioventricular connection often associated with atrioventricu-
lar valve regurgitation. First-stage palliation (2–4 weeks after birth) is a control of
pulmonary blood flow with pulmonary banding or systemic-pulmonary shunt.
Pulmonary venous obstruction due to total anomalous pulmonary venous drainage
should be precisely diagnosed and repaired by surgical operation.
The second-stage palliation is the bidirectional Glenn shunt, where the right
and/or left superior vena cava is isolated and is connected to the pulmonary artery.
This operation is, in general, performed around 6 months after birth.
The third-stage palliation is Fontan procedure. Recently, a modification using
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Fig. 6.1 Signal transmission of nodal to the left lateral plate mesoderm followed by Pitx2
activation and the consequent heart morphogenesis in normal and heterotaxy embryos (Adapted
and modified from Ref. [1] with permission)
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most often employed, because the long-term prognosis of the conventional atrio-
pulmonary connection is proved to be unsatisfactory characterized by enlargement
of the atrium, intractable atrial tachyarrhythmias, and thromboembolisms.
After successful completion of the TCPC, cyanosis disappears and the general
conditions of the patients improve. However, number of patients who underwent
successful Fontan procedure is approximately 50 % because right isomerism often
accompanied with combination of severe and complicated congenital heart
diseases [16].
6.3.2 Left Isomerism
Left isomerism is typically associated with atrioventricular septal defect, persistent
left superior vena cava, interrupted hepatic portion of the inferior vena cava, and
atrioventricular conduction disturbance. In left isomerism, sinus node and atrioven-
tricular nodes are usually hypoplastic, and sinus bradycardia or complete atrioven-
tricular block is frequently accompanied.
6.4 Long-Term Prognosis of Heterotaxy Patients
Although the medical and surgical treatments of the heterotaxy syndrome have
remarkably advanced, long-term prognosis of the patients remains unsatisfactory.
Right isomerism has been recognized as one of the worst forms of CHD with
overall 5-year survival ranging from 30 to 74 %. The results are better in left
isomerism with 5-year survival rates ranging between 65 and 84 %, which is still
considerably lower than survival for most other forms of CHD [17]. The main
reason is that the nature of the Fontan single ventricle physiology is fundamentally
imperfect. Representative long-term complications of the Fontan operation are
illustrated in Fig. 6.2.
6.4.1 Protein-Losing Enteropathy
Protein-losing enteropathy (PLE), one of the most severe manifestations of the
failing Fontan circulation, occurs in 5–10 % of the total postoperative cases
[15]. Chronic loss of serum proteins into the gastrointestinal tracts results in
systemic edema, ascites, pleural effusion, diarrhea, gastrointestinal bleeding, sus-
ceptibility to infections, and ultimately cachexia. The underlying mechanism of
PLE remains uncertain. Elevated inflammatory reactions such as TNF-α or IFN-α,
dilatation of intestinal lymphatic vessels, and widening between intestinal epithelial
cells may be involved in the protein and fluid losses [18]. Steroids, high molecular
weight heparin, sildenafil, surgical interventions, for instance, fenestration of atrial-
level communications or conversion of the Fontan circuit, are effective. To date,
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Fig. 6.2 Possible complications of mid- to long term after completion of Fontan procedure for
heterotaxy patients (Adapted and modified from Ref. [1] with permission)
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6.4.2 Arrhythmias
Reentrant atrial tachyarrhythmias are the commonest in patients after Fontan
procedure and are often associated with deterioration of hemodynamics, either
causally or as a result [15]. Hemodynamic abnormalities such as valve regurgitation
or outflow obstruction, if present, should be aggressively treated by surgery.
6.4.3 Heart Failure
Initial feature of heart failure long after the Fontan procedure is characterized by
worsening of ventricular relaxation and compliance [15]. These abnormalities may
be caused by exposure of hypoxia and volume/pressure overload preceding the
Fontan procedure, repetitive surgical operations, and hemodynamic disadvantages
of the Fontan circuit. These changes are primarily progressive and consequently
lead to failure of the Fontan circuit. Late after the Fontan procedure, systolic
dysfunction becomes apparent. Administration of angiotensin converting enzyme
inhibitors or β-blockades may be beneficial for particular patients, although the
clinical evidence and cellular mechanisms remain to be elucidated.
6.4.4 Hepatic Dysfunction
Hepatic dysfunction, liver fibrosis, and cirrhosis are common complication of
patients long after Fontan operation. Recently, cases with hepatocellular carcinoma
after Fontan operation have been reported [19, 20]. Careful observation should be
necessary to detect the hepatic changes long after Fontan operation.
6.4.5 Management of Failing Fontan Patients
Patients who underwent atrio-pulmonary connection or lateral tunnel procedure are
likely to be complicated with thromboembolism or intractable arrhythmias due to
enlargement of the right atrium [14]. Surgical intervention with conversion to
TCPC is required before such complications become irreversible. Cardiac trans-
plantation may be the only option for patients with severe heart failure, intractable
arrhythmias, or recurrent PLE.
6.5 Future Direction and Clinical Implications
In the basic science field, embryonic development of left-right asymmetry has been
uncovered by means of mouse genetic engineering. In addition, advanced human
genetics have uncovered many responsible genes for heterotaxy syndrome. By
means of innovative technologies such as whole genome sequencing or patient-
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based human inducible pluripotent stem cells, novel genes will be clarified and
analyzed. In the clinical field, anatomical and physiological diagnosis from the fetal
period, better clinical managements after birth, and tailor-made surgical operations
will improve the prognosis. Cell- or tissue-based regeneration therapies and a new
ventricular assist device could improve cardiac function of failing Fontan patients.
Multiple approaches including basic and clinical science are necessary to improve
the prognosis and quality of life of heterotaxy patients.
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Roles of Motile and Immotile Cilia in
Left-Right Symmetry Breaking 7
Hiroshi Hamada
Abstract
Our body possesses three body axes, anteroposterior, dorsoventral, and left-right
(L-R) axes. L-R asymmetry is achieved by three consecutive steps: symmetry
breaking at the node, differential patterning of the lateral plate by a signaling
molecule Nodal, and finally situs-specific organogenesis. Breaking of L-R
symmetry in the mouse embryo takes place in the ventral node, where two
types of cilia are found. Whereas centrally located motile cilia generate a
leftward fluid flow, peripherally located immotile cilia sense a flow-dependent
signal. Although Ca2+ signaling is implicated in flow sensing, it is still not clear
what triggers Ca2+ signaling, a determinant molecule transported by the flow or
mechanical force induced by the flow.
Keywords
Cilia • Fluid flow • Laterality • Left-right asymmetry
7.1 Introduction
Most of visceral organs in vertebrates including the human are left-right (L-R)
asymmetric in their position or shape. The process by which L-R asymmetry is
generated can be divided into three steps (Fig. 7.1):
1. The initial breaking of L-R symmetry, which occurs in or near the node and at
the late neural-fold stage
H. Hamada (*)
Graduate School of Frontier Bioscience, Osaka University, 1-3 Yamada-oka, Suita,
Osaka 565-0871, Japan
e-mail: hamada@fbs.osaka-u.ac.jp
# The Author(s) 2016
T. Nakanishi et al. (eds.), Etiology and Morphogenesis of Congenital Heart Disease,
DOI 10.1007/978-4-431-54628-3_7
57
2. Transfer of an L-R-biased signal(s) from the node to the lateral plate mesoderm
(LPM), which leads to L-R asymmetric expression of signaling molecules such
as the transforming growth factor-β (TGF-β)-related proteins Nodal and Lefty on
the left side of the LPM
3. L-R asymmetric morphogenesis of visceral organs induced by these signaling
molecules
7.2 Symmetry Breaking by Motile Cilia and Fluid Flow
The breaking of L-R symmetry takes place in the node, an embryonic midline
structure located at the anterior tip of the primitive streak in mouse embryos
(Fig. 7.2). At the central region of the node, there are about 200 motile cilia that
protrude from the ventral side of the node into the node cavity [1] (Fig. 7.2) and
rotate in the clockwise direction (when viewed from the ventral side) at a speed of
600 rpm [2]. This rotational movement of the cilia generates the leftward laminar
flow of extraembryonic fluid in the node cavity [2], occurs at a speed of ~15–20 μm/
s. This leftward fluid flow in the node, referred to as nodal flow, is responsible for
symmetry breaking. Many mutant mice that lack nodal flow because the node cilia
Fig. 7.1 Three steps underlying the generation of L-R asymmetry. Three steps that contribute to
the generation of L-R asymmetry are shown: (1) symmetry breaking, (2) molecular patterning of
the LPM, and (3) asymmetric organogenesis. The developmental stage (E, embryonic day)
corresponding to each step in the mouse is indicated on the left
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are either missing or immotile have been identified, all of which exhibit aberrant
L-R patterning of the LPM. Furthermore, L-R patterning of the embryo can be
reversed when the direction of the flow was experimentally reversed by imposing
the rightward artificial flow [3], establishing that the direction of the flow
determines L-R.
How is the unidirectional fluid flow generated by rotational movement of the
cilia? Hydrodynamic principles predict that the cilia can generate a unidirectional
flow if they are tilted toward a specific direction. When the cilia move closer to the
surface, the movement of fluid near the surface will be restricted as a result of the
“no-slip boundary effect.” Conversely, when the cilia move away from the surface,
they move the neighboring fluid more effectively. If cilia are tilted toward the
posterior side, they will be moving toward the right when they come close to the
surface and toward the left when they are far from the surface, thus generating a
leftward flow. Observation of these rotating cilia by high-speed video microscopy
revealed that they are indeed tilted posteriorly at an average angle of 30
[4, 5]. Recent evidence [6] suggests that, in addition to the “no-slip boundary
Fig. 7.2 Cilia and fluid flow in the node. A lateral view of the embryonic day 8.0 mouse embryo
(a). Note that the node is located at the midline. Left-right (L-R) and anteroposterior (A-P)
orientations are indicated. A ventral view of the mouse node at lower magnification (b). The red
arrow denotes the leftward flow of extraembryonic fluid. A scanning electron micrograph showing
that each cell on the ventral side of the mouse node has a monocilium (c)
7 Roles of Motile and Immotile Cilia in Left-Right Symmetry Breaking 59
effect,” intrinsic asymmetry in rotational stroke may also help generating the
unidirectional flow.
Since the L-R axis is the last axis to be determined, symmetry breaking of L-R
axis must be achieved by utilizing preexisting positional cues. In fact, two
preexisting positional cues are reflected in the cilia: The A-P and D-V axes are
thus represented by the posterior tilt and ventral protrusion of the cilia, respectively
(Fig. 7.3). The node cilia thus generate the leftward flow by making use both of the
preexisting positional cues and their structural chirality.
How is A-P information translated into the posterior tilt of the node cilia? Given
its similarity to positioning of the hair in the Drosophila wing, a mechanism
resembling the planar cell polarity (PCP) pathway involving noncanonical Wnt
signaling [7] seems to underlie positioning of the node cilia. Thus, some of the PCP
core proteins such as Prickle2 and Vangl1 are localized to the anterior side of node
cells [8, 9], whereas Dvl protein is localized to the posterior side [10] (Fig. 7.3).
However, it remains unknown what positional cue is responsible for the polarized
localization of these PCP core proteins.
Fig. 7.3 L-R symmetry breaking by preexisting information. Each node cilium (red bars on left)
is posteriorly tilted, likely because the basal body (green) is posteriorly shifted within the cell
(blue). The cilium protrudes from the cell toward the ventral side of the embryo and rotates in a
clockwise direction when viewed from the ventral side. Anteroposterior (A-P) and dorsoventral
(D-V) orientations are indicated. A schematic representation of a transverse section of a cilium,
revealing its chiral structure, is shown on the right. The cilium contains nine pairs of microtubules
(green) as well as inner and outer arms of dynein (pink)
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7.3 Sensing of the Fluid Flow by Immotile Cilia
In addition to the motile cilia, there are immotile cilia in the node [11, 12] (Fig. 7.4).
Cells located at the central region of the node (pit cells) possess motile cilia, which
generate the fluid flow. On the other hand, most cells located at the edge of the node
(crown cells) possess immotile cilia [13]. Immotile cilia act as sensors of the fluid
flow [13]. Mutant mouse embryo that lack all cilia including those at the node, such
as Kif3a/mouse embryos, fail to develop nodal flow and show L-R defects
[14]. Such cilium-less embryos are also unable to respond to the artificial flow.
However, when immotile cilia are restored in crown cells, the resulting embryo can
now respond to the artificial flow [13], demonstrating that immotile cilia sense the
flow.
Sensing of the fluid flow by immotile cilia requires a Ca2+ channel composed of
Pkd2 [15] and Pkd1l1 [16, 17]. Indeed, several Ca2+ signaling blockers have been
shown to disrupt asymmetric gene expression in crown cells [13]. In particular, the
effects of GdCl3 [an inhibitor of stretch-sensitive transient receptor potential (TRP)
channels], 2-ABP [an inhibitor of the inositol 1,4,5-trisphosphate (IP3) receptor],
and thapsigargin (an inhibitor of Ca2+-dependent ATPase activity in the endoplas-
mic reticulum) suggest involvement of a TRP-type channel such as Pkd2 and the
IP3 receptor in the sensing of nodal flow. A mutation in Pkd2 that disrupts the
ciliary localization of the encoded protein results in L-R defects similar to those of
Fig. 7.4 Two types of cilia in the node, motile and immotile. Two types of ciliated cell are present
in the node: Those located centrally (green) have motile cilia that generate nodal flow, whereas
those located peripherally (pink) possess immotile cilia that sense the flow. Sensing of the flow
requires ciliary localization of a Ca2+ channel, the Pkd2-Pkd1l1 complex. The flow-mediated
signal results in degradation of Cerl2 mRNA. In this model, the flow would bend an immotile
cilium on the left side
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Pkd2/embryos [13, 16], suggesting that Pkd2, together with Pkd1l1, functions in
the ciliary compartment of crown cells. Whereas Pkd2 encodes a Ca2+ channel with
a short extracellular domain, Pkd1l1 possesses a much larger extracellular domain
at its amino terminus. Pkd1l1 may be responsible for sensing of the flow signal and
regulating Ca2+ channel activity of Pkd2. While oscillations of Ca2+ signaling with
subtle L>R asymmetry were detected in the node [18], direct observation of L-R
asymmetric Ca2+ signaling in crown cells has not been successful [13].
A long-standing question since the discovery of nodal flow concerns the action
of the flow. Two models have been proposed (Fig. 7.5). According to the
chemosensor model (Fig. 7.5a), the flow would transport an unknown molecule
toward the left side of the embryo, which will eventually act as the L-R determi-
nant. In an alternative model (two-cilia model or mechanosensor model; Fig. 7.5b),
the embryo would sense the mechanical force generated by the flow. Several
molecules have been proposed to be the determinant transported by the flow.
However, none of them fulfill the requirements for the determinant. On the other
hand, many lines of circumstantial evidence, including the recent observation that
as few as two rotating cilia are sufficient for the breaking of L-R symmetry [19],
favor the latter model. However, it is still not clear what exactly the immotile cilia
sense during the symmetry-breaking event.
Fig. 7.5 Two models for the mechanism of action of nodal flow. (a) Determinant-transporting
model. (b) Mechanosensory model.Green arrows indicate the direction of nodal flow; yellow stars
denote determinant molecules
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7.4 Readouts of the Flow
Cerl2 is the most immediate readout of the flow signal [19, 20]. Cerl2 encodes a
Nodal antagonist, although its precise action is not clear. It is asymmetrically (R >
L) expressed in crown cells, and its absence results in randomization of L-R
decision making [21]. Whereas expression of Nodal is bilateral in crown cells,
the R > L expression of Cerl2 renders Nodal activity in crown cells higher on the
left side (Fig. 7.6). The Cerl2-generated asymmetry (R< L) of Nodal activity at the
node closely correlates with the asymmetric pattern of Nodal expression in LPM
[22]. Expression of Cerl2 is initially symmetric (R¼ L) at the early headfold stage,
but it becomes R> L as the velocity of nodal flow increases, with expression on the
left side being downregulated [19, 22]. Finally, Pkd2/Cerl2/double-mutant
embryos manifest randomized Nodal expression in LPM, resembling the Cerl2
single mutant [13]. Therefore, Cerl2 is the main target of the flow signal.
L-R asymmetry of Cerl2 expression is generated at a posttranscriptional level
[23], by degradation of Cerl2 mRNA via its 30 untranslated region. Preferential
decay of Cerl2 mRNA on the left is initiated by the leftward flow and further
enhanced by the operation ofWnt-Cerl2 interlinked feedback loops, in which Wnt3
Fig. 7.6 R>L expression of Cerl2 results in asymmetry in Nodal activity at the node. R>L
asymmetric expression of Cerl2makes Nodal activity at the node R<L (a), Cerl2 is an inhibitor of
Nodal (b)
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upregulates Wnt3 expression and promotes Cerl2 mRNA decay, whereas Cerl2
promotes Wnt degradation. Mathematical modeling and experimental data suggest
that these feedback loops behave as a bistable switch that is able to amplify in a
noise-resistant manner a small bias conferred by fluid flow.
7.5 Future Directions
Although rapid progress has been made in the last 20 years, many important
questions remain unanswered. Firstly, how is A-P information translated into the
posterior tilt of node cilia? Namely, what is the nature of the A-P information that
polarizes node cells along the A-P axis? Secondly, how is the direction of rotation
determined for node cilia? Thirdly, how does the nodal flow work? How do motile
cilia sense the flow? Do they sense a signaling molecule that is transported by the
flow or sense mechanical force? Fourthly, what is the precise role of Ca2+ signal-
ing? How does Ca2+ signaling induce degradation of Cerl2 mRNA? Finally, to what
extent is the mechanism for breaking of L-R symmetry conserved among species?
L-R symmetry breaking does not appear to depend on cilia in Drosophila and snail
[24]. Further development of various approaches (including genetic, cellular, bio-
physical, and mathematical) will be necessary to answer these questions.
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Role of Cilia and Left-Right Patterning
in Congenital Heart Disease 8
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Abstract
A central role for cilia in the pathogenesis of congenital heart disease was
uncovered by our large-scale mouse mutagenesis screen for mutations causing
congenital heart disease. This is supported by human clinical studies, which
showed a high prevalence of ciliary dysfunction and respiratory symptoms and
disease in patients with congenital heart disease. Our mouse studies indicate this
involves essential roles for both primary and motile cilia in the pathogenesis of
congenital heart disease. As laterality defects were also observed with high
prevalence among the congenital heart disease mutants, this further suggested
an important role for left-right patterning in the pathogenesis of congenital heart
disease. This finding is reminiscent of the high prevalence of heterotaxy among
human fetuses with congenital heart disease, indicating the fetal mouse screen
may provide a window into the unborn human fetal population. Clinically,
congenital heart disease patients with ciliary dysfunction were found to have
more respiratory symptoms and disease, a finding with significant clinical
implications, as congenital heart disease patients undergoing surgical palliation
often have respiratory complications with high morbidity. While this is usually
attributed to the heart disease, we propose this may involve intrinsic airway
clearance deficits from ciliary dysfunction. Thus the presurgical screening of
congenital heart disease patients for respiratory ciliary dysfunction may provide
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opportunities to provide perioperative pulmonary therapy to enhance airway
clearance for at-risk patients. Such change in the standard of care may improve
outcome, especially for those congenital heart disease patients who must endure
multiple rounds of cardiac surgeries.
Keywords
Cilia • Ciliary dysfunction • Respiratory symptoms • Laterality • Heterotaxy
8.1 Introduction
Complex congenital heart disease is clinically well described to be highly associated
with heterotaxy, a birth defect involving randomization of left-right patterning
[1]. The importance of left-right patterning in congenital heart disease is likely a
reflection of the fact that the heart is themost left-right asymmetric organ in the body.
This asymmetry is critical for establishing systemic and pulmonary circulation
required for efficient oxygenation of blood. While heterotaxy is relatively rare,
reported at approximately 1 in 10,000 live births, it is clinically of high importance
given it is often associatedwith complex CHDwith highmorbidity andmortality [2].
8.1.1 Heterotaxy, Primary Ciliary Dyskinesia, and Motile Cilia
Defects
Interestingly, heterotaxy and complex CHD have been reported in ~6 % of patients
with primary ciliary dyskinesia (PCD), a sinopulmonary disease that arises from
airway mucus clearance defects due to immotile or dyskinetic cilia in the respira-
tory epithelia [3]. Given PCD is also relatively rare at 1 in 16,000 [4], the
co-occurrence of heterotaxy and PCD would suggest a mechanistic link for
heterotaxy and PCD. This mechanistic link has now been demonstrated to involve
a shared disturbance of motile function. Thus animal model studies have shown
motile cilia play an important role in embryonic left-right patterning [5].
In the mouse embryo, motile cilia at the node generate nodal flow that helps
specify the left-right axis (Fig. 8.1). The nodal flow is sensed by nonmotile or
primary cilia at the node periphery, resulting in activation of calcium signaling at
the embryo’s left, followed by left-sided activation of the nodal signaling cascade in
the left lateral plate mesoderm. As motile cilia in the node and airway are
constructed in a similar manner with many of the same proteins, it is not surprising
that airway ciliary dysfunction might predict nodal cilia dysfunction. This likely
accounts for the high prevalence of heterotaxy among PCD patients.
8.1.2 Motile Respiratory Cilia Defects in Other Ciliopathies
Given primary cilia also has been shown to play a role in the embryonic node to
establish the left-right axis, this would suggest that mutations affecting primary
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cilia function may also contribute to complex CHD associated with heterotaxy.
Given the extensive overlap between proteins found in the primary and motile cilia,
this would suggest the clinical distinction may be blurred between patients with
ciliopathies considered mediated by primary cilia defects vs. those with PCD that
have motile cilia defects. Indeed in a recent study, we showed that a patient with
cranioectodermal dysplasia, a ciliopathy thought to involve the primary cilia, has
presentations consistent with PCD. This includes obstructive airway disease, low
nasal NO, and abnormal respiratory ciliary motion [6].
8.1.3 Ciliary Dysfunction in Congenital Heart Disease Patients
with Heterotaxy
Even as PCD patients were observed to have a 6 % incidence of heterotaxy, a study
of CHD patients with heterotaxy revealed an even higher prevalence of respiratory
ciliary dysfunction similar to that seen with PCD [7]. Two tests used for PCD
assessment were used to evaluate heterotaxy patients. Ciliary motion analyzed
Fig. 8.1 Motile and primary cilia in the mouse embryo. (a) Immunostaining with antibodies to
acetylated tubulin (red) and γ-tubulin (blue) was used to visualize motile cilia in the E7.75 mouse
embryonic node. (b–f) Immunostaining with antibodies to acetylated tubulin and IFT88 visualized
cilia in the newborn mouse tracheal airway epithelia (b), in E12.5 brain ependyma (c), and primary
cilia in the myocardium (d), outflow tract cushion (e), and atrioventricular cushion (f) of the E12.5
mouse embryonic heart
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using videomicroscopy of nasal tissue biopsy and nasal nitric oxide (nNO) was
measured, which is typically low in patients with PCD. This analysis showed 42 %
of the heterotaxy patients have ciliary dysfunction comprising abnormal ciliary
motion and low nNO, presentations typically seen with PCD [7].
Interestingly, a mouse mutant exhibiting complex congenital heart defect
associated with heterotaxy was identified to have a pathogenic mutation in
Dnah5, a cilium outer dynein arm component required for motile cilia function
and a gene well described to cause PCD [8]. This mutant exhibited mostly immotile
cilia in the airway and in the embryonic node [8], accounting for the laterality
disturbance and airway clearance defects seen in PCD patients with DNAH5
mutations. Interestingly, these Dnah5 mutant mice exhibited either of three differ-
ent laterality phenotypes: normal situs solitus, mirror symmetric situs inversus
totalis, or randomized visceral organ situs known as heterotaxy (Fig. 8.2). It is
only with heterotaxy that complex congenital heart disease was observed,
indicating that disturbance of the left-right patterning may play an important role
in congenital heart disease. As the mouse Dnah5 mutants with heterotaxy were
mostly inviable to term due to their complex congenital heart disease, this would
suggest considerable ascertainment bias in the human population. Consistent with
this, a study of PCD patients revealed most had either situs solitus or situs inversus,
with only a small fraction exhibiting heterotaxy [4].
Fig. 8.2 Situs anomalies, congenital heart defects and ciliogenesis defects in laterality mutants.
(a–g) Ap1b1b2b1660 mutants exhibit situs solitus (a), situs inversus (b), or heterotaxy (c). Situs
solitus, characterized by normal left-right visceral organ positioning, the heart apex (arrow) points
to the left (levocardia), four lung lobes are on the right and one on the left, stomach is to the left,
and the dominant liver lobe is on the right. With situs inversus, there is complete mirror reversal of
organ situs, while with heterotaxy, visceral organ situs is randomized, such as dextrocardia with
levogastria shown in (c). The heterotaxy mutant in (c) exhibit complex CHD with AVSD (d),
ventricular septal defect (VSD) (e), duplicated inferior vena cava (IVC) (f), and left pulmonary
isomerism with bilateral single lung lobes (g) (From Li et al. [11])
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8.1.4 Respiratory Complications in Heterotaxy Patients
with Ciliary Dysfunction
As the central hallmark of PCD is respiratory disease due to mucociliary clearance
defects, the question arises as to whether heterotaxy patients may also have
respiratory symptoms and disease. Indeed, heterotaxy patients with ciliary dysfunc-
tion are observed to have significantly more respiratory symptoms and disease
[7]. Furthermore, those undergoing surgical procedures show increased pulmonary
morbidity, including increased use of inhaled β-agonist [9]. β-agonist use is typi-
cally avoided in cardiac patients given its arrhythmogenic properties. Hence, the
increased use of this medication is a strong indicator of serious respiratory
complications.
These findings have important clinical translational ramifications, since respira-
tory complications in heterotaxy patients are usually attributed to the heart disease,
and thus any airway clearance defects are not systematically addressed clinically. In
light of these findings, a change in the standard of care may be warranted with the
presurgical screening of heterotaxy patients for mucociliary clearance defects and
providing airway clearance therapy to help reduce postsurgical respiratory
complications in those with airway ciliary dysfunction. This may help improve
the prognosis for these patients who typically have to endure multiple high-risk
cardiac surgeries to palliate their structural heart defects.
8.1.5 Left-Right Patterning and the Pathogenesis of Congenital
Heart Disease
The importance of left-right patterning in the pathogenesis of congenital heart
disease has also emerged from a large-scale mouse mutagenesis screen. High-
throughput screening of ENU-mutagenized mice using fetal echocardiography
allowed the ultrasound phenotyping of greater than 80,000 fetuses (Fig. 8.3)
[10, 11]. Fetal echocardiography is ideally suited for recovery of mutants with
congenital heart defects, as it is an imaging modality developed in the clinical
setting for the assessment of cardiac structure and function (Fig. 8.3). Over
200 mutant mouse lines with a wide spectrum of congenital heart defect were
recovered. Surprisingly, this included many mutant lines with laterality defects
(~30 %), recovered based on the finding of complex CHD in mutants with
heterotaxy. Given our screen was focused on congenital heart defects, not left-
right patterning defects, this enrichment of laterality mutants would suggest the
disturbance of left-right patterning plays an important role in the pathogenesis of
congenital heart disease.
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This unexpected finding of a high prevalence of heterotaxy is actually in line
with observations in the human fetal population. One clinical study using fetal
echocardiography for CHD diagnosis reported that 16 % of human fetuses with
congenital heart defects have heterotaxy [12]. This number is likely a minimal
estimate, given several clinical studies have shown human fetuses with heterotaxy
Fig. 8.3 Ultrasound diagnoses of congenital heart disease and cilia defects in mouse mutants with
congenital heart disease. Vevo 2100 color flow imaging showed crisscrossing of blood flow,
indicating normal aorta (Ao) and pulmonary artery (PA) alignment (a Supplemental Movie S1),
confirmed by histopathology (b). E16.5 mutant (line b2b327) exhibited blood flow pattern
indicating single great artery (PA) and ventricular septal defect (VSD) (c Supplemental Movie
S2), suggesting aortic atresia with VSD, confirmed by histopathology (d). Color flow imaging of
E15.5 mutant (line b2b2025) with heterotaxy (stomach on right; Supplemental Movie S3c) had
side-by-side Ao/PA with Ao emerging from the right ventricle (RV), indicating DORV/VSD (e,
f Supplemental Movie S3a) and presence of AVSD (g, h Supplemental Movie S3b,S3c). Histopa-
thology also showed bicuspid aortic valve (BAV, i), interrupted aortic arch (IAA, j), and common
AV valve (k). (l–n) Cc2d2a mutant exhibits dextrocardia with ventricular inversion
(dextroversion) (m) and AVSD (l) with malformed AV cushions (n) but normal outflow cushions.
(o–x) Confocal imaging of E12.5 Cc2d2a mutant (m/m) vs. wild-type (+/+) embryo sections
showed no cilia in AV cushion (o, p) but normal ciliation in outflow cushion (q, r). Fewer and
shorter cilia were observed in other mutant embryo tissues (s–x). Red, acetylated tubulin; green,
IFT88 (From Li et al. [11])
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and congenital heart defect have very high rates of prenatal/intrauterine death
(30–60 %) [13–15]. When combined with the fact that only 28 % of CHD is
clinically diagnosed prenatally [16], these findings point to the prevalence of
congenital heart disease associated with heterotaxy being significantly
underestimated clinically. In our mouse screen, we also noted most mouse fetuses
with congenital heart defects associated with heterotaxy died in utero. The recovery
of these heterotaxy mutants rests entirely on our screen having been conducted
prenatally with fetal ultrasound imaging.
Of importance to note is the fact that many of these mutant lines with heterotaxy
actually yielded three distinct phenotypes, similar to what had been observed for the
Dnah5 mutants. Thus animals harboring the same mutation can have normal situs
solitus, mirror symmetric situs inversus, or heterotaxy (Fig. 8.2). As with theDnah5
mutants, congenital heart defects were usually seen only in mutants with heterotaxy
[11]. In a subset of these mutants, videomicroscopy of the tracheal epithelia in these
mutants also showed immotile or dyskinetic cilia, suggesting they have mutations
affecting motile cilia function and may be PCD mouse models [11].
8.1.6 Ciliome Gene Enrichment Among Mutations Causing
Congenital Heart Disease
Whole-mouse exome-sequencing analysis was used to recover the pathogenic
CHD-causing mutations in mutants recovered from the large-scale mouse muta-
genesis screen. This was made possible given the screen was conducted in a
C57BL6 inbred strain background. From this analysis, 91 pathogenic mutations
were recovered in 61 genes (Fig. 8.4). Of the 61 genes, 35 (58 %) are in cilia-related
or ciliome genes (Fig. 8.5); this included 12 genes (34 %) required for motile cilia
function (Fig. 8.4). Indeed 8 of these genes are known to cause PCD, including
many alleles ofDnah5 andDnah11 (Fig. 8.5). Interestingly, 23 of the cilia genes are
actually primary cilia related (66 %). Of these, half are found in mutant lines with
laterality defects and half in lines without laterality defects (Fig. 8.4) [11]. These
findings suggest the link between cilia and CHD is broader, not merely a reflection
of the role of cilia in left-right patterning. This is further supported by the recovery
of 15 pathogenic mutations in genes involved in cilia-transduced cell signaling,
including mutations in genes involved in Shh, Wnt, Tgfβ, and calcium signaling
(Fig. 8.5), all pathways known to play important role in cardiovascular
development [11].
Relevant to this, we note cilia is broadly expressed in the embryonic heart,
including in the atrial and ventricular myocardium, the atrioventricular and outflow
endocardial cushions (Fig. 8.1d–f). Importantly, in the Cc2d2a mutant recovered
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from our screen, atrioventricular septal defects were commonly observed, and this
was associated with a selective loss of cilia only in the atrioventricular cushions,
while the outflow cushions remain unaffected (Fig. 8.5o–r). The overall marked
enrichment observed for cilia mutations in the context of a gene agnostic screen
would point to the cilia as playing a central role in the pathogenesis of congenital
heart disease, a role that is subserved by both motile and primary cilia and goes
beyond the role of cilia in left-right patterning.









vs. non-ciliome CHD genes
found in laterality
vs. nonlaterality CHD mutant
lines. Bottom: Distribution of
ciliome CHD genes affecting
motile vs. primary cilia
among laterality
vs. nonlaterality lines (From
Li et al. [11])
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Fig. 8.5 Congenital heart disease genes recovered from mouse mutagenesis screen. Diagrams
illustrate biological context of CHD gene function (color-highlighting indicates CHD genes
recovered; asterisk denotes CHD genes recovered from previous screen) (From Li et al. [11])
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8.1.7 Ciliary Dysfunction in Congenital Heart Disease Patients
Without Heterotaxy
The finding from our mouse studies that cilia defects play a central role in the
pathogenesis of CHD would suggest the clinical impact of ciliary dysfunction in
congenital heart disease may be broader and have relevance beyond heterotaxy. To
examine this question, we conducted a large clinical study of over 200 patients with
a broad spectrum of congenital heart disease mostly without heterotaxy to deter-
mine the prevalence of ciliary dysfunction [17]. As in our previous study of
heterotaxy patients, we assessed for respiratory ciliary dysfunction using
videomicroscopy of the nasal epithelia and measured nNO.
This study demonstrated a very high prevalence of ciliary dysfunction, in both
the heterotaxy and nonheterotaxy congenital heart disease patients [17]. Moreover,
patients with airway ciliary dysfunction had significantly more respiratory
symptoms and disease and this did not correlate with heterotaxy status (Table 8.1)
[17]. The respiratory symptoms were largely localized to the lower airway and were
also significantly associated with PCD symptoms such as chronic otitis media,
chronic sinusitis, chronic wet cough, neonatal respiratory distress, pneumonia,
and bronchiectasis. Together these findings suggest patients with congenital heart
disease of a wide spectrum with or without heterotaxy may have high risk for
respiratory ciliary dysfunction. These findings are in agreement with the mouse
studies showing a central role for cilia in the pathogenesis of congenital heart
disease.
8.1.8 Future Directions and Clinical Implications
We identified a central role for cilia in the pathogenesis of congenital heart disease.
This finding uncovered by our mouse mutagenesis screen was unexpected and
shows the power of a non-gene-biased phenotype-driven genetic screen to uncover
new insights into mechanisms of disease pathogenesis. The important role of cilia
in congenital heart disease is supported by the human clinical studies, which also
showed a high prevalence of ciliary dysfunction in congenital heart disease patients.
Our mouse screen identified primary and motile cilia both playing essential roles in
congenital heart disease. The high prevalence of laterality defects among congenital
heart disease mutants is reminiscent of the clinicalx observation of a high preva-
lence of heterotaxy among human fetuses with congenital heart disease. This
suggests that observations from our mouse fetal ultrasound screen may provide a
window into the unborn human fetal population.
Our finding that congenital heart disease patients with ciliary dysfunction have
more respiratory symptoms and disease has important clinical implications.
Patients with complex congenital heart disease typically must endure multiple
high-risk cardiac surgeries for palliation of their structural heart defects. Not
infrequently, respiratory complications with high morbidity are observed postoper-
atively that can negatively impact outcome. Such respiratory problems are typically
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attributed to the heart disease, and the possibility of intrinsic airway clearance
defects due to ciliary dysfunction is never considered and hence not tested nor
treated. The observations from the human and mouse studies combined would
strongly suggest congenital heart disease patients should be presurgically screened
for respiratory ciliary dysfunction, and those with ciliary dysfunction should be
provided perioperative pulmonary therapy to enhance airway clearance function.
Instituting such change in the standard of care may have significant benefit in
improving outcome, especially cumulatively through the multiple rounds of surgery
that patients with critical congenital heart disease must endure.
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Pulmonary Arterial Hypertension
in Patients with Heterotaxy/Polysplenia
Syndrome
9
Akimichi Shibata, Keiko Uchida, Jun Maeda,
and Hiroyuki Yamagishi
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Early progressive pulmonary arterial hypertension (PAH) is often observed in
patients with heterotaxy/polysplenia especially who have an intracardiac systemic-
to-pulmonary shunt. However, its etiology is uncertain and its management is not
well established. There was only a Japanese report about PAH in consecutive
patients with heterotaxy/polysplenia syndrome [1]. They seemed to develop pul-
monary vascular obstructive disease earlier and more severe than expected, even in
cases with only pre-tricuspid systemic-to-pulmonary shunt although more detailed
analysis is required.
Improved understanding and studies about the molecular genetics of heterotaxy
syndrome indicate that this disease can be caused by single gene mutations. Genes
currently implicated in human heterotaxy syndrome include ZIC3, LEFTYA, CRYP-
TIC, and ACVR2B [2]. The establishment of left-right asymmetry is regulated by a
number of developmental signaling pathways including the notch, which mediate
nodal expression surrounding the node [3]. Nodal, a growth regulator produced by
the node, is a signaling molecule belonging to the transforming growth factor
(TGF)-β superfamily that plays a variety of roles in the early development
[4]. Mouse nodal acts through type I (ALK-4, 5, and 7) and type II (ACVR2B)
receptors of the TGF-β superfamily. Ligand activation of the receptors requires one
or more co-receptors, Cryptic and Cripto. Lefty-1 (homologue of LEFTYA) is a
nodal antagonist that is expressed in medial left lateral plate mesoderm [5].
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The mutation in BMPR2, which encodes type II receptor of the bone morpho-
genic protein (BMP), is a well-known genetic cause of PAH [6]. BMP is also
belonging to the TGF-β superfamily. Although there has been no report that
describes the association between PAH and mutation of genes implicated in
heterotaxy syndrome, they might have some effect on the signaling pathway
downstream of BMP and, consequently, be relevant to the pulmonary vascular
pathogenesis in progressive PAH.
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Part III
Cardiomyocyte and Myocardial Development
Perspective
Adriana C. Gittenberger-de Groot
The heart is the first crucial functioning organ in a developing embryo. The cell
essential for the pumping of the blood through the vascular system is the
cardiomyocyte. Cardiomyocyte precursors (CPCs) develop in the mesoderm of
the embryo in close association with the endoderm. Recent advances in our
knowledge on CPC show that during the initial formation of the heart tube, the
so-called first heart field (FHF) progenitors are important. These primarily form the
left ventricle of the mature heart. Thereafter, second heart field (SHF) CPCs add the
right ventricle and outflow tract as well as part of the inflow tract to the looping
heart tube. During the process of addition and looping, septation and valve forma-
tion take place. The resultant is a four-chambered heart with a unidirectional flow
from the right and left atria to the right and left ventricles and respective pulmonary
trunk and ascending aorta. This complex remodeling process is highly dependent on
instructive and cellular contribution from various surrounding cell populations.
These comprise in the early embryo the endoderm as well as later on the endocar-
dium and the epicardium with its epicardium-derived cells (EPDCs). These cell
populations are essential in their interaction with the immature myocardial cells for
their proper differentiation and the eventual myocardial architecture. Last but not
least, the development of a coronary vascular system with endothelial cells and
EPDC-derived smooth muscle cells completes the demands of the oxygenation of
the cardiomyocytes. Whether the differentiation of a specific population of the
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cardiomyocytes into the cardiac conduction system requires an interaction with
surrounding cells is still unresolved.
Interest in cardiomyocyte origin and maturation has been highly augmented by
the use of cardiac stem cells and inducible progenitor cells (iPCs) for therapeutic
aims in life-threatening myocardial pathology and possibly in the future congenital
heart disease.
In this section, many aspects of cardiomyocyte (patho-)biology are addressed.
For the possible use in the future of CPCs, it is essential to know whether there are
differences between FHF- and SHF-derived CPCs as they have their specific
contributions to the right and left ventricle with again their specific cardiac failure
problems. Single cell transcriptome analysis might be a novel technique to unravel
this question. In early development, the inductive role of the endoderm with several
important molecular factors like FGFs including the importance of the related
thyroid hormone system should be considered with a possible impact on cardiac
disease.
Intriguing is the question of cardiomyocyte regeneration capacities in the mature
heart not only by reactivation of the dormant CPC population but also by under-
standing the molecular mechanism underlying the normal cardiomyocyte cell
cycle. Cardiomyocyte proliferation is highly active in the prenatal heart and stops
postnatally. Understanding of the mechanism underlying this process and the
possibility to extend or to reactivate cardiomyocyte proliferation, in which Meis1
is reported to have a role, might be of great clinical value.
Of similar interest are aspects of formation of the architecture of the myocardial
wall consisting of 30 % cardiomyocytes and 70 % cardiac fibroblasts. The
myocardial wall develops from a simple two-layered structure into a trabecular
layer on the inside and a compact layer on the outside. During development, the
relative contributions vary in which the compact layer increases in thickness and
the trabecular layer through compaction diminishes. A proper balance of trabecular
and compact layer formation seems to be regulated by the Notch pathway-mediated
endocardial to myocardial interaction. Disturbance of this pathway in mice may
result in a phenotype that resembles a left ventricular non-compaction cardiomyop-
athy (LVNC) also observed in human familial mutations in this pathway. Likewise,
epicardial to myocardial interaction is essential for compact myocardial layer
formation as well as ventricular septation. A role of the epicardium in the formation
of an anterior-folding ventricular septum is described, shedding new light on the
development of ventricular septal defects.
In conclusion, understanding of myocardial pathology and resultant therapeutic
and preventive measures, in CHD as well as adult cardiovascular disease, deserves
a highly diverse research approach as is elegantly highlighted in this section.
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Abstract
For this decade, heart development has been extensively elucidated by the
introduction of the concepts of “heart fields” and “cardiac progenitor cells
(CPCs)”. It is believed that multipotent CPCs are specified among the most
anterior part of lateral plate mesoderm as belonging to the two anatomical fields;
the first heart field (FHF), which is the future left ventricle and atria, and the
second heart field (SHF), which is the future right ventricle and outflow tract of
the heart. However, the paradigm of two heart fields dependent on conventional
marker genes is still disputed, so the existence of independent CPCs specific to
each HF remains an open question. In addition, the molecular mechanism
underlying the specification of CPCs remains largely unknown. A single-cell
transcriptomic approach, which is realized by the recent advances in molecular
biology, can be one of the solutions to bring some breakthrough in this subject.
Keywords
Cardiac progenitor cells • First heart field • Second heart field • Single-cell
transcriptomics
10.1 Introduction
Better understanding of the molecular mechanism of heart development is vital to
clarify the pathophysiology of congenital heart diseases and will benefit us in terms
of prediction, prevention and treatment of such diseases in the future. In addition,
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the information of multipotent cardiac progenitor cells (CPCs) is expected to be
valuable for stem cell-based regeneration therapy for the failed heart. However, our
knowledge is still insufficient for full translation to the clinical arena.
Here, we review the current knowledge of the earliest phase of cardiac develop-
ment in mice focusing on CPC specification and discuss the potential of single-cell
transcriptomic analyses to elucidate the mechanism [1, 2].
10.2 CPCs of the Two Heart Fields
The heart is one of the first anatomical structures formed during embryogenesis.
Fate mapping studies indicated that the nascent mesodermal cells contributing to
the heart came through the anterior half of primitive streak on embryonic day
(E) 6.5 (Fig. 10.1a) [3]. These mesodermal cells migrate anteriorly acquiring the
identity of lateral plate mesoderm. At E7.5, the anterior part of lateral plate
mesoderm is identified as the heart fields, the direct source of the heart tube
[1, 4]. Then the subsequent morphogenesis to create the heart with the four
chambers, including the heart tube formation and looping, occurs.
Fig. 10.1 The heart development. (a) Schematic illustration of the heart development. The
progeny of FHF is indicated by red and that of SHF is by blue. (b) A hypothetical model of the
lineage tree of the heart mesoderm. In this model, it is hypothesized that the independent
multipotent CPCs of each heart field. (c) An alternative model of the heart mesoderm lineage
tree. In this model, common CPCs are hypothesized, and only in the case of SHF, the multipotent
state might be maintained. al allantois, CC cardiac crescent, CMs cardiomyocytes, LA left atrium,
LV left ventricle, nm nascent mesoderm, OFT outflow tract, ps primitive streak, RA right atrium,
RV right ventricle
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According to the fate map, the anatomical heart fields are divided into two major
subgroups, the first heart field (FHF) and the second heart field (SHF) (Fig. 10.1a)
[1]. FHF is the classical cardiac crescent and is known to contribute to the left
ventricle and parts of the atria. SHF contributes to the right ventricle, outflow tract
and also parts of atria. These anatomical fields are currently distinguished with the
following molecular markers. The genes encoding transcription factors, Nkx2-5 and
Tbx5, mark the FHF, whereas Isl1 marks the SHF at E7.5 in the mouse [1].
CPCs are believed to appear in the period from gastrulation (E6.5) to the heart
fields’ formation (E7.5). It is thought that CPCs have been already committed
toward the heart but are multipotent to give rise to cardiomyocytes, electric
conduction system, smooth muscle and endothelium (Fig. 10.1b, c) [1]. Given the
paradigm of the anatomical two heart fields, CPCs are classified into FHF CPCs and
SHF CPCs (Fig. 10.1b). Unfortunately multipotent FHF CPCs have not been
identified (Fig. 10.1c). The cells in the cardiac crescent, the theoretical progeny
of FHF CPCs, are unlikely to be “multipotent progenitors”, because these already
express the terminal differentiation markers of cardiomyocytes, such as Actc1 and
Myl7 [1, 5, 6]. To add to this, no marker is available to identify FHF before Nkx2-5
and Tbx5 expression. By contrast, the presence of multipotent SHF CPCs, which are
marked by Isl1 expression, seems to be validated with clonal tracing experiments
[7]. However, the paradigm of FHF and SHF based on Nkx2-5 and Isl1 is now
disputed [1]. The expression of Isl1 was shown to be not specific for SHF and was
suggested to represent only the developmental stages [8, 9]. Thus, true
characteristics of CPCs should be clarified with revalidation of the conventional
biomarkers and the concept of two heart fields.
10.3 CPC Specification
The molecular mechanism underlying the specification of CPCs remains largely
unknown. In the mouse embryo, specification might occur inside the heart fields
[1, 4]. When the nascent mesoderm cells at E6.5 containing the presumptive heart
fields were transplanted heterotopically to a location other than the heart fields, the
fate was not the heart but the same as the cells of the recipient surrounding the graft
[4]. On the other hand, when the same graft was transplanted to the heart fields of
E7.5, it was committed almost only to the heart. These suggest that the migrating
presumptive heart fields are plastic and that some inductive cue for cardiac specifi-
cation is present within the heart fields. The surrounding tissue, especially the
endoderm, likely provides such an inductive cue [1, 4]. However, we cannot
exclude the possibility that some sequential events of specification take place
during the gastrulation and migration so that the unfixed cardiac competence
might be gradually and sequentially consolidated.
It has been shown that the signalling pathways of WNT, FGF, BMP, NODAL
(ACTIVIN), SHH and NOTCH are involved in the specification [1, 10]. However,
validating the precise role of each signalling pathway is difficult because their
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accurate cardiogenic function has been hard to distinguish from their overall
effects. Thus, some alternative strategy is needed to bring a breakthrough.
10.4 The Potential of Single-Cell Transcriptomics in the Study
of CPC Specification
Accurate quantitative evaluation of genome-wide gene expression provides an
essential platform to understand the states of cells of interest. In the case where a
specific subset of rare cells plays a vital role, single-cell transcriptomics are a strong
tool. Indeed, thus far, this strategy has given fruitful results in the study of the
specification of the olfactory receptors, spinal cord neurons and primordial germ
cells [11–13]. Currently, several protocols of single-cell transcriptomics have been
developed as applicable to next-generation sequencing (NGS) with sufficient cov-
erage, sensitivity and accuracy (Table. 10.1) [2].
The protocol for genome-wide analysis was first developed by Kurimoto and
colleagues for microarray and has been recently modified for NGS (Fig. 10.2a) [14–
16]. The feature of this protocol is to add artificially a poly A tail to the 30-end of the
first-strand cDNA to generate the appropriate adapter sites for PCR amplification.
At the final step, cDNA is obtained as PCR amplicon. Disadvantageously
Kurimoto’s protocol provides only strongly 30-biased cDNA, although Tang’s
protocol likely overcomes this problem [15].
Quartz-seq is also a method applicable to microarray and NGS, based on PCR
amplification, and the architecture of the protocol is based on “suppressive PCR”
(Fig. 10.2a) [17]. This method looks superior to Kurimoto’s in terms of simple
operation, coverage and technical reproducibility.
SMART-seq utilizes a unique nature of reverse transcriptase [18]. During
reverse transcription, Moloney murine leukaemia virus reverse transcriptase adds
a short poly C tail to the 30-end of the first-strand cDNA. Reverse transcriptase uses
a helper oligonucleotide with poly G motif as the template (“template switch”) after
annealing to the poly C tail, which results in the addition of adaptors to cDNA
(Fig. 10.2b). This template switch happens preferentially to 50-capped mRNA so
that finally a full-length cDNA library is obtained as suppressive PCR amplicon if
oligo(dT) primer is used for the first-strand synthesis. This enrichment of full length
Table 10.1 Methods of single-cell transcriptomics
Method Principle Application References
Kurimoto et al. 2006 Poly A tailing/PCR Microarray [14]
Tang et al. 2009 Poly A tailing/PCR NGS [15]
Brouilette et al. 2012 Poly A tailing/PCR NGS [16]
Quartz-seq/-chip Poly A tailing/suppressive PCR NGS/microarray [17]
SMART-seq Template switch/PCR NGS [18]
CEL-seq IVT/PCR NGS [19]
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is a merit, but simultaneously a demerit, because any partially synthesized cDNAs
are not amplified so that the yield of cDNAs is inevitably limited.
On the other hand, CEL-seq uses mainly isothermal amplification of in vitro
transcription (IVT) by T7 polymerase (Fig. 10.2c) [19]. Theoretically, IVT is
superior to PCR in terms of liner and proportional amplification to secure better
technical reproducibility. A demerit of this protocol is that reads by NGS are
strongly biased toward 30-end.
Lastly, we should discuss the limitations of single-cell transcriptomics. First,
there is always a technical noise due to pippetting error, difference of system
(including enzymes, thermal cycler and NGS machine) and amplification bias. Of
note, the “Monte Carlo effect”, the cause of large quantitative errors of small copy
number mRNAs due to the stochastic events within an initial few cycles of PCR
reaction, is uncontrollable. Amplification bias is inevitable to some extent in the
protocols dependent on PCR, although every protocol has been well validated to
secure its sufficient technical reproducibility. Second, the lack of topological
information precludes us from referring the obtained expression profile to the cell
in the embryo if no molecular markers exist. Thus it is necessary to consider how to
fill such lost information.
Fig. 10.2 Overview of the methods of single-cell transcriptomics. (a) Poly A tailing (Kurimoto’s,
Tang’s, Boulette’s protocol and Quartz-seq), (b) SMART-seq, (c) CEL-seq. Please refer to the
main text and the relevant references for details
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10.5 Future Direction and Clinical Implication
The strategy of single-cell transcriptomics has great potential to increase under-
standing of CPC specification, their ground state and differentiation. This knowl-
edge will be utilized in order to control the commitment of pluripotent stem cells
including ES cells and iPS cells for future clinical application as stem cell-based
regeneration therapy.
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Meis1 Regulates Postnatal Cardiomyocyte
Cell Cycle Arrest 11
Shalini A. Muralidhar and Hesham A. Sadek
Abstract
The neonatal mammalian heart is capable of substantial regeneration following
injury through cardiomyocyte proliferation (Porrello et al, Science 331:1078–
1080, 2011; Proc Natl Acad Sci U S A 110:187–92, 2013). However, this
regenerative capacity is lost by postnatal day 7 and the mechanisms of
cardiomyocyte cell cycle arrest remain unclear. The homeodomain transcription
factor Meis1 is required for normal cardiac development but its role in
cardiomyocytes is unknown (Paige et al, Cell 151:221–232, 2012; Wamstad
et al, Cell 151: 206–220, 2012). Here we identify Meis1 as a critical regulator of
the cardiomyocyte cell cycle. Meis1 deletion in mouse cardiomyocytes was
sufficient for extension of the postnatal proliferative window of cardiomyocytes
and for reactivation of cardiomyocyte mitosis in the adult heart with no deleteri-
ous effect on cardiac function. In contrast, overexpression of Meis1 in
cardiomyocytes decreased neonatal myocyte proliferation and inhibited neonatal
heart regeneration. Finally, we show that Meis1 is required for transcriptional
activation of the synergistic CDK inhibitors p15, p16, and p21. These results
identify Meis1 as a critical transcriptional regulator of cardiomyocyte prolifera-
tion and a potential therapeutic target for heart regeneration.
Keywords
Cardiomyocytes • Heart injury • Regeneration • Meis1 • Cell cycle
S.A. Muralidhar, Ph.D. • H.A. Sadek, M.D., Ph.D. (*)
Department of Internal Medicine, Division of Cardiology, The University of Texas Southwestern
Medical Center, Dallas, TX 75390, USA
e-mail: hesham.sadek@utsouthwestern.edu
# The Author(s) 2016




The past decade witnessed a revolution in our understanding of cardiac biology,
with groundbreaking research demonstrating that the adult mammalian heart is
capable of limited but measurable cardiomyocyte turnover [5–9]. However, the
ultimate goal of complete regeneration of the heart remains elusive. In stark
contrast to the adult mammalian heart, we recently demonstrate that the mammalian
heart is in fact capable of complete regeneration following apical resection of 15 %
of the ventricular myocardium [1]. This remarkable regenerative capacity was
associated with robust cardiomyocyte proliferation throughout the myocardium.
Moreover, lineage-tracing studies demonstrated that the newly formed myocytes
were derived from preexisting cardiomyocytes, rather than from a progenitor
population. Finally, we showed that cessation of this regenerative phenomenon
occurred at postnatal day 7 (P7), which coincides with the developmental window
when cardiomyocytes become binucleate and withdraw from the cell cycle
[9, 10]. It is unclear whether the loss of this regenerative potential in the adult
heart is due to an intrinsic cell cycle block in adult cardiomyocytes or to loss of
mitogenic stimuli as the heart ages (or both). Thus, it is important to determine the
mechanisms by which the mammalian heart switches off this regenerative capacity
in the week after birth.
In an effort to identify genes involved in postnatal regeneration arrest, we
performed several gene arrays following MI at multiple postnatal time points.
This allowed us to identify Meis1 as one of the few transcription factors that
were dysregulated between injury at P1 and injury at P7 and P14. Meis1 has been
studied extensively in the hematopoietic system, is required for normal hematopoi-
esis, and also plays an important role in leukemogenic transformation [11–
14]. What little is known about the role of Meis1 in the heart comes from global
KO studies resulting in numerous cardiac defects. However, given that global
Meis1 deletion results in embryonic lethality by E14.5, full characterization of
the role of Meis1 in cardiomyocytes has been difficult [13, 15, 16]. Despite the role
of Meis1 in regulation of hematopoiesis and cardiac development, the mechanism
of action of Meis1 remains poorly characterized. Our results indicate that Meis1
expression and nuclear localization in cardiomyocytes coincide with cell cycle
arrest. Cardiomyocyte cell cycle exit is associated with downregulation of positive
cell cycle regulators (CDK2, CDK3, CDK4, CCND1, and CDK cofactors) and
induction of cell cycle inhibitors (CDKI, members of the INK4 and CIP/KIP
families) [10, 17–20]. We identified conserved Meis1 domains in only two key
CDK inhibitors, namely, p16 and p21, which are known to regulate all three cell
cycle checkpoints. We demonstrated that Meis1 regulates the pattern of expression
of these two cell cycle inhibitors following Meis1 knockdown. These results
provide role and mechanism of cell cycle regulation by Meis1.
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Fig. 11.1 Expression profile of Meis1 in postnatal heart. (a) qRT–PCR showing increased
expression of Meis1 at postnatal day 7 (P7), a time point that coincides with cell cycle arrest of
cardiomyocytes. (b) qRT–PCR showing expression levels of Meis1 7 days post Sham or MI at P1
or P7. (c) Expression of Meis1 is absent at P1 and nuclear localization of Meis1 in P7 and P21
cardiomyocytes
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11.2 Results
11.2.1 Expression of Meis1 During Neonatal Heart Development
and Regeneration
Transcriptional regulation of postnatal cardiomyocyte cell cycle arrest is unclear.
Our initial screens identified Meis1 as a potential transcriptional regulator of
neonatal heart regeneration. Therefore, we conducted this study to determine the
role of Meis1 in regulation of cardiomyocyte cell cycle. We first examined the
expression pattern of Meis1 during neonatal heart development and regeneration.
qPCR showed a modest increase in Meis1 expression between postnatal day
1 (P1) and P7 (Fig. 11.1a). Meis1 was localized to perinuclear regions in neonatal
cardiomyocytes at P1 and nuclear localized by P7 and P21 (Fig. 11.1c). Myocardial
infarction (MI) at P1, which is associated with an induction of robust
cardiomyocyte proliferation at day 7 post-MI, was associated with a modest
decrease in the expression of Meis1, whereas Meis1 mRNA expression levels
were significantly increased following MI at P7, a time point coinciding with lack
of mitotic induction of cardiomyocytes (Fig. 11.1b).
11.2.2 Cardiomyocyte Proliferation Beyond Postnatal Day
7 Following Meis1 Deletion
We generated cardiomyocyte-specific Meis1 knockout (KO) mice by crossing
Meis1f/f mice with αMHC-Cre mice (Fig. 11.2a). qRT–PCR of cardiomyocytes
from Meis1f/f αMHC-Cre (Meis1KO) compared to αMHC-Cre (control) mouse
hearts confirmed a change in gene expression consistent with Meis1 deletion in
cardiomyocytes (Fig. 11.2b). Phenotypic characterization of Meis1KO mice at P14
(1 week beyond the normal window of postnatal cardiomyocyte cell cycle arrest)
demonstrated that heart size (Fig. 11.2c, d) and cardiac function (Fig. 11.2e) were
unaffected by Meis1 deletion. However, Meis1KO cardiomyocytes were smaller
compared to control cardiomyocytes (Fig. 11.2f), which may imply that the
cardiomyocyte number is increased in Meis1KO (smaller cardiomyocyte size,
with no change in heart-to-body weight ratio). Therefore, we examined the
Meis1KO hearts for myocyte proliferation using the mitosis marker pH3
(phosphorylated histone H3) and the cytokinesis marker Aurora B kinase. Meis1
deletion resulted in induction of cardiomyocyte proliferation as quantified by an
increase in the number of pH3+TnnT2+ (troponin T2) cells (Fig. 11.2g). In addi-
tion, we found that Aurora B was markedly expressed in the cleavage furrow
between proliferating myocytes in the KO hearts (0.5-fold) (Fig. 11.2h). We also
found a significant increase which did not result in an increase in myocyte apoptosis
by TdT-mediated dUTP nick end labeling (TUNEL) staining (Fig. 11.2k).
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11.2.3 MI in Meis1 Overexpressing Heart Limits Neonatal Heart
Regeneration
To determine whether forced Meis1 expression can inhibit neonatal cardiomyocyte
proliferation, we generated a cardiac-specific Meis1 overexpressing mouse (Meis1
OE) by crossing pTRE-Meis1 mice with αMHC-tTA mice to allow for specific
overexpression of Meis1 in cardiomyocytes (Fig. 11.3a) around birth in the absence
of tetracycline. We used a Meis1 line that overexpressed Meis1 by 2.5-fold
(Fig. 11.3b). Overexpression of Meis1 did not result in a significant increase in
heart-to-body weight ratio (Fig. 11.3c, d), normal systolic function (Fig. 11.3e), and
increased cardiomyocyte size (Fig. 11.3f). Despite the increase in cardiomyocyte
size in Meis1 (OE) hearts, the lack of decrease in heart-to-body weight ratio most
probably reflects a decrease in the number of cardiomyocytes. This is supported by
a decrease in the number of mitotic cardiomyocytes in the neonatal Meis1
(OE) hearts (Fig. 11.3g). More notably, Meis1 OE inhibited neonatal heart regen-
eration following induction of MI at P1 (Fig. 11.3h–j), whereas the wild-type hearts
regenerated normally. Finally, Meis1 OE in cardiomyocytes resulted in
upregulation of CDK inhibitors, most significantly p21 (Cdkn1a) (Fig. 11.3k).
These results indicate that Meis1 overexpression in the neonatal heart results in
premature cardiomyocyte cell cycle arrest.
Fig. 11.2 Cardiomyocyte proliferation at P14 following Meis1 deletion. (a) Schematic of Meis1
floxed allele. Control mice were αMHC-Cre, Meis1KO mice were Meis1f/fαMHC-Cre. (b) qRT–
PCR demonstrates deletion of Meis1 in cardiomyocytes at P14. (c) Trichrome staining of wild-
type (WT) and Meis1KO hearts at P14. (d) Heart weight (HW)-to-body weight (BW) ratio in WT
and Meis1KO hearts. (e) Left ventricular (LV) systolic function quantified by ejection fraction
(EF) and fractional shortening (FS). (f) Wheat germ agglutinin (WGA) staining and cell size
quantification. (g) Confocal image with z-stacking showing co-localization of pH3, TnnT2, and
Hoechst in a Meis1KO heart at P14. Immunostaining showing sarcomere disassembly and normal
sarcomeric structure in Meis1KO hearts. Graph shows quantification of the number of
pH31+TnnT21+ nuclei. (h) Expression of Aurora B in Meis1KO cardiomyocytes at P14 and
quantification of the number of Aurora B+TnnT2+ cardiomyocytes
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11.2.4 Regulation of Cyclin-Dependent Kinase Inhibitors by Meis1
In order to determine the mechanism by which Meis1 regulates cardiomyocyte
proliferation, we performed a cell cycle PCR array. We found that Meis1 deletion
resulted in downregulation of cyclin-dependent kinase inhibitors in isolated
cardiomyocytes, including members of the Ink4b–Arf–Ink4a locus (p16, p15, and
p19ARF) and CIP/ KIP family (p21 and p57), as well as upregulation of a number
of positive regulators of the cell cycle (Fig. 11.3a, b). qRT–PCR confirmed these
results (Fig. 11.4a). Of all the dysregulated cell cycle genes, we identified
conserved Meis1 consensus binding sequences in the promoter region of only two
loci, namely, the Ink4b–Arf–Ink4a (which includes p16INK4a, p19ARF, and
p15INK4b) (Fig. 11.4b) and p21 loci (Fig. 11.4c) using the UCSC genome browser
(http://genome.ucsc.edu). To test if Meis1 can transcriptionally activate Ink4b–
Fig. 11.3 Meis1 overexpression limits neonatal heart regeneration following MI. (a) Schematic
of Meis1 overexpression (OE) in the heart. Control mice were αMHC-tTA, Meis1 (OE) mice were
pTREMeis1-αMHC-tTA. (b) qRT–PCR demonstrates overexpression of Meis1. (c) HW-to-BW
ratio in control and Meis1 (OE) mice. (d) H & E staining of WT and Meis1 (OE) hearts. (e) LV
systolic function quantified by EF. (f) WGA staining and cell size quantification. (g)
Immunostaining image showing co-localization of pH3, TnnT2, and Hoechst in Meis1
(OE) heart at P3. Graph shows quantification of pH3+TnnT2+ nuclei. (h) Schematic of neonatal
MI during the regenerative window at P1. (i) LV systolic function of WT and Meis1 (OE) hearts at
21 days post-MI. (j) Trichromes at day 21 post-MI. (k) qRT–PCR of CDKIs in hearts of Meis1
(OE) compared to control
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Arf–Ink4a and p21, we generated luciferase reporter constructs containing the
conserved Meis1 binding motifs. Luciferase reporter assays with INK4b–ARF–
INK4a–pGL2 (Fig. 11.4b) and p21–pGL2 reporters (Fig. 11.4c) demonstrated a
dose-dependent activation by Meis1. Mutation of the putative Meis1 binding sites
abolished the Meis1-dependent activation of the luciferase reporters (Fig. 11.4b, c).
Finally, we demonstrated an in vivo interaction between Meis1 and Ink4b–Arf–
Ink4a and p21 promoters in the adult mouse heart by ChIP (Figs. 11.4d and 11.5).
11.3 Future Direction and Clinical Implications
The current study identifies Meis1 as a critical transcriptional regulator of
cardiomyocyte cell cycle, upstream of two synergistic CDKI inhibitors. Although
the mechanism of activation of Meis1 in the postnatal heart is not quite fully
understood, results have demonstrated that Meis1 expression coincides with Hox
genes that are known to interact with Meis1, stabilize its DNA binding, and enhance
its transcriptional activity. Therefore, it would be important for future studies to
define the transcriptional network involved in mediating the effect of Meis1 on
postnatal cardiomyocytes. Ultimately, we hope to utilize our understanding of the
role and mechanism of Meis1 in cardiomyocyte proliferation to uncover new
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Fig. 11.4 Regulation of cyclin-dependent kinase inhibitors by Meis1. (a) qPCR of CDKIs in
purified Meis1KO cardiomyocytes demonstrates significant downregulation of CDKN1A (p21),
CDKN2B (p15), CDKN2A (p16), p19ARF, CDKN2C (p18), and CDKN1C (p57). (b) Highly
conserved Meis1 motifs located in p16INK4a/p19ARF/p15INK4b promoter and luciferase
reporter assay for INK4b–ARF–INK4a promoter demonstrating induction of INK4b–ARF–
INK4a pGL2 reporter by Meis1 and loss of reporter activity following mutation of Meis1 motifs
(INK4b–ARF–INK4a-Mutant). (c) Highly conserved Meis1 motif located in p21 promoter and
luciferase assay for p21 demonstrating induction of p21 pGL2 reporter by Meis1 and loss of
reporter activity following mutation of Meis1 motifs (p21 Mutant). (d) In vivo confirmation of
Meis1 interaction with INK4a/ARF/INK4b and p21 promoters by ChIP assay
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Intercellular Signaling in Cardiac
Development and Disease: The NOTCH
pathway
12
Guillermo Luxán, Gaetano D’Amato, and José Luis de la Pompa
Abstract
The heart is the first organ to develop in the embryo, and its formation is an
exquisitely regulated process. Inherited mutations in genes required for cardiac
development may cause congenital heart disease (CHD), manifested in the
newborn or in the adult. Notch is an ancient, highly conserved signaling pathway
that communicates adjacent cells to regulate cell fate specification, differentia-
tion, and tissue patterning. Mutations in Notch signaling elements result in
cardiac abnormalities in mice and humans, demonstrating an essential role for
Notch in heart development. Recent work has shown that endocardial Notch
activity orchestrates the early events as well as the patterning and morphogenesis
of the ventricular chambers in the mouse and that inactivating mutations in the
NOTCH pathway regulator MIND BOMB-1 (MIB1) cause left ventricular
non-compaction (LVNC), a cardiomyopathy of poorly understood etiology.
Here, we review these data that shed some light on the etiology of LVNC that
at least in the case of that caused byMIB1 mutations has a developmental basis.
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Heart development begins in the mouse at embryonic day 7 (E7) when pre-cardiac
precursor cells move forward bilaterally into the lateral plate mesoderm to form the
cardiac crescent [14]. By E8, a linear heart tube is formed after folding of the
mesodermal layers from both sides of the embryo, and the two main tissues of the
heart are present, the endocardium inside and the outer myocardium. At E9.0, the
heart loops and grows by addition of cells from both cardiac poles [20]. At E9.5, the
heart divides afterward into developmental domains that would allow the formation
of two regions, the valve and the chamber regions [24] (Fig. 12.1a).
We will describe in some detail the process of ventricular chamber development
because it is the focus of this review. At E9.5, the process of trabeculation begins in
the primitive ventricles. Trabeculae are highly organized sheets of cardiomyocytes
that protrude toward the light of the ventricles [3]. Trabeculae are the first structural
landmark of the developing ventricles [31]. They increase the ventricular surface
and allow the myocardium to grow in the absence of coronary vessels that will be
formed later. Trabeculae are important for contractibility, formation of the conduc-
tion system, and blood flow direction in the ventricle. Although trabeculae start to
form first in the left ventricle and later in the right ventricle, there are no differences
between these structures in the two ventricles. Formed trabeculae have no free ends
and they make the ventricle appear like a sponge [31] (Fig. 12.1b). From E10.5
onward, the ventricular myocardium has two well-defined regions, morphologically
and molecularly, the outer compact myocardium and the inner trabecular layer. The
compact myocardium is less differentiated and shows a higher proliferation rate
than the trabecular myocardium [31]. Differentiated cardiomyocytes will give rise
to the working myocardium and the conduction system [31]. After completion of
ventricular septation around E14.5, further growth and maturation of the ventricular
chambers require a complete trabecular remodeling and reorganization into an
apico-basal orientation that determines the shape of the ventricles (Fig. 12.1c).
Trabeculae become compacted and as a result there is a significant change in the
ratio of compact vs. trabecular myocardium in the ventricle. Trabeculae compac-
tion is accompanied by the hypoxia-dependent invasion of the coronary vasculature
from the epicardium into the compact layer of the myocardium [33]. As they
compact, the intertrabecular recesses are transformed into capillaries of the rising
coronary plexus. This is followed by a reorganization of the muscle fibers of the
heart that organize in a three-layered spiral around the heart reflecting the twisting
pattern of heart contraction [31]. Trabeculae stop proliferating while the prolifera-
tion of the compact zone sustains the growth of the chamber and the contribution of
the compact layer to the heart becomes more significant than the one of the luminal
trabeculations that will eventually disappear. How exactly this happens and what
molecular mechanisms drive this process is unknown.
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Fig. 12.1 Overview of early heart development. (a) Ventral views of the developing mouse
embryo. At E7.0, cardiac progenitors (yellow) migrate to the center of the embryo to form the
cardiac tube and at E7.5, two cardiac fields can be distinguished: the first heart field (FHF; yellow)
and the second heart field (SHF; green). By E8.0, the cardiac tube is formed where endocardium
and myocardium are already present. At E9.0 the tube loops and at E9.5, has four anatomically
distinct regions: atrium, atrioventricular canal (AVC), ventricle (V), and outflow tract (OFT).
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12.2 Left Ventricular Non-compaction (LVNC)
LVNC is a cardiomyopathy of poorly understood etiology that is characterized by
prominent and excessive trabeculations with deep recesses in the ventricular wall
[18]. LVNC was first diagnosed in 1984, in a 33-year-old woman assessed by
echocardiography [10]. Since then, the heterogeneity of its symptoms might have
left many LVNC cases undiagnosed [18], giving a lower estimation of its real
impact as a cardiomyopathy. The improvement in imaging technologies and the
advent of CMRI allow now a better diagnosis of this disease, and 10 years after the
first description, LVNC was included in the World Health Organization (WHO)
catalogue of cardiomyopathies [30]. In 2006, the American Heart Association
included LVNC to its list of genetic cardiomyopathies caused by an arrest of the
normal compaction process of the developing myocardium [23]. LVNC can be
almost asymptomatic or manifest as depressed systolic function [7], accompanied
by systemic embolism, malignant arrhythmias, heart failure, and sudden death [25],
although its clinical manifestation and the age of the affected individual at symptom
onset are variable. LVNC was shown to be caused by mutations in genes encoding
mainly structural proteins of the cardiac muscle, cytoskeleton, nuclear membrane,
and chaperone proteins. In general, familial forms of LVNC are transmitted as an
autosomal-dominant trait [7]. The underlying molecular mechanisms that produce
the structural abnormalities leading to LVNC are still unknown [34].
12.3 The NOTCH Signaling Pathway
Notch is a conserved signaling pathway that regulates cell fate specification,
differentiation, and tissue patterning via local cell interactions [2]. There are four
Notch receptors in mammals, Notch1–Notch4, which are expressed in different
tissues and at different times during embryonic and adult life. Notch is a large type I
transmembrane receptor that has two distinct domains, an extracellular domain
(NECD) responsible for the interaction with the ligands and an intracellular domain
(NICD) responsible for signal transduction (Fig. 12.2). NECD contains a varied
number of tandem arrays of epidermal growth factor (EGF)-like repeats [2]. NICD
is composed of the RAM23 domain and 6 ankyrin repetitions responsible for the
interaction with RBPJK, the transcriptional effector of the pathway; two nuclear
localization signals; a transcriptional activation domain only present in Notch1 and
Notch2; and a terminal PEST domain that negatively regulates the stability of the
receptor [21]. NECD and NICD are synthesized as a single polypeptide, which is
directly cleaved after translation by a furin convertase in the Golgi. This first
Fig. 12.1 (continued) Endocardial cushions are formed in valvulogenic regions of the heart
(green, OFT and blue, AVC) and trabeculae appear in the ventricles (b). At E15.5, trabeculae
are undergoing compaction and there is a thick compact myocardium (c) that becomes very
prominent in the adult ventricle that has a smooth surface (d)
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cleavage [6] is necessary to form the functional heterodimeric receptor that will be
translocated to the membrane where the two domains are still associated by Ca2þ-
dependent non-covalent bonds [28]. In mammals, the Notch ligands belong to the
Delta-like (Dll1, Dll3, and Dll4) and Jagged (Jag1 and Jag2) families. The ligands
Fig. 12.2 The Notch signaling pathway. The Notch ligands Delta and Jagged are tethered to the
membrane of the signaling cell. On their way to the plasmatic membrane, the Notch receptors are
modified in their extracellular domains (NECD) by Fringe. Upon ligand-receptor interaction, Mib1
ubiquitylates the ligand, targeting it for endocytosis. Pulling of NECD allows the cleavage and
release of NICD by γ-secretase. NICD translocates to the nucleus and forms a transcriptional
activation complex together with RBPJK and MAML that activates target genes transcription,
including Hes and Hey that encode transcriptional repressors
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are type I transmembrane proteins and their extracellular domains are composed by
a repetition of EGF-like domains responsible for the interaction with the receptor
and the DSL (Delta, Serrate, Lin12) domain (Fig. 12.2) [21]. The glycosyl-
transferase Fringe can modify the EGF-like domain in the NECD of the receptor
by adding O-fucose glycans [5] (Fig. 12.2). This modification determines which
ligand preferentially binds to the receptor. There is evidence that the presence of
Fringe shifts the activation balance toward Delta-like ligands at the expense of
Jagged ligands when both molecules are expressed at the same time in the same
tissue [4]. The E3 ubiquitin ligase Mind bomb1 (Mib1) regulates the endocytosis of
the Notch ligands when bound to NECD, a prerequisite for Notch activation
[16]. Mib1 binds to the two families of Notch ligands, and it is a point of regulation
of the pathway in the signaling cell. Upon interaction of ligand and receptor, Mib1
targets by ubiquitylation the ligand for endocytosis [16]. The ligands are
endocytosed, mechanically pulling NECD producing a conformational change
that exposes a second cleavage site [27] allowing a metalloprotease of the
ADAM family to cleave NECD [13] that is finally endocytosed into the signaling
cell together with the ligand. Immediately after, γ-secretase/Presenilin cleaves the
receptor in a third site liberating the NICD in the cytoplasm of the receiving cell
[26] (Fig. 12.2). NICD translocates to the nucleus where it binds to the transcription
factor CSL or RBPJK via by the RAM23 domain [32]. In the absence of Notch
signaling activation, RBPJK is bound to nuclear corepressors that inhibit gene
expression. Upon the interaction of NICD with RBPJK, the transcriptional
repressors are released and transcriptional activators such as Master mind-like
(Maml) [35] are recruited forming a protein complex that activates the expression
of target genes (Fig. 12.2).
12.4 NOTCH in Ventricular Chamber Development
Notch pathway elements show a complex expression pattern in the developing
mouse chambers. At E9.5, Mib1 is expressed in endocardium and myocardium,
Dll4 in the endocardium especially at the base of the forming trabeculae, Jag1 in the
myocardium, and N1ICD is only active at discrete sites where the trabeculae form
[9]. Analysis of standard and endothelial-specific Notch1 and RBPJkmutants shows
that trabeculation is severely impaired and only primitive, poorly organized
trabeculae can be observed in these mutants [12]. Molecular analysis indicates
that during trabeculation, Notch modulates three different signals: EphrinB2 [1],
expressed in the endocardium, is a direct Notch target. Nrg1 [15], also expressed in
the endocardium, is an indirect Notch target, and its expression depends both of
Notch and EphrinB2 [12]. Nrg1 induces the formation of the ventricular conduction
system, a feature of ventricular maturation [29]. A third signaling pathway is
Bmp10 [8], expressed in trabecular myocardium and whose expression is severely
downregulated in Notch pathway mutants, suggesting that Notch is required to
produce a signal that activates Bmp10 in the myocardium [12]. During these early
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stages, the ligand Dll4 is the main Notch activator in the endocardium [12]
(Fig. 12.3).
To precisely determine the contribution of Notch ligands to ventricular chamber
development, we bred mice bearing a conditional allele ofMib1 with myocardium-
specific Cre driver line cTnT-Cre [19]. Histological examination at E16.5 revealed
thatMib1flox;cTnT-Cremutants had a dilated heart with a thin compact myocardium
and large, non-compacted trabeculae, protruding toward the ventricular lumen.
Morphological and functional analysis using echocardiography and cardiac mag-
netic resonance imaging (CMRI) showed prominent trabeculations, deep
intertrabecular recesses, and a significantly reduced ejection fraction in mutant
mice [22]. The hearts of these mice had a ratio of non-compacted to compacted
myocardium (non-compaction index, NC) of 2.0, a feature diagnostic of LVNC in
humans [11, 17]. These features are all strongly reminiscent of LVNC, establishing
Mib1flox;cTnT-Cre mice as the first animal model of LVNC [22]. Analysis of
chamber markers in E15.5 Mib1flox;cTnT-Cre mice revealed expansion of various
compact myocardium markers (Hey2, Tbx20 and n-myc) to the trabeculae and
Fig. 12.3 Proposed
mechanism of Notch function
in trabeculation. (a, b detail)
Dll4 activates Notch1 at the
base of the developing
trabeculae. N1ICD/RBPJK
activates EphrinB2(Efnb2)/
EphB4 signaling in the
endocardium, which in turn is
required for Nrg1 expression
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reduced expression of the trabecular markers Anf, Bmp10, and Cx40. These markers
were normally expressed at earlier stages, suggesting that maintenance of
trabecular maturation and patterning is impaired in Mib1flox;cTnT-Cre mutants.
Likewise, lost or reduced Hey1, Hey3, and EphrinB2 expression in the vessels of
the compact myocardium suggested that coronary artery development was defec-
tive. Proliferation analysis revealed increased proliferation of trabecular
cardiomyocytes in the hearts of E15.5 Mib1flox;cTnT-Cre embryos, suggesting
this as the cause of the enlarged, non-compacted trabeculae in these mutants.
RNA sequencing analysis of E14.5 Mib1flox;cTnT-Cre mutant ventricles identified
altered expression of 315 genes (132 upregulated and 183 downregulated). The
expression of genes involved in the differentiation of cardiac endothelium/endo-
cardium and cardiomyocytes and coronary vasculogenesis was altered. RNA-Seq
data also confirmed the in situ hybridization analysis and demonstrated that Mib1
inactivation in the myocardium disrupts the differentiation and maturation of
cardiac endothelial cells and cardiomyocytes. This may impact in turn the process
of ventricular maturation and compaction. Genetic ablation ofMib1 in the myocar-
dium thus leads to LVNC cardiomyopathy in mice by arresting ventricular
trabeculae maturation and compaction and increasing cardiomyocyte proliferation
during fetal development [22].
We next examined whether mutations in the human MIB1 homologue were
associated with clinical LVNC and identified two mutations in a cohort of
100 Southern European LVNC cases; one was a heterozygous G to T transversion
of nucleotide 2827 in exon 20 (causing a change in amino acid 943 from valine to
phenylalanine, the p.Val943Phe mutation). Val943 is located within a region that
mediates protein-protein interactions and constitutes the site of MIB1 ubiquitin
ligase activity. The second mutation was a heterozygous C to T transition of
nucleotide 1587 in MIB1 exon 11 (causing a premature stop codon instead of
arginine at position 530 in the MIB1 ankyrin repeats region, the p.Arg530X
mutation). These two mutations were tracked back through three and two
generations of LVNC-affected individuals, revealing co-segregation with LVNC,
confirming the hereditary nature of the disease [22].
In silico modeling suggested that MIB1 is a homodimer where the p.Val943Phe
mutant will alter the alignment of the ring finger domains in heterodimers formed
by wild-type and mutant p.Val943Phe MIB1, as well as the angle of interaction
with JAG1 of the p.Val943Phe wild-type dimers. This possibility was supported by
co-immunoprecipitation experiments with tagged wild-type MIB1 and mutant
MIB1 isoforms co-transfected in pair-wise combinations into HEK293 cells. The
effect of the MIB1 mutations on Jag1 ubiquitylation was tested also in HEK293
cells. Jag1 ubiquitylation was strongly reduced in cells co-transfected with wild-
type MIB1 plus p.Val934Phe or wild-type MIB1 plus the p.Arg530X mutant [22].
Lastly, to study the effect of these mutant MIB1 variants in vivo, their mRNAs
were microinjected into zebra fish embryos expressing GFP in the developing
myocardium. Examination of 72 hpf larvae injected with p.Val943Phe or p.
Arg530X mRNAs revealed severely disrupted embryonic development, disrupted
cardiac looping, and kinked tail, typical of defective Notch activity. To complement
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these findings, we cocultured Jag1-HEK293 cells expressing MIB1 variants with
Notch1-expressing HEK293 cells co-transfected with a Notch luciferase reporter.
Jag1-HEK293 cells expressing wild-type MIB1 increased Notch reporter activity,
whereas the p.Val934Phe and p.Arg530X mutant forms reduced reporter activity,
indicating that both human mutations disrupt Notch signaling [22].
Accumulated data suggested that both MIB1 mutations result in loss of MIB1
WT function. In the case of p.Arg530X, this would be due to haploinsufficiency
caused by insufficient synthesis of WT MIB1 protein; in the case of p.Val934Phe,
this would be due to a dominant-negative effect of the mutant protein, titrating
down the amount of functional WTMIB1 dimers through heterotypic or homotypic
interactions. In both cases, loss of MIB1 function leads to disease inherited in an
autosomal-dominant fashion.
As to the role of Mib1 in ventricular chamber development, we have proposed
that myocardial Mib1 activity enables Jag1-mediated activation of Notch1 in the
endocardium, to sustain trabeculae patterning, maturation, and compaction [22] and
(Fig. 12.4). Abrogation of Mib1-mediated signaling in the myocardium disrupts
trabeculae maturation and patterning, arresting the development of chamber myo-
cardium and resulting in LVNC (Fig. 12.4). The expansion of compact zone
markers to the trabeculae of E15.5 Mib1flox;cTnT-Cre mutants further suggests
that trabeculae patterning and maturation is impaired (Fig. 12.4). In addition, the
disruption of coronary vessel markers in Mib1flox;cTnT-Cre mutants indicates that
abrogation of myocardial-endocardial Notch signaling indirectly impairs coronary
vessel formation.
12.5 Future Directions and Clinical Implications
The data reviewed here establish the causal role of NOTCH dysregulation in
LVNC, a congenital cardiomyopathy that results from a developmental arrest in
ventricular maturation and myocardial compaction. These findings will lead to a
better diagnosis and risk stratification, allowing timely intervention in LVNC-
associated complications. In addition, since other NOTCH pathway elements may
be involved in LVNC, they could serve as novel diagnostic or therapeutic disease
targets. Further research is required to determine the molecular mechanisms and
regulatory interactions underlying NOTCH function in ventricular chamber devel-
opment using genetically modified mouse models and the full implication of altered
NOTCH signaling in human LVNC.
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Fig. 12.4 Proposed mechanism of Notch function in trabecular maturation and compaction. (a) In
wild-type (WT) embryos, ubiquitylation of Jag1 (and another ligand?) by Mib1 in the myocardium
allows Notch1 activation in the endocardium. N1ICD is required to sustain trabecular patterning,
maturation, and compaction. The compact myocardium (expressing Hey2, Tbx20 and n-myc)
proliferates actively, unlike the trabecular myocardium (expressing Anf, Bmp10 and Cx40).
Notch-dependent chamber maturation leads to compacted ventricular myocardium in the adult
mouse. (b) In Mib1flox; cTnT-Cre mutants, Notch1 activity is impaired and compact myocardium
markers (Hey2, Tbx20 and n-myc) are consequently expanded to the trabeculae, which remain
abnormally proliferative. The resulting disruption of trabecular patterning, maturation, and com-
paction manifests as LVNC (Modified from [22])
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The Epicardium in Ventricular Septation
During Evolution and Development 13
Robert E. Poelmann, Bjarke Jensen, Margot M. Bartelings,
Michael K. Richardson, and Adriana C. Gittenberger-de Groot
Abstract
The epicardium has several essential functions in development of cardiac archi-
tecture and differentiation of the myocardium in vertebrates. We uncovered a
novel function of the epicardium in species with partial or complete ventricular
septation including reptiles, birds and mammals. Most reptiles have a complex
ventricle with three cava, partially separated by the horizontal and vertical septa.
Crocodilians, birds and mammals, however, have completely separated left and
right ventricles, a clear example of convergent evolution. We have investigated
the mechanisms underlying epicardial involvement in septum formation in
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embryos. We find that the primitive ventricle of early embryos becomes septated
by folding and fusion of the anterior ventricular wall, trapping epicardium in its
core. This ‘folding septum’, as we propose to call it, develops in lizards, snakes
and turtles into the horizontal septum and, in the other taxa studied, into the
folding part of the interventricular septum. The vertical septum, indistinct in
most reptiles, arises in crocodilians and pythonids at the posterior ventricular
wall. It is homologous to the inlet septum in mammals and birds. Eventually, the
various septal components merge to form the completely septated heart. In our
attempt to discover homologies between the various septum components, we
draw perspectives to the development of ventricular septal defects in humans.
Keywords
Evolution and development • Homology • Ventricular septum • Congenital heart
disease • Epicardium
13.1 Introduction
Evolution of full division of the heart into left and right chambers by septa started
with the atrium in amphibians, followed by the ventricle in amniotes. Full ventric-
ular septation evolved independently in the lineages of the archosaurs, whose extant
representatives are the birds and crocodilians and mammals [1]. Not only is
evolution and development of ventricular septation of considerable biological
interest, it is also of clinical relevance to the understanding of many types of
ventricular septal defects in humans [2].
We demonstrated that part of the ventricular septum depends on interactions
between myocardium and the epicardium including the epicardium-derived cells
(EPDCs) for its development [3]. The septum will develop abnormally if the
epicardium is disturbed [4, 5]. Ventricular development, starting with a primitive
common ventricular tube, leading to separation into the left and right ventricle,
involves complex mechanisms including the ventricular inflow and outflow com-
partment [6, 7]. Most reptile groups show a more primitive pattern comprising a
horizontal and a vertical septum separating the ventricle into three interconnected
cavities. How the primitive reptilian pattern was modified into the complete septum
is a matter of debate. Here we report the functional role of the epicardium in
ventricular septation in lizard, snake, turtle, chicken, mouse and human using
descriptive and experimental approaches including quail-chicken chimeras by
transplantation of quail proepicardial organ into the pericardial cavity of chicken
[4]. Furthermore, epicardium-deficient animal models such as the podoplanin
knockout mouse and epicardial ablation experiments in chicken embryos were
investigated [4, 5]. With DiI labelling [8] of the myocardial surface in chicken
embryos, the outgrowth of the cardiac compartments was analysed. Tbx5 expres-
sion showed gradients along the cardiac tube and so may be a useful marker for
regionalisation of the heart [9]. For experimental details and full material and
method description, we refer to [10].
116 R.E. Poelmann et al.
13.2 Septum Components in the Completely Septated Heart
Varying terminology is used for components of the ventricular septum and their
respective boundaries; we adopted the following. The posterior component of the
interventricular septum, between the left and right atrioventricular junctions, is the
inlet septum. We propose to use the term ‘folding septum’ (newly defined here) for
the anterior component. The septal band is a muscular ridge on the right ventricular
septal surface between the inlet and folding septum, extending as the moderator
band towards the right ventricular free wall. In the completely septated heart, the
aortopulmonary septum is the last component that closes the interventricular
communication, but has not been specifically studied here.
13.3 The Presence of the Epicardium in Amniotes
Among other species we examined embryos of Macklot’s python (Liasis mackloti),
European pond turtle (Emys orbicularis) and Chinese soft-shell turtle (Pelodiscus
sinensis). The presence of epicardium on the outer face of the myocardial heart tube
is confirmed. A pronounced subepicardium in the inner curvature of the looping
heart tube at the site of the bulboventricular fold is confirmed, here referred to as
epicardial cushion, being almost as elaborate as the adjacent endocardial atrioven-
tricular and outflow tract cushions (Fig. 13.1a). In chicken (Fig. 13.2a, b) and mouse
embryos, the presence of the (sub)epicardium is less extensive compared to the
turtle. In human embryos at Carnegie stages, 11–15 (3.6–7 mm), the surface of the
heart is closely covered by the epicardial epithelium, whereas the inner curvature
harbours an extensive epicardial cushion (Fig. 13.1b) comparable to the turtle.
Fig 13.1 (a, b) Sections of turtle (Emys orbicularis) (a) and human embryo (b) of comparable
developmental stages showing the epicardial cushion (EC) in the inner curvature of the looping
heart tube. AVC atrioventricular cushion, OFT outflow tract cushion
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13.4 The Epicardium in the Avian Heart
To investigate the fate of the epicardium during ballooning of the ventricles and
subsequent folding of the septum, we constructed quail-chicken chimeras. An
isochronic quail proepicardial organ (PEO) including a small piece of adjacent
liver tissue to provide endothelial cells was transplanted into the pericardial cavity
of HH15–17 chick embryos in an anterior position. Antibody staining revealed that
quail EPDCs and endothelial cells were present in the anterior folding septum, but
not in the dorsal inlet septum (Fig. 13.3a, b). The quail epicardial sheet dispersed
into individual cells that became distributed between the cardiomyocytes in later
stages, mostly in the core of the folding septum. In a second set of chimeras, the
quail PEO was positioned more dorsally, providing for quail EPDCs and endothe-
lial cells on the posterior ventricular surface, subsequently migrating into the inlet
septum including the septal band, without crossing over to the anterior folding
septum. This indicates the inlet septum as a separate component. Furthermore, an
epicardial sheet, characteristic for the folding septum, was not encountered. As a
consequence, expansion of the ventricles results in anterior folding of the ventricu-
lar wall, but not of the posterior wall, probably because of the physical constraints
imposed by attachment of the heart to the dorsal body wall [10].
To study septum folding during ballooning of the ventricle, fluorescent DiI was
tattooed (HH15–17) onto the ventral myocardial surface and embryos were
sacrificed between HH22 and 33. DiI was applied on the surface of the future
fold and the dye fragmented during further development into a left-sided part,
incorporated into the left side of the folding septum and a right-sided part. This
Fig 13.2 (a) Chicken embryo stage 27 showing the start of the folding septum between OFT and
AVC, stained for the Wilm’s tumour antigen (WT1) marking the epicardium (brown). (b) Chicken
embryo stage 31 with an elaborate folding septum (FS) showing dispersed EPDCs (brown)
between the cardiomyocytes. LV left ventricle, RV right ventricle
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Fig 13.3 (a, b) Quail-chicken chimeras from the anterior position. The folding septum
(FS) harbours quail-derived endothelial cells stained with the QH1 antibody (brown), whereas
the inlet septum (IS) is virtually negative
Fig 13.4 Podoplanin wild type (a) and –/– mouse (b), embryonic day 12.5. Note the diminished
number of epicardial cells and EPDCs (brown in this WT1 staining) and the thin folding septum in
the mutant
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indicates a longitudinally directed morphogenetic expansion of the right ventricular
wall compared to a transverse expansion of the left ventricle. At stage 31 the dye
was completely embedded in the folding septum as a narrow fluorescent strip
(Fig. 13.5) markedly close to the right ventricular face of the septum, indicative
of a less elaborate right ventricular contribution to the septum [10].
13.5 Disturbance of the Epicardium
Deficient septation is known in several mouse mutants and we have analysed the
podoplanin mutant mouse. Podoplanin has multiple roles in the maintenance of the
epithelium and is expressed in the mesothelium of the body cavities including the
epicardium. The knockout mouse presents with an underdeveloped PEO and
abnormal epicardial covering resulting in only a few EPDCs [5]. The phenotype
shows multiple malformations including an atrioventricular septum defect. At
embryonic day 12.5, the myocardium and the folding septum are very thin, and
the inlet septum is spongy. The diminutive septum is nearly devoid of EPDCs
suggestive of an instructive role for these cells in septation (Fig. 13.4a, b).
Fig 13.5 DiI-labelled
chicken embryo stage 31 with
a thin strip of the dye in the
folding septum adjacent to the
right ventricular surface
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13.6 Septum Components in Reptilian Hearts
The horizontal septum of developing reptiles is found in comparable stages and
location, separating ventricular cavities and harbouring an epicardial sheet similar
to the folding septum in mammals and birds. We prefer to address this structure as
‘folding septum’. The presence and extent of the vertical septum (homologous to
inlet septum) differs among reptiles, being virtually absent in turtles and most
non-crocodilian reptiles, but more prominent in varanids and pythonidae [11]. In
the python myocardial apical trabeculations traverse the ventricle to partly separate
the cavum pulmonale from the cavum arteriosum.
13.7 Tbx5 Expression Patterns
The transcription factor Tbx5 is implicated in full ventricular septation in mammals
and is expressed strongly in the left part of the cardiac tube, with expression
declining towards the right side [9]; we confirmed this expression pattern also in
early stages of the copperhead rat snake, Coelognathus. Slightly later in the
development, we show that embryonic turtle and python show expression of
Tbx5 that declines at the folding septum, but not over the dorsal wall, where a
sharp decline was found only near the outflow tract. In the chicken the Tbx5mRNA
gradient identifies the right ventricle (weak expression) from the outflow tract
(negative expression). Furthermore, a Tbx5 decline is found at the folding septum
showing only strong left-sided expression, whereas Tbx5 expression is present on
both sides of the inlet septum including the septal band. Thus, in the chicken the
folding and inlet septa are differentially identified by Tbx5 gradients. In the mouse
two Tbx5 gradients identify the inlet and folding septum. Protein expression is
strongest in the trabeculations of the left ventricle, weaker in the right ventricular
inlet including septal band and weakest to negative in the right ventricular outflow.
13.8 Discussion
All amniotes exhibit a folding (horizontal) septum, and here we showed the
involvement of the epicardium in fusion of the two opposing myocardial walls. In
mammals and birds, the folding septum forms the anterior part of the definitive
septum. Reducing the size of the PEO leads to diminished or retarded covering of
the myocardium and diminished production of EPDCs [4, 5, 12]. The latter can
differentiate into smooth muscle cells of the coronary vessels and into perivascular
and interstitial fibroblasts [13]. It is evident that mechanical or genetic interference
with the epicardium or EPDCs not only disturbs coronary vascularisation but can
also strongly influence cardiomyocyte differentiation and ventricular septation.
Different septal components [6, 7] have been identified in the completely
septated hearts which have been the subject of continued debate also involving
exploration of the position of central muscular ventricular septal defects and the
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connection of the tricuspid valve tendinous cords related to either septal
components. It was generally agreed that the septal band belonged to the primary
septum being the anterior or, as we now refer to it, the folding component of the
septum, but we demonstrated that it belongs to the posterior inlet septum.We newly
identified the border between inlet and folding component using several criteria:
(1) the atrioventricular cushions connect to the inlet component including the septal
band; (2) the tip of the septal outflow tract cushion originates where the folding
septum merges with the inlet septum; (3) quail cells derived from posterior PEO
chimeras do not crossover from inlet septum including septal band to the folding
septum, and vice versa in anterior chimeras, there is no crossover from folding to
inlet septum; and (4) Tbx5 expression, in contrast to earlier publications [9, 14], is
strong on the left and right side of the posteriorly located inlet septum including the
septal band, whereas only left-sided positivity is found at the anterior folding
septum. From this we postulate that the avian and mammalian embryonic ventricle
(homologous to the cavum dorsale of reptiles, which is the cavum arteriosum and
venosum combined) give rise to both the left ventricle and the inlet of the right
ventricle. This is an indication that the inlet septum originates in its entirety from
the wall of the primitive ventricle, the cavum dorsale. In the right ventricle, the
boundary of the inlet septum is provided by the septal band, which is not present in
the left ventricle, leaving here the boundary between the inlet and folding septum
less well determined. Our new model for separating the ventricles implicates more
than one component and has consequences for understanding the development of
central muscular ventricular septal defects. (Note: The development of the mem-
branous and the outflow tract septum has not been specifically addressed in this
study) Interestingly, elephants and some relatives including seacows show a very
deep anterior interventricular sulcus [10]. The anatomy of the right ventricular
septal band and the attachment of the tricuspid chordae tendineae suggest a
diminished folding mechanism resulting in retention of an early embryonic state,
also known as neoteny.
In conclusion, we have explored an evo-devo context for the hitherto overlooked
role for the epicardium in septation and have clarified complex homologies in
amniotes of the ventricular septum to understand clinical disorders of the heart in
humans.
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S1P-S1p2 Signaling in Cardiac Precursor
Cells Migration 14
Hajime Fukui, Shigetomo Fukuhara, and Naoki Mochizuki
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During embryogenesis, zebra fish cardiac precursor cells (CPCs) originating from
anterior lateral plate mesoderm migrate toward the midline between the endoderm
and the yolk syncytial layer (YSL) to form cardiac tube. The endoderm functions as
a foothold for CPCs as evidenced by the endodermal mutants (cas/sox32, sox17,
oep, fau/gata5, and bon) showing two hearts (cardia bifida) [1]. Furthermore,
mutant zebra fish (toh) lacking sphingosine-1-phosphate (S1P) transporter which
is expressed in the YSL show two hearts [2], indicating the essential role for
S1P-mediated signal in cardiac development. This is also supported by a S1p2
receptor mutant (mil) which exhibits two hearts [3]. However, it is still unclear how
S1P released from YSL regulates CPC migration.
S1p2 is expressed in the endoderm. Thus, we assume that S1P released from the
YSL might activate S1p2 expressed in the endoderm, thereby regulating CPC
migration. One possibility is that S1p2-mediated signal controls the endoderm
formation as a foothold for CPCs. Another possibility is that endodermal cells
activated by S1p2 might secrete the chemokines which accelerate CPC migration or
secrete the extracellular matrix proteins for guiding CPC movement.
To test these possibilities, we need to delineate the downstream signaling of
S1p2. Recently, Gα13 is reported to inhibit Hippo-mediator Lats1/2 kinase through
a RhoGEF/Rho/Rho-kinase signaling [4, 5]. We demonstrate that the inhibition of
Hippo signaling in the endoderm by activated S1p2 is essential for endodermal cell
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survival and that the endoderm maintained by S1P signaling indeed becomes the
foothold for CPC migration (Fig. 14.1).
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Fig. 14.1 A model of
S1P-S1p2 signaling regulated
CPC migration. S1P secreted
from the yolk activates S1p2
in the endoderm. Hippo
signaling acts downstream of
S1P-S1p2 signaling and
maintains the endoderm to act
as scaffolds for CPC
migration
126 H. Fukui et al.
Myogenic Progenitor Cell Differentiation Is
Dependent on Modulation
of Mitochondrial Biogenesis through
Autophagy
15
Yoshimi Hiraumi, Chengqun Huang, Allen M. Andres, Ying Xiong,
Jennifer Ramil, and Roberta A. Gottlieb
Abstract
Over the last decade, stem/progenitor cell therapy has emerged as an innovative
approach to promote cardiac repair and regeneration. However, the therapeutic
prospects of are currently limited by inadequate means to regulate cell prolifer-
ation, homing, engraftment, and differentiation. Autophagy, a lysosome-
mediated degradation pathway for recycling organelles and protein aggregates,
is recognized as important for facilitating cell differentiation. Studies have
shown that induced pluripotent stem cells (iPCs), which exhibit a predominantly
glycolytic metabolism, shift toward oxidative mitochondrial metabolism as a
prerequisite for the formation of sarcomeres and differentiation into
cardiomyocytes. C2C12 myoblasts are a mouse-derived myogenic progenitor
cell line which can be induced to differentiate into myotubes. We hypothesize
that autophagy is essential in coordinating transcription factor activity and
metabolic reprogramming of mitochondria to support myocyte differentiation.
Keywords
Autophagy • Stem cell • Differentiation
C2C12 myoblasts were cultured in DMEM (10 % FBS) and induced to differentiate
into myotubes with DMEM (2 % horse serum) for 6 days. To disrupt autophagy,
cells were (1) transfected with 50 nM Atg5 siRNA for 8 h twice over a 48 h period
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or (2) treated with 10 nM bafilomycin A1 or vehicle control for a 3 h/day for the first
3 days of differentiation. GFP-LC3 adenovirus was employed to visualize
autophagy. Western blot and real-time qPCR were used to examine proteins and
transcripts of interest. We observed increased LC3-II levels and GFP-LC3 puncta
during the differentiation of C2C12 cells, suggesting the involvement of autophagy
in this process. Transient inhibition of autophagy during the early stages of differ-
entiation with either Atg5 siRNA or bafilomycin A1 interfered with myotube
formation and attenuated the upregulation of myogenic transcription factors
MyoD and myogenin. Differentiation was accompanied by an increase in PGC1α
mRNA, mitochondrial mass, and oxygen consumption, all of which were blocked
by disruption of autophagy. Autophagy coordinates transcription factor expression
and mitochondrial turnover essential for cell differentiation (Fig. 15.1).
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Fig. 15.1 Proposed mechanism for the role of autophagy in C2C12 cell differentiation.
Upregulation of PGC1α, MyoD, and myogenin is a hallmark of cell differentiation. Transcription
factor regulation by autophagy may affect mitochondrial turnover required for C2C12 cell
differentiation. Autophagy is essential for coordinating transcriptional regulation and mitochon-
drial dynamics to support the progression of cell differentiation
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The Role of the Thyroid in the Developing
Heart 16
Kazuhiro Maeda, Sachiko Miyagawa-Tomita, and Toshio Nakanishi
Keywords
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Congenital hypothyroidism (CH) is one of themost common diseases of the endocrine
system among newborns. Infants with CH have been reported to have a high fre-
quency of congenital cardiovascular malformations (CM), such as ventricular and
atrial septal defects [1]. Some studies have demonstrated that these cases were due to
gene mutations and neural crest abnormality. Infants with CH and CM have been
shown to have significantly lower T4 levels than those with isolated CH. However, the
role of thyroid hormone in the developing heart has not been reported. In this study,we
show the thyroid anlage in chick embryos by immunohistochemistry and follow the
expression of thyroid hormone receptor during heart development.
1. The thyroid anlage appeared close to the aortic sac at H/H 14 of chick embryos,
as determined by immunohistochemistry (Fig. 16.1a).
2. Avians have access to thyroid hormone long before the embryonic thyroid gland
starts to secrete hormones due to the hormone deposition in the yolk and egg
white [2].
3. We found that the expression of thyroid hormone receptors during embryonic
heart development was earlier than that reported previously published study
using RT-PCR (Fig. 16.1b) [3].
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These results suggest that thyroid hormone may contribute to the development of
the heart.
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Part IV
Valve Development and Diseases
Perspective
Roger R. Markwald
Cardiac valve diseases are common clinical problems that affect from 4 to 10 % of
the human population, increasing with age. For many valve problems, there are few
options other than surgery, adding to the more than 16,000 surgical cases occurring
each year. While surgical techniques continue to improve, the number of surgical
cases and associated mortality rates still continue to increase. Secondary
complications such as arrhythmias, heart failure, aortic dissection, myocardial
hypertrophy, and sudden cardiac death exacerbate primary effects upon blood
flow and hemodynamics, indicating the importance of identifying remedial
etiologies which remain poorly understood.
Discovery of mutations in patients with congenital heart defects or valve
diseases which display progressive (age related) forms of matrix degeneration
(e.g., a myxomatous or a calcification phenotype) is currently providing a useful
approach for uncovering mechanisms that impact heart valve development and
provide candidate targets for therapy. One example of this was the discovery in
2007 by Profs. Herve Le Marec and Jean-Jacques Schott (Nantes, France) of a point
mutation in patients with a non-syndromic form of mitral valve prolapse (MVP)
that is characterized by progressive, degenerative changes in the extracellular
matrix. The mutation occurred in the actin-binding region of a multifunctional
cytoskeletal protein, filamin A (FLNA). In mice models, loss of cytoskeletal
FLNA function revealed a similar phenotype to MVP resulting in hypertrophied
valves with reduced mechanical properties. Further studies indicated that
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downstream kinase pathways associated with increased canonical and noncanonical
TGFβ signaling were associated with the FLNA mutation. How this information
might be used to help patients with valve diseases like MVP is an opportunity for
basic scientists and clinicians to come together to achieve remedial therapies. In this
instance, the finding of altered TGFβ signaling in MVP patients evokes the question
of whether similar pharmacological approaches currently being used to treat
Marfan patients who also have elevated TGFβ signaling could be used to treat
patients with a myxomatous valve phenotype.
The FLNA gene is normally expressed in the mesenchymal progenitors of valve
or ventricular interstitial fibroblasts and is downregulated during neonatal life as
shown by Russell Norris and his colleagues (Developmental Dynamics 2010). This
has two important implications: (i) the roots of adult valve defects and diseases can
extend back into embryonic life and (ii) heart valve development does not end at
birth but is completed postnatally in neonatal life. The expression of the FLNA gene
only in mesenchyme progenitors of valve or ventricular fibroblasts points to yet
another important implication for valve development: lineage.
In addition to endothelial-derived, progenitor cells, extracardiac mesenchymal
cells of neural crest origin or epicardial origin migrate into the heart adding to the
mesenchymal population of future valve cells in the outflow track and AV inlets,
respectively. Why multiple lineages of progenitor cells are needed for
valvulogenesis, especially those derived from outside the heart, is an important
unresolved question in heart development and a subject touched upon by three
papers presented in Part IV. Dr. AndyWessels and his collaborators indicate in their
chapter that epicardial-derived cells specifically migrate into the lateral (future
parietal) AV cushions and uniquely contribute to the posterior leaflets of the left
and right AV valve. He then discusses the role of Bmp signaling, through the Bmp
receptor BmpR1A/Alk3, in regulating the migration of epicardial-derived cells or
EPDCs initially as an epithelial sheet under the endocardium of the AVmitral valve
and later as free cells within the matrix. In another paper presented in Part IV,
Dr. Scott Baldwin utilizes tissue-specific Cre lineage drivers in mice to differen-
tially assess whether Tie1 is expressed in the endocardium vs. the prevalvular
mesenchyme of the AV junction or outflow tract. Dr. Baldwin’s lineage-tracing
studies revealed that a non-cell autonomous form of cross talk occurs between the
endocardial epithelium and subjacent valve interstitial cells that affects the secre-
tion of extracellular matrix and the normal formation and the differential
remodeling of the valves of the AV junction and outflow tract in late gestation
and postnatal life. His work also provides in vivo support for the in vitro
observations presented in the chapter by Drs. Kei Inai and Yukiko Sugi and their
collaborators that valvular endocardial cells can regulate the migration and differ-
entiation of valve interstitial cells. Similarly, in another chapter in Part IV, Mizuta
et al. demonstrate that if Tmem100, a novel, endothelial-specific,membrane protein
that is a downstream of BMP9/BMP10-ALK1 signaling, is genetically deleted, the
resulting Tmem100 null embryos exhibit an atrioventricular defect. The authors
suggest that the atrioventricular septal defect is the result of disrupting an active
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dialogue or cross talk between the AV endocardial endothelial cells and the
subjacent AV prevalvular mesenchyme.
Whether this putative cross talk between endocardium and prevalvular mesen-
chyme involves the secretion of a paracrine signal into the extracellular matrix,
transport of developmental cues within membrane-enclosed exosomes
(or adherons) or direct cell contact (e.g., gap junctions) remains another important
developmental heart question to be resolved. The answer to this question could
provide more candidate targets for developing or engineering remedial therapies,
especially if the signal requires extracellular processing or specific receptors and
downstream signaling pathways.
Cross talk does not have to be unidirectional from the endocardium to the
mesenchyme but may also originate from the mesenchyme and induce changes in
the endocardium. One frequently suggested function for the EPDCs is that they
somehow signal the termination of the transformation of AV endothelial cells into
new valve progenitor mesenchyme. If correct, this could serve as a mechanism for
regulating the normal size or shape of lateral AV cushions and their future parietal
leaflets. Whether the neural crest plays a similar instructive “cross-talk” role in
determining the size, shape, or fate of the semilunar valves derived from the outflow
tract cushions also remains to be determined. Understanding how lineage and
“cross talk” may intersect to shape and model inlet and outlet valve development
is likely to be one of the more exciting and promising future directions for research
into the mechanisms of cardiac valvuloseptal morphogenesis. Already, there are
emerging clues and new insights that point to primary (non-motile) cilia as
specialized structures on the surfaces of embryonic epithelial and/or mesenchymal
cells that may potentially act as sites for sending or receiving developmental signals
between interactive cells.
Finally, valve development – be it AV or semilunar – is largely a story about the
extracellular matrix and the progenitor cells that normally differentiate into valve
interstitial fibroblasts. Like all fibroblasts, they can be “friend or foe.” During
normal development, they secrete a collagenous matrix which they organize and
compact into mature cusps and leaflets. In disease states, they may transdif-
ferentiate into myofibroblasts that secrete metalloproteinases and proteoglycans
that disrupt the matrix resulting in a myxomatous phenotype in the AV valves, or,
in the outflow tract, they may abnormally enter osteogenic lineages resulting in
calcified aortic valves. In her chapter, Dr. Katherine Yutzey and her colleagues
review positive and negative changes in the extracellular matrix that precede
normal or pathological remodeling and dissect some of the candidate transcrip-
tional regulatory mechanisms that regulate lineage progression and organization of
valve extracellular matrix.
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Atrioventricular Valve Abnormalities: From
Molecular Mechanisms Underlying




Malformation of the atrioventricular (AV) cushion is a common congenital heart
defect. Ebstein’s anomaly, characterized by a heart defect related to the AV
cushion, involves not only a valve defect but also a myocardial abnormality such
as Uhl’s anomaly. The morphogenetic features of the heart in the case of these
diseases can be used as a reference for investigating valvuloseptal and
myocardial formations in the human heart.
The AV endocardium transforms into the cushion mesenchyme through
epithelial–mesenchymal transition (EMT). After the EMT, distal outgrowth
and maturation of endocardial cushions are important morphogenetic steps for
AV valvuloseptal morphogenesis. While bone morphogenetic protein (BMP)-
2 is known to be critical for AV EMT, little is known about the functional
relationship between BMP and ECM and their roles in cushion mesenchymal
cell (CMC) migration after EMT. In our previous study, we showed that BMP-2
and BMP signaling induced AV CMC migration. We have been exploring the
role of BMP-2 in the regulation of valvulogenic extracellular matrix (ECM)
components, periostin, versican, and hyaluronic acid (HA), and cell migration
during post-EMT AV cushion expansion and maturation.
We further examined whether BMP-2-promoted cell migration is associated
with expression of periostin, versican, and HA. BMP-2-promoted cell migration
is significantly impaired by treatment with versican siRNA and HA oligomer.
We also found that transcription of Twist and Id1, implicated in cell migration in
embryogenesis and activation of the periostin promoter, was induced by BMP-2
but repressed by noggin in CMC cultures.
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Taken together, we provide evidence that BMP-2 induces expression and
deposition of three major ECM proteins, periostin, versican, and HA, and that
these ECM components contribute to BMP-2-induced CMC migration during
post-EMT AV cushion expansion and maturation.
Based on these findings, we discuss the morphogenetic process of AV valve
abnormalities and crosstalk between valve and cardiomyocytes morphogenesis.
Keywords
Bone morphogenetic protein (BMP) • Cardiac cushions • Periostin •
Extracellular matrix protein • Valvulogenesis
17.1 Introduction
Our institute houses a huge amount of congenital heart disease specimens, of which
approximately 4,000 are referred to as Prof. Ando’s collections, and the late
Dr. Ando, former professor at our department, wrote 30 books describing the
anatomical features of the specimens.
In one of the books, I read the following text at the edge of a page: “I think there
is a right ventricle (RV)–tricuspid valve (TV) dysplastic syndrome as a new clinical
entity, which comprises three abnormalities, Ebstein’s anomaly, Uhl’s anomaly,
and tricuspid absence.” This note can be likened to the one written by Fermat, on
the basis of which Fermat’s son Clément-Samuel deduced Fermat’s last theorem
(Fig. 17.1).
Tricuspid valve anomalies syndrome
Ebstein Disease
Uhl’s anomaly TV absence




anomaly and tricuspid valve
absence sometimes coexist in
a heart
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17.2 RV–TV Dysplastic Syndrome
17.2.1 Anatomic Features of the Heart in Ebstein’s Anomaly
Patients
Ebstein’s anomaly is a rare congenital cardiac disease in which the TV leaflets are
displaced to the right ventricular cavity, resulting in atrialization of the RV
[1]. Marked right atrial enlargement caused by severe tricuspid insufficiency,
cardiomegaly, and increased right atrial pressure; cyanosis caused by right–left
shunt by way of interatrial communication, if present; and right ventricular volume
overload are often observed. Figure 17.2 illustrates Ebstein’s anomaly with severe
TV insufficiency involving two-thirds of the RV.
17.2.2 Morphogenetic Features of the Heart in Patients with Uhl’s
Anomaly
In the case of patients with Ebstein’s anomaly, the RV of the heart often shows
partial or total loss of myocardium; in other words, the features of Ebstein’s
anomaly overlap those of Uhl’s anomaly. Uhl’s anomaly, a rare congenital heart
disease characterized by the absence of apical trabeculations in the right ventricular
cavity with a thin hypokinetic ventricular wall, was first described in 1952 [2]. In
Fig. 17.3, almost complete absence of the right ventricular myocardium, preserved
septum, and left ventricular myocardium is seen. These clinical and anatomic
findings strongly indicate that AV valve formation and ventricular myocardium
formation may play a role during cardiac morphogenesis.
RVOT
Fig. 17.2 Ebstein’s anomaly
with severe TV plastering
down into two thirds of right
ventricle (RV). The cushion
tissue plastered almost
throughout RV with a
something like plaster and it
looks very smooth surface
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17.2.3 Absence of the TV
Unguarded TV orifice is an unusual cardiac malformation that involves partial or
total agenesis of the TV tissue (absence of the TV). Kanjuh et al. described the
anatomic features of the heart in this disease: the wall of the RV is formed by
slightly trabeculated muscle and lined by thickened endocardium [3]; the free wall
of the RV is only 2 mm thick, and the ventricular septum is intact. In Fig. 17.4, the
specimen shows TV absence and partial loss of the right ventricular myocardium.
TV–RV dysplastic syndrome revealed the important link between TV morpho-
genesis and right ventricular myocardium formation during the biological process
of cardiac morphogenesis. Therefore, it is vital to determine the biological key
factors that link the myocardium and cushion tissue.
17.3 Bone Morphogenetic Proteins (BMPs) and Their Important
Role in Cushion Formation
17.3.1 Role of BMP2 in Cushion Mesenchymal Cell (CMC) Migration
Anomalies related to valvuloseptal formation are some of the most common
congenital heart anomalies. Two segments of the endocardium, the atrioventricular
(AV) and outflow tract (OT) endocardium, transform into the cushion mesen-
chyme—the primordia of the valves and membranous septa—through epithelial–
mesenchymal transformation (EMT). Transformed endocardial cells subsequently
migrate to the underlying extracellular matrix (ECM), called “cardiac jelly,” and
remodel the ECM into cardiac cushions [4]. Distal outgrowth and maturation of the




Fig. 17.3 Ebstein’s anomaly
with Uhl’s anomaly. Note the
complete absence of the right
ventricular myocardium and
preserved septal and left
ventricular myocardium
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BMP is a member of the TGF-ß superfamily proteins, one of many molecules
related to AV EMT. BMP signaling was found to be crucial for AV EMT in studies
involving explant cultures in mice and chicks and BMP-2 conditional knockout
(CKO) experiments in mice [5]. BMP-2 conditional KO at the EMT stage, however,
causes subsequent lethality, thereby hindering the examination of the role of
BMP-2 in post-EMT valve formation. BMPs bind to the cell surface of BMP
receptors (BMPRs)—Type I and Type II receptors. Type II receptors transpho-
sphorylate the glycine–serine-rich domain of Type I receptors and transduce intra-
cellular signals. The Type II BMP receptor, BMPRII, is reported to be expressed
ubiquitously throughout the embryonic period [6].
We previously showed the expression patterns of Type I BMPRs by localizing
BMPR-1A (ALK3), BMPR-1B (ALK6), and ALK2 in the post-EMT AV cushion
mesenchyme in a chick. These findings indicate that BMP signaling regulates the
biological processes necessary for distal outgrowth and maturation of post-EMT
cushion mesenchyme during early valvulogenesis [4].
17.3.2 BMP2 Induces CMC Migration and Id and Twist Expression
BMP-2 is localized in the AV cushion mesenchyme during post-EMT valve forma-
tion, suggesting autocrine signaling by BMP-2 in CMCs during post-EMT valve
formation. Therefore, to determine the roles of BMP-2 and BMP signaling in
post-EMT AV CMCs, we established a hanging-drop culture system and spatiotem-
poral viral gene-transfer technique using chick AV CMC cultures both in vitro and
RA
Hypoplastic RV
Fig. 17.4 Ebstein’s anomaly with tricuspid valve absence and Uhl’s anomaly. Unguarded
tricuspid valve orifice and partial absence of the right ventricular myocardium concomitant with
Ebstein’s anomaly. Note the absence of the rudimentum of the tricuspid valve and tension
apparatus
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whole embryo cultures in vivo (ovo) [5]. Although most BMP receptors have ligand-
binding affinity with other TGF-ß superfamily proteins, BMPR-1A and BMPR-1B
bind specifically with BMP-2 and BMP-4 (bind with BMP-7 at low affinity) but do
not bind with other TGF-ß superfamily proteins. We showed that dnBMPR-1B
infection as well as treatment with a BMP antagonist, noggin, significantly inhibited
endogenous phospho-Smad 1/5/8 expression in AV CMCs, indicating that intracel-
lular BMP signaling in the CMCs is effectively inhibited by treatment with dnBMPR-
1B or noggin. On the other hand, BMP-2 or caBMPR-1B-virus treatment induced






Fig. 17.5 AV cushions were microinjected with caBMPR-1B virus (a) or dnBMPR-1B virus.
Cushion mesenchyme microinjected with dnBMPR-1B virus showed a significant decrease in
periostin immunostaining (red colour in b). Conversely, infection with caBMPR-1B virus showed
significant increase periostin expression in cushion mesencyme (red colour in a). High magnifica-
tion view of virus-infected cushion mesenchyme (c and d). In the caBMPR-1B infected cushion,
there was extensive overlapping of viral marker expression (green) and periostin expression (red)
(yellow arrows in c). Although periostin staining (red) was detected in the dnBMPR-1B infected
cushion, there was little overlapping of periostin expression (red) and viral marker expression
(green arrows in d)
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effectively intensified by BMP-2 or caBMPR-1B. Based on these findings, it can be
said that the effects of dnBMPR-1B treatment on CMC migration and phosphor-
Smad1/5/8 expression are as profound as the effects of noggin treatment. Moreover,
caBMPR-1B treatment enhances CMC migration as much as BMP2 treatment does
(Fig. 17.5). These facts strongly suggest that BMP signaling plays an important role
in mesenchymal cell migration after EMT.We also showed that expressions of Id and
Twist-1, which are important transcriptional factors involved in cell migration, are
enhanced by BMP signaling [4].
17.3.3 BMP2 Induces Expression of ECM Proteins in the Post-EMT
Cushion
We showed the expression patterns of three major ECM components, periostin,
versican, and hyaluronic acid (HA), during AV cushion expansion and maturation.
We also elucidated the role of BMP2 in the production of periostin, versican, and
HA. Using a well-defined 3D CMC aggregate by hanging-drop culture on hydrated
collagen gels, we found that BMP2 induces production of periostin, versican, and
HA and that these ECM components contribute to BMP2-supported CMC migra-
tion during post-EMT cushion expansion and maturation [7].
Taken together, BMP signaling plays a critical role for AV cushion formation
and AV valve maturation.
17.4 The Role of BMP2 for Cardiomyocytes Formation
It is well known that the BMP signaling pathway plays a central role in
cardiomyogenesis [8–10]. In the past, it was found that administration of BMP-2
counteracts apoptosis of neonatal cardiomyocytes in culture, induced by serum
starvation [9]. Moreover, BMP10 expression is restricted to cardiomyocytes in the
developing and postnatal heart. Ligands of BMP10 have specificity for ALK1,
ALK6, and BMPR2 receptors. Global disruption of BMP10 is embryonic lethal
with severely impaired cardiomyocyte proliferative capacity [11]. BMP2 and
BMP10 appear to control cardiomyocyte differentiation through activation of
transcription factors NKX2.5, MEF2C, and TBX20 [12].
Chakraborty et al. reported that cardiomyocyte-specific Tbx20 overexpression
beginning in the fetal period is sufficient for promoting cardiomyocyte
proliferation [12].
Therefore, BMP signaling plays special role in linking AV cushion and
cardiomyocyte formation.
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17.5 Future Direction
At present, many aspects of the molecular mechanisms underlying RV–TV dys-
plastic syndrome remain to be elucidated. To fully describe the morphogenetic
mechanisms underlying TV–RV dysplastic syndrome, we need to determine the
molecular mechanisms underlying the interaction between TV and RV myocar-
dium through BMP signaling. Moreover, we need to outline the steps involved in
cardiac valve and myocardium morphogenesis.
What is the next target molecule? Here, I would like to discuss about the
potential of the “Notch” signaling pathway. The Notch signaling pathway plays
multiple roles in cardiac morphogenesis, including regulation of valve formation,
outflow tract development, and cardiac chamber maturation [13]. Notch activation
is upstream of ephrin- and neuregulin-based modulation of trabeculation and
BMP-2 and BMP-10 modulation of cardiomyocyte proliferation. Consistent with
the involvement of Notch signaling in multiple aspects of cardiac development,
components of the Notch pathway show dynamic spatial and temporal expression
patterns in the developing vertebrate heart, and both endocardial and myocardial
expression have been observed. Furthermore, the cross reaction between NOTCH
and BMP signaling is a well-known fact [14]. Therefore, understanding the com-
plicity of these signaling pathways is imperative for elucidating the relationship
between cardiac valve and myocardium formation.
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Molecular Mechanisms of Heart Valve
Development and Disease 18
M. Victoria Gomez Stallons, Elaine E. Wirrig-Schwendeman, Ming
Fang, Jonathan D. Cheek, Christina M. Alfieri, Robert B. Hinton,
and Katherine E. Yutzey
Abstract
The mature heart valves consist of stratified extracellular matrix (ECM) layers,
and heart valve disease is characterized by ECM dysregulation and mineraliza-
tion. There is increasing evidence that regulatory pathways that control heart
valve development also are active in disease. In human diseased valves and
mouse models, the expression of valve progenitor markers, including Twist1,
Msx1/2 and Snail1/2, is induced. Additional markers of osteogenesis, including
Runx2, osteocalcin and bone sialoprotein, also are expressed in calcific aortic
valve disease (CAVD) in humans and mice. New mouse models have been
developed for studies of valve disease mechanisms. Klotho-null mice are a
model for premature aging and exhibit calcified nodules in aortic valves with
osteogenic gene induction. Osteogenesis Imperfecta mice, bearing a collagen1a2
mutation, develop features of myxomatous valve disease, including thickening,
increased proteoglycan deposition and chondrogenic gene induction. Together,
these findings demonstrate specific molecular indicators of valve disease pro-
gression, including the identification of early disease markers, which represent
potential targets for therapeutic intervention.
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The semilunar and atrioventricular (AV) valves of the heart are made up of highly
organized extracellular matrix (ECM) layers populated by quiescent valve intersti-
tial cells (VICs) [1]. In healthy valves, the ECM is compartmentalized into layers
composed of collagens, proteoglycans, and elastin, which are maintained by the
VICs for proper valve function throughout life (Reviewed in [2]). In diseased
valves, the leaflets are thickened as a result of ECM dysregulation and VIC
activation. Calcific aortic valve disease (CAVD) includes calcification of the
cusps [3], whereas mitral valve prolapse (MVP) is accompanied by increased
proteoglycans and myxomatous changes in the leaflets [4]. Currently, the standard
treatment for severe heart valve disease is surgical replacement, and new therapies
based on molecular mechanisms are needed.
Molecular mechanisms associated with heart valve disease include activation of
signaling pathways involved in progenitor specification, cell proliferation, and
differentiation of heart valve and bone precursors [5, 6]. We have reported that
pediatric and adult diseased valves are characterized by expression of markers of
valve mesenchymal and chondrogenic progenitor cells, while adult diseased aortic
valves express markers of osteogenic calcification [7]. We also have identified
novel mouse models of calcific and myxomatous valve disease [8] that will be
useful in determination of the underlying mechanisms driving disease and in
development of pharmacologic-based therapies.
18.2 Heart Valve Development
Heart valve development in vertebrate embryos begins with the formation of
endocardial cushions in the AV canal and outflow tract of the primitive heart tube
[5]. The mesenchymal cells of the endocardial cushions originate from the endo-
cardium after an endothelial-to-mesenchymal transition (EMT). Valve progenitors
are highly proliferative and migratory and express transcription factors Twist1,
Tbx20, Sox9, Msx1/2, and Snai1. The endocardial cushion cells diversify into
lineages that express distinct ECM profiles regulated by BMP and FGF signaling
[9]. Wnt/β-catenin signaling also is active during endocardial cushion maturation,
but the specific role for this pathway in valve lineage differentiation is yet to be
determined [10]. Valve development continues with the remodeling of the endo-
cardial cushions into thin elongated leaflets composed of stratified ECM, which
occurs soon after birth in mice and humans [2]. The ECM layers consist of the
collagen-rich fibrosa, proteoglycan-rich spongiosa, and elastin-rich atrialis/
ventricularis [2]. These layers are oriented in the semilunar and AV valves with
the elastin layer adjacent to blood flow. While it is likely that hemodynamics has a
role in leaflet stratification, the regulatory pathways that control ECM organization
and compartmentalization during valve maturation are largely unknown.
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18.3 Heart Valve Disease
Heart valve disease can result from congenital malformation or gene mutations, or
it may be acquired later in life [1]. The prevalence of heart valve disease increases
significantly with age, such that ~10 % of people >75 years old have moderate
aortic or mitral valve disease [11]. However, the pathogenic mechanisms that drive
the development of heart valve disease and that could serve as potential therapeutic
targets are not well understood. There is increasing evidence that regulatory
pathways that control heart valve and bone development also are active in disease.
However, the roles of these pathways in valve pathogenesis and/or repair are not
well defined.
18.3.1 Calcific Aortic Valve Disease (CAVD)
CAVD is a progressive disease, initially presenting with aortic valve (AoV)
thickening (sclerosis) and resulting in valve stenosis and insufficiency later in life
[12]. End-stage disease is characterized by the presence of calcific nodules at the
hinge region of the AoV, underlying the pathology of CAVD [3]. In an effort to
draw parallels between the progression of disease and the underlying molecular
mechanisms, pediatric and adult diseased AoV were analyzed for markers of valve
development and endochondral bone formation [7]. Activated VICs in both pediat-
ric and adult valves have increased expression of valvulogenic markers Twist1,
Msx2, and Sox9. Strikingly, the formation of calcific nodules was found to be an
exclusive feature of adult calcified AoV. Furthermore, phosphorylation of Smads1/
5/8, indicative of active BMP signaling, in addition to expression of osteogenic
genes, such as Runx2, was observed only in adult calcified AoV. These findings
demonstrate that both pediatric and adult diseased AoV express valvulogenic
markers, while adult calcified AoV also express markers of osteogenic calcification.
Differential expression of these markers suggests that an osteogenic regulatory
mechanism contributes specifically to CAVD.
The incidence of human CAVD strongly correlates with aging, which is an
independent risk factor for AoV disease. We have recently identified Klotho-/- mice,
a model of premature aging, as a novel mouse model of CAVD [8]. Notably,
Klotho-/- mice develop calcific nodules at the hinge region of the fibrosa side of
the AoV (Fig. 18.1a, b), similar to human CAVD. In these mice, calcification occurs
independent of inflammation and cusp thickening, providing initial evidence for a
valve-intrinsic molecular mechanism for age-related calcification common in
elderly patients. Klotho-/- AoV have increased expression of osteogenic factors
Runx2 andOsteopontin, in addition to increased expression of chondrogenic factors
Sox9 and Col10a1, consistent with an osteochondrogenic-like mechanism of dis-
ease (Fig. 18.1e). Increased activation of pSmad1/5/8 also precedes calcification in
the Klotho-/- mice, and inhibition of BMP signaling represents an attractive new
therapeutic approach for CAVD.
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Fig. 18.1 Valvulogenic, chondrogenic, and osteogenic programs are induced in mouse models of
calcific (Klotho-/-) and myxomatous (Oim/Oim) valve disease. Klotho-/- mice (b) exhibit AoV
nodular calcification (arrows), as compared to wild-type littermate controls (a) at 6 weeks of age,
as detected by von Kossa staining. Oim/Oim AoV cusps (d) exhibit distal thickening and increased
proteoglycan deposition (aqua, arrows), compared to WT littermates (c) at 9 months of age as
observed by Movat’s pentachrome staining. Expression of genes involved in valvulogenesis,
chondrogenesis, and osteogenesis was examined by qRT-PCR of RNA isolated from Klotho-/-
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18.3.2 Myxomatous Valve Disease
The most common cause of MVP is myxomatous valve disease, which is defined by
pathological thickening of the valve leaflets, primarily due to accumulation of
proteoglycans [4]. This is accompanied by alterations in the distribution of ECM
components, such as disrupted collagen fiber organization and elastic fiber frag-
mentation. The pathogenesis of MVP is not well understood; however, MVP is
often linked to connective tissue disorders or specific mutations in ECM genes,
supporting the concept that defects originating during valve development could
underlie adult disease.
While myxomatous disease most commonly affects the mitral valves, myxoid
AoV have been reported. Osteogenesis imperfecta murine (Oim) have a spontane-
ous mutation in the Col1a2 gene and display bone fragility characteristic of human
osteogenesis imperfecta (OI) [13]. Interestingly, humans with OI or Col1a2
mutations have a predisposition to AoV disease [14]. Likewise, the AoV of Oim/
Oim mice exhibit distal cusp thickening and increased proteoglycan accumulation,
characteristic of myxomatous valve disease (Fig. 18.1c, d) [8]. Furthermore, the
Oim/Oim mice have increased expression of valve progenitor markers Twist1,
Col2a1, Mmp13, Sox9, and Hapln1, in addition to increased Col10a1 and Asporin
expression (Fig. 18.1e). These changes in gene expression are consistent with
increased proteoglycan accumulation and cartilage gene induction, which are key
features of myxomatous disease.
18.4 Signaling Pathways in Heart Valve Development
and Disease
Similar to heart valve and bone development, studies of human explanted valves
implicate BMP, Notch, and Wnt signaling pathways in the progression of CAVD.
Thus, heart valve disease shares signaling networks with valve and bone develop-
mental pathways. Together, these studies demonstrate that activation of both BMP
and Wnt signaling correlates with progression of CAVD [15, 16]. On the other
hand, loss-of-function mutations in NOTCH1 are associated with bicuspid aortic
valve (BAV) and CAVD, in humans and mice, suggesting an inhibitory function for
the Notch pathway in valve calcification [17]. Human genetic conditions including
Marfan syndrome and Loeys-Dietz syndrome lead to myxomatous mitral valve
disease and are associated with increased TGF-β signaling [18, 19]. However, the
specific mechanisms by which these different pathways contribute to the develop-
ment and progression of heart valve disease remain unknown.

Fig. 18.1 (continued) and Oim/Oim mice aortic valves relative to wild-type littermate controls
(e). Normalized values are shown as average fold changes compared to wild-type group set at 1.0.
* is p-value 0.05 calculated by paired student’s t-test
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18.5 Future Directions and Clinical Implications
Klotho-/- and Oim/Oim mice are novel mouse models of CAVD and myxomatous
valve disease that will be useful for determination of the underlying pathogenic
mechanisms driving valve disease. Understanding how signaling networks contrib-
ute to disease will likely have a significant impact on clinical outcomes, since
knowledge gained from these studies will allow for the development and design of
new drugs/treatments for patients with valve disease.
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A Novel Role for Endocardium in Perinatal
Valve Development: Lessons Learned from
Tissue-Specific Gene Deletion of the Tie1
Receptor Tyrosine Kinase
19
Xianghu Qu and H. Scott Baldwin
Abstract
The mechanisms regulating late-gestational and early postnatal semilunar valve
remodeling and maturation are poorly understood. Tie1 is a receptor tyrosine
kinase with broad expression in embryonic endothelium. During semilunar valve
development, Tie1 expression becomes restricted to the turbulent, arterial
surfaces of the valves in the perinatal period. Previous studies in our laboratory
have demonstrated that Tie1 can regulate cellular responses to blood flow and
shear stress. We hypothesized that Tie1 signaling would regulate the flow-
dependent remodeling of the semilunar valves associated with the conversion
from maternal/placental to independent neonatal circulation. To circumvent the
embryonic lethality of the Tie1 null mutation, we developed a floxed Tie1 allele
and crossed it with an Nfactc1enCre line that mediates gene excision exclusively
in the endocardial cushion endothelium. Excision of Tie1 resulted in aortic valve
leaflets displaying hypertrophy with perturbed matrix deposition. The valves
demonstrated insufficiency and stenosis by ultrasound, and atomic force micros-
copy documented decreased stiffness in the mutant aortic valve consistent with
an increased glycosaminoglycan to collagen ratio. These data suggest that active
endocardial to mesenchymal signaling, at least partially mediated by Tie1, is
uniquely required for normal remodeling of the aortic but not pulmonary valve
in the late gestation and postnatal animal.
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19.1 Introduction
Cardiovascular defects are the most common congenital abnormality in the human
population, affecting approximately 1 out of every 100 live births worldwide
[1]. Defects in valve development account for 25–30 % of these malformations.
Therefore, there is significant interest in understanding the mechanisms that under-
lie the complex process of heart valve development. During heart valve formation,
a subset of endothelial cells overlying the future valve site are specified to delami-
nate, differentiate, and migrate into the cardiac jelly, a process referred to as
endothelial-mesenchymal transformation or transdifferentiation (EMT). Locally
expanded swellings of cardiac jelly and mesenchymal cells are referred to as
cardiac cushions. In a poorly understood process, these cardiac cushions undergo
extensive remodeling from bulbous swellings to eventual thinly tapered heart valve
leaflets [2]. Numerous studies have focused on identifying the major regulators of
valve development using murine and avian embryos and have particularly focused
on the early stages of valve development; however, the pathways regulating the
final events of remodeling and maturation have not been well defined.
The orphan receptor tyrosine kinase Tie1 is primarily expressed in endothelial
cells and is closely related to Tie2, the receptor for the angiopoietins. Both Tie1 and
Tie2 are essential for developmental vascularization where they appear to have
roles in promoting microvessel maturation and stability. Targeted disruption of
Tie1 gene in mice results in a lethal phenotype between E14.5 and P0 characterized
by extensive edema, hemorrhage, and defective microvessel integrity [3–5]. Expres-
sion of Tie1 is first detected in the endothelium of mice at E8.0, and by E12.5, Tie1
is robustly expressed in the valvular endothelium, vasculature, heart, and lungs [6–
9]. Tie1 expression subsides in the postnatal period, although low levels of Tie1
persist into adulthood on the arterial side of the valve leaflet as well as branch points
of the descending aorta [10]. Thus, Tie1 is expressed in the vasculature, valves, and
other endothelial cell populations in the developing heart during critical periods of
valve morphogenesis. However, its potential roles in heart valve development are
totally unknown. Here, using a conditional knockout mouse model, we show that
lack of Tie1 in endocardial cells leads to hypertrophic semilunar valves in the
postnatal and adult heart.
19.2 Model for Valvar Endocardial-Specific Gene Deletion
To specifically determine the potential role of Tie1 in valve morphogenesis, we
have developed a novel valve endocardial cell-specific Cre mouse line
(Nfatc1enCre). We previously identified a transcriptional enhancer that regulates
the sustained expression of Nfatc1 exclusively in the endocardium overlying the
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endocardial cushions [11]. We then utilized this enhancer to develop a transgenic
mouse line, Nfactc1enCre, which has recently been described by our lab [12]. To
determine the utility and efficiency of this model for deletion at latter stages of
cardiac development, we have analyzed Cre expression in the developing valves by
lacZ staining and qRT-PCR of Nfactc1enCre transgenic mice bred with R26R
reporter mice (Fig. 19.1a–d). lacZ staining confirmed that Cre activation is first
detected at E9.5 in the developing AVC region and in OFT region by E10.5 (data
not shown). Cre activation is localized to endocardial cushion endocardium of the
outflow track at E12.5 and at E14.5 (Fig. 19.1a, b) and remains restricted to the
endocardium of overlying the developing valves throughout gestation into the
perinatal period (Fig. 19.1c) and in the adult (data not shown). To determine the
utility of Nfactc1enCre for tissue-specific deletion, we crossed these mice with our
mice harboring a floxed Tie1 allele previously described [5]. When Tie1 expression
as determined by QT-PCR was normalized to expression detected in the adult
animal, we observed the normal attenuation of Tie1 previously described by our
group [5]. In addition we observed significant attenuation of Tie1 expression as a
result of Cre-mediated deletion in the heart that was not detected in other vascular
beds (data not shown). Thus our Cre transgenic line Nfactc1enCre mediates loxP
excision exclusively in the endocardium overlying the endocardial cushions and not
in mesenchyme derived from EMT or other endothelial populations.
19.3 Tie1 Is Required for Late-Gestational and Early Postnatal
Aortic Valve Remodeling
To investigate the potential role of Tie1 in valve morphogenesis, we generated
endocardial-specific Tie1 knockout (Tie1fl/lz;Nfactc1enCre) mice by breeding mice
homozygous for a floxed Tie1 allele [5] with mice heterozygous for a null mutation
in Tie1fl/lz (Tie1þ/lz is a “knock-in”/knockout” insertion of lacZ into the Tie 1 locus
[3]) as well as the Nfactc1enCre transgene. Analysis of timed matings revealed that
no embryos died in utero during early gestation. However, within a few days after
birth, Tie1fl/lz;Nfactc1enCre pups could be distinguished from Tie1fl/fl or Tie1fl/lz
littermates as the mutants were often growth retarded (Fig. 19.2) and lethargic, both
of which are characteristics of human patients with heart defects. Most of mutants
did not survive to adulthood. Histological analysis revealed no significant
differences in valve formation between mutants and littermates until E16.5
(Fig. 19.3a, b), indicating early events of valvulogenesis occur normally in Tie1
mutant mice. However, an increase in semilunar valve size was noted in Tie1fl/lz;
Nfactc1enCre mice from E18.5 (Fig. 19.3c, d) and early perinatal periods with the
discrepancy in valve size continuing into the adult (Fig. 19.3e, f). Interestingly, the
valve abnormalities were not only limited to the late gestation and postnatal period,
but they were also primarily only detected in the aortic valves. The aortic valve
areas of adult Tie1fl/lz;Nfactc1enCremice were nearly twice as large as Tie1fl/fl aortic
valves (increased by 88.3 %). The pulmonary valves of Tie1fl/lz;Nfactc1enCre mice
were somewhat thicker than the controls, but the difference was not significant.
There were no differences in cell proliferation or apoptosis between mutant mice













Fig. 19.1 Nfactc1enCre mediates loxP excision exclusively in the valvular endocardium. (a)
Schematic of breeding of Nfatc1enCre and R26fslz mice. X-gal staining of R26fslz;Nfactc1enCre
heart sections shows that expression of the Cre is restricted to the endothelium of the developing
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and littermates suggesting a difference in extracellular matrix (ECM) composition
or production. Consistent with this, Movat’s pentachrome stain revealed an increase
in proteoglycan/glycosaminoglycan (GAGs) production and/or degradation in the
valve interstitium of postnatal Tie1fl/lz;Nfactc1enCre mice. As compared to Tie1fl/fl,
GAGs content (Fig. 19.3e, f) was increased and total collagen content (data not
shown) was decreased in aortic valve leaflets of Tie1fl/lz;Nfactc1enCre animals.
Thus, attenuation of Tie1 results in severe abnormalities in ECM remodeling that
are characteristic of critical events in late gestation and postnatal valve develop-
ment in chicken, mouse, and humans [13, 14]. This work suggests that there is a
non-cell autonomous defect that results from endocardial-specific Tie1 deletion as
the ECM is produced primarily from the valvular interstitial cells (VICS), not the
endocardium. This work also provides in vivo support for the in vitro observations
that valvular endocardial cells regulate the phenotype of VICS. In addition, Tie1
mutant aortic valves demonstrated a decrease in rigidity as measured by atomic
force microscopy and valvular insufficiency, as determined by high-resolution
ultrasound (data not shown).
19.4 Future Directions
This study describes a unique dosage-dependant role for Tie1 during later stages of
valve remodeling. Tie1 is essential for valve remodeling, and abnormalities within
late-gestational valve remodeling lead to flaccid valve leaflets, which in turn do not
function correctly in the animal. It is likely that the mortality observed in Tie1fl/lz;
Nfactc1enCre mice can be attributed to aortic insufficiency and ultimate heart
failure. However, the mechanisms regulating late-gestational and early postnatal
semilunar valve remodeling and maturation are still poorly understood.

Fig. 19.1 (continued) valves (arrowhead) at E14.5 (b, c) and at P0 (d), and weak lacZ expression
remains in the majority of the valvular endothelial cells through adulthood (d). HSP68 indicates





smaller than the controls
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Tie1, although a close sequence homologue of Tie2, does not interact directly
with the angiopoietins, and its in vivo ligands are yet to be identified. Nevertheless,
growing reports based on in vitro studies suggest that a primary function of Tie1
might be to modulate Tie2 signaling and function [15–17]. Furthermore, both Tie1
and Tie2 are co-expressed in endocardial cells from very early endocardial cushion
stage to the mature valve stage. So, we hypothesize that Tie1 signals independent of
Tie2 and also acts an inhibitory co-receptor for Tie2 activation. Further investiga-
tion on this project using double (Tie1 and Tie2) conditional knockouts is currently
on the way. Additional animal models are being developed to characterize the
mechanism of Tie1-Tie2 interactions in modulating critical events in cardiac
ontogeny in vivo, and expression profiling is being implemented to delineate
A








Fig. 19.3 Tie1 attenuation leads to enlarged aortic valves and abnormal ECM deposition and
organization. H&E-stained sections of valves of Tie1fl/fl and Tie1fl/lz;Nfactc1enCre mice at E16.5
(a, b) and at E18.5 (c, d). Compared to Tie1fl/fl mice, Tie1fl/lz;Nfactc1enCre mice have enlarged
aortic valves. Movat’s pentachrome stain shows enlarged aortic valves with increased GAGs
deposition (blue) in adult (9 weeks) Tie1fl/lz;Nfactc1enCre mice (f) as compared to the controls (e).
Arrows indicate valve leaflets. Scale bars: 50 μm
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downstream signaling cascades that are activated by Tie1 and Tie1-Tie2
interactions. These studies will be essential for understanding the role of the
endocardium in modulation valve matrix deposition and remodeling in an effort
to unravel basic mechanisms of congenital heart disease.
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The Role of the Epicardium
in the Formation of the Cardiac Valves
in the Mouse
20
Marie M. Lockhart, Maurice van den Hoff, and Andy Wessels
Abstract
In recent years, insights into the role of the epicardium in cardiac development
have significantly changed. An important contribution to this increasing knowl-
edge comes from the availability of mouse models that facilitate the study of the
fate of the epicardial cell lineage and that allow epicardial-specific manipulation
of expression of genes involved in regulation of epicardial cell behavior. In this
contribution we will discuss our growing understanding of the role of the
epicardium and epicardially derived cells in the formation of the atrioventricular
valve leaflets. We will illustrate how epicardially derived cells specifically
contribute to the development of the leaflets that derive from the lateral atrio-
ventricular cushions, and we will discuss the role of Bmp signaling, through the
Bmp receptor BmpR1A/Alk3, in the regulation of the preferentially migration of
EPDCs into the parietal AV valve leaflets.
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20.1.1 The AV Valves and Their Leaflets
The atrioventricular (AV) valves are important cardiac components that, when
properly formed, prevent the retrograde flow of blood through the AV junction
during ventricular systole. The precursor tissues of the AV valves are the endocar-
dial AV cushions, formed by (1) the accumulation of cardiac jelly in the AV canal
followed by (2) the population of these cushions by endocardially derived cells
(ENDCs) resulting from an endocardial epithelial-to-mesenchymal transformation
(or endoEMT) [1]. Not all AV cushions develop at the same time. The two “major”
AV cushions (the inferior and superior cushion) form first, while the two “lateral”
cushions form later [2, 3]. The major AV cushions will eventually fuse together.
They will also fuse with the mesenchymal cap of the primary atrial septum and the
dorsal mesenchymal protrusion (DMP) to form the AV mesenchymal complex
[4]. This process is essential in the partition of the left and right atrial and
ventricular components. The AV mesenchymal complex is also involved in the
formation of the septal leaflet of the right AV valve and the aortic (or anterior)
leaflet of the left AV valve [4, 5]. The lateral AV cushions are significantly smaller
than the major AV cushions and develop at the lateral myocardial AV junctions.
Just like the major AV cushions, the lateral AV cushions become populated with
ENDCs. The right lateral cushion eventually forms the parietal leaflet of the right
AV valve, while the left lateral cushion forms the parietal (or mural/posterior)
leaflet of the left AV valve (Fig. 20.1).
Fig. 20.1 This cartoon shows the fate of the individual AV cushions. The superior and inferior
AV cushion (sAVC and iAVC) fuse at the midline and give rise to the septal leaflet of the right AV
valve (SL) and the aortic leaflet (AoL) of the left AV valve. The right lateral AV cushion (rlAVC)
forms the right parietal leaflet of the right AV valve (RPL), whereas the left lateral AV cushion
forms the left parietal leaflet of the left AV valve (LPL)
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20.1.2 The Epicardium and Epicardially Derived Cells (EPDCs)
In the mouse, epicardial development starts around embryonic day 9.5 (ED9.5)
when the proepicardium, a heterogeneous cluster of cells, can be seen as a “cauli-
flower-like” mesothelial structure at the inferior margin of the cardiac sinus
venosus at the venous pole of the heart. Around ED10, proepicardial cells reach
and attach to the myocardium. Subsequently, they migrate out over the surface of
the developing heart, ultimately covering the heart entirely. As a result of an
epicardial epithelial-to-mesenchymal transition (epiEMT), epicardially derived
cells (EPDC) are generated that migrate into the sub-epicardial space and into the
underlying myocardium. Over the last 15 years or so, a series of cell fate studies in
avian and murine models have been published reporting that EPDCs can, or have
the potential to, differentiate in multiple cell types including coronary smooth
muscle cells, interstitial fibroblasts, coronary endothelium, and potentially
cardiomyocytes [6–9]. It is important to note that the contribution of EPDCs to
the coronary endothelium and myocardium remains controversial.
20.1.3 The Contribution of EPDCs to the Developing AV Valves
In recent papers we have discussed the cascade of epicardial-related events
involved in the formation and development of the AV junction [7, 10]. This process
starts with the establishment of the AV-epicardium. After the formation of the
AV-epicardium, subsequent AV-epiEMT leads to the generation of AV-EPDCs, a
process regulated by a variety of factors. These AV-EPDCs eventually form the AV
sulcus, which can be seen as a mesenchymal wedge between the expanding atrial
and ventricular myocardial walls. As AV-EPDCs from the sulcus start to penetrate
the AV myocardial junction, the formation of the annulus fibrosus is initiated. The
annulus fibrosus is a fibrous tissue plane that physically and electrically separates
the atrial from the ventricular working myocardium. From the annulus fibrosus, a
subset of AV-EPDCs continues to migrate into the parietal AV valve leaflets, where
they eventually comprise a large percentage of the mesenchymal cells found of the
leaflet (Fig. 20.2). Just like the ENDCs found in the developing leaflets, the
AV-EPDCs in the valves eventually become valve interstitial cells (VICs). It is
important to note that very few AV-EPDCs are found in the leaflets that are
developing from the fused major AV cushions [7].
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20.2 The Role of Bmp Signaling in Regulating the Contribution
of EPDC to the AV Valves
20.2.1 Epicardial-Specific Deletion of the Bmp Receptor BmpR1A/
Alk3 Leads to Disruption of AV Junction Development
To elucidate the mechanisms that regulate the events that are responsible for the
contribution of AV-EPDCs to the tissues of the AV junction, we investigated the
importance of bone morphogenetic protein (Bmp) signaling in the epicardium. Bmp
isoforms are known to be involved in a variety of developmental steps in heart
development. In particular Bmp2, found at high levels in the AV myocardium, has
been shown to be important for the development of the AV cushions by promoting
endoEMT [11]. In our study, we determined that Bmp4 is highly expressed in the
AV-epicardium and in the AV-EPDCs that form the AV sulcus. Furthermore,
strong phospho-Smad-1/5/8 labeling of the AV-EPDCs indicates that canonical
Bmp signaling is active in these cells, strongly suggesting that this signaling
pathway is important in regulating the events associated with the cascade of
epicardial-related events at the AV junction [12]. To test the hypothesis that Bmp
Fig. 20.2 A section of a 17EDWt1-cre mouse crossed with a ROSA26mT/mG reporter mouse was
stained for the presence of epicardial and epicardially derived cells (red), the transcription factor
Sox9 (green), and cardiac myosin heavy chain (blue). The section shows the abundant presence of
EPDCs in the right parietal leaflets and the virtual absence of EPDCs in the septal leaflet of the
right AV valve
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signaling is important for the development of the structures that rely on the
contribution of AV-EPDCs, we deleted the Bmp receptor Alk3 from the epicardial
and epicardially derived cells using an epicardial-specific cre-mouse (the Wt1-cre
mouse [7, 12]). This approach resulted in a decrease in the size of the AV sulcus, an
inhibition of the formation of the annulus fibrosus, and a reduction of the number of
EPDCs that migrate into the parietal AV valve leaflets. Remarkably, electrophysi-
ological analysis of postnatal Wt1-cre;Alk3 mice did not show, despite the defect in
the formation of the annulus fibrosus, ventricular pre-excitation [12]. In addition,
and also quite unexpectedly, postnatal Wt1-Cre;Alk3 showed a myxomatous mitral
valve phenotype, particularly of the left parietal leaflet (Fig. 20.3).
20.2.2 Discussion
Our studies convincingly show that Bmp signaling plays a critical role in the
establishment of the mesenchymal and fibrous tissues at the AV junction. We
propose that during normal development, AV-epiEMT is a crucial process as it is
responsible for generating the critical amount of AV-EPDCs needed for the
subsequent formation of the annulus fibrosus and the associated migration of
AV-EPDCs into the parietal leaflets. We believe that perturbation of Bmp signaling
by conditionally deleting Alk3 from the epicardial cell population inhibits
AV-epiEMT resulting in a domino effect leading to (1) inhibition of AV sulcus
formation, (2) failure of the annulus fibrosus to form, and (3) reduction of the
number of EPDCs that migrate into the AV valve leaflets (Fig. 20.4).
20.2.3 Future Direction and Clinical Implications
Myxomatous valve disease is generally considered an acquired disease, often
observed in patients with mitral valve prolapse. The observed myxomatous changes
Fig. 20.3 Masson’s trichrome staining of adult wild-type (a) and Wt1-cre;Alk3 mouse hearts.
Panel (b) demonstrates the myxomatous phenotype of the left parietal leaflet of the epicardial Alk3
knockout mouse (arrow in b)
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in the leaflets of the postnatal Wt1-cre;Alk3 mice, however, are associated with a
reduced influx of EPDCs within those leaflets during embryonic development. We
therefore propose that perturbation in the normal development of EPDCs in the AV
junction might play the role in the etiology of myxomatous valve degeneration in
human heart disease.
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Fig. 20.4 Simplified hypothetical model showing the cascade of epicardial-related events at the
AV junction. (a) In normal development, Bmp signaling positively regulates epiEMT resulting in
the formation of the AV sulcus and subsequent development of annulus fibrosus, followed by the
migration of EPDCs into the parietal leaflets. (b) When Bmp signaling is perturbed, AV sulcus
formation and all AV-epicardial events downstream of this are inhibited
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Among members of the TGFβ superfamily, bone morphogenetic protein (BMP)
9 and BMP10 regulate vascular endothelium differentiation and morphogenesis by
activating the specific receptor complex, which consists of ALK1 (or ACVRL1),
BMPR2, and endoglin. Mutations in ACVRL1, BMPR2, or ENG are associated with
hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension in
humans [1, 2]. We previously identified TMEM100 as a downstream target gene
of BMP9/BMP10-ALK1 signaling pathway [3]. TMEM100 is a novel intracellular
protein with two putative transmembrane domains, and its amino acid sequence is
highly conserved from fish to humans.
To clarify the physiological significance of TMEM100, we generated Tmem100-
deficient mice and found that all mutant embryos died in utero around embryonic
day 10.5 (E10.5). LacZ reporter driven by the Tmem100 locus was predominantly
expressed in endothelial cells of developing arteries and endocardium. Tmem100
null embryos showed severe vascular dysmorphogenesis and cardiac enlargement
at E9.5 and massive pericardial effusion and growth retardation at E10.5
(Fig. 21.1). These phenotypic abnormalities were virtually identical to those
observed in Alk1/Acvrl1-deficient mice, suggesting that Tmem100 is an important
downstream gene of BMP9/BMP10-ALK1 signaling during cardiovascular
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development. We also demonstrated that Tmem100 null embryos showed atrioven-
tricular canal cushion formation defect, indicating Tmem100 works also as an
important factor for valve and septum morphogenesis.
Taken together, our studies indicate that TMEM100 is a novel endothelial-
specific protein for cardiovascular morphogenesis downstream of BMP9/BMP10-
ALK1 signaling. Clarifying the function of TMEM100 will lead to a better under-
standing of the mechanisms of cardiovascular morphogenesis and the etiologies of
human congenital diseases.
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BMP in Endocardial Cushion Cells in AV
Valvuloseptal Morphogenesis
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Distal outgrowth and fusion of the mesenchymalized AV endocardial cushions are
essential morphogenetic events in AV valvuloseptal morphogenesis. BMP-2
myocardial conditional knockout (cKO) mice die by embryonic day (ED) 10.5
[1] at the initial stage for the formation of endocardial cushions, hampering
investigation of the role of BMP-2 in AV valvuloseptal morphogenesis at the
later stages. In our previous study, we localized BMP-2 and type I BMP receptors,
BMPR1A and Alk2, in AV endocardial cushions [2, 3]. Based on their expression
patterns, we hypothesize that autocrine signaling by BMP-2 within
mesenchymalized AV cushions plays a critical role during AV valvuloseptal
morphogenesis. To test this hypothesis, we employed recently generated endocar-
dial/endocardial cushion-specific cre-driver line Nfact1Cre. Unlike a previously
generated Nfatc1enCre line whose cre-mediated recombination is restricted to AV
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and OT endocardium, this Nfatc1Cre line confers cre-mediated recombination
within the endocardial cells as well as their mesenchymal progeny. Using the
Nfactc1Cre driver line, we disrupted BMPR1A (Alk3) and BMP-2 specifically
from AV endocardium and endocardial cushions. BMPR1A endocardial cushion
cKO (cKOEndo) mouse embryos died by ED 12.5 and exhibited failure of
cellularization of AV cushions (Fig. 22.1a–c) and disruption of extracellular matrix
(ECM) protein deposition in the cushion mesenchyme. On the other hand, AV
cushion formation occurred in the BMP-2 cKOEndo mice that survived beyond the
AV cushion formation stage because BMP-2 expression remained intact in the AV
myocardium during AV cushion formation. BMP-2 cKOEndo mice exhibited
perimembranous ventricular septal defects (VSDs) (Fig. 22.1d, e), defective depo-
sition of ECMs in the membranous septum, and AV mitral valve dysplasia,
suggesting the cell autonomous requirement of BMP-2 in AV endocardial cushions.
Fig. 22.1 (a–c) BMPR1A cKOEndo mouse embryos exhibit failure of cellularization in AV
cushions. Arrows indicate abundant mesenchymal cells in AV and outflow tract (OT) cushions
in a control heart (A). Arrows show a few mesenchymal cells in AV and OT in a mutant heart (B).
Arrowheads indicate abundant cells at the distal part of the mutant OT, which appear to be neural
crest-derived and not reduced by BMPR1A endocardial/cushion-specific inactivation (C). (d, e)
Endocardial/cushion-specific deletion of BMP-2 results in perimembranous septal defects (arrow
in E), whereas control mouse heart shows well-formed ventricular septum (arrow in D). Ao aorta,
IVS interventricular septum, TV tricuspid valves, MV mitral valves
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BMP-2 cKOEndo did not exhibit muscular VSDs. These data strongly support our
hypothesis that cell autonomous signaling by BMP-2 in the endocardial line-
age plays a critical role in mesenchymalized AV cushions during AV valvuloseptal
morphogenesis.
Open Access This chapter is distributed under the terms of the Creative Commons Attribution-
Noncommercial 2.5 License (http://creativecommons.org/licenses/by-nc/2.5/) which permits any
noncommercial use, distribution, and reproduction in any medium, provided the original author(s)
and source are credited.
The images or other third party material in this chapter are included in the work’s Creative
Commons license, unless indicated otherwise in the credit line; if such material is not included in
the work’s Creative Commons license and the respective action is not permitted by statutory
regulation, users will need to obtain permission from the license holder to duplicate, adapt or
reproduce the material.
References
1. Ma L, Lu MF, Schwartz RJ, Martin JF. Bmp2 is essential for cardiac cushion epithelial-
mesenchymal transition and myocardial patterning. Development. 2005;132:5601–11.
2. Sugi Y, Yamamura H, Okagawa H, Markwald RR. Bone morphogenetic protein-2 can mediate
myocardial regulation of atrioventricular cushion mesenchymal cell formation in mice. Dev
Biol. 2004;269:505–18.
3. Inai K, Norris RA, Hoffman S, Markwald RR, Sugi Y. BMP-2 induces cell migration and
periostin expression during atrioventricular valvulogenesis. Dev Biol. 2008;315:383–96.
22 The Role of Cell Autonomous Signaling by BMP in Endocardial Cushion Cells. . . 173
Part V
The Second Heart Field and Outflow Tract
Perspective
Seema Mital
Outflow tract defects account for around 30 % of all congenital heart disease and are
associated with a significant health burden and ongoing late mortality despite
complete repair. Although outflow tract defects manifest as a range of anatomically
distinct and apparently heterogeneous lesions – tetralogy of Fallot, double-outlet
right ventricle, interrupted aortic arch, transposition of great arteries, truncus
arteriosus, and other related defects – embryologically they appear to have a
common origin related to abnormal development of the embryonic conotruncus
during the septation of the arterial outflow tract. In the vast majority of cases
(80 %), the genetic etiology is not known. The most common defect causing
outflow tract defects is the 22q11del that only accounts for 10–15 % of cases
overall.
In the past decade, major advances using mouse models have created a paradigm
shift in our understanding of cardiac development through the discovery of the
second heart field. While the primary heart field gives rise to the left ventricle and
most other cardiac structures, the right ventricle and the outflow tract arise from the
embryologically distinct second heart field. Proliferation and differentiation of the
second heart field are controlled by a complex transcriptional network. Pioneering
work in the understanding of the second heart field including lineage-tracing studies
has shown that perturbations in genes of the second heart field result in abnormal
formation and septation of the arterial outflow tract resulting in outflow tract
defects. Computer-assisted 3D reconstruction analysis to assess spatial and
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developmental gene expression patterns, morphogenesis, and proliferation in situ
has further helped understand outflow tract morphogenesis and effect of
dysregulation of genes regulating its development.
The foregoing chapters discuss the history of the second heart field, the central
role of multipotent second heart field progenitors in cardiac development and their
contribution to the definitive arterial pole, the major signaling pathways that control
second heart field progenitors including the role of genes like Mef2c, Cadm4, and
Foxc2, as well as the environmental factors in outflow tract defect development.
Eventually, knowledge gained from these model organisms can be used to guide
genetic screening of human subjects to identify causal genes associated with
outflow tract defects in humans.
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Properties of Cardiac Progenitor Cells
in the Second Heart Field 23
Alexandre Francou and Robert G. Kelly
Abstract
Heart tube elongation occurs by progressive addition of cells from pharyngeal
mesoderm to the poles of the heart. These progenitor cells, termed the second
heart field, contribute to right ventricular and outflow tract myocardium at the
arterial pole of the heart and to atrial myocardium at the venous pole. Perturba-
tion of this process results in congenital heart defects. Since the discovery of this
progenitor cell population, much has been learned about the signaling pathways
and transcription factors regulating second heart field deployment. However,
fundamental questions about the molecular and cellular mechanisms underlying
heart tube elongation remain. Here we briefly review a selection of recent
findings in the area of second heart field biology and discuss the clinical
implications of these new studies for our understanding of the etiology of
congenital heart defects.
Keywords
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23.1 Introduction
In 2001 a cardiac progenitor cell population situated in pharyngeal mesoderm was
found to give rise to myocardium of the right ventricle and outflow tract. In the
intervening period, it has become apparent that this progenitor cell population (1) is
part of a larger population of cardiac progenitor cells termed the second heart field
(SHF) that also contributes to atrial myocardium, (2) corresponds to a genetic
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lineage distinct from the first heart field (FHF) that gives rise to the cardiac crescent
and left ventricle, and (3) is progressively deployed in the pharyngeal region during
embryonic heart development through the activity of multiple signaling pathways
and transcription factors. Of particular relevance is the discovery that perturbation
of SHF development in animal models and human patients results in a spectrum of
congenital heart defects (CHD) affecting the poles of the heart, including
conotruncal and atrial septal defects. Details of these features of SHF development
have been documented in a series of recent reviews [1, 2]. Here we will discuss a
selection of recently published studies that impact on our understanding of second
heart field biology, with focus on mechanistic insights into the etiology of CHD.
23.2 Demarcating the First and Second Heart Fields and Their
Contributions to the Heart
The distinction between the FHF and SHF has been controversial, despite evidence
from clonal analysis and genetic lineage studies that these progenitor populations
correspond to separate lineages [1, 2]. Further support for a two-lineage model of
heart development has been provided by a study involving Boolean modeling of
gene regulatory networks in heart development [3]. This work identified two stable
states corresponding to the FHF and SHF and suggests that the differences between
these states are hardwired into the signaling and transcription factor interactions
operative in the early embryo. This modeling approach highlights the temporal
distinction between the FHF and SHF and can be used to predict gene function,
providing an important step toward integrated understanding of regulatory
networks during early heart development.
The discovery that Hcn4, encoding a nucleotide-gated channel protein, is
expressed in the FHF, in a complementary pattern to the SHF gene Isl1, has
reinforced the concept that the vertebrate heart is built from distinct progenitor
cell populations [4, 5]. An inducible Cre allele of Hcn4 has allowed evaluation of
the contribution of the FHF to the definitive heart. Unlike the SHF, which contains
multipotent cardiovascular progenitor cells, FHF derivatives appear to be restricted
to myocardium [4]. Interestingly, the two lineages contribute differently and in a
complementary manner to different components of the cardiac conduction system
[5]. In particular, the right bundle branch and majority of the right Purkinje fiber
system have a SHF origin. Similar observations have recently been made based on
retrospective clonal analysis and regionalized transgene expression data, supporting
dual contributions of the FHF and SHF to the conduction system [6]. These findings
are of relevance in understanding the origins of arrhythmias resulting from
perturbed development of particular segments of the conduction axis.
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23.3 New Insights into the Role and Regulation
of Noncanonical Wnt Signaling in the Second Heart Field
and the Origins of Conotruncal CHD
Continued proliferation and delayed differentiation are defining properties of the
SHF; indeed, separation of the sites of proliferation and differentiation provides a
mechanism allowing rapid growth of the embryonic heart. The role and regulation
of the noncanonical Wnt ligands Wnt5 and Wnt11 in these processes have been the
focus of a number of recent studies. While both ligands were known to be individ-
ually required for outflow tract morphogenesis, they have now been shown to be
co-required for SHF development [7], by downregulating the canonical Wnt path-
way during myocardial differentiation and activating noncanonical Wnt planar cell
polarity (PCP) signaling. Wnt5 is expressed before Wnt11 in SHF cells in the
posterior dorsal pericardial wall and has been shown to be directly activated by
the DiGeorge syndrome candidate gene Tbx1, a key regulator of proliferation and
differentiation in the SHF [8]. The severity of conotruncal defects in Wnt5a null
mice is increased in the presence of a Tbx1 null allele, while double mutant embryos
lack the right ventricle and outflow tract and die at midgestation. TBX1 directly
regulates Wnt5a through interaction with BAF60a, a progenitor cell-specific com-
ponent of the BAF chromatin remodeling complex, as well as the histone
methyltransferase SETD7, interactions shown to be necessary for activation of a
number of TBX1 transcriptional targets in the SHF [8]. Tbx1 itself is regulated by
the activity of a histone acetyltransferase, MOZ, loss of function of which partially
phenocopies DiGeorge syndrome [9]. The intersection of Tbx1 with chromatin
regulators is highly significant given the recent finding that de novo mutations in
genes encoding such molecules are overrepresented in human CHD patients [10].
In support of a role for Tbx1 upstream of noncanonical Wnt signaling, wnt11r is
downregulated in tbx1mutant zebrafish; heart looping and differentiation defects in
the absence of tbx1 can be partially rescued by ectopic wnt11r or a wnt11r target
gene encoding a cell adhesion molecule, alcama [11]. Altered cell shape in tbx1
mutant fish hearts suggests that noncanonical Wnt signaling regulates
cardiomyocyte cell polarity downstream of tbx1 [11]. Whether Tbx1 and nonca-
nonical Wnt signaling also regulate cell polarity in the SHF remains to be seen. SHF
and conotruncal development is impaired in mice lacking Dvl1 and Dvl2, regulators
of both canonical Wnt signaling and the noncanonical Wnt PCP pathway [12]. In
this study, the PCP signaling function of Dvl genes was shown to be specifically
required in the SHF lineage and the cardiac phenotype to resemble that of embryos
lacking the core PCP gene Vangl2; furthermore, Wnt5a and Vangl2 interact to
increase the severity of outflow tract defects [12]. Loss of PCP gene function results
in disorganization of progenitor cells in the posterior dorsal pericardial wall,
potentially resulting in impaired SHF deployment toward the outflow tract and
conotruncal anomalies.
Among the last myocardial derivatives of the SHF to be added to the elongating
heart tube is future subpulmonary myocardium, a cell population specifically
affected in Tbx1 mutant embryos [13]. Asymmetric addition of SHF progenitor
23 Properties of Cardiac Progenitor Cells in the Second Heart Field 179
cells giving rise to subpulmonary myocardium continues on the left side of the
outflow tract up until embryonic day 12.5 in the mouse; furthermore, this late
contribution drives rotation of the outflow tract, positioning subpulmonary myo-
cardium on the ventral side of the heart and aligning the ascending aorta with the
left ventricle [14]. Failure of this process, termed the “pulmonary push,” results in
outflow tract alignment defects such as double outlet right ventricle. Underdevel-
opment of subpulmonary myocardium has been implicated in the etiology of
tetralogy of Fallot [15], and further analysis of the regulation of future
subpulmonary myocardium is an important step toward deciphering the etiology
of CHD.
23.4 Involvement of the Second Heart Field in Atrial
and Atrioventricular Septal Defects
At the venous pole of the heart, SHF cells contribute to the dorsal mesenchymal
protrusion that bridges the atrioventricular cushions and primary atrial septum.
Failure of proliferation or precocious differentiation of these cells results in primum
atrial septal defects when canonical Wnt or hedgehog signaling, respectively, is
compromised [1, 2]. BMP signaling has now been shown to promote the prolifera-
tion of DMP progenitor cells, in contrast to the pro-differentiation role of this
signaling pathway during SHF addition at the arterial pole [16]. Isl1, Wnt2, and
the transcription factor Gli1 are expressed in this region of the SHF and have been
shown to identify a multipotent cardiopulmonary progenitor cell population that
contributes not only to the venous pole of the heart but also to diverse pulmonary
lineages, including smooth muscle and endothelium [17]. The development of these
cells that ensure the vascular connection between the heart and lung is coordinated
by hedgehog signaling from future pulmonary endoderm. The Holt-Oram syndrome
gene Tbx5 also operates in this posterior component of the SHF and is required for
normal atrial septation through regulating proliferation and hedgehog signal recep-
tion by direct activation of cell cycle progression genes such as Cdk6 and the
hedgehog signaling component Gas1 [18]. Genetic and retrospective lineage stud-
ies have revealed that venous pole and future subpulmonary myocardium are
clonally related, suggesting that a population of common SHF progenitor cells
segregates to the arterial and venous pole of the heart [19]. Where such common
progenitor cells are located and how their segregation to the poles is regulated
remains unknown.
23.5 Future Directions and Clinical Implications
The importance of perturbed SHF development in the etiology of common forms of
CHD affecting both poles of the heart is now clear. The studies discussed here
provide new insights into the underlying mechanisms, although much remains to be
learnt about the regulatory interactions between signaling pathways and
180 A. Francou and R.G. Kelly
transcription factors controlling cellular properties of the SHF and how different
regions of the heart are prepatterned and segregate within the progenitor cell
population. Future research will address these questions in the context of dynamic
heart tube elongation. The human SHF, as defined by ISl1 expression, coincides
with that observed in avian and mouse embryos [20], and thus findings from these
models are directly relevant to a better understanding of the origins of CHD in man.
Furthermore, insights into how the differentiation of cardiac progenitor cells is
controlled are essential for future regenerative therapies.
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Nodal Signaling and Congenital Heart
Defects 24
Ralston M. Barnes and Brian L. Black
Abstract
Nodal is aTGF-β familymember ligand that is critical for early embryonic patterning
in vertebrates. Nodal signaling functions through core TGF-β receptors to activate a
Smad transcription factor signaling cascade. However, unlike other TGF-β ligands,
Nodal signaling requires an additional co-receptor of theEGF-CFC family to activate
intracellular signaling. Nodal signaling is also subject to extensive negative regula-
tion by Lefty and other factors. Work in numerous model organisms, including
mouse, chicken, and zebrafish, established that Nodal signaling plays an essential
role during germ layer formation, anterior-posterior axis patterning, and left-right
axis determination. Incomplete or delayed loss ofNodal signaling results in defective
organogenesis and birth defects, including congenital heart defects, and clinical
studies have linked aberrant Nodal signaling in humans withmany common congen-
ital malformations, including congenital heart defects. Congenital heart defects
associated with disrupted Nodal signaling in mammals include those that arise due
to global defects in left-right patterning of the embryo, such as heterotaxy. Other
Nodal-associated heart defects appear to occur asmore subtle isolatedmalformations
of the great arteries and atrioventricular septum, which may not be related to overall
perturbations in laterality. A more detailed understanding of the Nodal signaling
pathway and its targets in the heart is required to more fully understand the etiology
of Nodal signaling pathway-associated congenital heart defects.
Keywords
Nodal signaling • Tdgf1 • Cripto • Congenital heart defects • TGF-β • Laterality
defects
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The Nodal signaling pathway is critical for early embryonic patterning in all
vertebrates. Nodal is a secreted signaling molecule that belongs to the transforming
growth factor-β (TGF-β) family and functions primarily to activate downstream
signaling through a receptor-mediated response [1–3]. The Nodal pathway plays a
critical role in mesoderm specification and anterior-posterior patterning during
gastrulation and is also essential for establishing the left-right axis in the developing
embryo [4–7]. Changes in Nodal expression or dosage can disrupt left-right pat-
terning and result in a range of congenital defects that affect development of the
forebrain, the craniofacial skeleton, and several other organs, including the heart.
24.2 The Nodal Signaling Pathway
The Nodal signaling pathway shares many similarities with other TGF-β signaling
pathways in that it utilizes core Smad-dependent signaling components (Fig. 24.1).
Nodal is secreted extracellularly as a proprotein homodimer like other TGF-β
ligands [8]. Once cleaved into the mature ligand, the Nodal homodimer binds
tightly to a TGF-β receptor heterodimer consisting of both Type I and Type II
receptors [9]. Nodal ligand binding causes the constitutively active Type II receptor
serine/threonine kinases to associate with the inactive Type I receptor kinases and
leads to phosphorylation and the subsequent dissociation of R-Smad from the
TGF-β receptor [10]. Following formation of a trimeric complex composed of
two R-Smads and the common partner Smad, Smad4, the Smad oligomer
translocates to the nucleus where it regulates gene expression through direct and
indirect DNA binding (Fig. 24.1) [1, 11, 12].
The Nodal signaling pathway has important distinctions from other
TGF-β-mediated signaling pathways. Nodal can only activate TGF-β receptor
signaling in the presence of an EGF-CFC protein (Fig. 24.1). There are two
EGF-CFC proteins, Cripto and Cryptic, which function as co-receptors for Nodal
[13]. Cripto and Cryptic are extracellular proteins that contain an epidermal growth
factor-like motif and a novel cystine-rich domain named the CFC [13]. EGF-CFC
proteins function primarily by binding to the Type II TGF-β receptor through the
CFC domain and by binding to Nodal through the EGF domain [14].
In response to Nodal signaling, the Smad complex cooperates specifically with
FoxH1, a winged helix transcription factor, or Mixer, a member of the Mix subclass
of homeodomain proteins [15, 16]. These cofactors are critical for Nodal-dependent
downstream gene activation and act to stabilize Smad-DNA interactions, since
Smads have relatively weak DNA-binding affinity [17, 18]. FoxH1 and Mixer
recruit the Smad complex to promoter and enhancer elements and help to establish
temporal and spatial regulation of Nodal-dependent target genes.
In addition, the Nodal signaling pathway is subject to specific negative regula-
tion not found for other TGF-β family members. Proteins of the Lefty family,
specifically Lefty1 and Lefty2, inhibit Nodal-dependent activation of TGF-β
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Fig. 24.1 The Nodal signaling pathway. The Nodal ligand binds to a dimer of the TGF-β Type I
and Type II receptors. In association with an EGF-CFC co-receptor (Cripto or Cryptic), Nodal
activates the receptor complex causing the phosphorylation of either Smad2 or Smad3 followed by
oligomerization with the common partner Smad4. The Smad2/Smad3-Smad4 complex then
translocates to the nucleus where it binds to DNA with the transcriptional cofactor FoxH1 or
Mixer, leading to transcription of downstream target genes. The Nodal signaling pathway is
negatively regulated by proteins such as Lefty, which can bind to either EGF-CFC or the Nodal
dimer to prevent activation of the receptor complex, or TGIF1, which recruits histone deacetylases
to Smad2/Smad3 and represses transcriptional activation
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receptors by interacting directly with the Nodal ligand and preventing binding to
the TGF-β receptor heterodimer and by binding to the EGF-CFC Nodal
co-receptors Cripto and Cryptic and preventing their association with the TGF-β
receptor complex (Fig. 24.1) [19–21].
24.3 Requirement for Nodal in Development
Nodal signaling is critical for the patterning of the developing embryo [4, 22]. Loss-
of-function studies in vertebrate model organisms indicate that Nodal signaling is
first required during gastrulation. Germline loss of Nodal in mice results in severe
patterning and differentiation defects and embryonic lethality due to a failure to
induce the primitive streak from the ectoderm and to disrupted specification of
mesoderm and endoderm from the epiblast [5]. Additionally, loss of Nodal in mice
results in impaired anterior-posterior axis formation due to the lack of anterior
visceral endoderm formation [22]. The requirement of Nodal signaling for early
embryonic pattern formation was further highlighted by loss-of-function studies of
the EGF-CFC Nodal co-receptor Cripto. Inactivation of Tdgf1, the gene encoding
Cripto, in mice results in a phenocopy of early Nodal defects, including lethality
shortly after gastrulation. Tdgf1 mutants lack a primitive streak, fail to form
embryonic mesoderm, and exhibit anterior-posterior axis defects [6]. The one-
eyed pinhead (oep) mutation in zebrafish results in a complete loss of function of
the fish ortholog of the Nodal co-receptor Cripto [23]. These mutants exhibit a
phenocopy of the early Nodal defects seen in mice, including an absence of
mesoderm and anterior-posterior axis abnormalities [23]. Together, both animal
models establish that EGF-CFC proteins are required for Nodal signaling and
support an early requirement for the Nodal pathway in embryo morphogenesis.
Following gastrulation, Nodal signaling is indispensable for the establishment of
left-right asymmetry. Conditional deletion of Nodal in the lateral plate mesoderm in
mice circumvents the early requirement for Nodal signaling during gastrulation and
results in heterotaxy, a condition characterized by left-right ambiguity of thoracic
and abdominal visceral organs [24]. These mice exhibit transposition of the great
arteries of the heart, right-sided isomerism of the lungs, and right-sided stomach
[25]. Similarly, germline deletion of Cfc1, the gene encoding Cryptic, results in
left-right laterality defects with mutants exhibiting heterotaxy [26].
In addition to playing a role in the establishment of laterality following gastru-
lation, Nodal signaling is also required for midline patterning of the ventral
forebrain [27]. Zebrafish mutants for the Nodal ligands and for the ortholog of
Cripto result in holoprosencephaly, a condition where bifurcation of the ventral
forebrain fails to occur and results in fusion of the two brain hemispheres [28]. Sim-
ilarly, mice heterozygous for germline knockout alleles of both Nodal and Smad2
have cyclopia, a rare and severe form of holoprosencephaly [29], further supporting
the relationship between Nodal signaling and forebrain development. Mechanisti-
cally, this phenotype is thought to occur due to the patterning of Sonic Hedgehog
(Shh) expression in the forebrain by Nodal [30, 31].
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24.4 Congenital Heart Defects Associated with Perturbations
in Nodal Signaling
It is perhaps not surprising to find that the Nodal signaling pathway is associated
with pathogenesis in humans, given its critical role in patterning during embryonic
development. Nodal signaling was first linked to human congenital defects through
the identification of mutations associated with left-right laterality defects. These
include mutations in genes encoding Lefty family members, the EGF-CFC
co-receptor Cryptic, and the Type II TGF-β receptors [32–34]. In addition,
mutations in genes encoding transcriptional inhibitors of Smad2, such as TGIF1,
are associated with holoprosencephaly, a defect strongly associated with disrupted
Nodal signaling [30, 35]. Interestingly, these human pathologies are similar to the
defects observed in animal models with defective (but not incomplete) Nodal
signaling.
Congenital heart defects have also been linked to aberrant Nodal signaling
(Table 24.1) [36]. Loss-of-function mutations in genes encoding numerous Nodal
signaling components, including Nodal, Cripto, Cryptic, and FoxH1, have been
identified in patients with heart defects [37, 38]. The spectrum of heart defects in
these patients can be roughly grouped into two broadly defined classes: (1) those
that occur as a result of overall isomerism or heterotaxy and (2) those that occur as
isolated congenital heart defects. The isomerisms of the heart can be classified as
situs inversus totalis, a complete mirror image of the visceral organs of the body
including the heart, or situs inversus ambiguous, where the abdominal and visceral
organs are distributed abnormally and randomly in a condition more commonly
called heterotaxy [39]. Both of these conditions can be linked to aberrant Nodal
signaling [40]. Heterotaxy often results in complex congenital heart defects
[41, 42]. These defects include levo-transposition of the great arteries (l-TGA)
and atrial isomerism [36, 39]. The feature characteristics of l-TGA are improper
positioning of the aorta and the pulmonary artery such that the arteries are switched
in conjunction with the ventricles such that they still have the normal relationship
between the ventricles and the arteries [43].
Isolated congenital heart defects associated with Nodal mutations can result in
structural and functional abnormalities that appear to be independent of overall left-
right ambiguity. These isolated defects include dextro-transposition of the great
arteries (d-TGA), double outlet right ventricle (DORV), tetralogy of Fallot, and
isolated ventricular septal defects [37, 38]. Unlike l-TGA, which results in a proper
alignment of the arteries with respect to the ventricles, d-TGA results in a switching
of aorta and the pulmonary artery such that the pulmonary artery connects to the left
ventricle and the aorta emanates from the right ventricle [43]. DORV, as the name
implies, occurs when the aorta and the pulmonary artery connect to the right
ventricle. Tetralogy of Fallot is essentially a milder form of DORV in which the
aorta overrides the ventricular septum and empties blood from both ventricles
[44]. There is also pulmonary artery stenosis and a hypertrophic right ventricle
secondary to pulmonary artery blockage associated with tetralogy of Fallot
[44]. These defects appear to be independent of overall laterality, although the
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mechanistic basis for why these defects occur when Nodal signaling is disrupted is
unclear. Interestingly, Nodal expression occurs well prior to the patterning and final
alignment of the aorta and pulmonary artery [40]. Furthermore, the temporal
expression pattern of Nodal observed during development is tightly regulated
within a narrow developmental window due, at least in part, to the extensive
negative feedback by Lefty proteins and other factors. The diverse nature of
heterotaxy in humans suggests that some isolated congenital heart defects
associated with perturbed Nodal signaling may still be secondary to overall
laterality defects.
A role for Nodal signaling in isolated congenital heart defects is also supported
by studies in mice in which subtle perturbations of Nodal signaling result in less
severe defects (Table 24.1), suggesting that the Nodal ligand functions in a dosage-
dependent manner. For example, deletion of an intronic enhancer of Nodal resulted
in decreased expression of Nodal in the lateral plate mesoderm. These mouse
Table 24.1 Some of the congenital defects associated with altered Nodal signaling in mammals
Component Species CV defects Other defects References






















Mouse l-TGA, ASD Heterotaxy, r-isomerism of
the lung, hyposplenia
[26]
Cripto Human TOF, VSD, ASD HPE [37, 50,
51]




Smad2 Human Dextrocardia, d-TGA,
DORV, ASD
Heterotaxy, asplenia, HPE [37, 53]





R-isomerism of the lung,
axial skeleton abnormalities
[54]
FoxH1 Human VSD, TGA, TOF HPE [37, 55]
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embryos developed laterality defects that were less severe than the heterotaxy
observed in Nodal conditional knockouts where Nodal expression in lateral plate
mesoderm was completely abolished [25, 45].
Consistent with Nodal function in left-right patterning, Nodal-dependent target
genes are also critical for left-right patterning and heart development [21]. Pitx2 is
perhaps the best-described target gene of Nodal signaling and is expressed asym-
metrically on the left side after gastrulation [46]. Misexpression of Pitx2 on the
embryonic right side in mice results in heterotaxia with conditions such as aberrant
heart looping, cardiac isomerism, and visceral organ laterality defects [46]. In the
mouse, germline loss of function of Pitx2 results in left-right asymmetry defects in
specific organs, such as the lung [47]. Interestingly, Pitx2-null and isoform-specific
Pitx2c-null embryos undergo normal heart looping but have a subset of congenital
cardiovascular anomalies such as DORV and ventricular and atrial septal defects
[47, 48]. These observations suggest that Pitx2 functions in heart development after
left-right determination and that other Nodal-dependent target genes may be
required for cardiac laterality. Together, these observations suggest that other
unappreciated Nodal-dependent target genes are involved in the establishment of
left-right identity and cardiac development. A more detailed elucidation of this
fundamental pathway, including target genes in the cardiac mesoderm, is required
to more fully understand the role of Nodal signaling in heart development and in
congenital heart defects.
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Utilizing Zebrafish to Understand Second
Heart Field Development 25
H.G. Knight and Deborah Yelon
Abstract
Heart formation relies on two sources of cardiomyocytes: the first heart field
(FHF), which gives rise to the linear heart tube, and the second heart field (SHF),
which gives rise to the right ventricle, the outflow tract, parts of the atria, and the
inflow tract. The development of the SHF is of particular importance due to its
relevance to common congenital heart defects. However, it remains unclear how
the SHF is maintained in a progenitor state while the FHF differentiates.
Likewise, the factors that trigger SHF differentiation into specific cardiac cell
types are poorly understood. Investigation of SHF development can benefit from
the utilization of multiple model organisms. Here, we review the experiments
that have identified the SHF in zebrafish and investigated its contribution to the
poles of the zebrafish heart. Already, zebrafish research has illuminated novel
positive and negative regulators of SHF development, cementing the utility of
zebrafish in this context.
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25.1 Introduction
The embryonic origins of the heart have been a topic of intense interest due to the
prevalence of congenital heart defects [1]. Cardiac progenitors (CPs) from the first
heart field (FHF) form the initial heart tube, and CPs from the second heart field
(SHF) contribute to most of the structures of the mature heart including the outflow
tract, right ventricle, and much of the atria [2]. The SHF is generally defined as a
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population of CPs that originates adjacent to the FHF, differentiates after the initial
heart tube has formed, and is responsible for cardiomyocyte accretion at both poles
of the heart tube [2]. The SHF is particularly significant to congenital heart disease;
many common cardiac abnormalities are caused by defects in SHF-derived tissues,
including ventricular and atrial septal defects, transposition of the great arteries, and
double outlet right ventricle [3]. Despite the importance of the SHF, the
mechanisms that distinguish FHF and SHF development remain unclear. What
signals or factors prevent the SHF from differentiating while the FHF is deployed,
and what eventual change triggers SHF differentiation? Recent advances in
zebrafish research offer new approaches that can complement work in mice to
deepen our comprehension of SHF regulation.
Several lines of evidence indicate the presence of a population of late-
differentiating CPs in zebrafish that is likely to be analogous to the mammalian
SHF. The conservation of the SHF provides exciting opportunities to advance our
understanding using the distinct advantages of zebrafish embryos [4]. Zebrafish
embryos develop rapidly and have small hearts that are particularly tractable for
cellular resolution of cardiogenesis. Furthermore, the transparency of the zebrafish
embryo facilitates exceptional opportunities for time-lapse imaging of heart forma-
tion and tracking of cardiac cell fates. Finally, zebrafish are particularly well suited
for conducting both genetic and chemical screens, which have the potential to
identify novel regulators of heart development. Here, we review the studies that
support the existence of a zebrafish SHF and demonstrate the utility of the zebrafish
for opening new avenues in SHF research.
25.2 Late-Differentiating Cardiomyocytes Originate from
the SHF in Zebrafish
Two types of assays have demonstrated that late-differentiating cardiomyocytes are
recruited to the poles of the zebrafish heart tube. First, a developmental timing assay
that relies on the different kinetics of GFP and DsRed fluorescence was used to
visualize the dynamics of cardiomyocyte differentiation. Analysis of Tg(myl7:
GFP); Tg(myl7:DsRed) embryos showed that newly differentiated cardiomyocytes
populate the cardiac poles at 48 h postfertilization (hpf), whereas cardiomyocytes in
the middle of the heart differentiate at an earlier stage (Fig. 25.1a; [5]). Second,
photoconversion assays have consistently revealed late-differentiating
cardiomyocytes in the outflow tract. UV exposure of Tg(myl7:kaede) or Tg(myl7:
KikGR) embryos after the heart tube has formed, followed by imaging at 48 hpf,
showed addition of cardiomyocytes to the outflow tract after the time of
photoconversion (Fig. 25.1b, [5, 6]). Together, these experiments revealed the
existence of late-differentiating cardiomyocytes at the arterial pole of the zebrafish
heart that seem to be analogous to SHF-derived cardiomyocytes in mammals.
Fate mapping in zebrafish has shown that early SHF precursors seem to neighbor
the FHF. Prior to gastrulation, arterial pole progenitors are found adjacent to
ventricular progenitors at the embryonic margin (Fig. 25.1c; [7]). After
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Fig. 25.1 Late-differentiating cardiomyocytes originate from the zebrafish SHF. (a) A develop-
mental timing assay reveals late-differentiating cardiomyocytes displaying GFP, but not DsRed
[5]. (b) Green-to-red conversion of photoconvertible proteins expressed in differentiated
cardiomyocytes at 24 hpf, followed by imaging at 48 hpf, reveals newly added green
cardiomyocytes in the outflow tract [6]. (c) Fate mapping in the late blastula shows that outflow
tract progenitors (purple) are located close to the margin, adjacent to ventricular progenitors (red),
and separate from atrial progenitors (yellow) [7]. In the early gastrula, outflow tract progenitors are
located in a medial cranial portion of the ALPM [7]
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gastrulation, arterial pole progenitors map to a medial cranial region next to the
FHF in the anterior lateral plate mesoderm (ALPM) (Fig. 25.1c; [7]). Finally, DiI
labeling has shown that the SHF resides adjacent to the heart tube in older embryos:
pericardial cells just outside the outflow tract at 24 hpf move into the arterial pole at
later stages [7]. The SHF has also been identified using Cre-mediated lineage
tracing. This technique has shown that arterial pole progenitors express both
gata4 and nkx2.5 during somitogenesis, confirming that SHF progenitors originate
in the ALPM [8]. Furthermore, Cre-mediated lineage tracing has confirmed that
cells from the pericardial mesenchyme adjacent to the heart tube migrate into the
outflow tract [9]. Taken together, these analyses show that the late-differentiating
cardiomyocytes at the zebrafish arterial pole meet the criteria that define the SHF.
Outflow tract cells remain undifferentiated until after the linear heart tube has
formed, are recruited to the arterial pole from outside the heart, and map to an
area adjacent to the FHF. These data, combined with conserved molecular
mechanisms regulating mouse and zebrafish arterial pole development, suggest
that the SHF is a conserved vertebrate feature.
25.3 Mechanisms Regulating Outflow Tract Development
in Zebrafish
Studies of the regulation of outflow tract formation have demonstrated conservation
of the transcription factors utilized in zebrafish and mice. Zebrafish embryos
deficient in mef2cb lack late-differentiating cells that form the outflow tract [6],
which is strikingly similar to the phenotype of Mef2c mutant mice that lack the
SHF-derived outflow tract and right ventricle [10]. Zebrafish tbx1 mutants have
several outflow tract defects, including reduced migration of cells into the heart [7]
and reduced proliferation of cells at the arterial pole, resulting in a small outflow
tract [11]. This phenotype is reminiscent of mouse Tbx1 mutants, which also
display outflow tract abnormalities due to severely reduced proliferation in the
SHF [12].
Signaling pathways also seem to have conserved roles in the mouse and
zebrafish SHF. Hedgehog signaling is important for zebrafish SHF development;
migration of cells into the heart is impaired in smoothened mutants, resulting in a
small outflow tract [7]. Similarly, hedgehog signaling is crucial for mammalian
SHF survival and outflow tract septation [13]. In zebrafish, reduced FGF signaling
eliminates accretion of cardiomyocytes at the arterial pole [5] and blocks mef2cb
expression in the SHF [6]. This requirement for FGF signaling mimics mouse Fgf8
mutants, which have a severely hypoplastic outflow tract and right ventricle
[13]. These findings underscore the conserved mechanisms regulating outflow
tract development and suggest that new discoveries in the zebrafish SHF are likely
to be relevant to mammals.
Importantly, novel insights into outflow tract development have emerged
through studies in zebrafish. The role of Ltbp3, a secreted protein that regulates
TGF-β ligand availability, has been of particular interest. ltbp3 is expressed in the
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zebrafish SHF, and Cre-mediated lineage tracing has shown that ltbp3-expressing
cells give rise to outflow tract cardiomyocytes [9]. Ltbp3-deficient embryos lack an
outflow tract due to reduced SHF proliferation, a consequence of reduced TGF-β
signaling [9]. This work not only illuminated Ltbp3 as a new SHF regulator but also
uncovered a novel role for TGF-β signaling in SHF development. Additional
studies have revealed that Nkx2.5 promotes maintenance of ltbp3 expression
[8]. This is exciting, as it elucidates a new pathway downstream of Nkx2.5:
Nkx2.5 facilitates the activation of TGF-β signaling through regulation of ltbp3
and thereby drives SHF proliferation. Since Nkx2.5 is highly relevant to congenital
heart disease, factors downstream of Nkx2.5 are excellent candidates for transla-
tional research. Thus, investigations in zebrafish can lead to the discovery of novel
regulators of SHF development and provide new insight into connections between
important factors.
25.4 Mechanisms Regulating Inflow Tract Development
in Zebrafish
In mice, the SHF has been shown to contribute to the venous pole in addition to the
arterial pole [2]. The mammalian SHF is thought to be subdivided into the anterior
SHF, which gives rise to the right ventricle and outflow tract, and the posterior SHF,
which gives rise to the atria and the inflow tract [2]. The zebrafish heart has a
distinct population of inflow tract cells that express the canonical SHF marker Isl1
[14]. In addition, developmental timing assays have shown that the zebrafish inflow
tract contains a population of late-differentiating cardiomyocytes (Fig. 25.1a; [5]).
However, the degree of overlap between these two populations has not been
examined, and the precise timing of when inflow tract cells are added to the heart
is unclear. Furthermore, it is not known where zebrafish inflow tract cells originate
in the early embryo and if inflow and outflow tract progenitors share a common
lineage. Future experiments will be valuable to elucidate the zebrafish equivalent of
the mammalian posterior SHF.
Studies of inflow tract development in zebrafish have revolved around the role of
Isl1. Zebrafish Isl1 mutants lack late-differentiating cardiomyocytes at the venous
pole [5]. This phenotype is similar to that of Isl1 null mouse embryos, which lack
SHF-derived atrial cardiomyocytes [15]. Interestingly, studies in zebrafish have
identified a novel requirement for the LIM domain protein Ajuba, which directly
interacts with Isl1 [14]. Ajuba-deficient embryos have large hearts with an excess of
Isl1-expressing cells and an expansion of SHF markers in the ALPM. Conversely,
Ajuba overexpression eliminates Isl1 in the inflow tract [14]. Ajuba is one of the
first factors that has been shown to limit SHF development, and the presence of
Ajuba may determine whether Isl1 activity promotes or limits cardiomyocyte
formation. The identification of Ajuba as a negative regulator of inflow tract
formation further illustrates the utility of zebrafish for the discovery of novel factors
involved in SHF development.
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25.5 Future Directions and Clinical Implications
Altogether, the studies summarized here support the value of the zebrafish for the
investigation of SHF development. It will be particularly exciting for future work in
zebrafish to probe important open questions in this area. For example, zebrafish
studies may be valuable for elucidating the mechanisms that pattern the SHF into its
anterior and posterior subdivisions. In addition, it will be interesting to use zebrafish
to examine the factors that control differentiation of multipotent SHF cells into
myocardial, endocardial, and smooth muscle lineages [9]. Zebrafish will also be
valuable for exploring whether multipotent SHF cells are maintained after embryo-
genesis, perhaps to be deployed after injury. In the long term, use of the zebrafish
for analysis of SHF development is likely to illuminate pathways that facilitate our
understanding of the etiology of congenital heart disease.
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A History and Interaction of Outflow
Progenitor Cells Implicated in “Takao
Syndrome”
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Abstract
Progenitor cells, derived from the cardiac neural crest (CNC) and the second
heart field (SHF), play key roles in development of the cardiac outflow tract
(OFT), and their interaction is essential for establishment of the separate pulmo-
nary and systemic circulation in vertebrates. 22q11.2 deletion syndrome
(22q11DS) or Takao syndrome is the most common human chromosomal
deletion syndrome that is highly associated with OFT defects. Historically,
based on the observations in animal models, OFT defects implicated in the
22q11/Takao syndrome are believed to result primarily from abnormal develop-
ment of CNC that populate into the conotruncal region of the heart. In the
twenty-first century, elegant efforts to model 22q11/Takao syndrome in mice
succeeded in the identification of T-box-containing transcription factor, Tbx1, as
an etiology of OFT defects in this syndrome. Subsequent investigations of the
Tbx1 expression pattern revealed that Tbx1 was surprisingly not detectable in
CNC but was expressed in the SHF and provided a new concept of molecular and
cellular basis for OFT defects associated with 22q11/Takao syndrome. More
recently, it was reported that mutations in the gene encoding the transcription
factor GATA6 caused CHD characteristic of OFT defects. Genes encoding the
neurovascular guiding molecule semaphorin 3C (SEMA3C) and its receptor
plexin A2 (PLXNA2) appear to be regulated directly by GATA6. Elucidation
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of molecular mechanism involving GATA6, SEMA3C, PLXNA2, and TBX1 in
the interaction between the CNC and the SHF would provide new insights into
the OFT development.
Keywords
Congenital heart disease • 22q11.2 deletion syndrome • Neural crest • Second
heart field • GATA6
26.1 Introduction
Cardiac outflow tract (OFT) defects account for approximately 30 % of congenital
heart disease (CHD) and usually require an intervention during the first year of life
[1, 2]. A variety of OFT defects results from disturbance of the morphogenetic
process for the establishment of separated systemic and pulmonary circulation.
Despite their clinical importance, the etiology of most OFT defects remains
unknown because of the multifactorial nature of the diseases.
Progenitor cells derived from the cardiac neural crest (CNC) and the second
heart field (SHF) play key roles in development of the OFT. The SHF cells give rise
to the OFT myocardium along with subpulmonary conus, and CNC cells give rise to
the OFT septum during development. Defects of these progenitor cells may lead to
a variety of OFT defects, including tetralogy of Fallot (TOF), characterized by
malalignment of the major vessels with the ventricular chambers; interrupted aortic
arch type B (IAA-B), resulting from maldevelopment of the left fourth pharyngeal
arch artery; and persistent truncus arteriosus (PTA), resulting from failure of
septation of the OFT into the aorta and pulmonary artery [3, 4].
26.2 The 22q11.2 Deletion Syndrome (Takao Syndrome)
The 22q11.2 deletion syndrome (22q11DS) is the most common genetic cause of a
spectrum of OFT defects with an incidence of 1 in 4000–5000 births [5, 6]. Most are
sporadic in origin, while 10–20% of deletions are inherited as an autosomal dominant
trait. 22q11DS involves three distinct syndromes, namely, DiGeorge syndrome
(DGS; OMIM#188400), velocardiofacial syndrome (VCFS; OMIM#192430), and
conotruncal anomaly face syndrome (CAFS; OMIM#217095) which is so-called
Takao syndrome. Historically, DGS was originally characterized by CHD, hypopara-
thyroidism, and immune deficiency reported in 1965 from the field of immunology
[7]; VCFS was associated with cleft palate, CHD, a distinct facial appearance, and
learning difficulties reported in 1978 from the field of plastic surgery [8]; and CAFS
or Takao syndrome was characterized by conotruncal CHD (OFT defects), a distinct
facial appearance and hyper-nasal voice reported in 1976 (in Japanese) from the field
of pediatric cardiology [9]. In 1993, clinical genetics revealed that these syndromes
shared a common heterozygous deletion of 22q11.2 region and thus had overlapping
phenotype [10–12].
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Although the acronym “CATCH22 (cardiac defects, abnormal facies, thymic
hypoplasia, cleft palate, hypocalcemia, and 22q11 deletions)” was proposed to
encompass these syndromes in 1993 [13], clinical use of this term is restricted
today, because (1) the term “CATCH22” has a negative meaning which represents a
situation where it is impossible for you to do anything, originally from a novel
entitled “Catch-22” by Heller [14]; (2) the term “abnormal facies” represented by
“A” is difficult to be accepted by patients and their family; and (3) the clinical
spectrum associated with 22q11DS is much wider than was previously recognized
as “CATCH” [15].
Approximately 75 % of patients with 22q11 DS have CHD. The type of CHD are
characterized as OFT defects including TOF, estimated about 30 %; IAA-B,
estimated about 15 %; ventricular septal defect (VSD), estimated about 15 %;
PTA, estimated about 10 %; and others, estimated about 5 %. Alternatively,
22q11.2 deletion is present in approximately 60 % of patients with IAA-B, 35 %
of patients with PTA, and 15 % of patients with TOF. Specifically, it is detected in
55 % of patients with TOF plus pulmonary atresia and major aortopulmonary
collateral arteries (MAPCA) [16–18].
Although CHD are the major cause of mortality in 22q11DS, survivors have an
exceptionally high incidence of psychiatric illness, including schizophrenia and
bipolar disorder, in adolescents and adults, making del22q11 the most frequent
genetic cause of such psychiatric disorders [16, 19, 20]. In our experience of
18 adults with 22q11DS, common school and employment were observed in
11 of 18 cases, and 2 females got married; however, difficulties with social
interaction and employment were observed in 7 cases. The main reason of
difficulties for social interaction and employment was incomplete repair of CHD
in four cases, and all of them had TOF with pulmonary atresia and MAPCA. One
case was also diagnosed as schizophrenia. Other three cases had repaired VSD and
are away from hospital care. Taken together, lifelong comprehensive evaluation
and management of patients with 22q11DS, like as shown in Table 26.1, are
required for multisystem disorders [6]. The primary care physician, a pediatric
cardiologist in most cases, has an important role in the follow-up for the patients
and their families and needs to collaborate with many specialists for the associated
abnormalities.
26.3 Identification of TBX1
Because of the high incidence and association with OFT defects, 22q11DS has
attracted attention as a model for investigating the genetic basis for OFT defects
[21, 22]. The structures primarily affected in patients with 22q11DS are derivatives
of the embryonic pharyngeal arches, or neural crest cells, suggesting that
haploinsufficiency of the gene(s) on the 22q11.2 deleted region is essential for
pharyngeal arch and/or CNC development [1, 2, 21, 22]. Extensive gene searches
have been successful in identifying more than 30 genes in the deleted segment.
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Although standard positional cloning has failed to demonstrate a role for any of
these genes in the syndrome, elegant efforts by several groups to model 22q11DS in
mice by creating orthologous chromosomal deletions were successful in revealing
the T-box-containing transcription factor, Tbx1, as the etiology of OFT defects
associated with 22q11DS [23–26]. Heterozygosity of Tbx1 in mice alone also
caused aortic arch defects, while homozygous mutation of Tbx1 in mice resulted
in most main clinical presentations of 22q11DS, including OFT defects, abnormal
facial features, cleft palate, and hypoplasia of the thymus and parathyroid glands.
26.4 Expression of TBX1
The delineation of the expression pattern of Tbx1 provided a new concept on the
molecular and cellular basis of normal and abnormal development of the OFT. We
and other group found that Tbx1 was expressed in the SHF but not in the CNC [27–
29]. This finding was surprising because CHD associated with 22q11DS had been
believed to result primarily from abnormal development of CNC as mentioned
above. Interestingly, in mouse and chick embryos, Tbx1 is preferentially expressed
in the pharyngeal arches, in the ventral half of the otic vesicle, and in the head
(Fig. 26.1) [27, 28]. Within the pharyngeal arch region, Tbx1 is expressed in the
pharyngeal mesoderm, including the SHF, the pharyngeal endoderm, and the head
mesenchyme. These results suggest that defects of neural crest-derived tissues in
22q11DS may occur in a non-cell autonomous fashion. Our cre-mediated murine
Fig. 26.1 Expression patterns of Tbx1. (a–d) RNA in situ hybridizations for whole mount (a–c)
and section (b, d) in mouse (a, b) and chick (c, d) embryos demonstrate Tbx1 expression (purple
or white signals) in the mesodermal core (arrows) and endodermal epithelium (arrowheads) of
pharyngeal arches, head mesenchyme (hm), and otic vesicle (ov). Asterisks indicate pharyngeal
arch arteries. (e, f). Transverse sections demonstrate Tbx1-lacZ expression (blue signals) in the
myocardial layer of the cardiac outflow tract (oft) but not in the oft cushion (cu) which is mainly
contributed by cardiac neural crest cells. (g) Tbx1-descendant cells marked by Tbx1-Cre/Rosa26R
mouse system are localized in the anterior portion (oft) of the right ventricle (rv) and the main
trunk of the pulmonary artery (mpa). ao Aorta, h head, ht heart, la left atrium, ra right atrium
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transgenic system revealed that Tbx1-expressing descendants representing a subset
of cells derived from the SHF contribute predominantly to the pulmonary infundib-
ulum (Fig. 26.1) [30].
Although precise embryological mechanisms underlying OFT defects remain
uncertain, the anatomical defects in TOF are believed to result from malrotation of
the OFT that leads to misalignment of the outlet and trabecular septum and
consequent overriding of the aorta above the malaligned ventricular septum
[2, 3]. Contribution of CNC is thought to be essential for proper rotation and
septation of the OFT. Alternatively, hypoplasia and underdevelopment of the
pulmonary infundibulum may also be responsible for the infundibular obstruction
and malalignment of the outlet septum [2, 3]. Accordingly, our data suggest that
developmental defects of the SHF may cause hypoplasia of the pulmonary infun-
dibulum, resulting in TOF [30]. More severe decreased number or absence of this
subset of cells may affect development and/or migration of CNC, resulting in PTA.
This hypothetical model is supported by the observation that the OFT defects
ranging from TOF to TA are highly associated with 22q11DS (Fig. 26.2).
26.5 Mutations of GATA6
Recently, we identified and characterized mutations of GATA6 in our series of
Japanese patients with OFT defects [31]. Mutations in GATA6 disrupted its tran-
scriptional activity on downstream target genes involved in the development of the
OFT. We also found that the expression of SEMA3C and PLXNA2 was directly
regulated during development of the OFT through the consensus GATA binding
sites well conserved across species. Mutant GATA6 proteins failed to transactivate
SEMA3C and PLXNA2, and mutation of the GATA sites on enhancer elements of
Sema3c and Plxna2 abolished their activity, specifically in the OFT/subpulmonary
myocardium and CNC derivatives in the OFT region, respectively. These results
indicate that mutations of GATA6 are implicated in genetic causes of OFT defects,
as a result of the disruption of the direct regulation of semaphorin-plexin signaling
(Fig. 26.2).
26.6 Future Direction: Elucidating the Interaction Between CNC
and SHF
Recent studies have demonstrated that reciprocal epithelial-mesenchymal signaling
is essential for proper development of the pharyngeal arches and that the primary
impairment of epithelial endoderm may secondarily affect migration or differentia-
tion of neural crest cells during the pharyngeal arch development [32–34]. As for
the development of the OFT, clear roles of CNC- and SHF-derived cells have been
established [35]. Future direction in this research field is to reveal how the CNC and
SHF interact using complex reciprocal signaling essential for precise morphogene-
sis of the OFT. Importantly, mutations in genes expressed in either CNC or SHF can
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result in similar OFT defects in mice. For example, Pax3 is expressed in the CNC,
and Tbx1 is expressed in the SHF, and both Pax3-null mice and Tbx1-null mice
show PTA. Studies are, thus, required to focus on the signals that mediate
interactions between CNC and SHF in order to uncover the developmental
mechanisms underlying various types of the OFT defect. Our result from the
research of mutation of GATA6, described above, is an example that revealed
such a molecular mechanism. Our recent preliminary data suggest that a molecular
cascade involving Gata6, Foxc1/2, Tbx1, Sema3C, and Fgf8 may play roles in
reciprocal signaling between SHF and CNC that are essential for the migration of
CNC toward the OFT myocardium derived from the SHF (in revision). Further
Fig. 26.2 Cellular interaction of the second heart field (SHF) and cardiac neural crest (CNC) for
the outflow tract (OFT) development and diseases. Progenitor cells derived from the SHF and the
CNC give rise to the OFT myocardium and septum, respectively. TBX1 is exclusively expressed
in the SHF cells. TBX1 deletion in 22q11DS may affect not only the SHF cells but also the
interaction between the SHF cells and CNC, resulting in OFT defects ranging from TOF, which is
characterized by malalignment of the OFT septum, to PTA, which results from aplasia of the OFT
septum. GATA6-SEMA3C (ligand)-PLXNA2 (receptor) pathway also plays a role in interaction
between the SHF and CNC during the OFT development (Modified from [36])
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study utilizing our model system may provide new insights into the OFT develop-
ment and embryogenesis of OFT defects.
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The Loss of Foxc2 Expression
in the Outflow Tract Links the Interrupted
Arch in the Conditional Foxc2 Knockout
Mouse
27
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Congenital heart disease is the most common birth defects, affecting 1 % live births
[1]. The cardiovascular system undergoes a series of morphogenetic events to form
a heart and an aorta in fetuses. Formation of the heart and aorta requires migration,
differentiation, and precise interactions among multiple cells from several embry-
onic origins [2]. Forkhead box2 (Foxc2) encodes a transcription factor and is
expressed in mesodermal tissues, such as the pharyngeal artery, outflow tract
endothelial/surrounding mesenchyme, bone, and kidney [3]. Simple knockout of
Foxc2 in mouse causes an interrupted aortic arch, ventricular septal defect, cleft
palate, and skeletal malformation [4]. The heart is made from primary and second-
ary heart field progenitors. The primary heart field gives rise to the left ventricle and
atria, while the secondary heart field contributes mainly to the right ventricle and
outflow tract [5] (Fig. 27.1).
To explore the tissue-specific roles of Foxc2 in aortic arch remodeling, we
generated mice carrying a floxed allele of Foxc2 (Foxc2flox) and crossed them
with several Cre mice, including the primary heart field (Nkx2.5-Cre knock-in)-
specific and secondary heart field (Islet1-Cre knock-in and Tbx1-Cre transgenic)-
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specific Cre lines. Surprisingly, conditional knockout (cKO) of Foxc2 in the
primary heart field (Nkx2.5-Cre;Foxc2flox/flox) and secondary heart field (Islet1-
Cre;Foxc2flox/flox and Tbx1-Cre;Foxc2flox/flox) resulted in an interrupted aortic arch
and perinatal lethality in mice. X-gal staining and immunostaining with anti-Foxc2
antibody confirmed that Foxc2 expression in the aortic arch was intact but deleted
in the outflow tract in these cKO embryos. These results indicate that the Foxc2
expression in the outflow tract, rather than direct role in the aortic arch, is crucial for
the aortic arch remodeling. It assumed that Foxc2 in the outflow tract regulates
aortic arch remodeling via secreted factors such as Fgf8, Fgf10, and other genes.
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Fig. 27.1 Aortic arch abnormalities in Foxc2 conditional knockout mice. (a) Normal aortic arch
formation in control mice (Foxc2flox/flox). (b–d) Conditional knockout mice showed interrupted
aortic arch (IAA) type B where part of the aorta between LCC and LSC is missing (arrow). LCC
left common carotid artery, LSC left subclavian artery, aAo arch of the aorta, Pt pulmonary trunk,
RCC right common carotid artery, RSC right subclavian artery, BC brachiocephalic artery
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Modification of Cardiac Phenotype
in Tbx1 Hypomorphic Mice 28
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Tbx1 • Truncus arteriosus • Environmental modification
Congenital heart disease is still the leading cause of death within the first year of
life. Our lab forces on understanding the morphology of congenital heart disease.
Outflow tract anomalies, including abnormal alignment or septation, account for
30 % of all congenital heart disease. To solve the developmental problem of these
defects, we are interested in the role of the second heart field (SHF) that gives rise to
the outflow tract structure.
TBX1, a member of the T-box family of transcription factors, is a major genetic
determinant of 22q11 deletion syndrome (22q11DS) in human. 22q11DS is the
most frequent chromosomal microdeletion syndrome in human and characterized
by abnormal development of the cardiac outflow tract, such as persistent truncus
arteriosus (PTA), tetralogy of Fallot, interrupted aortic arch, and ventricular septal
defects.
In the developing murine heart, Tbx1 is expressed in the SHF, but not in the
cardiac neural crest cells (NCCs). Our past experiments suggested that sonic
hedgehog signal was necessary for maintenance of the Tbx1 expression in the
pharyngeal mesoderm including the SHF [1]. Tbx1 null (Tbx1/) mice
demonstrated PTA reminiscent of the 22q11DS heart phenotype. We generated
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Tbx1 hypomorphic allele (Tbx1neo/þ) [2] for attempting to recapitulate the human
genotype and phenotype correlation. Mice homozygous for this hypomorphic allele
expressed around 25 % of Tbx1 mRNA compared to wild-type mice. We
demonstrated that Tbx1 is a dosage-dependent gene and believe that the Tbx1
dosage can be affected by genetic and/or environmental modifiers because of highly
variable phenotype of 22q11DS instead of the relatively uniform chromosomal
microdeletion. We are trying to create the phenotype variability of PTA in this
hypomorphic model (Fig. 28.1) by application of environmental modifiers.
Through this study, we would better understand the interaction between the gene
dosage and environmental factors during the development of outflow tract defects.
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Fig. 28.1 Coronal sections of Tbx1þ/þ (a, b) and Tbx1neo/neo (c, d) embryos at E13.5. Tbx1þ/þ
showed the normal outflow tract (OFT) septation, whereas Tbx1neo/neo demonstrated PTA. Ao
Aorta, PA pulmonary artery
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Part VI
Vascular Development and Diseases
Perspective
H. Scott Baldwin
While the critical pathways that are important for normal cardiac development have
focused extensively on transcriptional regulation of myocyte differentiation, criti-
cal mediators of vascular development have received much less attention. One
reason for this has been the inability in the past to manipulate gene expression in a
temporal and tissue-specific manner. There is no doubt that both normal vascular
and normal myocardial development are essential for early embryonic survival and
the two are inextricably linked; normal vascular development requires normal flow,
and maturation of the myocardium requires simultaneous maturation and
remodeling of the extracardiac vasculature. Ubiquitous or global gene deletions,
resulting in both cardiac and extracardiac mutations, have resulted in numerous
“chicken and egg” quandaries: Did the heart fail because of a primary defect in
heart development, or were the defects merely secondary to upstream perturbations
in extracardiac vascular defects? In this section, investigators used tissue-specific
mutagenesis strategies as well as a focus on cell membrane and extracellular matrix
regulation to begin to elucidate important aspects of extracardiac vascular develop-
ment that are particularly relevant to human disease. Sakebe et al. generated an
endothelial-specific deletion of Hrt2/Hey2, repressors of Notch signaling, to dem-
onstrate that both Hrt1 and Hrt2 are essential for vascular development independent
of their role in myocardial development. Furthermore, they suggest that the
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endothelial or vascular processes mediated by these factors, rather than the defects
in myocardial development, might be the primary mechanism for embryonic
demise. Exploring the role of calcium signaling in extraembryonic vascular devel-
opment, Uchida and colleagues were able to document dramatic defects in placen-
tation as early as E9.5 in the mouse as a result of combinatorial deletion of the
inositol IP3 receptors. This work clearly establishes a role for calcium handling in
cardiovascular viability. Changing the focus to later stages of vascular develop-
ment, Dr. Imanaka-Yoshida provides a detailed description of the role of the
extracellular matrix protein, tenascin-C, in smooth muscle cell recruitment of
both the descending aorta and coronary arteries and provides in vitro evidence
that tenascin-C promotes SMC precursor expansion and differentiation by
augmenting PDG-BB/PDGFR-β signaling. Finally, Yoshikane et al. show the
potential importance of delineating the role of tenascin-C in normal and abnormal
coronary artery remodeling as they discuss a model of the most common acute
systemic vasculitis in children, Kawasaki disease. By studying the inflammatory
and abnormal vascular remodeling induced by Candida albicans, they demonstrate
accentuation of tenascin-C expression associated with aneurysm formation. Fur-
thermore, they document that inhibition of JNK signaling attenuated aneurysm
formation potentially providing a mechanistic link between JNK signaling and
tenascin-C signaling that could provide a therapeutic target for treatment of
Kawasaki disease. In summary, the investigations presented in this section provide
an overview of exciting work that expands the focus of cardiovascular development
and disease beyond myocyte transcriptional regulation and provides new insights
into extracardiac vascular development and remodeling while emphasizing the
importance that the extracellular matrix is ontogeny of cardiovascular disease.
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Extracellular Matrix Remodeling
in Vascular Development and Disease 29
Kyoko Imanaka-Yoshida
Abstract
Blood vessels constantly subjected to mechanical stress have well-developed
elastic fiber-rich frameworks, which contribute to the elasticity and distensibility
of the vascular wall. Destruction of the fibrous structure due to genetic predispo-
sition as well as acquired disorders such as Kawasaki disease often induces
irreversible dilation of blood vessels, e.g., aneurysm formation. In addition to
their structural role, extracellular matrix molecules also provide important
biological signaling, which influences various cellular functions. Among them,
increased attention has been focused on matricellular proteins, a group of non-
structural extracellular matrix (ECM) proteins highly upregulated in active tissue
remodeling, serving as biological mediators by interacting directly with cells or
regulating the activities of growth factors, cytokines, proteases, and other ECM
molecules. Tenascin-C (TNC) is a typical matricellular protein expressed during
embryonic development and tissue repair/regeneration in a spatiotemporally
restricted manner. Various growth factors, pro-inflammatory cytokines, and
mechanical stress upregulate its expression. TNC controls cell adhesion, migra-
tion, differentiation, and synthesis of ECM molecules. Our recent results suggest
that TNCmay not only play a significant role in the recruitment of smooth muscle/
mural cells during vascular development, but also regulate the inflammatory
response during pathological remodeling. TNC may be a key molecule during
vascular development, adaptation, and pathological tissue remodeling.
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Tissue, including the cardiovascular system, is composed of diverse cells and the
extracellular matrix (ECM) synthesized by those cells. Several ECM molecules
form a fibrous framework and provide structural support for the tissue. Blood
vessels constantly subjected to mechanical stress have a well-developed fibrous
framework, which contributes to the elasticity and distensibility of the vascular wall
in concert with vascular smooth muscle cells. Highly ordered structures consisting
of cells and fibrous elements are formed during development and are remodeled
during tissue repair/regeneration after injury. In addition to their physical role,
several ECM molecules provide important biological signaling, which influences
various cellular functions in physiological and pathological tissue remodeling. In
particular, ECM, termed matricellular protein, has attracted increasing attention as
a biological mediator. Tenascin-C (TNC) is a prototype matricellular protein
expressed during embryonic development and tissue repair after injury. This chap-
ter will focus on the role of TNC in vascular development, especially coronary
arteries and the aorta.
29.2 Extracellular Matrix in Vascular Wall
Blood vessels have abundant fibrous matrix tissue: well-developed elastic fibers in
the medial layer and rich collagen fibers in adventitia. It is known that several gene
mutations related to these fibrous components cause vascular fragility, eventually
leading to aneurysm formation or dissection. For example, the collagen gene and
fibrillin-1 gene, which is important for microfibril formation, have been identified
as the genes responsible for Ehlers-Danlos syndrome (reviewed in [1]) and
Marfan’s syndrome [2], respectively. In addition to genetic predisposition, inflam-
mation of blood vessels in acquired disease may induce fragmentation and destruc-
tion of normal elastic fibers in the vascular wall and causes irreversible dilation of
blood vessels. For example, coronary aneurysm formation is sometimes seen in
patients with Kawasaki vasculitis, one of the most common acquired heart diseases
in children. Evidently, the structural support by fibrous ECM is essential to main-
tain the proper morphology and function of blood vessels.
Besides these fibrous elements, unique ECM molecules, matricellular protein
[3], have attracted considerable attention. The matricellular proteins have common
unique properties: (1) do not contribute directly to structures such as fibrils or
basement membranes; (2) high levels of expression during embryonic development
and in response to injury; and (3) binding to many cell surface receptors,
components of ECM, growth factors, cytokines, and proteases [4]. This is a growing
family originally including SPARC, tenascin, and thrombospondin [3].
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29.3 Tenascin-C in Vascular System
Tenascins are a family of four multimeric extracellular matrix glycoproteins:
tenascin-C, X, R, and W [5]. The first member, tenascin-C (TNC), is a typical
matricellular protein. It is a huge molecule of about 220–400 kDa as an intact
monomer and is assembled with a hexamer. The molecule consists of an N-terminal
assembly domain, followed by EGF-like repeats, constant and alternatively spliced
fibronectin type III repeats, and a C-terminal fibrinogen-like globular domain.
Several receptors including integrins, EGFR, annexin II, syndecan-4, and toll-like
receptor 4 (TLR-4) bind to the respective domains of TNC and transmit multiple
signals (see [6]). Numerous studies have shown that TNC can control the balance of
cell adhesion and de-adhesion, cell motility, proliferation, differentiation, and
survival (reviewed in [5–7]). Recently, the role of TNC in the modulation of
inflammation is highlighted [8].
Tenascin-C is found in many developing organs, including the cardiovascular
system, but is often restricted transiently to specific sites, for example, near
migrating cells and at sites of epithelial–mesenchymal/mesenchymal–epithelial
transition. In normal adults, tenascin-C expression is sparsely detected; however,
marked expression is seen in injury, regeneration, and cancer at sites where the
tissue structure is being dynamically remodeled. Various factors, including growth
factors and pro-inflammatory cytokines, can activate TNC expression (reviewed in
[9]). It is particularly of interest that mechanical stress is an important inducer of
TNC. Moreover, it is also noteworthy that TNC itself is an elastic molecule and may
contribute to tissue elasticity [10].
As well as in other tissue, the expression of TNC in the normal vascular wall is low
and upregulated in pathological conditions. The major source is medial smooth muscle
cells [11]. However, TNC in the vascular system appears more complex in contrast to
the heart [7]. For example, constitutive expression of TNC is observed in the medial
layer of the abdominal aorta of normal adult mice but not in the thoracic aorta [12].
29.3.1 Development of Aorta and Tenascin-C
The origin of vascular smooth muscle cells (VSMC) of the aorta is heterogeneous
[13]. The second heart field gives rise to VSMC of the root of the aorta. The cardiac
neural crest contributes ascending and arch portions of the aorta. The origin of VSMC
of the descending aorta is more complex. Primitive VSMC of the thoracic aorta
originate from the lateral plate mesoderm and are replaced by cells derived from the
paraxial mesoderm (somites). Moreover, individual somites build up restricted spatial
domains of the “segmental” aortic wall. However, no evident segmental expression
pattern of TNC is observed during development of the aorta. In E12–13 mouse
embryos, very weak expression of TNC is observed in the ascending aorta and
pulmonary truncus. Whereas elastic fibers in the medial layer of the aorta become
mature around E12–13, the expression of TNC is upregulated after ED14–15
(Fig. 29.1) when the systemic circulatory system is established. This upregulated
expression of TNC may reflect the increased hemodynamic stress on the aortic wall.
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29.3.2 Development of Coronary Artery and Tenascin-C
Coronary vessels are formed with the cells originating mostly from extracardiac
tissue known as the proepicardial organ (PE) (see [14] for review). During coronary
development, strong expression of TNC is observed, closely associated with
thickening of the medial layer when the primitive coronary vasculature connects
with the aortic sinuses [15], suggesting a significant role of TNC in maturation of
the wall of coronary arteries. Indeed, TNC accelerates the differentiation of mesen-
chymal cells of PE to smooth muscle cells in culture [15]. Maturation of the
vascular wall is regulated by various signaling pathways. In particular, the
PDGF-BB/PDGFR-β signaling loop is known to be a key regulator of smooth
muscle cell recruitment. In vitro, TNC amplifies crosstalk signaling between
integrin αvβ3 and PDGF receptor (PDGFR) -β in smooth muscle cells, followed
by enhancing cell proliferation and migration [16]. TNC may promote smooth
muscle precursor expansion and differentiation in maturation of the vascular wall
by enhancing PDGF-BB/PDGFR-β signaling (Fig. 29.2).
Tenascin-C in developing aorta 







Fig. 29.1 Expression pattern of TNC during development of the aorta. Whole mount lacZ
staining and histological sections of descending portion of the thoracic aorta of TNC-reporter
mouse embryos at ED12–15. The sections were immunostained with anti-TNC or anti-α-smooth
muscle actin or stained with elastica sirius red
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29.4 Future Direction and Clinical Implications
The characteristic spatiotemporally restricted expression of TNC has suggested its
significant role during embryonic development. Several in vitro functional assays
support this possibility. Although the grossly normal phenotype of knockout mice
suggests the importance of redundancy and compensatory mechanisms during
embryonic development, it is not straightforward to understand its molecular
function. Meanwhile, TNC expression is linked to a range of vascular diseases,
such as aortic aneurysm, acute aortic dissection, and Kawasaki disease (reviewed in
[11, 17], also see Yoshikane et al. in this proceeding). Increasing numbers of studies
have reported that TNC is highly upregulated, associated with inflammation and
destruction of the vascular wall, suggesting that TNC may be a diagnostic bio-
marker. Furthermore, we have succeeded in endovascular treatment of a rat aneu-
rysm model with a TNC-coated coil [18]. Although TNC could contribute to both
favorable and undesirable effects during pathological processes in a context-
dependent manner, it could be a potential therapeutic target for vascular disease.
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Fig. 29.2 Crosstalk signaling between TNC/integrin αvβ3 and PDGF-BB/PDGFR-β in vascular
smooth muscle cells (Adapted from Ref. [7])
29 Extracellular Matrix Remodeling in Vascular Development and Disease 225
Open Access This chapter is distributed under the terms of the Creative Commons Attribution-
Noncommercial 2.5 License (http://creativecommons.org/licenses/by-nc/2.5/) which permits any
noncommercial use, distribution, and reproduction in any medium, provided the original author(s)
and source are credited.
The images or other third party material in this chapter are included in the work’s Creative
Commons license, unless indicated otherwise in the credit line; if such material is not included in
the work’s Creative Commons license and the respective action is not permitted by statutory
regulation, users will need to obtain permission from the license holder to duplicate, adapt or
reproduce the material.
References
1. Byers PH, Murray ML. Ehlers-Danlos syndrome: a showcase of conditions that lead to
understanding matrix biology. Matrix Biol. 2014;33:10–5.
2. Dietz HC, Cutting GR, Pyeritz RE, et al. Marfan syndrome caused by a recurrent de novo
missense mutation in the fibrillin gene. Nature. 1991;352:337–9.
3. Sage EH, Bornstein P. Extracellular proteins that modulate cell-matrix interactions. Sparc,
tenascin, and thrombospondin. J Biol Chem. 1991;266:14831–4.
4. Bornstein P. Matricellular proteins: an overview. J Cell Commun Signal. 2009;3:163–5.
5. Chiquet-Ehrismann R, Tucker RP. Tenascins and the importance of adhesion modulation.
Cold Spring Harb Perspect Biol. 2011;3.
6. Midwood KS, Orend G. The role of tenascin-c in tissue injury and tumorigenesis. J Cell
Commun Signal. 2009;3:287–310.
7. Imanaka-Yoshida K. Tenascin-c in cardiovascular tissue remodeling. Circ
J. 2012;76:2513–20.
8. Udalova IA, Ruhmann M, Thomson SJ, et al. Expression and immune function of tenascin-c.
Crit Rev Immunol. 2011;31:115–45.
9. Tucker RP, Chiquet-Ehrismann R. The regulation of tenascin expression by tissue
microenvironments. Biochim Biophys Acta. 2009;1793:888–92.
10. Marin JL, Muniz J, Huerta M, et al. Folding-unfolding of fn-iii domains in tenascin: an
elastically coupled two-state system. J Biomech. 2003;36:1733–7.
11. Imanaka-Yoshida K, Yoshida T, Miyagawa-Tomita S. Tenascin-c in development and disease
of blood vessels. Anat Rec. 2014;297:1747–57.
12. Kimura T, Furusho A, Ito S et al. Tenascin c protects aorta from acute dissection in mice. Sci
Rep. 2014;4:4051.
13. Majesky MW. Developmental basis of vascular smooth muscle diversity. Arterioscler Thromb
Vasc Biol. 2007;27:1248–58.
14. Nakajima Y, Imanaka-Yoshida K. New insights into the developmental mechanisms of
coronary vessels and epicardium. Int Rev Cell Mol Biol. 2013;303:263–317.
15. Ando K, Takahashi M, Yamagishi T, et al. Tenascin c may regulate the recruitment of smooth
muscle cells during coronary artery development. Differentiation. 2011;81:299–306.
16. Ishigaki T, Imanaka-Yoshida K, Shimojo N, et al. Tenascin-c enhances crosstalk signaling of
integrin alphavbeta3/pdgfr-beta complex by src recruitment promoting pdgf-induced prolifer-
ation and migration in smooth muscle cells. J Cell Physiol. 2011;226:2617–24.
17. Gaengel K, Genove G, Armulik A, et al. Endothelial-mural cell signaling in vascular develop-
ment and angiogenesis. Arterioscler Thromb Vasc Biol. 2009;29:630–8.
18. Toma N, Imanaka-Yoshida K, Takeuchi T, et al. Tenascin-c-coated platinum coils for accel-
eration of organization of cavities and reduction of lumen size in a rat aneurysm model. J
Neurosurg. 2005;103:681–6.
226 K. Imanaka-Yoshida
The “Cardiac Neural Crest” Concept
Revisited 30
Sachiko Miyagawa-Tomita, Yuichiro Arima, and Hiroki Kurihara
Abstract
Neural crest cells (NCCs) are a unique stem cell population, which originate
from the border between the neural plate and surface ectoderm and migrate
throughout the body to give rise to multiple cell lineages during vertebrate
embryonic development. The NCCs that contribute to heart development,
referred to as the cardiac NCCs, have been assigned to the neural crest at the
level of the postotic hindbrain. Recently, we found that the NCCs from the
preotic region migrate into the heart and partially differentiate into coronary
artery smooth muscle cells. This finding indicates that the origin of the cardiac
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NCCs appears more widely extended to the anterior direction than Kirby
et al. first designated.
Keywords
Neural crest • Preotic • Postotic • Coronary artery • Endothelin
30.1 Introduction
The neural crest (NC) was first identified by Wilhelm His as “Zwischenstrang,” the
intermediate cord, in 1868 [1], the year of Meiji Ishin, the westernizing revolution
of Japan. It is located at the border between the developing neural plate and surface
ectoderm and serves as a source of migratory cells spreading throughout the body.
The NC research was greatly accelerated by the establishment of quail-chick
chimera technique accomplished by Nicole Le Douarin [2]. This technique enabled
tracing the origin and fate of the NC during embryonic development and revealed
that NC cells (NCCs) differentiate into a wide variety of cell types including
neurons, glia, pigment cells, and craniofacial bones and cartilages in different
developmental contexts [2]. Thus, NCCs are nowadays regarded as a multipotent
stem cell population with unique differentiation capacities.
30.2 Cardiac Neural Crest Arising from the Postotic Region
Since Margaret Kirby discovered that NCCs at the level of occipital somites 1–3
migrate to the region of the aorticopulmonary septum [3], the concept “cardiac
neural crest” has prevailed to cover NCCs contributing to the formation of the heart
and great vessels. NCCs arising from the postotic hindbrain posterior to the
mid-otic vesicle, corresponding to rhombomeres (r) 6–8, migrate into the third,
fourth, and sixth pharyngeal arches and contribute to the formation of the tunica
media of pharyngeal arch artery-derived great vessels, the aorticopulmonary sep-
tum, and the outflow tract endocardial cushion as well as some noncardiac organs
such as the thymus, parathyroid glands, and thyroid glands [4]. Ablation of the
cardiac NC in chick embryos results in aortic arch anomalies and persistent truncus
arteriosus [3, 5, 6]. In addition to direct contribution to the cardiovascular structure,
cardiac NCCs affect the migration and alignment of myogenic precursors from the
second heart field migrating into the outflow region.
Chromosome 22q11.2 deletion syndrome, formerly known as DiGeorge syn-
drome, velocardiofacial (Shprintzen) syndrome, and conotruncal anomaly face
(Takao) syndrome, is a disease complex characterized by craniofacial, thymic,
and parathyroid anomalies and cardiac manifestations including tetralogy of Fallot,
persistent truncus arteriosus, and aortic arch anomalies [7]. This syndrome was
formerly recognized as an NC disorder because of its resemblance to the avian
phenotype of NC ablation. However, identification and analysis of the responsible
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genes in the 22q11.2 locus such as TBX1 and CRKL and related factors have
revealed that the pathogenesis is far more complex, involving interaction among
NCCs, second heart field, endoderm, and other cell components.
30.3 Endothelin Signal and Neural Crest Development
Endothelin (Edn)-1 (Edn1), originally identified as a potent vasoconstrictor peptide,
is a key regulator of craniofacial and cardiovascular development, acting on NCCs
expressing Edn receptor type A (Ednra), a G protein-coupled receptor [8–10]. Inac-
tivation of Edn1-Ednra signaling causes homeotic-like transformation of the lower
jaw into an upper jaw structure and cardiovascular anomalies similar to chromo-
some 22q11.2 deletion syndrome. The craniofacial and cardiovascular anomalies
are attributed to the disordered development of cranial (preotic) and cardiac
(postotic) NCCs, respectively. In craniofacial development, the Edn1-Ednra signal-
ing activates Gαq-/Gα11-dependent pathway, resulting in the induction of Dlx5/
Dlx6, homeobox genes critical to ventral (mandibular) identity of the pharyngeal
arches [10–12]. In cardiovascular development, the Edn1-/Ednra-null phenotype of
aortic arch anomalies is independent of Dlx5/Dlx6 [13], indicating that the Edn1-
Ednra signaling pathway appears differently involved in craniofacial and cardiac
development.
30.4 Preotic Neural Crest Contributing to Heart Development
Recently, we identified an additional cardiac phenotype of Edn1-/Ednra-null mice
in the coronary artery [14]. The mutant mice exhibit marked dilatation of the septal
branch and abnormalities of orifice and proximal branch formation. Labeling of
NCCs using Wnt1-Cre;Rosa26R reporter mice revealed that NCCs contribute to
coronary artery smooth muscle cells in the proximal region and septal branch, and
NCC-derived smooth muscle cells are hardly detected in the smooth muscle layer in
Edn1-/Ednra-null embryos. Correspondingly, NCC-specific knockout of Gα12/
Gα13 rather than Gαq/Gα11 results in similar dilatation of the coronary artery septal
branch [15], indicating that Edn1/Ednra signaling is necessary for NCC recruitment
to coronary artery formation via Gα12/Gα13 and downstream Rho signaling.
Here, we faced to a conundrum where the NCCs came from. It had long been
controversial whether and how NCCs contribute to coronary artery formation.
Although NC-derived cell clusters are formed in association with the proximal
portion of coronary arteries, quail-chick chimera experiments have shown that the
cardiac NCCs do not differentiate into coronary smooth muscle cells [16, 17]. In
contrast,Wnt1-Cremice have indicated the possible direct involvement of NCCs as
the source of coronary artery smooth muscle cells [18]. The apparent discrepancy
was sometimes ascribed to differences in species, but no definite explanation had
been given for it.
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This controversy was settled by quail-chick chimera experiments, in which
different regions of the chick neural folds were homotopically replaced by quail
tissues. When the cardiac (postotic) NC at the level of r6-r8 (posterior to the
mid-otic vesicle) was replaced, no contribution of quail NCCs to the wall of
coronary arteries was observed. In contrast, replacement of the NC by exchanging
the midbrain and preotic hindbrain (r1-r5) neural folds anterior to the otic vesicle
resulted in a significant number of quail NCCs distributing into the heart and
differentiating into coronary artery smooth muscle cells. The intracardiac migration
of preotic NCCs and their contribution to the coronary artery smooth muscle layer
were also confirmed by experiments using R4-Cre;Z/AP reporter mice, in which
r4-derived preotic NCCs were specifically and permanently labeled. Furthermore,
ablation of the preotic NC in chick embryos caused abnormalities in coronary septal
branch and orifice formation, reminiscent of the Edn1-/Ednra-null phenotype.
Are preotic and postotic NCCs spatially segregated within the heart region to
play distinct roles? Double labeling with different dyes of premigratory NCCs at the
levels of r3/4 (preotic) and somites 1/2 (postotic) in chick embryos revealed
sequential migration of NCCs from preotic to postotic neural folds. Consequently,
preotic and postotic NCCs distribute differently within the heart and great vessel-
forming regions after migration, with anteroposterior order of NCCs corresponding
to their proximodistal location within the heart. Preceding preotic NCCs are likely
to differentiate into coronary artery smooth muscle cells, whereas subsequent
postotic NCCs predominantly form the aorticopulmonary septum and the smooth
muscle layer of the aorta and pulmonary artery (Fig. 30.1). In addition, both NCC
populations differently distribute within semilunar valves, suggesting their distinct
roles in valve formation (Fig. 30.1).
30.5 Future Direction and Clinical Implications
Identification of preotic NCCs as an origin of cardiac cellular components may
provide a novel insight into cell lineage-based understanding of cardiac develop-
ment, anatomy, and (patho-)physiology. The spatiotemporal pattern of preotic NCC
migration and distribution suggests close interaction with second heart field-derived
mesodermal cells. In coronary artery formation, interactions between preotic NCCs
and other precursor cells from different origins such as the proepicardium and
endocardium seem to be an important issue to be addressed. Considering endothe-
lial and endocardial cells are major source of Edn1, the Edn signaling may play a
role in these interactions.
From a clinical viewpoint, it is intriguing to pursue the relationship between the
NC origin and susceptibility to atherosclerosis and calcification of the proximal
coronary arteries. Preotic NCCs retain multipotent capacities including osteogenic
and chondrogenic differentiation, leading us to speculate a possibility that these
capacities may be related to the pathogenesis and progression of coronary artery
diseases. Characterization of preotic NC-derived smooth muscle cells and other
derivatives may open perspectives toward novel therapeutic strategies.
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des Hühnchens im Ei. Leipzig: FCW Vogel; 1868.
2. Le Douarin N, Kalcheim C. The neural crest. 2nd ed. Cambridge: Cambridge University Press;
1999.
3. Kirby ML, Gale TF, Stewart DE. Neural crest cells contribute to normal aorticopulmonary
septation. Science. 1983;220:1059–61.
4. Kirby ML, Hutson MR. Factors controlling cardiac neural crest cell migration. Cell Adh Migr.
2010;4:609–21.
5. Nishibatake M, Kirby ML, Van Mierop LH. Pathogenesis of persistent truncus arteriosus and









• Smooth muscle of the aorta 
and pulmonary artery
• Valvular tissue
• Coronary artery 
smooth muscle
• Valvular tissue
Fig. 30.1 Different contributions of preotic and postotic NCCs to craniofacial and cardiovascular
development. Preotic NCCs migrate into the first and second pharyngeal arches to differentiate
into the bone, cartilage, teeth, and connective tissue, a part of which further migrates into the heart
to differentiate into the coronary artery smooth muscle and valvular tissues. Postotic NCCs follow
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Roles of Endothelial Hrt Genes for Vascular
Development 31
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Various cellular signaling pathways play essential roles in regulating embryonic
vascular development. Among them, Notch signaling is implicated in arterial
endothelium differentiation and vascular morphogenesis. Mice that lack Notch
receptors or other signaling components die in utero due to severe vascular
abnormalities. We previously identified the Hairy-related transcription (Hrt) factor
family, also called Hey, Hesr, CHF, Herp, and Gridlock, as downstream mediators
of Notch signaling in the developing vasculature [1]. The Hrt family proteins, Hrt1/
Hey1, Hrt2/Hey2, and Hrt3/HeyL, mainly act as transcriptional repressors, by
binding to consensus DNA elements or by associating with other DNA-binding
transcription factors. The mice deficient for Hrt2 showed perinatal lethality due to
ventricular septal defects and mitral valve insufficiency, and cardiomyocyte-
specific deletion of Hrt2 caused abnormal expression of atrial-specific genes in
the ventricle and cardiac dysfunction in adulthood [2].
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It was also reported that combined loss of Hrt1 and Hrt2 resulted in early
embryonic lethality due to vascular demise similar to that observed in Notch
signal-deficient embryos. While Hrt1 and Hrt2 are expressed in endothelial cells
as well as smooth muscle cells of embryonic vasculature, it remained unclear which
vascular cell type requires Hrt1/Hrt2 functions. In the present study, we generated
the mice with endothelial-cell-specific deletion of Hrt2 combined with global Hrt1
null mutation and analyzed their vascular phenotypes during embryonic develop-
ment. The loss of endothelial Hrt1/Hrt2 caused early vascular abnormalities virtu-
ally identical to those observed in the global Hrt1/Hrt2 knockout mouse embryos
(Fig. 31.1), suggesting that Hrt functions in endothelial cells are indispensable for
normal vascular development.
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Fig. 31.1 The mice in which Hrt2 was deleted specifically in endothelial cells with the global
Hrt1 null background (H1ko/H2eko) show embryonic lethality with severe defects of vascular
morphogenesis. Whole mount PECAM1 immunostaining demonstrated impairment of vascular
network formation in H1ko/H2eko embryos
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The placental circulation is crucial for the development of mammalian embryos
[1]. The labyrinth layer in the placenta is created by extensive villous branching of
the trophoblast and vascularization arising from the embryonic mesoderm. In the
labyrinth, materials are exchanged between the maternal and embryonic circula-
tion. Recently, we have found that inositol 1,4,5-trisphosphate (IP3) receptors
(IP3Rs) may be required for the placental vascularization.
IP3Rs are intracellular Ca
2+ release channels that have three subtypes in
mammals (IP3R1, IP3R2 and IP3R3) [2]. We previously showed that IP3R1 and
IP3R2 played an essential role in heart development from the analysis of mouse
embryo double knockout for IP3R1 and IP3R2 [3]. A previous report on the
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requirement for phospholipase (PLC) δ1 and δ3 [4] that produce IP3 for placenta-
tion led us to investigate the placental defects by deletion of any subtypes of IP3Rs.
Our preliminary result revealed that embryonic vasculature in the labyrinth was
impaired in the placenta double knockout for IP3R1 and IP3R3 at E9.25 (Fig. 32.1).
The detailed phenotype and the underlying mechanism how the intracellular Ca2+
signaling via IP3Rs may be implicated in the development of extraembryonic
vasculature are under investigation.
This work was supported by a Grant-in-Aid for Scientific Research from the
Ministry of Education, Culture, Sports, Science and Technology, Japan (to K.U.
and H.Y.).
Open Access This chapter is distributed under the terms of the Creative Commons Attribution-
Noncommercial 2.5 License (http://creativecommons.org/licenses/by-nc/2.5/) which permits any
noncommercial use, distribution, and reproduction in any medium, provided the original author(s)
and source are credited.
The images or other third party material in this chapter are included in the work’s Creative
Commons license, unless indicated otherwise in the credit line; if such material is not included in
the work’s Creative Commons license and the respective action is not permitted by statutory
regulation, users will need to obtain permission from the license holder to duplicate, adapt or
reproduce the material.
Fig. 32.1 Cross sections of E9.25 placentas from the IP3R1
+/3/ (a and b) and IP3R1
/3/
(c and d) mice. (b) and (d) show higher-power fields of the rectangular areas of the labyrinth in (a)
and (c), respectively. Embryonic vessels (arrowheads) fail to elongate to the maternal sinuses in
the placenta of IP3R1
/3/ compared to that of IP3R1
+/3/ (wild type). al allantois, de
decidua, gi trophoblast giant cells, la labyrinth layer, sp spongiotrophoblast layer. Scale bars,
0.5 mm in (a) and (c) and 0.2 mm in (b) and (d)
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Kawasaki disease is the most common acute systemic vasculitis of unknown
etiology in children [1] and can cause inflammation of the coronary arteries leading
to aneurysms. Tenascin-C, an extracellular matrix protein, and c-Jun N-terminal
kinase (JNK), an intracellular signaling protein, are known to be associated with
inflammation and tissue remodeling [2, 3]. The purpose of this study was to
demonstrate tenascin-C and JNK might be involved in tissue remodeling in a
Candida albicans-induced murine model of aneurysm.
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1. More than 80 % of the mice showed the macroscopic features of aneurysms in
the aorta and/or iliac and coronary arteries.
2. Marked inflammatory cell infiltration was observed in vascular wall and
perivascular connective tissue, accompanied by fragmentation of elastic fibers.
3. Expression of tenascin-C was highly observed in vascular wall, accompanied by
active degradation of elastic fibers.
4. Pharmacologic inhibition of JNK attenuated the aneurysm formation in the mice
model.
In conclusion, these findings suggest that both tenascin-C and JNK are involved
in abnormal tissue remodeling and inflammation in the Candida albicans-
induced Kawasaki disease murine model of aneurysm and that JNK inhibition
may represent a novel therapeutic target for preventing a Kawasaki disease-related
aneurysm.
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The ductus arteriosus (DA), an important fetal artery that connects the main
pulmonary artery and the aortic arch, closes immediately after birth. Therefore,
closure of the DA is a symbolic event of the change from fetal to neonatal
circulation. When the DA remains open after the first 3 days of life in humans,
the condition is called patent DA (PDA), and it usually causes a left-to-right shunt.
If the shunt volume significantly increases, neonates may exhibit pulmonary edema
and respiratory distress. Especially in preterm infants, PDA could be a serious life-
threatening risk. The incidence of PDA unaccompanied by any other cardiovascular
abnormality has been estimated to be 0.06 % of term infants, and the incidence
sharply increases in premature infants. Symptomatic PDA cases have been found in
28 % of infants with very low birth weight (<1500 g) and 55 % of infants with
extremely low birth weight (<1000 g). On the other hand, PDA is lifesaving in
some patients with congenital heart diseases such as hypoplastic left heart syn-
drome and pulmonary atresia. The DA must be open to maintain blood flow in the
systemic or pulmonary circulation. Current pharmacological treatment for closing
or maintaining PDA is limited to the agents that control the vasodilatory effect of
prostaglandin E2 (PGE2), such as cyclooxygenase inhibitors or PGE1 preparations.
DA closure is thought to occur in response to a combination of two different
mechanisms. One mechanism is an acute response of smooth muscle constriction
within the first several hours of life, known as functional closure of the DA. The
other is a relatively chronic response of structural change in the DA during the
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perinatal period, known as anatomical closure or vascular remodeling, such as
progression of neointimal thickening and impaired elastic fiber formation. After
shutting down blood flow, progressive apoptosis and fibrotic changes occur in the
DA, resulting in permanent DA closure and a remnant structure known as the
ligamentum arteriosum. In this part, four studies highlight the recent advances in
molecular mechanisms underlying DA closure from the perspective of functional
and anatomical closure.
The primary driving force behind functional DA closure is an increase in oxygen
tension and a decrease in circulating PGE2. The DA is an oxygen-sensitive vessel.
Several potassium channels are known to play an important role in the oxygen-
sensing system. Momma et al. show that ATP-sensitive potassium channels (KATP
channels) are another oxygen sensor. They show that sulfonylureas, which are
commonly used to treat diabetes, inhibit KATP channels to constrict the DA,
suggesting that sulfonylureas can be used for patients with PDA. The response to
oxygen is weaker in premature DA than in mature DA. Hayama et al. investigate the
developmental changes in the contractile apparatus and sarcoplasmic reticulum in
the DA and its connecting arteries that may contribute to the oxygen-sensitive
mechanism.
Anatomical closure of the DA is associated with distinct differentiation of the
vessel wall. Intimal thickening is the most prominent phenotypic change, and it
involves several processes: (a) an area of subendothelial extracellular matrix
deposition, (b) the migration of undifferentiated medial smooth muscle cells
(SMCs) into the subendothelial space, and (c) the disassembly of the internal elastic
lamina and the loss of elastic fibers in the medial layer. Yokoyama
et al. demonstrate that chronic activation of the PGE2 receptor EP4 plays a pivotal
role in neointima formation and impaired elastic fiber formation in the
DA. Therefore, PGE2 signaling has dual roles in functional and anatomical DA
closure. DA remodeling is known to resemble the vascular remodeling of aging
arteries. Gittenberger-de Groot et al. demonstrate that progerin, an alternative splice
variant of lamin A/C, is highly expressed in the closing DA as well as in premature
aging of vessels in children with Hutchinson progeria syndrome, suggesting that
progerin plays a role in vascular remodeling of the DA.
These studies show that development of a new strategy to treat DA closure or
opening first requires understanding of the precise molecular mechanisms underly-
ing both functional and anatomical DA closure.
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Progerin Expression during Normal Closure
of the Human Ductus Arteriosus: A Case
of Premature Ageing?
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Abstract
The ductus arteriosus (DA) is a fetal vessel bypassing the still nonfunctional
lungs. Closure of the DA at birth is essential for the transition from a fetal to a
neonatal circulation. This closing process begins with a physiological contrac-
tion followed by definitive anatomical closure. The latter process starts already
before birth by development of intimal thickening followed after birth by
degeneration of the inner media, including cytolytic necrosis and apoptosis.
The DA will remain patent when there is insufficient maturation in prematurely
born babies or when there is a structural abnormality as seen in persistent DA
(PDA). The histological changes during normal DA closure resemble the
features seen in the premature ageing vessels in children with the Hutchinson
progeria syndrome. The latter syndrome is caused by a mutation in the lamin
A/C gene resulting in accumulation of the progerin splice variant. We studied
human DA biopsies from the fetal to the neonatal period to investigate whether
lamin A/C and progerin might be involved in the DA closure process. The results
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show an increase in the intima and inner media of progerin in the normal
neonatal DA, while expression of lamin A/C is diminished. In the non-closing
aorta, the fetal DA and the PDA, no or hardly any progerin expression was
found. We postulate that the lamin A/C to progerin balance is important during
normal anatomical closure of the DA presenting a unique case of physiological
premature vascular ageing.
Keywords
Lamin A/C Progerin • Atherosclerosis • Apoptosis • Vascular biology •
Persistent ductus arteriosus
34.1 Introduction
The ductus arteriosus (DA) is a fetal vessel that connects the pulmonary trunk to the
distal aortic arch. The patent DA is functional before birth directing oxygen-rich
blood from the placenta to the systemic circulation bypassing the still immature
lung vascular bed. After birth, the DA contracts, and this physiological closure is
followed by definitive anatomical closure. Ultimately, the DA will be remodeled
into a fibrous strand [1, 2]. The physiological closure is regulated by many
substances in which prostaglandins play an important role [3]. The onset of
anatomical closure in the human fetus starts already in the second trimester of
gestation with blebbing of the endothelium and formation of intimal thickening
[2]. The degenerative changes in the media, in which cytolytic necrosis and
apoptosis play an important role [4], start immediately after birth. By then, marked
intimal thickening supports the closure of the DA upon contraction. This maturation
process of ductal closure (Fig. 34.1) follows a temporo-spatial pattern. Upon
premature delivery of the baby, the DA closure process may not be effective already
resulting in an immature patent DA. Usually, this resolves spontaneously within a
few days to weeks after birth. The process might be enhanced by providing
prostaglandin inhibitors like indomethacin [2]. Another reason for non-closure
resulting in a persistent DA (PDA) may be structural abnormalities, in most cases
based on an elastin deposition problem [3]. The histological features of normal DA
closure resemble atherosclerotic changes in the vessel wall albeit without the
atheroma component [5]. The mature DA vessel wall structure is highly similar
to the premature ageing histopathology seen in vessels of children with the
Hutchinson-Gilford syndrome (HGPS) [6]. This syndrome is based on a genetic
defect in the lamin A (LMNA) gene which leads to pathological accumulation of the
splice variant progerin [7, 8]. Increased progerin expression has also been reported
during normal vascular ageing [9, 10]. Based on the observed similarities, we
investigated the role of an LMNA/progerin balance during normal perinatal closure
of the DA.
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34.2 Material and Methods
Following aortic arch reconstruction and surgical closure of the DA, a biopsy
specimen of human neonatal DA (n¼ 16) and adjoining descending aorta (n¼ 2)
was obtained. The fetal DA (one of 14 weeks’ and one of 18 weeks’ gestation) was
Fig. 34.1 Schematic representation of the aortic arch and the cross sections of the muscular
ductus arteriosus with intimal thickening (DA) and the elastic aorta (AO) and pulmonary artery
(PA), during the fetal, neonatal, and adult stage of DA, in which the latter is remodeled into a
ligament
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acquired from postmortem fetal specimen after legal or spontaneous abortion. One
biopsy specimen was obtained from a 2-year-old child with PDA. Details on
sectioning, fixation, and immunohistochemistry have been described as well as
the technique for RNA isolation and RT-PCR reactions [11].
34.3 Results
The RT-PCR studies of the aorta and neonatal DA revealed that next to lamin A
also progerin was detected. Lamin A was seen both in the aorta and neonatal DA,
while low levels of progerin were only seen in the neonatal DA [11]. The elastin
expression showed clearly that the DA is a muscular artery, while the aorta is an
elastic artery (Fig. 34.2a, d, e, j). Immunohistochemistry of the tissue sections
Fig. 34.2 Transverse histological sections of the ductus arteriosus (DA) and the aorta (AO). (a)
Overview of the DA wall with a resorcin-fuchsin staining (RF) showing the morphology of a
muscular artery with an internal elastic membrane (IEL) (a, d) between the intima (I) and the
media (m). In the inner media, there is cytolytic necrosis (CN), which is better appreciated by the
alpha smooth muscle actin loss (actin) in the smooth muscle cells (b). The endothelial cells (ECs)
are negative for actin, also in the AO (f, g). (e) Overview of the elastic wall of the AO with a
regular manifestation of elastic lamellae (j) and marked actin staining in the smooth muscle
cells (k). There is no CN in the aorta. (c, h, i, l) In both the DA and AO lamin A/C, positive
cells are found. ECs are negative for lamin A/C. Adventitia: A
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revealed alpha smooth muscle actin to be present in all cases studied both in the
intima (when thickened) and in the media. The expression level of alpha
smooth muscle actin became less in the cases of a normal closing neonatal DA
where inner media degeneration was seen with developing cytolytic necrosis
(Fig. 34.2a, b). Furthermore, the expression of lamin A/C was found in all DA
and the aorta with exception of the 14-week fetal DA. There was a clear difference
with regard to progerin expression (Fig. 34.3). This was only found in the normal
closing neonatal DA. If the latter was already fully developed including apoptosis
and loss of nuclei, the progerin expression was diminished. This shows that
progerin expression precedes apoptosis and degeneration. Progerin was not
detected in the fetal 18-week DA, being also absent in the non-closing PDA and
aorta.
Fig. 34.3 (a) Overview of the intima (I) and media (M) of a 10-day-old neonatal ductus arteriosus
(DA) with faint cytoplasmic and strong nuclear and perinuclear expression of progerin in the
vascular smooth muscle cells of the media (c) and intima (d). The endothelial cells (ECs) are
negative (b, d). (e) In the aortic wall (AO), no regions with strong progerin expression are found
(g, h). ECs are also negative (f, h). IEL internal elastic lamina. Bars ¼ 30 μm
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34.4 Discussion
Normal ductal closure is regulated by many molecular pathways [3]. In our study,
we introduced for the first time a role for lamina A/C and progerin [11]. This
observation was triggered by the histopathology found in the vessel wall of young
adolescents with the HGPS [8], in which premature atherosclerosis was observed.
The physiological development of prenatal intimal thickening and the development
of cytolytic necrosis in the DA showing contractions after birth mimic the degener-
ative changes seen in the HGPS. Alterations in the farnesylation process can be the
cause of accumulation of progerin at the nuclear membrane. This process is
associated with the initiation of apoptosis in these progerin-expressing cells [12],
being characteristic for degeneration in the DA media [13]. The cause for progerin
increase in the closing DA needs further investigation, but it is known that alterna-
tive splicing is affected by oxidative stress [14] which is activated during normal
DA closure [15]. Accumulation of reactive oxygen species has also been observed
during vascular ageing [10] in which an increase of progerin has been described in
the smooth muscle cells of the coronary vessels of elderly persons as well as a
gradual increase of progerin-expressing cells in other vessels with upclimbing age
[7, 10]. It is noteworthy that the non-closing PDA, although only one case has been
studied, and the aorta did not show progerin increase in the neonatal stage. This
aspect needs further study as in families with bicuspid aortic valve (BAV) a
correlation with PDA [16] has been reported. Unpublished data from our group
show a diminished progerin expression in the dilated ascending aorta in BAV as
compared to dilation of the aorta in tricuspid valves. The latter shows an increase in
progerin indicative of advanced ageing.
Potentially, ductal closure based on increased progerin expression could lead to
fetal demise in HGPS; this has, however, not been reported.
34.5 Future Directions and Clinical Applications
Further research is necessary to elucidate the role of the lamin A/C to progerin
balance in vascular pathology, ageing, and the unique observation in selective DA
closure at birth.
Clinical applications might be related to the use of farnesyltransferase inhibitors
which may prevent onset and progression induced by the accumulation of progerin
[17]. It cannot be excluded that inhibition of physiological progerin expression
might prevent anatomical closure of the DA, which can be relevant in ductus-
dependent congenital heart disease.
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The Multiple Roles of Prostaglandin E2
in the Regulation of the Ductus Arteriosus 35
Utako Yokoyama, Susumu Minamisawa, and Yoshihiro Ishikawa
Abstract
The ductus arteriosus (DA) is a shunt vessel between the aorta and the pulmo-
nary artery during the fetal period. It is well recognized that prostaglandin E2
(PGE2) dilates the DA through activation of its receptor EP4 and subsequent
cyclic AMP (cAMP) production during the fetal period and that oxygen
constricts the DA by inhibiting potassium channels immediately after birth. In
addition to the regulation of vascular tone, morphological remodeling of the DA
throughout the perinatal period, such as prominent intimal thickening and poor
elastogenesis, has been demonstrated.
We recently identified the molecular mechanisms of the acquisition of unique
morphological remodeling in the DA during development. During the fetal
period, PGE2-EP4 signaling decreases elastic fiber formation through degrada-
tion of the cross-linking enzyme lysyl oxidase (LOX) and increases hyaluronan-
mediated intimal thickening in the DA. This remodeling is mediated by activa-
tion of the EP4 receptor via diverse downstream intracellular signaling
pathways. Hyaluronan-mediated intimal thickening was induced by the
EP4-Gs protein-cyclic AMP-protein kinase A pathway. The attenuation of
elastogenesis is mediated through a non-cyclic AMP signaling pathway, such
as c-src-phospholipase C (PLC). These data suggest that placental PGE2-
mediated vascular remodeling via different signaling pathways orchestrates the
subsequent luminal DA reorganization, leading to complete obliteration of
the DA.
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35.1 Introduction
The ductus arteriosus (DA) normally closes immediately after birth. Although the
DA is a normal and essential fetal structure, it becomes abnormal if it remains
patent after birth. DA closure occurs in two phases: functional closure of the lumen
in the first hours after birth by smooth muscle constriction and anatomic occlusion
of the lumen over the next several days due to extensive neointimal thickening in
human DA [1–3]. There are several events that promote DA constriction immedi-
ately after birth. Increasing oxygen tension and a dramatic decrease in circulating
PGE2 promote muscular constriction of the DA. In addition, DA remodeling is also
necessary for its complete closure. Remodeling is characterized by (a) an area of
subendothelial deposition of extracellular matrix [4], (b) the disassembly of the
internal elastic lamina and loss of elastic fiber in the medial layer [5], and
(c) migration into the subendothelial space of undifferentiated medial smooth
muscle cells (SMCs). Some of these changes begin about halfway through gesta-
tion, and some occur after functional closure of the DA in the neonate [3, 6]. In
addition to the well-known vasodilatory role of PGE2, our findings revealed the role
of PGE2 in the anatomical closure of the DA.
35.2 The Molecular Mechanisms of Intimal Thickening
of the Ductus Arteriosus
35.2.1 Hyaluronan-Mediated Intimal Thickening
PGE2 plays a primary role in maintaining the patency of the DA via its receptor EP4.
However, previous studies have demonstrated that genetic disruption of the PGE
receptor EP4 paradoxically results in fatal patent DA in mice [7, 8]. In addition,
double mutant mice in which cyclooxygenase (COX)-1 and COX-2 are disrupted also
exhibit patent DA [9]. We found that intimal thickening was completely absent in the
DA of EP4-disrupted neonatal mice [3]. Moreover, a marked reduction in hyaluronan
production was found in EP4-disrupted DA, whereas a thick layer of hyaluronan
deposit was present in wild-type DA. PGE2-EP4-cyclic AMP (cAMP)-protein kinase
A (PKA) signaling upregulates hyaluronan synthase type 2 mRNA, which increases
hyaluronan production in the DA. Accumulation of hyaluronan then promotes SMC
migration into the subendothelial layer to form intimal thickening [3].
EP4 is a Gs protein-coupled receptor that increases intracellular cAMP by
adenylyl cyclases (ACs) consisting of nine different isoforms of membrane-
bound forms of ACs (AC1 through AC9). We found that AC2 and AC6 are more
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highly expressed in rat DA than in the aorta during the perinatal period [10]. Our
data using AC subtype-targeted siRNAs and AC6-deficient mice suggest that AC6
is responsible for hyaluronan-mediated intimal thickening of the DA, whereas AC2
inhibits AC6-induced hyaluronan production. The activation of both AC2 and AC6
induces vasodilation.
35.2.2 Epac-Mediated SMC Migration
In addition to PKA, a new target of cAMP that is an exchange protein activated by
cAMP has recently been discovered; it is called Epac [11]. Epac is a guanine
nucleotide exchange protein that regulates the activity of small G proteins and
has been known to exhibit a distinct cAMP signaling pathway that is independent of
PKA [12]. There are two variants: Epac1 is expressed in most tissues, including the
heart and blood vessels, whereas Epac2 is expressed in the adrenal gland and the
brain. Although both Epac1 and Epac2 are upregulated during the perinatal period,
Epac1, but not Epac2, acutely promotes SMCmigration and thus intimal thickening
in the DA [13]. Since Epac stimulation does not increase hyaluronan production,
the effect of Epac1 on SMC migration is independent of that of hyaluronan
accumulation, which operates through a mechanism different from that underlying
PKA stimulation.
35.2.3 Regulation of Elastogenesis
Elastic fiber formation begins in mid-gestation and increases dramatically during
the last trimester in the great arteries. However, the DA exhibits lower levels of
elastic fiber formation [5], which may contribute to vascular collapse and
subsequent closure of the DA after birth. We found that EP4 significantly inhibited
elastogenesis and decreased lysyl oxidase (LOX) protein, which catalyzes elastin
cross-links in DA SMCs but not in aortic SMCs. In EP4-knockout mice, electron
microscopic examination showed that the DA acquired an elastic phenotype that
was similar to the neighboring aorta. More importantly, human DA and aorta
tissues from seven patients showed a negative correlation between elastic fiber
formation and EP4 expression, as well as between EP4 and LOX expression.
Together with in vitro experiments, these data suggest that PGE2-EP4 signaling
inhibits elastogenesis in the DA by degrading LOX protein. The EP4-cSrc-PLC-
γ-signaling pathway, a signaling pathway that has not previously been recognized,
most likely promoted the lysosomal degradation of LOX [14, 15].
35.3 Future Direction and Clinical Implications
The persistently patent DA after birth is a major cause of morbidity and mortality,
especially in premature infants, that can lead to severe complications, including
pulmonary hypertension, right ventricular dysfunction, postnatal infections, and
35 The Multiple Roles of Prostaglandin E2 in the. . . 255
respiratory failure [16]. The incidence of DA patency has been estimated to be 1 in
500 in term newborns [17]. In preterm babies with birth weights <1,500 g, the
incidence of patent DA exceeds 30 % [18]. Therefore, it is important to improve
current pharmacological therapy through understanding the precise mechanisms of
the regulation of the DA. Since both vascular contraction and remodeling are
required for complete DA closure, pharmacological therapies that promote vaso-
constriction and remodeling would be ideal for premature infants with persistently
patent DAs. On the other hand, vasodilation and inhibition of intimal thickening are
required for DA-dependent congenital heart diseases.
Our data suggest that PGE2-EP4-cAMP signaling promotes hyaluronan and
Epac-mediated intimal thickening and that the EP4-PLC pathway attenuates
elastogenesis in the DA. These cascades of events via different signaling pathways
are thought to orchestrate the subsequent luminal DA reorganization (Fig. 35.1),
Fig. 35.1 The diverse EP4 signaling pathways. Both PKA and Epac synergistically promoted
intimal cushion formation in the DA, but they work in two distinct ways. The cSrc-PLC pathway
inhibited elastogenesis via degrading LOX proteins
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leading to complete obliteration of the DA. In addition to its role in controlling
vascular tone in the functional closure of the DA, the vascular remodeling of the
DA is now attracting considerable attention as a target for novel therapeutic
strategies for patients with persistently patent DA and DA-dependent cardiac
anomalies.
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Developmental Differences
in the Maturation of Sarcoplasmic
Reticulum and Contractile Proteins in Large
Blood Vessels Influence Their Contractility
36
Emiko Hayama and Toshio Nakanishi
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Developmental changes in the contractile system of blood vessels such as the
ductus arteriosus (DA), pulmonary artery (PA), and aorta (Ao) have not been
investigated extensively. We assessed the developmental changes in the expression
of genes that regulate vasoconstriction of fetal blood vessels.
DA, PA, and Ao were taken from rabbit fetuses at 21, 27, and 30 days of
gestation (full term ¼ 31 days) as well as 2-day-old rabbits. Total DA, PA, and
Ao RNA were isolated from pooled segments. Expression of target mRNAs was
quantified using absolute quantitative real-time PCR:
1. Contractile proteins Contractile activity in smooth muscles is determined pri-
marily by the phosphorylation state of myosin regulatory light chain (MRLC).
During muscle contraction, intracellular Ca2+ levels increase substantially, and
binding of Ca2+ to calmodulin activates MLC kinase, which then phosphorylates
MRLC. Expression of calmodulin and MLC kinase was not significantly differ-
ent among the vessels. Expression of tropomyosin 2 was higher in DA compared
to PA.
2. Sarcoplasmic reticulum (SR) Cytosolic Ca2+ levels are increased through Ca2+
release from SR and Ca2+ entry from the extracellular space via Ca2+ channels.
Expression of SR cardiac-type ryanodine receptor (RYR) increased throughout
fetal maturation and was much higher than skeletal-type RYR. Expression of SR
calcium storage protein calsequestrin-2 increased with development in Ao but
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not in DA and PA, with expression levels remaining very low in the latter two.
Expression of SR Ca2+ pump regulator phospholamban increased with develop-
ment in PA and Ao but remained very low in DA. The expression of SR genes
differs significantly at development stages and is vessel dependent, indicating
differential maturity of SR in fetal vessels.
3. Rho/Rho-kinase The Ca2+-independent Rho/Rho kinase pathway inhibits MLC
phosphatase activity and promotes phosphorylation of MLC. Expression of
small GTPase RhoB and Rho kinase-1 was higher than that of RhoA and Rho
kinase-2. The expression levels of these Rho/Rho kinase pathway genes were
similar in fetal and newborn vessels.
In conclusion, contraction of the premature DA, PA, and Ao may be regulated
predominantly by the Rho/Rho kinase pathway, owing to the poor expression of the
component protein genes in the immature SR. DA contractile systems may be well
developed compared with those of the surrounding PA and Ao (Fig. 36.1).
Fig. 36.1 Vascular smooth muscle contraction. Contractile activity in smooth muscle (SM) is
determined primarily by the phosphorylation state of myosin regulatory light chain (MRLC).
Increase in intracellular Ca2+ levels leads to Ca2+-calmodulin binding, which activates MLC
kinase (MLCK) to phosphorylate MRLC. Cytosolic Ca2+ is increased through Ca2+ release from
the sarcoplasmic reticulum (SR) and Ca2+ entry from extracellular space via Ca2+ channels. The
Ca2+-independent Rho/Rho kinase pathway inhibits MLC phosphatase (MLCP) activity and
promotes phosphorylation of MLC. RYR ryanodine receptor, SERCA sarcoplasmic/endoplasmic
reticulum Ca2+-ATPase, PLN phospholamban, TPM2 tropomyosin 2
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Fetal and Neonatal Ductus Arteriosus Is
Regulated with ATP-Sensitive Potassium
Channel
37
Kazuo Momma, Mika Monma, Katsuaki Toyoshima, Emiko Hayama,
and Toshio Nakanishi
Keywords
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Potassium channel opener
The fetal patency and neonatal closure of the ductus arteriosus (DA) are regulated
with oxygen and prostaglandins. The proposed oxygen sensors of fetal and neonatal
DA include P450-endothelin and the Kv channel [1]. We hypothesized that the
ATP-sensitive potassium channel (KATP channel) is another oxygen sensor [2].
Fetal and neonatal DA was studied with Wistar rats; sulfonylurea drugs includ-
ing tolbutamide, chlorpropamide, gliclazide, glimepiride, and glibenclamide (KATP
channel inhibitors); diazoxide and pinacidil (KATP channel openers, KCOs); and
rapid whole-body freezing (Fig. 37.1).
Tolbutamide, chlorpropamide, and gliclazide easily passed across the placenta
and constricted fetal DA dose-dependently following orogastric administration to
near-term pregnant rats. The fetal DA constricted 30 % with clinical doses of
sulfonylurea drugs and closed completely with larger doses.
Glimepiride and glibenclamide passed across the placenta minimally and only
mildly constricted the fetal DA after maternal administration, but constricted and
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closed the fetal DA dose-dependently with direct fetal injection. Fetal DA closure
was associated with hydrops and fetal death.
Diazoxide and pinacidil delayed DA closure following neonatal injection imme-
diately postnatally and dilated the closing DA with injection at 60 min postnatally.
All tested sulfonylurea drugs constricted fetal DA dose-dependently and with
complete closure at large doses. KCOs dilated the neonatal DA. These results
indicate physiological regulation of fetal and neonatal DA with KATP channels.
This study has several clinical implications. Sulfonylurea-associated fetal death
was first reported 50 years ago. The mechanism of death remained unclear prior to
this study. Sulfonylureas may be useful for closing patent DA in premature
neonates.
Recently reported neonatal DA reopening associated with the use of diazoxide
for hyperinsulinemic hypoglycemia has been proved experimentally. DA-dilating
effect of KCO drugs may be useful as a bridge to surgery in neonatal DA-dependent
congenital heart diseases.
Open Access This chapter is distributed under the terms of the Creative Commons Attribution-
Noncommercial 2.5 License (http://creativecommons.org/licenses/by-nc/2.5/) which permits any
noncommercial use, distribution, and reproduction in any medium, provided the original author(s)
and source are credited.
The images or other third party material in this chapter are included in the work’s Creative
Commons license, unless indicated otherwise in the credit line; if such material is not included in
Fig. 37.1 The fetal ductus arteriosus was studied in the near-term fetus or newborn rat following
rapid whole-body freezing, cutting on the freezing microtome, with a microscope and a microme-
ter. The control fetus shows a widely open ductus (a), and the fetus with glibenclamide (10 mg/kg;
10–100 times clinical dose injected at 1 h before) shows severely constricted ductus (b). AA aortic
arch, DA ductus arteriosus, LA left atrium, LPA left pulmonary artery, LSVC left superior vena
cava, RPA right pulmonary artery, T thymus
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Part VIII
Conduction System and Arrhythmia
Perspective
Michael Artman
One of the fascinating and essential characteristics of the cardiovascular system is
that it functions automatically without requiring conscious input. In other words,
the normal heart beats regularly and spontaneously regardless of whether or not the
individual is thinking about it. Electrical impulses arise in the sinoatrial node, pass
through the atria, pause at the atrioventricular node, and then are distributed in a
tightly orchestrated spatial and temporal manner to the ventricles for coordinated
and effective pumping activity. This elegantly synchronized process repeats itself
over and over approximately three billion times during the average human life.
Even minor disruptions in this normal process can have devastating consequences.
Considerable morbidity and mortality result from abnormalities in intrinsic cardiac
pacemaker activity and conduction of impulses. Congenital and acquired
arrhythmias remain a significant health problem. Consequently, a clear understand-
ing of the molecular and cellular processes involved in the formation and mainte-
nance of normal electrical signaling in the heart has profound implications for
human cardiovascular health and disease. Furthermore, it is likely that insights into
the developmental processes involved in building a cardiac conduction system will
likely have implications for understanding fundamental biology applicable to other
organ systems.
This part reviews and summarizes the current state of understanding of the
development of spontaneous pacemaker activity and the cardiac conduction system.
Christoffels’ group reviews the signaling pathways and molecules involved in the
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development of the cardiac conduction system. The authors emphasize the impor-
tance of understanding the three-dimensional architecture of genomic loci to
provide insight into the regulation (normal and abnormal) of gene expression.
Mikawa and colleagues identify and characterize a previously unrecognized source
of cells that are destined to become pacemaker cells, even before cardiac morpho-
genesis begins. These results will likely lead to better understanding of the
mechanisms involved in pacemaker cell differentiation, which in turn may ulti-
mately have therapeutic implications. Additional information on the mechanisms,
molecular signals, and pathways involved in specification of cell fate are provided
by Asai et al. and by Morikawa et al. Taken together, the papers presented in
Part VIII provide an interesting, informative, and elegant overview of the current
understanding of pacemaker and conduction system development. Moreover, they
provide a road map for future investigations into this essential and fundamental
biological process.
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Regulation of Vertebrate Conduction
System Development 38
Jan Hendrik van Weerd and Vincent M. Christoffels
Abstract
The cardiac conduction system (CCS) consists of distinctive components that
initiate and conduct the electrical impulse required for the coordinated contrac-
tion of the cardiac chambers. The development of the CCS involves complex
regulatory networks of transcription factors that act in stage, tissue and dose-
dependent manners. As disrupted function or expression of these factors may
lead to disorders in the development or function of components of the CCS
associated with heart failure and sudden death, it is crucial to understand the
molecular and cellular mechanisms underlying their complex regulation. Here,
we discuss the regulation of genes driving CCS-specific gene expression and
demonstrate the complexity of the mechanisms governing their regulatory
networks. The three-dimensional conformation of chromatin has recently been
recognized as an important regulatory layer, shaping the genome in regulatory
domains and physically wiring gene promoters to their regulatory sequences.
Knowledge of the mechanisms by which distal-acting regulatory sequences
exert their function to drive tissue-specific gene expression and understanding
how the three-dimensional chromatin landscape is involved in this regulation
will increase our understanding of how disease-associated genomic variation
affects the function of such sequences.
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The cardiac conduction system (CCS) initiates and propagates the electrical
impulse that is required for the rhythmic and synchronized contraction of the
heart. The impulse initiates in the sinoatrial node (SAN) and is rapidly propagated
through the atria, thereby activating the contraction of the atrial myocardium. The
impulse is then propagated through the atrioventricular node (AVN), the only
electrical connection between the atria and ventricles. The AVN delays conduction
of the impulse, allowing for the atrial contraction and ventricular filling to complete
before the ventricles contract. Further propagation of the impulse to the fast-
conducting atrioventricular bundle (AVB), bundle branches (BBs) and Purkinje
network causes the depolarization of the ventricular myocardium, leading to ven-
tricular contraction. The development of the CCS is regulated by transcription
factors that act in strictly stage, tissue and dose-dependent manners [1, 2]. A
disruption in the function or expression of these factors could lead to disorders in
the development or function of the CCS that can lead to lethal arrhythmias and heart
failure. Knowledge of the mechanisms underlying regulation of genes involved in
CCS development is therefore crucial.
38.2 Genetic Pathways Controlling SAN and AVC Development
The heart is the first organ to form during embryonic development and starts as a
primitive, linear tube with the inflow region at the caudal side and the outflow
region at the cranial side. The slow conductive properties of the embryonic muscle
cells within the primitive tube at this stage and dominant pacemaker activity at the
caudal end cause a slow peristaltic pattern of contraction along the tube to propa-
gate the blood. At this stage, the entire sinus venosus acts as pacemaker,
characterized by the expression of the pacemaker channel Hcn4, a member of the
family of channels responsible for the hyperpolarization-activated current if that is
crucial for the pacemaker potential [3, 4]. The heart tube elongates by the addition
of rapidly proliferating progenitor cells that differentiate to cardiac muscle. This
implies that cells added to the inflow tract will acquire dominant pacemaker
activity. With further development, specific regions in the heart tube start to divide
rapidly and activate a working myocardial gene program, resulting in the balloon-
ing of the primitive atrium and ventricle. Concomitant with the ballooning of the
primitive atria is the formation of the sinus venosus including the SAN. Dominant
pacemaker activity will gradually be confined to the SAN at the junction of the
sinus venosus and atrium.
The transcriptional activator Tbx5 is required for the sinus venosus expression of
Shox2 [5], a homeobox transcription factor necessary for SAN formation and
function [6, 7]. Shox2 represses cardiac homeobox transcription factor Nkx2-5
[6]. In the chambers, Nkx2-5 activates chamber-specific genes including Nppa
and high-conductance gap junction subunit-encoding genes Gja5 (Cx40) and Gja1
(Cx43), whereas it represses SAN/CCS-specific genesHcn4 and T-box transcription
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factor Tbx3 [8]. Tbx3 is required for the formation of the SAN by directly repressing
atrial myocardial genes Gja5, Gja1 and Nppa to prevent atrialization of the SAN
and indirectly activating Hcn4 and other SAN genes [9, 10].
During ballooning of the primitive cardiac chambers, the region in between the
atria and ventricles does not proliferate and forms a constriction, the atrioventricu-
lar canal (AVC). Bmp2 expression in the AVC activates the expression of Tbx3 and
Tbx2 [11]. Together with Msx2, these T-box factors repress the working
myocardial gene program in the AVC and AVC-derived AVN [12, 13] and stimu-
late the pacemaker gene program and the program required for the formation of the
AV cushions. Within the AVC, Tbx2 and Tbx3 interact with Nkx2-5 to repress
genes that are activated by Nkx2-5 and Tbx5 in the working myocardium of the
atria and ventricles [14–16]. Tbx2 and Tbx3 thus suppress working myocardial
differentiation of the AVC, thereby causing the retention of the primitive phenotype
of slow conduction and low rates of proliferation, providing a primitive morpho-
logical and functional constriction in between the atrial and ventricular chambers.
Other factors that regulate the formation of the AVC and its border with the
chamber myocardium include Wnts, acting upstream of Bmp2; Hey1 and Hey2,
Notch target genes expressed in the chambers that suppress Tbx2 [17]; Tbx20,
which represses BMP-mediated activation of Tbx2 in the chambers [18]; and
Gata4/6, which act in complex with Smads and histone acetyltransferases (HATs)
to activate AVC-specific enhancers in the AVC and with histone deacetylases
(HDACs) and Hey1/2 to suppress these enhancers in the chambers [19]. The
resulting pattern of conduction—fast in the atria, slow in the AVC and fast in the
ventricles—results in the alternating contraction pattern of the chambers and an
ECG that resembles the adult ECG (Fig. 38.1a).
38.3 Transcriptional Regulation of CCS Genes
Although the expression patterns and functions of genes involved in the develop-
ment of the cardiac conduction system are relatively well studied, little is known
about the molecular mechanisms underlying their regulation of expression. Tissue-
specific gene expression often involves long-range regulatory elements, such as
enhancers, which dictate the strictly time-, tissue- and dosage-dependent expression
of their target genes. The identification and function of such enhancers is therefore
highly relevant to fully understand the complex regulatory networks in CCS
formation. However, to date only few studies have been carried out investigating
in depth the regulation of genes driving CCS development.
The T-box transcription factor Tbx5 plays indispensable roles in the early
patterning of the heart and CCS and is involved in limb development [15, 20,
21]. Mutations in TBX5 are associated with Holt-Oram syndrome, a developmental
disorder characterized by hand-heart defects [22, 23]. Using modified bacterial
artificial chromosomes (BACs), the regulatory landscape of the TBX5 locus was
determined, and within this landscape, multiple cardiac-specific enhancers were
identified by utilizing multiple genome-wide ChIP-seq datasets and evolutionary
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conservation. These enhancers were shown to recapitulate part of the TBX5
expression pattern in the heart, but interestingly, none of these fragments drove
reporter expression in the limbs, suggesting that the cis-regulation of TBX5 in the
heart and limbs is compartmentalized [24]. Such knowledge can highly improve the
understanding of the mechanisms underlying the development of congenital heart
diseases by decoupling the heart and hand phenotypes seen with Holt-Oram syn-
drome, thereby presenting more compartmentalized phenotypes compared to












































Fig. 38.1 Schematic overview of cardiac development. (a) The early heart tube has a primitive
phenotype of slow conduction, represented by a sinusoidal ECG. With further development,
regions at the outer curvatures of the primary heart tube expand and obtain a working myocardium
phenotype of fast conduction (grey). The sinus venosus (sv), AVC, outflow tract (oft) and inner
curvatures retain their primitive pacemaker-like phenotype and slow conductivity (purple). A
more mature ECG can be derived from these hearts. Eventually, these non-chamber myocardial
regions will give rise to the mature conduction system components. (b) The transcriptional
repressors Tbx2 and Tbx3 compete with the transcriptional activator Tbx5 to regulate their target
genes. In the AVC, expression of chamber myocardium genes like Nppa is actively repressed by
Tbx2 and Tbx3, whereas in the developing chambers Tbx5 activates these genes. Transcriptional
activation in the AVC is regulated by GATA binding site-dependent histone modifications which
render the chromatin more (e.g. HATs) or less (e.g. HDACs) accessible for transcription factors to
bind their target regulatory sequences, resulting in activation or repression of gene expression
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Another example of how enhancer-mediated gene expression is involved in the
tight regulation of the CCS is presented by the transcriptional repressor Id2. This
factor was identified by serial analysis of gene expression (SAGE) as having
CCS-specific expression. Id2 is expressed throughout development in the AVB
and BB and in non-CCS compartments such as the AV endocardial cushions and
valves. The requirement of Id2 for ventricular CCS structure and function was
demonstrated as Id2-deficient mice exhibit structural and functional conduction
system abnormalities, including left bundle branch block. Id2 is cooperatively
regulated by Nkx2-5 and Tbx5 in the developing ventricular conduction system by
binding of both Tbx5 and Nkx2-5 to a 1052 bp fragment of the Id2 promoter.
Mutation of the Tbx5 binding site within this promoter region completely abolished
CCS expression whereas extracardiac expression was unaltered, illustrating the
specificity of this transcriptional mechanism in the coordinated development of
the ventricular conduction system [20].
The hyperpolarization-activated channel HCN4 is required for the generation of
pacemaker action potentials in the embryonic heart. Using a transgenic BAC
approach, it was shown that the regulatory regions sufficient to recapitulate the
endogenous Hcn4 expression pattern in the SAN, AVN, His bundle, bundle
branches and left ventricular Purkinje fibres reside within the region covered by
one bacterial artificial chromosome (BAC) of 200 kbp [25]. Using transgenic
mouse assays, multiple evolutionary conserved cis-acting regulatory sequences
were identified to drive Hcn4 expression in the AV conduction system. One of
these regions drives reporter expression specifically in the non-chamber myocar-
dium in a Mef2c-dependent manner. Furthermore, depletion of histone deacetylases
resulted in ectopic expression of reporter activity in chamber myocardium, reveal-
ing a role for histone modifications in Mef2c-regulated enhancer-mediated expres-
sion of Hcn4 in components of the CCS [26].
More recently, Contactin-2 (Cntn2), a cell adhesion molecule critical for neuro-
nal patterning and ion channel clustering, was described as a marker for the
ventricular conduction system, with expression in the AVB, BBs and Purkinje
fibres. Using a GFP-modified BAC, the boundaries of the regulatory domain
involved in the control of Cntn2 expression were identified, since reporter activity
of the modified BAC completely recapitulates endogenous Cntn2 expression
[27]. Such knowledge facilitates in the identification of single, individual regulatory
elements driving CCS development and will greatly add to our understanding of
how genes involved in the complex development of CCS components are regulated.
Enhancer function is regulated by modifications of specific histone tails that
mark active or poised enhancers. Active enhancers are associated with an open,
accessible chromatin state, whereas poised enhancers are associated with dense,
closed chromatin. Histone modifiers such as histone deactelyases (HDACs), histone
methyltransferases (HMTs) and histone acetyltransferases (HATs) therefore regu-
late the accessibility of long-range regulatory sequences, allowing for the binding
by cell type-specific transcription factors to activate transcription in a
tissue-dependent manner. Specification of the AVC is regulated by Gata4, which
activates AVC enhancers in synergy with Bmp2/Smad signaling to recruit HATs
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such as p300 [19, 28]. This leads to H3K27 acetylation, a marker of active
enhancers. In contrast, in chamber myocardium, Gata4 cooperates with HDACs
and chamber-specific genes Hey1 and Hey2, leading to H3K27 deacetylation and
repression (Fig. 38.1b) [19].
38.4 Common Genomic Variants Influence CCS Function
The importance of the strict regulation of the spatial and temporal expression of
CCS genes is illustrated by findings from recent genome-wide association studies,
which revealed common genomic variation to be associated with conduction
parameters like PR interval and QRS duration. Such variation was identified in
non-coding regions flanking genes encoding ion channels like SCN5A/10A, KCNQ1
and KCNH2 and cardiac transcription factors like NKX2-5, MEIS1 and TBX3/5,
indicating they might affect the function of enhancers controlling the precise
regulation of these genes [29–31]. Tbx5 is broadly expressed and acts as transcrip-
tional activator, inducing transcription of genes involved in cardiac differentiation
[15, 20]. The activity domain of Tbx3 is much more restricted and confined to the
developing and mature CCS, where it acts as a transcriptional repressor, thereby
imposing the pacemaker phenotype on cells within its expression domain
[10, 32]. Tbx3 and Tbx5 both recognize the same regulatory sequences [33],
suggesting that these factors compete for binding and implicating a fine balance
between activation and repression of CS genes by these factors. The precise
regulation of transcription and activity of both factors is therefore crucial for proper
CCS patterning, and minor changes in regulatory elements controlling the regula-
tion of expression of these factors could thus potentially have large consequences
for CCS function and development. Knowledge of the mechanisms by which such
developmental genes are regulated to exert their spatio-temporal transcriptional
activity is therefore crucial in the understanding of how variation identified by
GWAS influences development.
38.5 3D Architecture Regulates Transcription
Physical enhancer-promoter contacts are a requirement for enhancer-mediated cell
type-specific gene expression, and as such, the three-dimensional topology of
chromatin plays an indispensable role in gene regulation by physically wiring
long-range regulatory sequences with their target promoters [34]. Several protein
complexes, including CTCF, cohesin and mediator, have been proposed to be
involved in the organization of these contacts [35]. Furthermore, recent data
suggest that such genomic structural organizers not only mediate single enhancer-
promoter contacts but also mediate the organization of the genome in relatively
cell-type invariant topologically associated domains (TADs) within which
sequences particularly contact each other. Genes located within the same TAD
exhibit greater expression correlation than genes located in distinct ones,
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suggesting that such domains may act as a backbone for tissue-specific regulatory
contacts [36]. The recent emergence of techniques aimed at capturing the 3D
conformation of genomic loci [37] therefore provides valuable tools to elucidate
regulatory mechanisms on the chromatin level.
38.6 Regulation of Tbx3 by a Large Regulatory Domain
The evolutionary conserved Tbx3/5 genomic locus is one of the few genomic loci of
which the 3D architecture has been studied and reveals an example of the complex-
ity of gene regulation on the level of chromatin topology. Tbx3 and Tbx5 form an
evolutionary conserved gene cluster derived from a primordial T-box gene [38]
and, as mentioned above, play crucial roles in the formation and function of the
cardiac conduction system. Using circular chromosome conformation capture
sequencing (4C-seq), which captures all the genomic regions in close proximity
to a chosen point of view [39], the 3D architecture of the Tbx3/5 locus was probed,
and genomic regions contacting Tbx3 or Tbx5 were identified in different tissues
(Fig. 38.2a). Interestingly, these data revealed that the regulatory landscape is in a
preformed conformation that is similar in embryonic heart, brain and limb. Rather
than the de novo formation of enhancer-promoter loops upon binding by cell-type
relevant transcription factors to initiate transcription, the locus is in a fixed,
permissive structure in which enhancer-promoter loops are pre-existing
[40]. Such a permissive structure has previously been described for different loci,
including the Hox and Shh gene loci. Long-range enhancer-promoter contacts in
these loci were shown to be irrespective of cell type, revealing a preformed
topology [36, 41]. The permissive, preformed nature of these loci was exemplified
by the fact that even in the absence of a distal-acting Shh enhancer, contacts
between the Shh promoter and the enhancer region still occur [41]. The benefit of
such preformed regulatory landscapes is believed to lie in the ease by which tissue-
specific transcription factors can utilize preformed contacts to target the gene of
interest, involving only slight variations in internal contacts within an otherwise
rigid and conserved structure. In agreement with this, small differences in contact
profiles for the different tissue types were observed in the Tbx3/5 locus despite the
fact that the domain is largely preformed, most probably caused by cell type-
specific transcription factor mediated enhancer activation. Among the multiple
sites contacting Tbx3 in the gene desert upstream of the gene, two evolutionary
conserved enhancers have been identified that also contact each other. They are
bound by cardiac-specific transcription factors Nkx2-5, Gata4, Tbx5 and Tbx3 and
were shown to respond to a BMP-mediated signalling pathway to drive atrioven-
tricular conduction system expression of Tbx3 [40].
As mentioned before, Tbx3 and Tbx5 are expressed in overlapping patterns and
have overlapping functions in CCS development. It could therefore be expected that
both genes share common regulatory mechanisms on a genomic level. Studies on
the transcriptional regulation of other clustered developmental genes, like the Irx
and Hox clusters, revealed that regulatory sequences are not uniquely associated
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with single promoters, but rather are shared by multiple genes within the cluster.
Such interplay between multiple enhancers coordinates the strict regulation of their
expression patterns, and it has been proposed that such extensive enhancer sharing
explains the conservation of the genomic organization throughout evolution
[42, 43]. Interestingly, however, Tbx3 and its flanking gene desert form a loop
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Fig. 38.2 The regulatory domains of Tbx3 and Tbx5 are physically separated. (a) Contact profiles
of the Tbx3 and Tbx5 loci as determined by circular chromosome conformation capture (4C) reveal
the genomic regions that physically contact Tbx3 (upper track) or Tbx5 (lower track) in mouse
embryonic heart cells. Red and dark blue depict a high contact frequency, whereas light blue and
grey depict a low contact frequency. The contact profiles of Tbx3 and Tbx5 hardly overlap,
indicating that both genes do not share regulatory sequences and suggesting that common variants
in humans upstream of TBX3 as identified by GWAS (star) can be exclusively assigned to TBX3
[40]. (b) Model of the 3D conformation of the Tbx3/Tbx5 locus. The regulatory domains of Tbx3
and Tbx5 are physically separated; however, on the protein level, both genes recognize the same
binding sequences and compete with each other to activate or repress their target genes, e.g. Gja5
(Cx40). Despite the strict regulation on the chromatin level, Tbx5 also directly regulates Tbx3 by
binding target sequences to activate transcription in, for example, the SAN
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Genomic regions within the Tbx3 loop solely contact Tbx3 but not Tbx5 and vice
versa, indicating enhancer sharing between these evolutionary conserved clusters is
unlikely to occur [40]. The strict separation of the regulatory landscapes of Tbx3
and Tbx5 is not only cell type-independent, but also evolutionary conserved
between mouse and human. Recent Hi-C data in human fibroblasts [36], revealing
genome-wide contact profiles, reveal a similar separation of the TBX3 and TBX5
regulatory domains with hardly any overlap of the contact profiles. This organiza-
tion of the Tbx3 locus in a ~1 Mb-scale self-regulatory domain corresponds well to
the previously mentioned TADs. These domains are separated by boundary regions
enriched for insulator binding protein CTCF, housekeeping genes, transfer RNA
and short interspersed elements, hampering interactions of sequences within one
TAD with regions exceeding the domain boundaries. Regions located within the
regulatory domain of Tbx3 are thus suggested to exclusively contact Tbx3 and not
Tbx5 and vice versa.
38.7 Assigning Function to Genomic Variation
Understanding the 3D architecture of a genomic locus not only provides insight into
the tight relationship between chromatin topology and the complex regulation of
developmental gene expression, it could also provide valuable clues in the under-
standing of the role of functional variation as identified by genome-wide associa-
tion studies on gene expression. Common genomic variation in the non-coding
region upstream of TBX3 and TBX5 was found to influence PR interval and QRS
duration in humans [29–31]. The fact that the regulatory domains of TBX3 and
TBX5 are strictly separated indicates that the variation found in one of the domains
can be exclusively assigned to its respective gene, facilitating our understanding of
the functional effect of disease-associated variation.
A similar example of how knowledge on the chromatin conformation can
increase our understanding of function of common variants is illustrated by studies
on the SCN5A/SCN10A locus. SCN5A and SCN10A encode sodium channels
important for conduction. GWAS implicated an intronic region in SCN10A as a
major risk region for prolonged QRS duration [30]. The role of SCN10A in cardiac
conduction however was not previously described, whereas mutations in the adja-
cent SCN5A are well established to cause several arrhythmogenic disorders, includ-
ing Brugada and Long QT syndrome [44, 45]. It is therefore possible that the
variation identified within the intron of SCN10A impacts the expression of
SCN5A, rather than or in addition to that of SCN10A. Indeed, probing the 3D
architecture with the promoters of both SCN5A and SCN10A and the site of the
variation in the intron as point of view using 4C-seq revealed that this variant region
contacts the SCN5A promoter and a strong enhancer downstream of SCN5A,
suggesting that it might act as enhancer regulating the expression of SCN5A in
the heart. Transgenic reporter assays revealed that indeed this enhancer is essential
for cardiac Scn5a expression. In humans, the SNP located within the enhancer that
correlates with slowed conduction is associated with lower SCN5A expression
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[46]. Taken together, these results provide another example of how our understand-
ing of the 3D architecture of a genomic locus harbouring functional variation can
facilitate in the assignment of function to such variations, improving our under-
standing of the effect of disease-associated variation.
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Cardiac Pacemaker Development from
a Tertiary Heart Field 39
Michael Bressan, Gary Liu, Jonathan D. Louie, and Takashi Mikawa
Abstract
Rhythmic heartbeats are paced by electrical impulses that are autonomously
generated by cardiac pacemaker cells. This chapter briefly summarizes our
recent findings regarding the embryonic origin of and molecular mechanism
delineating cardiac pacemaker cells, showing that pacemaker cells are physi-
cally segregated and molecularly programmed, in a tertiary heart field, prior to
the onset of cardiac morphogenesis.
Keywords
Differentiation • Fate determination • Fate mapping • Lateral mesoderm
patterning • Pacemaker • Pacemaker cell fate specification • Tertiary heart
field • Wnt
39.1 Introduction
Rhythmic heartbeat is initiated by electrical impulses evoked at the sinoatrial node
(SAN) that are then conducted to atrial muscle and converge to the atrioventricular
node. After a brief delay, pacemaker-initiated action potentials (APs) rapidly pass
down the conduction system network and finally spread into ventricular muscle
(Fig. 39.1a). The SAN was first described more than a century ago [1], and its
anatomical, physiological, and molecular characteristics have been thoroughly
investigated [2]. While significant progress has been made in our understanding
of the mechanism responsible for the differentiation and patterning of the distal
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conduction components, the developmental pathway of the SAN remains contro-
versial (Fig. 39.1b).
The identification of the definitive origin of and inductive mechanisms that
define SAN pacemaker cells (PCs) will be critical for systematic investigation of
developmental mechanisms, such as cell fate specification and differentiation, of
this specialized cell population essential for cardiac function. We have recently
identified a novel role of Wnt signaling in promoting pacemaker cell induction and
differentiation, which is completely contrary to its well-documented inhibitory role
in heart field induction [3].
39.2 Pacemaking Site Transitions From Left To Right During
Heart Looping
Classic studies in the chick embryo have shown that as soon as the primitive heart
tube forms, myocytes in the posterior inflow tract become electrically active and
predominantly evoke pacemaking impulses [4]. While this population has been a
priori thought as the progenitor of the SAN pacemaker, no direct cell lineage-
tracing study has tested this dogma. Therefore, we have revisited this critical issue.
Consistent with previous studies, our optical mapping analysis has detected that the
primitive heart tube evokes APs preferentially at the left inflow. Importantly,
however, our fate mapping studies have revealed that cells of the left inflow later
differentiate into AV junction myocytes rather than the right side pacing cells at the
Fig. 39.1 (a) Diagram of the pacemaking and conduction system network consisting of distinct
subcomponents. (b) Controversies in the developmental pathway of SAN pacemaker cells. The
classic model assumes that this cell population differentiates from atrial myocytes. A current
dogma suggests that SAN pacemaker cells arise from a part of the heart field mesoderm which
remains as immature myocytes. These models are based on phenotypic similarities between
embryonic myocytes and SAN cells in action potential shape and the expression of unique
genes in common. The only way to reliably establish the origins of a cell type is to tag its
antecedents. Our direct cell fate mapping studies have identified an origin and novel developmen-
tal pathway for SAN pacemaker cells (proposed model)
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SA [5]. The above findings are consistent with a hypothesis that there are a
successive series of pacemaker zones present in the early developing heart [6],
indicating that the true origin of SAN pacemaker cells remains to be identified.
39.3 A Novel Cell Population That Juxtaposes the Right Atrium
Takes Over Pacing Function by Mid-heart Looping Stage
While classic and current models assume that SAN PCs arise from a subpopulation
of atrial precursors (Fig. 39.1b), to our surprise, our optical mapping data showed
that a small region juxtaposing the right atrium preferentially evokes pacemaking
action potentials [5]. This pacemaking site has often been neglected in previous
studies as this region is routinely dissected away during isolation of the embryonic
heart. Our optical mapping and in situ hybridization analyses [5] have identified
that this pacemaker site preferentially expresses HCN4, a major member of the
HCN gene family expressed in the heart responsible for the hyperpolarization-
activated inward “funny” current, and an atrial-type myosin AMHC1, but is nega-
tive for a cardiac transcription factor Nkx2-5 [9]. These are consistent with previous
reports on the adult mouse SAN. Other tissues of the conduction system, such as
AVN and Purkinje fibers, co-express HCNs and Nkx2-5. Thus, differentiated SAN
pacemaker cells can be distinguished by these physiological, pharmacological, and
molecular characteristics from other myocytes and conduction cells. Unfortunately,
expression of these marker genes is dynamic and no HCN4+/AMHC1+/Nkx2-5-
cells can be found in earlier stage embryos. It is therefore unclear when and where
SAN pacemaker cell fate is induced and specified. As the heart matures through the
processes of looping, heart primordium continually expands with cells being added
to both the inflow and outflow segments [7, 8]. The origin of this novel pacemaking
cell population needs to be determined.
39.4 The Right-Sided Pacemaking Cells Indeed Differentiate
into SAN Pacemaker Cells
Our in ovo cell-tracing studies have mapped the fate of these extracardiac right-
sided pacing cells to the physiologically correct SAN region of the resulting heart at
stage 35 (E9) [5]. Optical mapping of these labeled hearts has shown that action
potentials are predominantly evoked from these specific cells and propagate into the
atrium [5]. Thus, these studies have identified a novel extracardiac cell population
as SAN pacemaker precursors. However, until recently it was unknown where this
cell population came from. Indeed, the fate of cells in the inflow has been contro-
versial. No systematic fate mapping data was available about the pacemaker field
posterior to the heart field at pre-heart tube formation stages. Genetic lineage
tracing critically depends upon a gene that is exclusively expressed in pacemaker
precursors but not in daughter cells. To our knowledge, no such gene had been
identified to date. To explore the origin of SAN pacemaker cells, we performed fate
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mapping for earlier embryonic stages [5; Fig. 39.2]. For example, in stage 7–8
embryos, the PCs were mapped to a small region in the right lateral plate at somite
level 3. Importantly, “the pacemaker field (PF)” does not overlap with “the heart
field (HF)” defined by expression of either Nkx2-5 or Isl1 [9, 10]. The data show for
the first time that SAN precursors arise from an unpredicted small area of the lateral
mesoderm immediately posterior to the known HF. It should be noted that the PF is
embedded in the zone that also generates other cardiac-related tissues, such as the
proepicardium, right atrium, and vena cava (Bressan 2013). We therefore tenta-
tively termed this previously unrecognized mesodermal area “tertiary heart field,”
distinguishing it from the primary heart field and the secondary (anterior) heart field
(Fig. 39.3).
Fig. 39.2 Fate map of pacemaker field. (a) At early somite stages, heart precursors occupy
bilateral fields within the lateral plate mesoderm. The primary heart field is indicated in yellow, the
secondary heart field is indicated in pink, and the posterior tertiary heart field [5] is indicated in
blue. Fate mapping studies indicate the progenitors of the SAN pacemaker cells reside within the
tertiary heart field (asterisk). (b) At heart tube stages, the primary heart fields have fused along the
midline, while the secondary and tertiary heart fields have not yet been incorporated into the heart.
The pacemaker precursors maintain their position within the tertiary heart field mesoderm (blue).
(c) At looping stages, the pacemaker cells have incorporated into/can be seen attaching the right
inflow of the heart and begin to pace the heartbeat. at atria, avj atrioventricular junction, ht heart
tube, vt ventricle, a anterior, p posterior, r right, l left
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39.5 Pacemaker Cell Fate Specification Has Already Completed
Prior to Heart Morphogenesis
The fate mapping data alone however do not provide any information as to where
and when the pacemaker cell fate is specified. A protocol is needed to detect timing
and location of cell fate specification apart from marker gene expression. “The cell
fate specification” is defined by Harrison [11] and Slack [12] as “when a cell or a
tissue becomes capable of autonomously differentiating under a neutral environ-
ment, such as in petri dish or test tube.”
Using an established culture model that was previously used for studying classic
HF specification, we examined autonomous pacemaker differentiation from PF,
which has been mapped in stage 8 embryos (see Fig. 39.2). Under the neutral
culture condition, HF explants from stage 8 embryos initiated spontaneous
contractions within 24 h. Our data are consistent with previous studies on HF
specification. In striking contrast, PF explants did not show any contractions during
the first 24 h, but by 48 h many of them started rhythmic contractions with a higher
beat rate and exhibited AP waveform characteristic of PCs. PF explants continued
to rhythmically beat at a similar rate throughout the extended culture period for at
least up to 120 h. The data show that cells posterior to the HF autonomously
differentiate to initiate and maintain spontaneous rhythmic contractions, which
are distinct from those of the HF.
39.6 PF Explants Are Sensitive to Blockers Specific
for Pacemaking Ion Channel
Our pharmacological tests interrogated whether PF explants use ion channel char-
acteristic of pacemaker cells. Our data show that a HCN channel blocker, ZD7288,
induced PF explants to increase the interval between contractions by approximately
Fig. 39.3 Model for distinct
roles of Wnt signaling in HF
induction vs. PF induction
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~50 % without detectable loss of rhythmicity. An L-type Ca2+ channel blocker,
nifedipine, completely diminished spontaneous contraction of PF explants. These
pharmacological responses of PF explants are characteristic of SAN pacemaker
cells which evoke action potentials mainly through HCN channels and L-type Ca2+
channels and are distinct from cardiomyocytes which mainly use Na+ channels for
the upstroke of action potentials.
39.7 Current Models for Molecular Regulation of SAN
Pacemaker Differentiation
It was once postulated that the SAN pacemaker arises from a part of the HF
mesoderm which co-expresses Isl1 and Tbx18. Pitx2c, Shox2, Nkx2-5, Tbx3, and
Tbx5 are believed to play a role in SAN development. In mice, gene deletion of a
laterality gene, Pitx2c, leads to bilateral SANs. Shox2 deficiency results in
upregulation of Nkx2-5 and Cx43 in the SAN domain. Both Shox2 and Tbx3
expression require Tbx5. Because Nkx2-5 is absent in the SAN, Nkx2-5 is suggested
to suppress HCN4 and Tbx3. Tbx3 gene knockouts result in expression of atrial
genes in the SAN and partial loss of SAN-specific gene expression. Ectopic
expression of Tbx3 in the atria causes arrhythmia. Taken together, Tbx3 and
Tbx18 have been proposed as key transcription factors for SAN pacemaker differ-
entiation. Contradictory to these models, deletion of Tbx3, Tbx18, or Shox2 results
in no or only modest pacemaker defects. Further Tbx3 expression occurs at the AV
junction and AV node where Nkx2-5 is highly expressed. Our data have revealed,
however, that Tbx3, Tbx18, and Isl1 are absent from SAN pacemaker cells during
the early stages that correspond with cell fate specification and differentiation.
Thus, further elucidation was needed to better understand the molecular
mechanisms that regulate the specification and formation of SAN pacemaker cells.
39.8 A Novel Role of Wnt Signaling for Pacemaker Cell Fate
Specification
Heart field induction and specification are promoted by BMP signaling and are
restricted to the anterior region by inhibition of Wnt signaling [3, 13]. In chick, Wnt
from the neural plate ectoderm and the posterior mesoderm inhibits myocardial
differentiation in paraxial and posterior mesoderm, while the secreted Wnt antago-
nist, crescent, produced by the anterior endoderm supports myocardial develop-
ment. Noncanonical Wnts that block canonical Wnt/β-catenin signaling can act
positively on HF establishment and myocardial electro gradient. Isl1-Cre/β-catenin
mutants show defects in outflow tract formation with decreased expression of Tbx2,
Tbx3, Shh, and Wnt11. Canonical Wnt signaling is necessary for growth of second
HF-derived right ventricular myocytes during heart looping and onward but its role
for early specification of the second HF remains obscure. Taken together, inhibition
of canonical Wnt/β-catenin signaling is critical for restricting heart field induction
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to the anterior mesoderm. In contrast to extensive studies of heart field formation,
little is known about Wnt signaling in pacemaker development.
Activation of Wnt signaling in the HF diminishes the expression of several
cardiac genes, including Nkx2-5. However, it remains largely unknown what HF
fate becomes once “HF identity” is lost. Our fate mapping data indicated a
surprisingly posterior origin for pacemaker cell progenitors within the Nkx2.5
negative mesoderm, as well as an earlier timing of specification than previously
believed. These results led us to reexamine the question of heart field identity
following loss of Nkx2.5. Therefore, we investigated this untouched area of Wnt
signaling on heart field cells using physiological approaches. Our data have
revealed that Wnt-treated heart field cells do not lose contractility either in vivo
or in vitro. Instead, they developed a rhythmic, high-rate contraction pattern similar
to PF explants, including AP waveforms reminiscent of PCs [5]. A transient
exposure to Wnt for only 8 h was sufficient to obtain the pacemaker-like beating
pattern. Our in vivo and in vitro data have further demonstrated that inhibition of
Wnt signaling for pacemaker progenitors results in a conversion of their fate to the
ordinary cardiomyocyte type.
39.9 Concluding Remarks
An elucidation of the origin and molecular mechanisms that specify the pacemaker
cell fate is fundamental to dissecting the earliest steps critical for SAN pacemaker
development. Our data have revealed that the pacemaker cell fate is specified in a
previously unconsidered embryonic region at very early embryonic stages even
before heart morphogenesis begins. The work has also revealed that differential
Wnt-mediated signaling cues in the lateral plate mesoderm are sufficient to induce
pacemaker-like versus working myocardial fates, and that these fates are
maintained throughout early cardiac morphogenesis. These results will significantly
increase our understanding of the basis for the mechanisms that regulate pacemaker
cell specification and differentiation.
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Endothelin Receptor Type A-Expressing
Cell Population in the Inflow Tract
Contributes to Chamber Formation
40
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The avian and mammalian heart mainly originates from two distinct embryonic
regions: an early differentiating first heart field and a dorsomedially located second
heart field. It remains largely unknown when and how these subpopulations of the
heart field are established as regions with different fates.
Endothelin-1 (Edn-1) acts on cardiac neural crest cells through endothelin
receptor type A (Ednra) and is involved in the normal formation of pharyngeal
artery-derived great vessels and ventricular septum [1]. Previously, we identified a
distinct cell population defined by the expression of Ednra in the mouse inflow
region [2]. These cells are derived from a part of the first heart field, and largely
confined to the inflow region at E8.25.
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From the expression patterns of β-gal in the Ednra-lacZ knock-in mice, we
thought a possibility that this Ednra-positive cell population might move into
cardiac chambers from the inflow region. By dye injection and transplantation
experiments, we showed that the Ednra-positive cell population moved toward
not only the left and right atria but also the left ventricle.
Then, to perform lineage analysis, we have generated an Ednra-CreERT2mouse
line (unpublished). We activated Cre recombinase by tamoxifen at E7.25 and E8.25
and analyzed the distribution of β-gal-labeled cells in the EdnraCreERT2/þ;R26R
embryo hearts. As a result, the β-gal-labeled cells were found to contribute to the
left ventricle and both atria.
To facilitate this lineage analysis, we established a mouse-chick chimera model.
When we transplanted the inflow region of the EdnraCreERT2/þ;R26R mouse
embryos (tamoxifen i.p. at E7.25) to orthotopically into chick embryos,
β-gal-positive cells were detected in the right atrium and left ventricles 7 days
after transplantation.
From these results, we conclude that the Ednra-positive cell lineage in the early
inflow tract certainly contribute to chamber myocardial formation.
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Specific Isolation of HCN4-Positive Cardiac
Pacemaking Cells Derived from Embryonic
Stem Cells
41
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Bradycardia causes slow heart beating, which has high risk for heart failure or stroke.
The only available treatment for bradycardia is implantation of electronic
pacemakers. However, this treatment for bradycardia has several shortcomings:
requirement of operation for implantation and for exchange of battery and the lack
of response to autonomic nerve regulation. The purpose of this study was to develop a
biological pacemaker, which could be used for replacement of electronic pacemakers.
1. In differentiating mouse embryonic stem (mES) cells, cardiac pacemaker cells
can be specifically visualized with green fluorescent protein (GFP) on the basis
of their specific expression of hyperpolarization-activated cyclic nucleotide-
gated (HCN) channel 4 at sinoatrial node (SAN) [1]. GFP knock-in ES cells at
HCN4 locus (H7 clone) were established. The expression of GFP was specifi-
cally restricted at their contracting region in differentiating H7 ES cells.
2. Cell sorting revealed that a few cells (0.1–0.5 %) of H7 embryoid bodies (EBs)
were GFP positive, of which approximately 80 % of cells showed the spontane-
ous beating activity with cesium-sensitive action potential. Sorted GFP+ cells
expressed endogenous HCN4 and had essentially the same properties as the
cardiac pacemaker cells at SAN.
K. Morikawa (*)
Center for Promoting Next-Generation Highly Advanced Medicine, Tottori University Hospital,
36-1 Nishicho, Yonago 683-8504, Japan
e-mail: kumi@med.tottori-u.ac.jp
Y. Shirayoshi • I. Hisatome
Division of Regenerative Medicine and Therapeutics, Graduate School of Medical Science,
Tottori University, 86 Nishicho, Yonago 683-8503, Japan
# The Author(s) 2016
T. Nakanishi et al. (eds.), Etiology and Morphogenesis of Congenital Heart Disease,
DOI 10.1007/978-4-431-54628-3_41
291
(i) GFP+ cells expressed cardiac pacemaker specific markers such as HCN4,
Cav3.1, and Connexin43 as well as cardiomyocyte-specific marker,
Tropomyosin C.
(ii) Patch-clamp analysis revealed that GFP+ cells expressed pacemaker current
If with spontaneously oscillating action potentials (automaticity) (Fig. 41.1).
(iii) GFP+ cells were capable of actively responding to adrenergic stimulation
and cholinergic repression.
3. We further investigated whether mESC-derived HCN4+ cells can restore
myocardial electromechanical properties. Using imaging techniques, we
demonstrated that HCN4+ cells established electrical coupling with HL-1
cells, a cardiac muscle cell line derived from the mouse atrial cardiomyocytes
tumor, to induce rhythmic electrical and contractile activities in vitro. Similarly,
transplanted HCN4+ cells paced the hearts of rats with complete atrioventricular
block, indicating that HCN4+ cells could substitute for pacemaker cells and
elicit an ectopic rhythm.
These results demonstrated the potential of HCN4+ pacemaking cells derived
from ES cells to act as a rate-responsive biological pacemaker and for future
myocardial regenerative medicine to bradycardia.
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Fig. 41.1 Automaticity and If current from HCN4+ pacemaking cells. HCN4-GFP+ pacemaking
cells derived from mESCs show typical automaticity (a) and If current (b)
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Progenitor cell populations of multiple origins, including those from the
mesodermal primary heart field, secondary heart field, and neural crest, participate
in the formation of complex structures of the heart and great vessels. A variety of
differentiated cell types, such as cardiomyocytes, fibroblasts, endocardial cells, and
vascular cells, are coordinated to fulfill the mature functions of the heart and
circulatory system. Sequential and combinatorial functions of numerous genes in
these cells are necessary for proper cardiovascular development. Phenotype
analyses of mutant mice and genetic studies of human patients have revealed the
genes essential for cardiovascular cell differentiation, migration, proliferation, and
alignment in developing embryos. A significant fraction of those genes encodes
DNA-binding transcription factors and their cofactors, indicating that transcrip-
tional regulation plays central roles in cardiovascular differentiation and morpho-
genesis. Mutations of the genes for inter-/intracellular signaling molecules often
cause perturbation of downstream gene expression patterns. Genes associated with
the laterality control and those encoding the cardiac sarcomere components were
also found responsible for the congenital cardiovascular defects.
Emerging evidence indicates that additional molecules involved in the epige-
netic regulation of gene expression are indispensable for cardiovascular develop-
ment. Chromatin-remodeling protein complexes, SWI/SNF, ISWI, NuRD, and
INO80, control the chromatin structure and accessibility of transcriptional machin-
ery including DNA-binding proteins and RNA polymerase II. Gene deletion of a
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SWI/SNF complex factor Brg1/Smarca4 or its partner protein Baf60c/Smarcd3
caused various defects of cardiac structures and growth in mice. CHD7, a gene
responsible for CHARGE syndrome, functions as a component of the NuRD
transcriptional repressor complex. Histone modification was also shown to be
important for cardiovascular development. Mutations of MLL2/KMT2D, which
encodes a histone methyltransferase, are a major cause of Kabuki (Niikawa-Kuroki)
syndrome. Mutations in the genes involved in histone methylation are significantly
enriched in those identified in sporadic cases of congenital heart defects. Impor-
tance of histone methylation by polycomb group proteins, histone demethylation by
jumonji family proteins, and histone acetylation/deacetylation by HAT/HDAC
proteins was also documented using mouse models. In addition, noncoding func-
tional transcripts, namely, microRNAs and long noncoding RNAs, possess crucial
functions in the regulation of gene expression during cardiovascular development.
MicroRNAs repress gene expression through the degradation of target mRNAs
and/or the inhibition of their translation. Long noncoding RNAs modulate gene
expression by various mechanisms including the association with epigenetic
factors, transcriptional machinery, and microRNAs. Lack of miR-1, miR-133,
and many other miRNAs as well as long noncoding RNAs such as Braveheart
and Fendrr markedly affects differentiation and growth of cardiomyocytes in
experimental models.
In this part, among these epigenetic regulators of gene expression, Shirai
et al. describe the significance of polycomb group proteins in embryonic heart
development, while Kataoka and Wang provide an overview on the roles of
microRNAs and long noncoding RNAs in the developing heart and vasculature.
Studies of new molecular mechanisms of cardiovascular development will lead to a
better understanding of the etiologies of human congenital heart defects.
294 Part IX Current Molecular Mechanism in Cardiovascular Development
Combinatorial Functions of Transcription
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Abstract
Heart malformations are the most common type of birth defect, affecting more
than 2 % of newborns and causing significant morbidity and mortality. In the
past two decades, studies have revealed the function and importance of cardiac
transcription factors during heart development and in congenital heart disease.
Transcription factors generally form complexes with other transcription factors
and/or with chromatin factors to perform specific functions. This review focuses
on how chromatin factors modify cardiac transcription factors during cardiovas-
cular development and disease.
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42.1 Transcription Factors in Heart Development
The heart is an organ that pumps blood to and from the body’s tissues through the
blood vessels. Cardiac muscle contains cardiomyocytes, which ensure the heart’s
contractile ability; however, cardiomyocytes alone are not sufficient for the heart to
function. Other components, such as the conduction cells, fibroblasts, blood vessels,
and endocardial cells, are important for maintaining the heart’s systemic pumping
ability. Each cell type can be identified by its expression of specific transcription
factors, signaling molecules, and/or function-specific proteins (Fig. 42.1). The heart
is the first organ to form in vertebrates, and it performs a vital role in distributing
oxygen and nutrients throughout the embryo. The primordial heart is derived from
cardiovascular mesodermal cells that transiently express T (Brachyury),Mesp1, and
Flk1 during gastrulation. A subset of these cardiac mesodermal cells gives rise to
cardiac progenitor cells, which can differentiate into any type of cardiac cell.
T-box transcription factors compose a conserved family of genes that are
important for heart development and patterning. In humans, disruption of the
cardiac T-box genes leads to various congenital heart defects [1]. Mutations in
Tbx5 are associated with Holt-Oram syndrome [2, 3], whereas mutations in the
Tbx20 gene result in atrial septal defect [4, 5]. Interestingly, in the developing heart,
Tbx5 and Tbx20 are complementarily expressed in the left and right ventricle,
respectively (Fig. 42.2) [6]. The regions in which the T-box genes are expressed and
the regions that are defective in a given disease are very similar. Tbx5 is expressed




















































Fig. 42.1 Multiple cardiac cell types. Each cell type differentiates from mesoderm-derived
cardiac progenitor cells. The major molecules associated with each cell type are indicated
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the right ventricle; Tbx5 expression appears to be restricted to the first heart field
(FHF)-derived region [7]. Tbx5 knockout mice experience severe left ventricle
hypoplasia and die at approximately E9 without their hearts ever beating
(Fig. 42.2) [8]. By contrast, Tbx20 is primarily expressed in the outflow tract and
the right ventricle, which are derived from the second heart field (SHF). Tbx20
knockdown mice develop a single ventricle and show severe hypoplasia of the right
ventricle (Fig. 42.2) [9]. These facts indicate that Tbx5 and Tbx20 may specify the
identity of each ventricle. Tbx5 also acts in association with Sall4 in ventricular
septum formation. Sall4 is a zinc-finger transcription factor that, when mutated,
causes Okihiro syndrome (Duane-radial ray syndrome, DRRS) in humans
[10, 11]. The heart and limb phenotypes of Okihiro syndrome are very similar to
those of Holt-Oram syndrome. In fact, some Holt-Oram patients lack mutations in
TBX5 and instead have mutations in SALL4 [12]. Tbx5 and Sall4 participate in
protein-protein interactions and synergistically regulate downstream gene expres-
sion [13]. Furthermore, Tbx5 is a key gene involved in the acquisition of the
ventricular septum during vertebrate evolution [14]. During vertebrate evolution
from aquatic to terrestrial life, the morphology of the heart has changed. As a result,
avian and mammalian hearts contain four chambers—two atria and two
ventricles—and their circulatory systems contain two loops, the pulmonary and
systemic loops, that separate the oxygen-rich and oxygen-poor blood. In vertebrates
with four-chambered hearts, Tbx5 expression is restricted to the left ventricle,
whereas in animals with a single ventricle, Tbx5 expression is observed throughout
the ventricle. Reptiles show a unique Tbx5 expression pattern that is associated with




Fig. 42.2 The expression patterns of Tbx5 and Tbx20 in the mouse heart. These genes show
complementary expression patterns in the ventricles. The knockout mice for each gene show
hypoplasia in the same region in which the gene is normally expressed (Adapted from Bruneau
et al. [8] and Takeuchi et al. [9])
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their ventricular morphology. Anolis, which are a type of squamate, have a single
ventricle that expresses Tbx5 throughout this chamber and throughout develop-
ment. Interestingly, turtles show a left-high to right-low gradient of Tbx5 expression
during late developmental stages, and a septum-like structure forms in the middle of
the ventricle (Fig. 42.3). To confirm the precise interaction between Tbx5 expres-
sion patterns and ventricular septum formation, we performed Tbx5 mis-expression
experiments using transgenic mice. Transgenic mice that express Tbx5 throughout
the ventricle fail to form a ventricular septum. These results strongly indicate that
Tbx5 expression in the left ventricle is important for the development of
two-chambered ventricles. We hypothesized that the regulatory region of Tbx5
might have been modified during vertebrate evolution, thereby changing the Tbx5
expression pattern and the ventricular morphology, as shown in Fig. 42.3.
42.2 Chromatin Factors and Cardiac Differentiation
Recent studies have shown that chromatin factors are essential for determining cell
fate in several organs. In heart development, SWI/SNF-type chromatin remodeling
factors play key roles in the differentiation of cardiomyocytes by interacting with
heart-specific transcription factors [15, 16]. Cardiac transcription factors alone are
not sufficient to induce cardiomyocyte differentiation in vivo or in vitro (Figs. 42.4
and 42.5). This result suggests that chromatin accessibility is important for
Fig. 42.3 Tbx5 expression and heart morphology in vertebrates. Note that animals with two
ventricles express Tbx5 on the left side (Adapted from Koshiba-Takeuchi et al. [14])
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a EGFP               TFs        TFs + Baf60c b
Fig. 42.4 (a) A mixture of transcription factors (TFs), Baf60c and EGFP, but not the control
(EGFP) or TFs + EGFP, ectopically induce Actc1 in the lateral plate mesodermal region. (b) A
schematic of cardiac gene regulation. The SWI/SNF complex-mediated change in chromatin
conformation is important for the activation of cardiac gene transcription (Adapted from Takeuchi
and Bruneau [18] and Van Weerd et al. [15])
Fig. 42.5 Schematic diagram shows that ectopic expression of major cardiac contracted genes
(Actc1 and Myl7) are observed by combinatorial transfection of cTF and Baf60c into ex vivo
mouse
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transcription factors to bind to their target sites. Therefore, we searched for chro-
matin remodeling factors that are expressed in the cardiac region at early stages of
heart development. A previous study showed that a component of the SWI/SNF-
type chromatin remodeling complex, Baf60c (also known as Smarcd3), has specific
roles in heart development [17]. When a mixture of cardiac transcription factors and
Baf60c was injected into the lateral plate mesoderm of mouse embryos, alpha
cardiac actin-positive cells were ectopically induced (Fig. 42.4) [18]. These ectopi-
cally induced cardiac cells could beat, which showed that they were functional
cardiomyocytes. Baf60c can directly associate with the Tbx5, Nkx2-5, Gata4, and
RBPjk proteins and regulate the transcription of downstream genes
[17, 19]. Mutations in chromatin factors cause abnormal cardiac function in both
mice and humans. Baf60c determines a cell’s fate by not only loosening the
chromatin structure but also synergistically interacting with specific factors.
When associated with Tbx5, Brg1, a core protein of the SWI/SNF-type chromatin
remodeling complex, synergistically regulates cardiac differentiation in the pres-
ence of Baf60c [20]. Mice heterozygous for both Brg1 and Tbx5 had more severe















Fig. 42.6 The combinatorial functions of cardiac transcription factors and Baf chromatin
remodeling factors. Only the transcription factors can induce cardiac markers, but the differentia-
tion of beating cardiomyocytes requires both transcription factors and chromatin remodelers
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results indicate that the dosage of epigenetic factors affects the severity of the Tbx5
mutant phenotype (i.e., left ventricular hypoplasia). The severity of congenital heart
disease in humans may be related to the level of expression of epigenetic factors
and/or of partner factors. To address this possibility, we need to elucidate the
relationship between the expression level of epigenetic factors and the penetration
of heart failure.
42.3 Future Directions and Clinical Implications
We have analyzed the functions of Baf60c, a component of the SWI/SNF-type
chromatin remodeling complex, in heart development in vivo and in vitro, but the
mechanism by which Baf60c is regulated is still unknown. An important question is
whether the functions of Brg1 or Baf60c are altered in each type of tissue. If their
functions do not vary, they may be regulated in a partner-dependent manner. One
approach to confirm this hypothesis is to use ChIP-sequencing to compare Baf60c
and Brg1 target genes in different tissues. Another question that must be addressed
is how Baf60c’s expression pattern and dosage are regulated and which molecule
(s) participate in this regulation. We found a candidate transcription factor that
directly regulates Baf60c expression, but this molecule alone could not explain the
dynamic change in Baf60c’s expression pattern. Further analysis is required to
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Fig. 42.7 Immunoprecipitation experiments indicate that Brg1 can strongly bind to Tbx5 with
Baf60c. The lower panel shows the morphology of Brg1del/+, Tbx5del/+, and double heterozy-
gote mouse hearts. The heart of the double heterozygote shows severe hypoplasia of the left
ventricle (Adapted from Takeuchi et al. [20])
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Over the last 20 years, cardiac researchers have elucidated many causes of
congenital heart disease and have identified many genes that are involved. How-
ever, it is not sufficient to only understand the diversity or severity of the disease. In
the future, we must also determine the role of epigenetic factors in heart failure
because these factors regulate cardiac gene transcription (Fig. 42.7).
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Pcgf5 Contributes to PRC1 (Polycomb
Repressive Complex 1) in Developing
Cardiac Cells
43
Manabu Shirai, Yoshihiro Takihara, and Takayuki Morisaki
Abstract
Polycomb-group (PcG) proteins maintain transcriptional silencing through spe-
cific histone modification and are essential for cell-fate transition and proper
development of embryonic and adult stem cells. Recent advances in molecular
analysis of PcG proteins have revealed that the distinct subunit composition of
PRC1 confers specific and nonoverlapping functions for regulation of embryonic
and adult stem cells. Here, we provide an overview of recent findings regarding
the role of PcG proteins in cardiac development, with focus on the diversity of
PcG complexes.
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Cardiac development is a complex and ordered process that requires cellular
specification, proliferation, and differentiation, as well as further migration of cell
populations from diverse sites. The primary heart field (PHF) originates in the
anterior splanchnic mesoderm, then gives rise first to the cardiac crescent, later to
the linear heart tube, and ultimately contributes to parts of the left ventricular
(LV) region. The second cardiogenic region, known as the second heart field
(SHF), lies in the anterior, posterior, and dorsal to the linear heart tube and is
derived from the pharyngeal mesoderm located medial and anterior to the cardiac
crescent. Cells from the SHF are added to the developing heart tube and give rise to
the outflow tract (OFT), right ventricular (RV) region, and main parts of atrial
tissues [1].
Congenital heart defects (CHDs) represent the most common anomaly seen in
human newborns, with a prevalence of approximately 1 % of all births [1]. Tradi-
tionally, focus on causes of CHD has involved transcriptional networks during
cardiogenesis, because correct alignment and septation of cardiac structures
regulated by cardiac specific transcriptional factors, such as Tbx1, Tbx5, Tbx20,
Gata4, and Nkx2-5, are essential for cardiac morphogenesis [1]. In addition to these
multiple genetic factors, recent studies have shown that some chromatin
remodeling factors moderate gene expression to control cardiogenesis and are
also involved in the molecular pathogenesis of CHD [2–7].
Polycomb-group (PcG) proteins maintain transcriptional silencing by regulating
chromatin configuration [8, 9]. There are two principal PcG repressive complexes
(PRCs), PRC1 and PRC2. Mammalian PRC2 contains four core proteins (Ezh1/2,
Eed, Suz12, Rbbp4/7) and trimethylates histone H3 at lysine 23 (H3K27), while the
other complex, PRC1, consists of a combination of several protein families, includ-
ing chromobox (Cbx), Ring, polyhomeotic (Ph), and posterior sex combs (Psc), and
induces mono-ubiquitination of histone H2A at lysine 119 (Fig. 43.1). In recent
studies, PRC1 have been divided to Cbx-PRC1 (canonical PRC1) and Rybp-PRC1
(noncanonical PRC1) [10, 11]. Since development of high-throughput techniques
for analyzing the genome in the past decade, PcG-mediated transcriptional repres-
sion has resulted in increased molecular information regarding its role in a number
of important biological activities such as cell cycle progression, differentiation, and
cell-fate transition in multiple cell types and tissue contexts, including embryonic,
adult, and cancer stem cells. This PcG-mediated transcriptional repression can vary
during development and among cell types. However, the precise role in the context
of cell conditions remains unclear.
43.2 PcG Functions in Cardiac Development
In this review, we primarily focused on the functions of PcG proteins in cardiac
development. Their roles have been elucidated via generation of knockout
(KO) mice for each of the PcG components. Among the PRC2 components, loss
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of Suz12, Ezh2, or Eed results in embryonic lethality during the early postimplan-
tation stage [12–14]. To address the role of PRC2 in cardiac development, Ezh2 and
Eed were conditionally inactivated in specified cardiac cells using Nkx2-5:Cre or
TnT:Cre [3, 4]. Inactivation of Ezh2 by Nkx2-5:Cre (Ezh2NK) and Eed by TnT:Cre
(EedTnT) led to embryonic lethality and several cardiac defects including compact
myocardial hypoplasia, whereas inactivation of Ezh2 by TnT:Cre (Ezh2TnT) did not
result in severe defects in cardiogenesis despite a modest upregulation of some
cardiac genes, probably because of the redundant functions of Ezh1 and Ezh2.
Embryos deficient of Ring1b, a core component of PRC1, also displayed early
embryonic lethality caused by gastrulation arrest [15]. Although early developmen-



































Fig. 43.1 PcG complexes in
mammals. (A) Molecular
functions of PcG complexes
(PRCs). PRC2 trimethylates
lysine 27 of histone H3.
Canonical PRC1 binds to the
H3K27me3 mark and
mediates the mono-
ubiquitination of histone H2A
at lysine 119. (B) Canonical
PRC1 components and results
of KO of each in mice
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(Ink4a/ARF), cardiac tissue did not develop in double-KO embryos. Unlike early
developmental defects seen in KO mice lacking some of the core PRC1 and PRC2
components, deficiency of other components has been shown to give rise to
restricted effects. For example, loss of Rae28/Phc1 resulted in perinatal lethality
with cardiac anomalies, double outlet right ventricle, and tetralogy of Fallot
[6, 7]. In addition to cardiac defects, Rae28/Phc1 deficient mice also showed
craniofacial developmental defects, as well as thymus and parathyroid gland
defects as seen in human DiGeorge syndrome.
Among Cbx proteins, Cbx4 may play an important role in cardiogenesis.
SUMO-specific protease 2 (SENP2) was reported to regulate transcription of
Gata4 and Gata6, mainly through alteration of the occupancy of Cbx4 on their
promoters [5]. In SENP2-deficient embryos, sumoylated Cbx4 accumulates on the
promoters of target genes, leading to transcriptional repression ofGata4 andGata6.
Furthermore, Cbx4 mutant mice displayed postnatal lethality with severe hypopla-
sia of the developing thymus as a result of reduced thymocyte proliferation.
However, the function of Cbx4 in cardiogenesis has not been clearly elucidated
[16]. Thus, PcG proteins are essential for molecular regulation of the expression of
several cardiac genes during embryogenesis and important for cardiac
morphogenesis.
43.3 Diversity of PcG Proteins
In our recent studies, expression of the PRC1 components Ring1b, Bmi1/Pcgf4, and
Rae28/Phc1 was detected in embryonic hearts containing both the PHF and SHF
embryonic cardiac fields (Fig. 43.2), though their expression patterns were not
restricted in cardiac cells. Despite the ubiquitous expression of PRC1 components,
mice with single PcG KO except for the core proteins show more distinct and
restricted phenotypes. Among Psc proteins, genetic deletion of Mel18/Pcgf2 or
Bmi1/Pcgf4 resulted in postnatal lethality caused defects in anterior-posterior
specification, while there was no effect on cardiogenesis [17, 18]. Also, Mel18/
Bmi1 double-KO mice died around E9.5 and exhibited more severe developmental
defects than those with KO of either alone, suggesting that Mel18/Pcgf2 and Bmi1/
Pcgf4 have partially redundant functions [18]. In addition to functional redundancy,
recent studies have shown that distinct Cbx and Pcgf proteins confer specific and
nonoverlapping functions of PRC1 in embryonic and adult stem cells
[10, 11]. Exchanging Cbx protein in canonical PRC1 is involved in the switch
from self-renewal to a differentiation state, whereas Pcgf and other noncanonical
components, such as Rybp, Kdm2b, and L3mbtl2, also confer restricted functions to
PRC1.
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43.4 Pcgf5 Expression in the Developing Heart
Recently, we identified Pcgf5 as an upregulated gene during cardiomyocyte differ-
entiation of ES cells as well as strong expression of Pcgf5 in cardiac fields during
the early embryonic stages as compared to other embryonic tissues [19] (Fig. 43.3).
Unlike Bmi1/Pcgf4, Pcgf5 expression, patterns were more restricted to early mouse
embryos. Our hypothesis states that exchanging Pcgf components within PRC1
determines the specificity of their function in the developing heart.
43.5 Conclusions
Recent increasing evidence obtained in experiments with embryonic and adult stem
cells indicates that the diversity of PRC components, particularly PRC1, contributes













Fig. 43.2 Expression patterns of Ring1b and Rae28/Phc1 in E9.5 mouse embryos. Anti-Ring1b
and anti-Rae28/Phc1 antibody-positive cells are ubiquitously distributed on E9.5. AVC, atrio-
ventricular canal, LV, left ventricle, Nt, neural tube, RA, right atrium, RV, right ventricle




Fig. 43.3 Expression pattern of Pcgf5 in E8.0 mouse embryos. Whole-mount in situ
hybridization (WISH) showing expression of Pcgf5 at E8.0. High Pcgf5 expression was observed









Fig. 43.4 Recent insight regarding PRC1 complexes. Canonical PRC1 (Cbx-PRC1) is recruited
to H3K27me3 and causes mono-ubiquitination of lysine 119 of histone H2A. Noncanonical PRC1
(Rybp-PRC1) mediates the mono-ubiquitination of H2A in a PRC2-independent manner
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by PcG is essential for cardiogenesis. Understanding PcG functions and more
detailed characterization of the PcG complex during cardiogenesis may be crucial
for elucidating the molecular mechanisms regulating cardiac development.
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Noncoding RNAs in Cardiovascular Disease 44
Masaharu Kataoka and Da-Zhi Wang
Abstract
For decades, it has been recognized that proteins, which are encoded by our
genomes via transcription and translation, are building blocks that play vital
roles in almost all biological processes. Mutations identified in many protein-
coding genes are linked to various human diseases. However, this “protein-
centered” dogma has been challenged in recent years with the discovery that
majority of our genome is “noncoding” yet transcribed. Noncoding RNA has
become the focus of “next generation” biology. Here, we review the emerging
field of noncoding RNAs, including microRNAs (miRNAs) and long noncoding
RNAs (lncRNAs), and their function in cardiovascular biology and disease.
Keywords
Cardiac disease • Heart development • Long noncoding RNAs • MicroRNAs
44.1 Introduction
When the human genome project was completed, it was surprising that only about
20,000–25,000 protein-coding genes exist in our species, with less than 2 % of the
human genome used for coding proteins. What are the functions of noncoding
sequences, which make up more than 98 % of our genome? We are now finding
answers with the recognition that the majority of the genome is actively transcribed
to produce thousands of noncoding transcripts, including microRNAs (miRNAs)
and long noncoding RNAs (lncRNAs), in many cell types and tissues. miRNAs are
a class of small noncoding RNAs (~22 nucleotides) and were first discovered in
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C. elegans two decades ago. More than 2,000 miRNAs have been found in humans,
and many of them are evolutionarily conserved. By imperfect base pairing with
mRNAs in a sequence-dependent manner, miRNAs repress gene expression by
degrading target mRNAs and/or inhibiting their translation. Roles for miRNAs
have been demonstrated in the regulation of a broad range of biological activities
and diseases [1]. More recently, thousands of lncRNAs, which are transcribed
noncoding RNAs greater than 200 nucleotides, were discovered and implicated in
a variety of biological processes [2]. Clearly, investigating and understanding of
how miRNAs and lncRNAs regulate gene expression during cardiovascular devel-
opment and function will greatly facilitate therapeutic treatment of cardiovascular
disease.
44.2 miRNAs in Cardiac Development
Global disruption of all miRNA expression in the heart is the first step to under-
standing the function of miRNAs in cardiac development and physiology. Dicer, a
RNase III endoribonuclease, is a critical enzyme for the maturation of most
miRNAs. Conventional deletion of Dicer causes early embryonic lethality in
mice [3]. Disrupting miRNA expression in the early embryonic stage using
Nkx2.5-Cre leads to improperly compacted ventricular myocardium in mutant
embryos [4], and α-MHC-Cre-mediated conditional deletion of Dicer causes post-
natal lethality due to dilated cardiomyopathy and heart failure [5]. These studies
suggest that many miRNAs have crucial roles in cardiac development. miR-1 is
tissue-specifically expressed in the heart and skeletal muscle, and genetic deletion
of both miR-1-1 and miR-1-2 indicated that miR-1 is required for cardiomor-
phogenesis and the expression of many cardiac contractile proteins [6].
44.3 Cardiac Regeneration, Remodeling, and Ischemia
Regulated by miRNAs
Mammalian adult cardiomyocytes are terminally differentiated cells with very
limited regenerative ability. A recent report identified about 40 miRNAs that
strongly increased cell proliferation in neonatal mouse and rat cardiomyocytes.
Two of these miRNAs, miR-590 and miR-199a, were further demonstrated to
induce cardiomyocyte proliferation both in vitro and in vivo [7]. Using both gain-
and loss-of-function approaches in transgenic and knockout mice models, we
demonstrated that the miR-17-92 cluster is required for and sufficient to induce
cardiomyocyte proliferation. More specifically, we identified miR-19a/b as the
major contributors among the miR-17-92 cluster to the regulation of the
cardiomyocyte proliferation [8]. These studies suggest that miRNAs are key
regulators of cardiomyocyte proliferation and heart regeneration, suggesting their
significant therapeutic potential to treat cardiac-degeneration-associated heart
disease.
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Cardiac remodeling, which is defined as an alteration in the structure
(dimensions, mass, shape) of the heart, is one of the major responses of the heart
to biomechanical stress and pathological stimuli. Numerous studies have
demonstrated the functional involvement of many miRNAs during cardiac
remodeling [9]. Recently, we and others demonstrated that miR-22, a miRNA
enriched in cardiomyocytes but only mildly upregulated during cardiac hypertro-
phy, significantly promotes cardiac hypertrophy in vitro and in vivo [10, 11].
Ischemia is an independent risk factor of cardiovascular events, which leads to
myocardial infarction (MI) and ischemia-reperfusion (I/R) injury. Several miRNAs
participate in the regulation of these pathologic processes, especially
cardiomyocyte apoptosis following MI and I/R injury. miR-92a, a member of the
miR-17-92 cluster involved in cardiomyocyte proliferation, also participates in the
control of cardiomyocyte survival by targeting integrin subunit α5 and eNOS.
Inhibition of miR-92a by antagomir has improved cardiac function and reduced
cardiomyocyte apoptosis after MI in mice [12]. miR-21 serves as an anti-apoptotic
factor in MI animal models by targeting PDCD4 and repressing its expression.
Interestingly, miR-21 seems to target cardiac fibroblasts, not cardiomyocytes, in the
heart [13]. Conversely, miR-320 is downregulated after I/R injury. Gain- and loss-
of-function studies demonstrated that miR-320 promotes cardiomyocyte apoptosis
via maintaining HSP20 levels [14]. Together, these studies establish miRNAs as
key regulators of cardiomyocyte survival and cardiac remodeling in response to
pathophysiological stresses.
44.4 LncRNAs in Cardiac Development
While many lncRNAs have recently been discovered, relatively little is known
about their function. A novel lncRNA, Braveheart, has been defined as a critical
regulator of cardiovascular commitment from embryonic stem cells (ESCs)
[15]. Braveheart activates a cardiovascular gene network and functions upstream
of mesoderm posterior 1, a master regulator of a common multipotent cardiovascu-
lar progenitor. Braveheart mediates the epigenetic regulation of cardiac commit-
ment by interacting with SUZ12, a component of the polycomb repressive complex
2 (PRC2). Braveheart therefore represents the first lncRNA that defines cardiac cell
fate and lineage specificity, linking lncRNAs to cardiac development and disease. It
remains to be seen if Braveheart is required for normal heart development in vivo.
Equally critically, it will be important to determine whether genetic mutation of the
Braveheart gene is linked to human cardiovascular disorders. Nevertheless, the
discovery of Braveheart will significantly impact the cardiovascular research field
and link lncRNAs to human cardiovascular disease.
Fendrr, another novel lncRNA, has been defined as an essential regulator of
heart and body wall development. Fendrr is expressed in the mouse lateral plate
mesoderm, from which precursors for the heart and body wall are derived, and the
knockout of Fendrr resulted in defects in heart development [16]. Like Braveheart,
Fendrr interacts with the PRC2 complex to regulate gene expression. It is expected
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that many more lncRNAs will be found to play important roles in cardiovascular
development and function.
44.5 Noncoding RNAs in Cardiac Disease
The expression and function of multiple miRNAs have been associated with human
cardiovascular disease. Recent studies also linked several lncRNAs to heart disease.
ANRIL, a lncRNA, was identified as a risk factor for coronary disease [17]. Though
it is still not fully understood how ANRIL functions, evidence suggests that this
lncRNA may participate in the regulation of histone methylation [18]. Another
lncRNA MIAT (myocardial infarction-associated transcript) (or Gomafu/RNCR2)
was identified as a risk factor associated with patients with myocardial infarction
[19]. However, how MIAT controls MI status remains largely unknown. Intrigu-
ingly, the genetic loci that encode MYH6 and MYH7, the main myosin heavy chain
genes in cardiac muscle, appear to produce a noncoding antisense transcript (Myh7-
as). Myh7-as transcription may regulate the ratio of Myh6 and Myh7, altering the
function of muscle contraction [20].
We have just started the era of “noncoding.” We are looking forward to see more
and more reports on the roles of noncoding RNAs in the regulation of a variety of
essential biological processes. Furthermore, with efficient strategies for gain- and
loss-of-function investigations, more fruitful work about the molecular mechanism
and therapeutic application of noncoding RNAs in cardiovascular disease will
emerge.
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Part X




Human adult somatic cells can be reprogrammed to induced pluripotent stem (iPS)
cells upon the introduction of four transcription factors that are part of the
pluripotency network in embryonic stem cells. The ability to readily from patients
with disease has ushered in new opportunities to understand disease mechanisms,
screen for therapeutics, and consider regenerative approaches using personalized
human cells. In this session, several examples of the use of iPS cells in novel ways
were presented.
By making iPS cells from patients with genetically defined disease, the
investigators were able to differentiate the pluripotent cells into the cell type
affected by the congenital cardiovascular disorder. These cells carried the
disease-causing mutation and provided a platform for understanding the cellular
and molecular consequences of the mutation in the most relevant human cells. Deep
interrogation of such cells promises to reveal fundamental mechanisms of disease
and should point to new targets to intervene in the disease process. This is being
done for diseases involving cardiomyocytes, smooth muscle cells, and endothelial
cells, each of which can be easily differentiated from human iPS cells with good
efficiency and purity. Once new targets for disease pathology are discovered in such
cells, small molecule or biologic screens can be performed to identify lead
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candidates for new therapeutics. For those congenital diseases that have ongoing
consequences after birth, there is potential to intervene postnatally in the disease
evolution.
In addition to the use of iPS cells for disease modeling and drug discovery, there
are robust efforts to use pluripotent stem cells for regenerative medicine. Such
efforts often involve bioengineering approaches to assemble stem cell-derived
cardiomyocytes into a three-dimensional structure. This can be useful for
cardiomyocytes, valves, or vessels. The use of iPS cells may allow personalized
tissues to be developed, as tissue could be generated with one’s own cells. New
approaches using efficient gene-editing techniques may allow correction of abnor-
mal genes and subsequent use of corrected cells for transplant. Other types of
progenitor cells are also being studied for their regenerative capacity and are
discussed in this section.
While there is great hope that the use of iPS cells will lead to new therapeutic
approaches, many hurdles must be overcome. For disease modeling, purifying
specific subtypes of cells that are affected by disease will be important, as will
the ability to generate more mature, adult-like cells from the iPS cells. For regener-
ative medicine approaches, the ability to generate mature cells that can survive and
integrate upon transplantation will be critical and will likely require clever engi-
neering strategies. Nevertheless, it is likely that iPS-based technologies will provide
us a better understanding of human disease and lead to new interventions.
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Human Pluripotent Stem Cells to Model
Congenital Heart Disease 45
Seema Mital
Abstract
Congenital heart disease (CHD) is the most common cause of neonatal mortality
related to birth defects. Etiology is multifactorial including genetic and/or
environmental causes. The genetic etiology is known in less than 20 % cases.
Animal studies have identified genes involved in cardiac development. How-
ever, generating cardiac phenotypes usually requires complete gene knockdown
in animal models which does not reflect the haplo-insufficient model commonly
seen in human CHD. Human pluripotent stem cells which include human
embryonic stem cells (hESC) and human-induced pluripotent stem cells
(hiPSC) provide a unique in vitro platform to study human “disease in a dish”
by providing a renewable resource of cells that can be differentiated into
virtually any somatic cell type in the body. This chapter will discuss the use of
human pluripotent stem cells to model human CHD.
Keywords
Human embryonic stem cells • Induced pluripotent stem cells • Williams
syndrome • Hypoplastic left heart syndrome • Fetal reprogramming
45.1 Introduction
Human embryonic stem cells (hESC) can give rise to all three germ layers –
ectoderm, endoderm, and mesoderm – and can be used to generate differentiated
cells of different lineages [1]. The Nobel prize-winning discovery by Yamanaka of
the ability to reprogram somatic cells to induced pluripotent stem cells (iPSC) using
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specific reprogramming factors [2] uncovered a whole new field of research focused
on the use of iPSCs to model human disease, perform drug screens, and explore
strategies for autologous cell-based therapies in the future. Reprogramming
protocols include ectopic expression of four transcription factors [2, 3] that induce
reprogramming of somatic cells into an embryonic state. Viral integration-free
protocols are also used albeit are less efficient. These cells can then be expanded
and differentiated into several somatic cell types including cardiac lineages such as
cardiomyocytes, vascular smooth muscles cells (SMCs), and endothelial cells. The
process of cardiac differentiation of hESCs and hiPSCs recapitulates cardiac
embryogenesis thereby providing a unique opportunity to explore the impact of
gene or environmental defects on early cardiac development and gain novel insights
into disease mechanisms [4]. Strategies for modeling cardiac malformations are
discussed.
45.2 Modeling Fetal Cardiac Reprogramming in Hypoplastic
Left Heart Syndrome (HLHS)
HLHS is one of the most severe cardiac malformations characterized by poor
growth of left-sided cardiac structures. This is commonly associated with endocar-
dial fibroelastosis (EFE). The mechanism of LV growth failure and fibrosis is
poorly understood. We studied 29 normal and 30 HLHS fetal hearts during second
trimester [5]. We found increased nuclear expression of hypoxia-inducible factor
1α (HIF1α) in fetal HLHS compared to normal LVs, a central hypoxia-responsive
gene that promotes activation of angiogenic, metabolic, and other genes to facilitate
cardiac adaptation to hypoxia. However, expression of vascular endothelial growth
factor (VEGF) was downregulated. The failure of hypoxia-induced angiogenesis
was likely related to cell senescence as shown by DNA damage (nuclear γH2AX
activation and p53 upregulation) and of cell senescence (β-galactosidase
upregulation). Senescent cells, although functional, do not produce growth factors
essential for the survival and proliferation of stem/progenitor cells thereby
compromising tissue renewal capacity. Not surprisingly, HLHS hearts showed
fewer cardiac progenitor markers, as well as reduced differentiated cardiomyocyte
and endothelial cells. DNA damage was most prominent in endothelial cells
followed by myocytes, with SMCs being least susceptible. Additionally, there
was increased transforming growth factor (TGFβ1) expression, increased
myofibroblast transformation, and increased interstitial and perivascular fibrosis
in fetal HLHS compared to controls. Together this suggested that the fetal LV may
be susceptible to chronic hypoxia or reduced blood flow (a phenomenon that occurs
in HLHS due to reduced antegrade flow through the diminutive ascending aorta)
resulting in DNA damage and cell senescence and consequent loss of cell replica-
tion and growth capacity as well as fibrosis.
To clarify the role of hypoxia in fetal cardiac differentiation, we exposed hESC-
derived cardiac lineages to 1 % hypoxia for 72 h. This was associated with
recapitulation of the fetal HLHS phenotype including increased HIF1α; reduced
322 S. Mital
Fig. 45.1 Effect of hypoxia on DNA damage and oncogene upregulation in hPSC-derived cardiac
lineages. (a) DNA damage-related marker γH2AX (green nuclear foci) and senescence marker
β-gal (blue) are increased in hypoxic cells. Blue represents nuclear staining with DAPI. (b) qPCR
results revealed higher mRNA expression of the tumor suppressor oncogene p53 and the G1 cell
cycle inhibitors p16 and p18 in hypoxic (gray bars) compared with control cells (black bars). (c)
Double immunostaining revealed co-localization of ph-p53 (green) with cTnT+ myocytes (red),
CD31+ endothelial cells (red), and SMA+ SMCs (red), indicating DNA damage in all three
lineages. Blue represents nuclear staining with TO-PRO-3. (d) Cellomics quantification confirmed
the higher number of phospho-p53+ cardiac lineages in hypoxic cells (gray bars) compared with
controls (black bars), with most severe injury in ECs followed by myocytes and then SMCs.
∗P< 0.01 versus controls; {P< 0.05 versus SMA+ cells; {P< 0.05 versus cTnT+ cells (n¼ 3
experiments in each group). Original magnification: 1,000 (γH2AX); 600 (β-gal) (a); 1,000
(c) (Reproduced with permission) [5]. Reprinted from Gaber et al. [5], Copyright (2013), with
permission from Elsevier [5])
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VEGF; TGFβ1 upregulation; DNA damage (highest in endothelial cells followed
by myocytes followed by SMCs); cell senescence; reduced cell proliferation,
resulting in a reduction in myocyte and endothelial lineages but increase in SMC
lineages; and reduced contractility (Fig. 45.1). Treatment with TGFβ1 inhibitor
reversed this abnormal phenotype. This suggests that immature cardiac lineages
may be susceptible to hypoxic injury and that this may be mediated in part by
TGFβ1 activation. This may contribute to the phenotype of LV growth failure and
fibrosis in cardiac malformations like fetal HLHS.
These findings have several implications. They suggest that antenatal interven-
tion for HLHS may be more effective in promoting LV growth if performed before
irreversible tissue injury. However, complementary strategies to provide missing
growth factors and/or inhibit TGFβ1 either pre- or postnatally may be needed to
promote LV growth and ameliorate progressive fibrosis.
45.3 hiPSCs to Model Williams-Beuren Syndrome (WBS)
WBS is a genetic disorder caused by deletion of 26–28 genes in the 7q11.23 region.
Cardiac manifestations are common and are related primarily to haploinsufficiency
of the elastin gene in the deleted region. Elastin insufficiency causes vascular SMC
proliferation resulting in either generalized arteriopathy or discrete arterial stenoses
including supravalvar aortic stenosis, coronary stenosis, pulmonary stenosis, and
renal artery stenosis [6]. Surgical correction is often associated with recurrence of
stenosis, and there are no medical therapies to prevent or reduce vascular stenoses.
Mouse models require complete elastin gene knockdown to reproduce supravalvar
aortic stenosis. We therefore generated iPSCs from a patient with WBS with
supravalvar aortic stenosis to provide a more human-relevant model for study.
Skin fibroblasts obtained at the time of surgery were reprogrammed using four
factor retroviral reprogramming. Four iPSC lines were characterized for
pluripotency and subjected to SMC differentiation using a published protocol
[7]. SMCs generated from iPSCs from normal BJ fibroblasts showed high elastin
expression, with 90 % positive for SM22α (a marker of SMC differentiation). These
cells showed a good contractile response (Ca2+ flux) to a vasoactive agonist like
endothelin and tube-forming capacity on Matrigel assay. In contrast, WBS iPSC-
derived SMCs showed low elastin expression, had fewer SM22α-positive cells,
were highly proliferative, showed poor tube-forming capacity on Matrigel, and did
not show a contractile response to endothelin (Fig. 45.2) [8]. Treatment with
rapamycin, a mTOR inhibitor and antiproliferative agent, showed partial rescue
of the abnormal phenotype in WBS-SMCs by enhancing differentiation, reducing
proliferation, and improving tube-forming capacity. However, it did not restore
contractile response to endothelin. Ge et al. used a similar approach to generate and
study SMCs from a patient with supravalvar aortic stenosis with WBS and another
with elastin loss-of-function mutation that showed a similar phenotype that was
rescued by ERK1/2 inhibition [9]. To identify additional compounds that not only
improve SMC differentiation but also promote functional maturation and
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vasoactive responsiveness, we are developing a high-throughput high-content
screening assay to facilitate screening of drug libraries using WBS-SMCs.
Compounds that fully rescue the abnormal SMC phenotype in WBS may guide
the development of new drugs to relieve vascular stenoses in WBS and, by
extension, in other vascular disorders including atherosclerosis, stent restenosis,
and transplant graft vasculopathy.
45.4 Future Directions and Clinical Applications
These studies provide proof of principle that hESCs and iPSCs can generate in vitro
models to study CHD. However, the cardiac lineages generated using this approach
are relatively immature, i.e., fetal stage. While fetal stage cells may be well suited
to study developmental cardiac disorders [10], maturation protocols that generate
Fig. 45.2 Functional characterization of BJ-smooth muscle cells (SMCs) andWBS-SMCs. (a) BJ
and WBS-SMCs (line B shown) were treated with 10 mM carbachol, a muscarinic agonist, and
phase-contrast live-cell imaging was done every 30 s. Change in cell surface area (white arrows)
was calculated from 0 min (top panel) to 30 min (bottom panel). (b) BJ-SMCs showed a 25 %
reduction in cell surface area compared with 14 % reduction in WBS-SMCs (average of all four
lines). *, p< 0.05 BJ versus WBS. (c) Calcium flux [Ca2+]i was measured in response to
endothelin-1 treatment (arrow) in BJ and WBS-SMCs (five cells each). The fluorescence intensity
ratio (F340 nm/F380 nm) showed a transient rise in [Ca
2+]i after activation by endothelin-1 in
BJ-SMCs but not in WBS-B SMCs. (d) Graph showing the changes in [Ca2+]i following
endothelin-1 treatment in BJ and all the WBS lines. Changes of [Ca2+]i ¼ peak [Ca2+]i  resting
[Ca2+]i. *, p< 0.01 BJ versus WBS. WBS Williams-Beuren syndrome (Reprinted from Kinnear
et al. [8], Copyright (2013), with permission from Alpha Med Press [8] (pending))
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more functionally mature lineages may be more useful to study late-onset disease
phenotypes and accurately evaluate drug responses [11–14]. Our study further
suggests that the technology can be expanded to study not just genetic influences,
particularly in the rapidly emerging era of genome editing [15], but also environ-
mental teratogens (toxins, chemicals, drugs, infections) to define the mechanisms
by which they impact fetal cardiac development or differentiation. This may
facilitate delineating the combined role of genetic and environmental factors in
CHD causation in the near future [16]. The ability to differentiate pluripotent stem
cells into many different organ or cell types may allow the study not only of cardiac
but also of extracardiac phenotypes particularly in syndromic disorders as recently
shown in a patient with Timothy syndrome [17, 18].
In summary, pluripotent stem cell-derived models are revolutionizing our under-
standing of disease pathogenesis and are positioned to expedite drug screening and
discovery particularly for rare cardiac disorders with a genetic basis for which no
therapies are available and where clinical studies are challenging. The technology
provides a renewable source of functional cardiomyocytes and other cardiac
lineages with genetic and epigenetic variation that are likely to be more human
relevant. While the use of these cells for in vivo therapies is several years away, this
platform is well positioned to study the molecular underpinnings of genetic cardiac
disorders and help identify new therapies for personalized care of the affected child.
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Engineered Cardiac Tissues Generated
from Immature Cardiac and Stem
Cell-Derived Cells: Multiple Approaches
and Outcomes
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Abstract
The translation of in vitro engineered cardiac tissues (ECTs) from immature
cardiac and stem cell-derived cells toward clinical therapies is benefiting from
the following major advances: (1) rapid progress in the generation of immature
cardiac cells from the cardiac and noncardiac cells of multiple species including
normal and disease human cells, (2) incorporation of multiple cell lineages into
3D tissues, (3) multiple scalable 3D formulations including injectable gels and
implantable tissues, and (4) insights into the regulation of cardiomyocyte prolif-
eration and functional maturation. These advances are based on insights gained
from investigating the regulation of cardiac morphogenesis and adaptation. Our
lab continues to explore this approach, including changes in gene expression that
occur in response to mechanical loading and tyrosine kinase inhibition, the
incorporation of vascular fragments into ECTs, and the fabrication of porous
implantable electrical sensors for in vitro conditioning and postimplantation
testing. Significant challenges remain including optimizing ECT survival post-
implantation and limited evidence of ECT functional coupling to the recipient
myocardium. One clear focus of current research is the optimization and expan-
sion of the cellular constituents, including CM, required for clinical-grade ECTs.
Another major area of investigation will be large animal preclinical models that
more accurately represent human CV failure and that can generate data in
support of regulatory approval for phase I human clinical trials. The generation
of reproducible human ECTs creates the opportunity to develop in vitro
myocardial surrogate tissues for novel drug therapeutics and toxicity assays.
B.B. Keller (*) • F. Ye • F. Yuan • H. Trada • J.P. Tinney • K.M. Walsh • H. Masumoto
Kosair Charities Pediatric Heart Research Program, Cardiovascular Innovation Institute,
University of Louisville, 302 E. Muhammad Ali Blvd, Louisville, KY 40202, USA
e-mail: brad.keller@louisville.edu
# The Author(s) 2016




Cardiomyocytes • Cardiac repair and regeneration • Engineered cardiac tissues •
Stem cells
46.1 Introduction
Following significant cardiac injury, the postnatal human heart lacks the ability to
restore lost myocardium, resulting in an adaptive response that often ultimately
leads to progressive cardiac dysfunction, morbidity, and mortality. There are
currently many strategies for cardiac “cellular therapy” undergoing both preclinical
and clinical trials [1–4]. While there has been modest success with improvement in
cardiac function in some of the early human clinical trials, it is clear that injected or
implanted cells do not survive, and functional improvement occurs via paracrine
mechanisms. In contrast, rapid advances in tissue engineering over the past two
decades have resulted in the generation of functional, multicellular, 3D cardiac
tissues with the potential for translation to human cardiac repair and regeneration
[5–8]. This chapter provides a concise overview of some of the key issues in the
generation, maturation, and translation of these engineered cardiac tissues (ECTs).
46.2 A Broad View of Bioengineering Cardiac Tissues
The bioengineering process for complex tissues begins with an understanding of the
cellular and noncellular constituents of the target tissue [9]. For replacement
myocardium, the major cellular constituents include cardiomyocytes (CM),
fibroblasts, and vessel-associated cells. There are also numerous extracellular
matrix (ECM) constituents including collagen, fibronectin, laminin, and multiple
growth factors bound within the ECM. Of course, the neonatal myocardium and the
adult myocardium have vastly different profiles for cellular and noncellular
constituents, architecture, and biomechanical properties. While all currently suc-
cessful ECTs are constructed using immature cells and simplified ECM
components, the target tissue is usually mature myocardium. The success of ECT
survival, integration, and functional maturation depends on the ability of these ECT
constituents to acquire “mature” fates.
46.3 Immature Cells for Engineered Cardiac Tissues
Because the goal for cardiac regeneration is the restoration of functionally coupled,
working myocardium, a variety of cell sources with the potential to generate CM
are under investigation. Immature CM can be isolated from the hearts of developing
chick, mouse, and rat embryos to generate ECTs for preclinical investigation
(Fig. 46.1) [5–7]. These cells mature in vivo or in vitro along timelines proportional
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to the gestational length of their species of origin. A variety of stem cell sources
(embryonic stem cells, induced pluripotent stem cells, cardiac stem cells, adipose
stem cells, etc.) have also been used to generate immature CM using a variety of
CM lineage specification and selection protocols [10–14]. Not surprisingly, stem
cell populations can be rapidly expanded in vitro along with the induction of cardiac
lineages; however, their functional maturation remains a major technical challenge
[15–17]. Because human cells are required for clinical translation, the optimization
of protocols that can generate large quantities of functional human CM is a high
priority for cardiac repair strategies. Further, there may be advantages to generating
ECTs that contain both cardiac and vascular lineage cells to accelerate angiogenesis
and vascular perfusion of implanted ECTs [11–13].
a b
dc
Fig. 46.1 Representative engineered cardiac tissues (ECTs) derived from (a) embryonic chick
heart cells; (b) human-iPS-derived cardiomyocytes; (c) embryonic rat heart cells and rat adipose
vascular fragments; and (d) enlarged image of vascular fragments within a rat ECT. Staining for
(a, b) are blue (DAPI, nuclei), green (cardiac troponin T), and red (EdU). Staining for (c, d) are red
(alpha actinin) and green (GFP+vascular fragments). Images (a, c) are 20magnification; images
(b, d) are 40 magnification (Keller lab, unpublished)
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46.4 Various Formulations for Engineered Cardiac Tissues
The constructs used for cardiac tissue repair include the implantation of multicellu-
lar cardiospheres [18], various formulations of 2D cellular sheets [19–22], and
various formulations of 3D tissues [5–8, 13]. The composition of the noncellular
constituents varies from minimal constituents for cardiosphere clusters to a range of
ECM components [23, 24] and growth factors [25–27] selected for their ability to
facilitate CM survival and functional maturation. Some of the ECT formulations
allow for in vitro preconditioning strategies that can stimulate cell proliferation
and/or maturation [5, 6]. While there can be wide variation in the formulation of
ECTs used for preclinical studies, all constituents used to generate ECTs for human
use are required to conform to strict FDA regulatory guidelines that include the
elimination of all sources for potential infectious agents and/or toxins and the
generation of clinical-use materials using good manufacturing practices [28].
46.5 In Vitro ECT Findings
Immature CM survive, proliferate, and functionally mature rapidly within ECTs as
quantified by standard measures of cell number, gene expression profiling
(Fig. 46.2) [29], sarcomeric protein content, electrophysiologic properties, and
the ability to generate substantial force [5–7, 13].
Maturing functional syncytia can include CM, myofibroblasts, and vascular cells
with a functional advantage noted for multiple lineage constructs over pure
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Fig. 46.2 Changes in rat ECT gene expression in response to mechanical loading and/or
p38MAPK inhibition. ECT transcript expression changes at least 1.5-fold measured by microarray
in response to stretch (dark solid bar), the p38MAPK inhibitor BIRB796 (gray solid bar), or
stretch+BIRB796 (dashed bar). Note that most transcripts increased by less than threefold (above
the X-axis) or decreased by less than fivefold (below the X-axis) [29]
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cell proliferation and/or maturation include the use of exogenous paracrine factors
[15, 26], electrical stimulation [17, 27], and/or mechanical conditioning
[6, 13]. Structural CM maturation is readily documented using immunohistochemi-
cal stains for sarcomeric proteins, gap junctions, and the presence of ion channels
[30]. Functional CM maturation is documented by decreasing pacing voltage
thresholds to initiate pacing, intrinsic rates and maximal beat rates in response to
electrical stimulation, increasing rates of electrical conduction across ECTs, devel-
oped force in response to pacing, and both force-length and force-frequency
relations reflecting increased contractility and increased calcium cycling efficiency
(Fig. 46.3). ECTs generated from human-derived cells are now proposed as in vitro
models for human diseases as well as surrogate models to detect drug toxicity prior
to clinical trials [31, 32].
46.6 In Vivo ECT Findings
Ultimately, ECTs require in vivo implantation to assess survival, structural integra-
tion to the recipient myocardium, functional integration, and evidence for recovery
of lost cardiac function. Preclinical implantation models have been primarily small
animals (rodents); however, there is an increasing experience with the preclinical
testing of ECTs using large animal models including pigs [22] and, eventually,
nonhuman primates. The in vivo results have been very encouraging and confirm
the capacity of implanted ECTs to survive, functionally couple, and recover
damaged myocardium within the context of the experimental design [33]. There
are several challenges to the interpretation of in vivo ECT studies. First, many of
the studies involve the implantation of ECTs into immune-compromised animals.
These studies are required to validate the capacity of implanted ECTs to function-
ally couple to recipient myocardium but underestimate the rapid inflammatory
degradation that occurs as evidenced by the presence of macrophage-associated
arginase and reduced ECT post-implant cellularity, even in syngeneic animals
(Fig. 46.4) [13, 30].
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Fig. 46.3 Representative force-frequency relations for chick embryo-derived ECT and human-
iPS-CM-derived ECT. Force-frequency relations quantify force generation in response to
increased beat rate and reflect ECT maturational ability to release and restore Ca2+. Chick embryo
and h-iPS ECT showed increased passive force and reduced active force as beat rate increased
from 120 to 240 bpm consistent with immature Ca2+ release during contraction and limited Ca2+
sequestration at faster rates (Keller lab, unpublished)
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Second, the in vivo results are often reported after relatively short periods that
may not reflect long-term, sustained functional recovery [13]. Finally, the acute
surgical models of cardiac injury in preclinical models often do not fully represent
the human disease state with medical comorbidities and recurrent episodes of
ischemia/injury. To date there are too few studies in large animal models to validate
the feasibility of scaling up CM and ECT production for cardiac repair and to
compare direct cell delivery strategies to ECT implantation strategies for short- and
longer-term efficacy.
46.7 Future Directions
One clear focus of current and future research is the optimization and expansion of
the cellular constituents, including CM, required for clinical-grade ECTs. Ulti-
mately, these cells will need to be from human sources and have minimal immuno-
genic profiles. Another major area of investigation will be large animal preclinical
Fig. 46.4 Representative postimplantation histology for rat embryo-derived ECT implanted onto
the epicardial surface of a syngeneic adult male rat 2 weeks after coronary artery ligation-induced
myocardial infarction. (a) Blue (DAPI, nuclei), (b) red (arginase marker for macrophages), (c)
green (GFP+ for recipient myocardium and inflammatory cells), (d) merged image. Images are
10 magnification. Note the high cellularity of the recipient myocardium (upper left corner) and
the implanted ECT. Note the increased presence of arginase along the outer margins of the
implanted ECT, consistent with the higher cell density noted in ECT (Keller lab, unpublished)
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models that more accurately represent human CV failure and that can generate data
in support of regulatory approval for phase I human clinical trials. Related to these
large animal models will be innovations in the ability to manufacture large-scale
ECTs and to implant them with minimally invasive techniques. Although it is
beyond the scope of this chapter, the generation of reproducible human ECTs
creates the opportunity to develop in vitro myocardial surrogate tissues for novel
drug therapeutics and toxicity assays.
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Dissecting the Left Heart Hypoplasia by
Pluripotent Stem Cells 47
Junko Kobayashi, Shunji Sano, and Hidemasa Oh
Keywords
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The genetic background of hypoplastic left heart syndrome (HLHS) is still
unknown. Cardiac differentiation from pluripotent stem cells (PSCs) can recapitu-
late the cardiogenesis in vitro, and PSC technology could be useful to dissect the
diseases with the complex mechanisms. In the past few years, some researches were
reported to seek the pathogenesis of HLHS by using PSCs. This paper reports the
achievements.
1. Gaber N et al. showed that human embryonic stem cells (hESCs) during cardio-
vascular lineage with hypoxia recapitulated the phenotype of the HLHS heart,
which was characterized by increased expression of the oncogenes and TGF-ß1,
damaged DNA, and senescence with cell cycle arrest [1]. The phenotypes were
rescued by TGF-ß1 inhibition.
2. Jiang Y et al. generated disease-specific induced pluripotent stem cells (iPSCs)
from a patient with HLHS [2]. HLHS-iPS-derived cardiomyocytes demonstrated
repression of MESP1, TNNT2, and delayed expression of GATA4 compared
with hESCs and control-iPSCs. HLHS-iPS-derived cardiomyocyte showed cal-
cium oscillation under caffeine and inositol trisphosphate receptor upregulation,
presumably as a result of ryanodine receptor dysfunction.
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3. Kobayashi J et al. generated five HLHS-iPSC lines and found repression of the
transcripts such as NKX2-5, HAND1, HAND2, NOTCH1, HEY1, HEY2, and
TBX2 in HLHS-iPS-derived cardiomyocytes [3]. The promoter activities of
SRE, TNNT2, and NPPA were suppressed in HLHS-derived cardiac progenitor
cells and iPSCs compared with those from bi-ventricle (BV). All promoter
activities of both cell types could be fully restored by co-transfection of
NKX2-5, HAND1, and NOTCH1, and co-transfection of the shRNAs into
BV-derived cells reduced the promoter activation. HLHS-derived
cardiomyocytes demonstrated repressed H3K4me2 and acH3 and increased
H3K27me3 in NKX2-5 promoter, implying suppressed NKX2-5 promoter
activity.
Taken together, the PSC technology can be useful to dissect the complex heart
diseases. Further investigation using this technique is necessary to determine the
pathogenesis of HLHS (Fig. 47.1).
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Fig. 47.1 PSC technology models HLHS. Three possible mechanisms of HLHS were unveiled by
PSCs. Bar, 200 μm
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Pompe disease is an inherited neuromuscular disorder caused by a genetic defi-
ciency of acid-glucosidase-alpha (GAA). The clinical symptoms of Pompe disease
include progressive weakness, respiratory failure, and ventricular hypertrophy.
Enzyme replacement therapy has been shown to ameliorate these symptoms.
Cardiomyocytes derived from patient/disease-specific iPS cells (iPS-CMs) have
been used for pathophysiological analyses, drug screening, and cell therapy. Our
research goal was to generate cardiomyocytes that can be differentiated from gene-
corrected Pompe disease-specific iPS cells.
We obtained iPSC (TkDA3-4) generated from human dermal fibroblasts
[1]. GAA was cloned into cDNA expressing third-generation lentiviral vectors
(CS2-EF1α-GAA). To assess the transfection efficacy, Venus, a YFP variant
protein, was also cloned into the vector (CS2-EF1α-Venus). Then, we transfected
lentiviral vectors containing GAA to iPSCs at three different concentrations to
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determine the optimized titer for gene correction. We showed that dose-dependent
expression of both GAA and Venus was observed in iPSCs, even though the
expression levels were relatively low compared to HEK293A cells.
Cardiomyocyte differentiation of iPS cells is the most important procedure for
replicating the disease hallmarks of Pompe disease. In fact, there is no single best
protocol for obtaining cardiomyocytes derived from iPS cells. The functional
assessment of iPSC-derived cardiomyocytes is another critical aspect of our
research. The differences between the function of iPSC-derived cardiomyocytes
obtained from normal control cells and those obtained from Pompe disease cells
should therefore be strictly evaluated in order to thoroughly discuss the efficacy of
gene therapy for iPSC (Fig. 48.1).
Acknowledgments The author thanks Dr. M. Otsu at Tokyo University for providing iPSC
TkDA3-4 cell lines. Third-generation lentiviral vector was a kind gift from Dr. H. Miyoshi at
RIKEN BRC, and Venus was kindly provided from A. Miyawaki at RIKEN BSI.
Open Access This chapter is distributed under the terms of the Creative Commons Attribution-
Noncommercial 2.5 License (http://creativecommons.org/licenses/by-nc/2.5/) which permits any
noncommercial use, distribution, and reproduction in any medium, provided the original author(s)
and source are credited.
Fig. 48.1 Gene transfer to HEK293A cells and TkDA3-4. Dose-dependent expressions of GAA
and Venus were observed in each cell line
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Molecular Analysis of Long-Term Cultured
Cardiac Stem Cells for Cardiac
Regeneration
49
Nanako Kawaguchi, Yohtaroh Takagaki, Rumiko Matsuoka,
and Toshio Nakanishi
Keywords
Cardiac stem cell • Myocyte • Regeneration • c-Kit • IGF-1
A c-Kit (CD117) is a well-known cell surface marker for adult somatic stem cells.
We harvested c-Kit-positive cardiac stem cells (CSCs) from adult rat hearts by
performing magnetic-activated cell sorting (MACS) and subjected them to long-
term bulk culture more than 40 times. We made 11 attempts to obtain c-Kit-positive
cells from adult (6–8-month-old) rats. Our initial expectation was of obtaining cells
with homogenous cardiac phenotypes. However, each CSC bulk culture expressed
varying degrees of the genes and cell surface markers belonging to cardiac and
other mesenchymal lineages. The results suggested that these CSCs retained multi-
ple developmental potential to some extent. Consequently, we investigated these
CSCs in detail, hoping to establish the regeneration method by using c-Kit-positive
cardiac cells [1–12].
• CSC-21E maintained the cell shape, yielding spherical aggregates under a
culture condition. The aggregate shape did not facilitate cell adherence to the
dish surface. Interestingly, the proteomic analysis of these two morphological
statuses revealed the drastic change of the protein profiles with the spherical
aggregates showing protein profiles characteristic of stem cells and the flat cells
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showing the profile indicative of differentiated cells, especially of the distinct
differences in stress proteins and metabolic enzymes [2, 3, 7].
• CSC5 differentiated into cells with a myocyte/adipocyte mixed phenotype.
Members of the transforming growth factor (TGF)-β superfamily were identified
as significant regulators of the differentiation of these cells into either adipocytes
or myocytes [1–6, 9, 10].
• CSC4A exhibited the ability for sustained contractibility shown by
cardiomyocytes that were cocultured with a membrane filter separating
cardiomyocytes from CSC4A. This suggests that the CSC4A cells release factors
that support cardiomyocyte contraction. Among the cytokines measured in the
cocultured medium, insulin-like growth factor-1 (IGF-1) levels appeared to
correlate with cardiomyocyte sustenance. However, CSC4A cells do not express
IGF-1. This suggests that some other unknown factors are released from CSC4A
that can induce IGF expression in cardiomyocytes [1–6, 8, 12].
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The adult mammalian heart is incapable of regeneration after injury, as shown by
the limited amount of cardiomyocyte proliferation and poor neovascularization. We
recently showed that neonatal mice have a remarkable ability to regenerate dam-
aged heart after apical resection or myocardial infarction (MI), which includes
complete reconstruction of myocardial wall with vascular network [2, 3]. Although
lineage tracing showed that the main source of newly formed cardiomyocyte is
preexisting cardiomyocytes, it is still possible that there is a minor contribution of
other types of cells to the cardiomyocyte. In addition, lineage origin of the newly
formed vasculature during postnatal cardiac maturation and neonatal heart regen-
eration remains unclear (Fig. 50.1).
In order to trace the lineage of non-myocyte-derived cells during neonatal heart
regeneration, we utilized Rosa26-tdTomato reporter mouse line crossed with
capsulin-merCremer line in which epicardial cells and interstitial fibroblasts are
labeled specifically and irreversibly after induction with tamoxifen [1]. At postnatal
day 0 (P0), Cre was activated by intraperitoneal injection of tamoxifen, and then MI
was induced 2 days later (P2). Subsequently the hearts were harvested at 21 days
after MI and tdTomato expression was examined. tdTomatoþ cells were detected
in the epicardium, interstitial fibroblasts, vascular endothelium, and smooth
muscle in the regenerated heart. Remarkably, we could detect a very small
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population (1–2 cells/section) of tdTomato+ cardiomyocyte in the regenerated
neonatal heart. No tdTomato+ cardiomyocyte was detected at P21 without inducing
MI. These results strongly suggest that capsulin-positive cardiac progenitor cells
play important roles during neonatal heart regeneration, primarily in neovascu-
logenesis by contributing directly to the endothelial/smooth muscle progenitor cells
and to a much lesser extent rare myocytes.
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Part XI
Current Genetics in Congenital Heart Diseases
Perspective
Hiroyuki Yamagishi
Congenital heart disease (CHD) occurs in nearly 1 % of all live births and is the
major cause of infant mortality and morbidity; about three per 1,000 live births will
require some intervention during the first year of life. Additionally, 95 % of CHD
patients survive to adulthood in these days, resulting in a growing population of
adult CHD. Despite their clinical importance, the underlying genetic etiology of
most CHD remains unknown, so-called “multifactorial” disease.
Identifying genetic cause of CHD is important not only to well understand the
disease but also to enhance current knowledge about the molecular biology and
genetics involved in the human cardiovascular development. Such knowledge may
lead to new preventive and/or therapeutic strategies. Identification of disease genes
would benefit the genetic counseling for CHD that is particularly important for the
growing population of adult CHD. Deeper understanding of factors and pathways
involved in differentiation of the cardiac stem cell and morphogenesis of the
cardiovascular system would also provide the development of regenerative therapy
for CHD.
During the last two decades, linkage analysis has been used to successfully
identify disease genes involved in isolated CHD or genetic syndromes where CHD
is part of the phenotype. However, this traditional approach is not generally suitable
for CHD because it requires many large families with multiple affected individuals.
During the same period, some of syndromes with chromosomal abnormalities have
been well studied to identify disease genes in syndromic CHD. CHD is commonly a
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characteristic part of the clinical spectrum in a significant number of syndromes
caused by chromosomal abnormalities, including submicroscopic deletions or
duplications. To date, these genetic approaches have led to the identification of
more than 50 human genes although they have limitation where large familial cases
and chromosomal abnormalities account for relatively small portion of CHD.
Recently, a technique of genome-wide association studies (GWAS) has provided
common genetic variations that can influence population-attributable risks of cer-
tain types of CHD although the information cannot be directly related to the
affected individual. Finally, application of the next-generation sequencing (NGS)
technologies is revolutionary in the field of genetics in CHD. In contrast to GWAS,
the results of NGS are directly applicable to the affected individual. NGS can be
targeted or nontargeted. Exome sequencing and whole-genome sequencing, scan-
ning the whole exome of ~20,000 base pairs and the whole genome of
~3,000,000,000 base pairs, respectively, are well suited to the study of complex,
heterogeneous diseases such as CHD and the current best technique for discovery of
novel genetic causes for CHD. The biggest obstacle during any NGS analysis is,
however, to single out the causal variant from the thousands of variants identified
during sequencing. Follow-up animal studies, particularly in mice, for candidate
genes discovered by genetic analyses have been successful in validating the
candidates and uncovering the function of their gene products for the cardiovascu-
lar development. More recently, fine mapping of genomic copy number variants
(CNVs) by NGS in patients with isolated or syndromic CHD has been used to
identify candidate disease genes.
In this part, authors describe the current advance in genetics in CHD using
linkage analysis, chromosomal studies, and CNVs studies by NGS, combined
with animal experiments that verified novel genetic causes of CHD and provided
new insights into the molecular and functional analyses of the cardiovascular
development. Current understandings about molecular pathways associated with
CHD involve numerous transcription factors and cofactors, including chromatin
modifiers, and signaling molecules from ligands to receptors.
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Congenital heart disease (CHD) behaves like a complex genetic trait in most
instances. Recent advances in genomics have provided tools for uncovering
genetic variants underlying complex traits that are now being applied to study
CHD. Massively parallel DNA sequencing has shown that de novo mutations
contribute to ~10 % of severe CHD and implicated chromatin remodeling in
pathogenesis. Genome scanning methods for copy number variants (CNVs)
identify likely pathogenic genomic alterations in 10 % of infants with hypoplas-
tic left heart syndrome and related single ventricle forms of CHD. The growth
and neurocognitive development of children with CHD and those CNVs is
worse, and clinical examination is relatively insensitive for detecting those
CNVs. In sum, new opportunities for preventing and ameliorating CHD and its
comorbidities are anticipated as its genetic architecture is elaborated through the
use of state-of-the-art genomic approaches.
Keywords
Congenital heart disease • Copy number variants • Exome sequencing • Genetics
51.1 Introduction
Congenital heart defects (CHD), with an estimated incidence of 2–3 % when
bicuspid aortic valve (BAV) is included, are widely believed to have strong genetic
underpinnings. Epidemiologic studies have shown considerable consistency in the
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distribution of CHD lesions across time and geographic location. The landmark
study by Ruth Whittemore, in which she examined recurrence risks for offspring of
women with CHD, revealed a 16 % rate with a 60 % concordance in the form of
CHD between mother and child [1]. Estimates of heritability for BAV and hypo-
plastic left heart syndrome (HLHS) are 89 % and 95 %, respectively [2, 3]. Recent
studies of CHD from Denmark, where the highly organized medical system enables
population studies, have provide estimates of the relative risks of various forms of
CHD among first-degree relatives that significantly increased, often to >5
[4]. Taken as a whole, these epidemiologic findings point to genetic defects
contributing importantly to CHD etiology.
Identification of the precise mutations has been challenging [5]. We have known
for some time that a modest percentage of CHD (~5 %) is attributable to
aneuploidies such as trisomy 21. With the advent of molecular genetic approaches,
point mutations with apparently strong effects have been identified in rare families
inheriting CHD in Mendelian or near-Mendelian fashion. More recently, the role of
larger genomic events generating pathologic copy number variants (CNVs) for
CHD has become apparent. This started with the recognition of 22q11 deletions
underlying DiGeorge, Takao conotruncal face, and velocardiofacial syndromes.
Several surveys have implicated a wide range of gain and loss CNVs in various
forms of CHD.
Based on the author’s oral presentation at the 2013 Takao Symposium, two
recent studies that further elaborate the genetic etiology of CHD will be
reviewed here.
51.2 De Novo Mutations
Through recent advances in molecular genetic technologies, it is now possible to
sequence the roughly 1% of the human genome that contains the coding regions for all
genes (called the exome), representing approximately 180,000 exons and
30 megabases (Mb), in a relatively rapid and affordable manner. While exome
sequencing was initially used to discover mutations underlying Mendelian disorders,
current efforts are increasingly focusing on unraveling complex genetic traits.
The Pediatric Cardiac Genomics Consortium (PCGC) [6], a National Heart,
Lung, and Blood Institute-funded research enterprise, recently completed a first-
of-kind study to determine the role of de novo mutations in the etiology of severe
forms of CHD [7]. Exome sequencing was performed for 362 parent-offspring trios,
in which the offspring had a sporadic conotruncal defect, left ventricular outflow
track obstructive lesion, or heterotaxy, and compared to comparable data from
264 control trios. While the overall rate of de novo point and small insertion/
deletion (indel) changes was equivalent between CHD cases and controls, there
was an excess burden of protein-altering mutations in genes highly expressed
during heart development (odds ratio (OR) of 2.53). Excess mutations had a role
in 10 % of CHD cases and led to the estimate that ~400 genes underlie these birth
defects. After filtering to retain variants most likely to be deleterious (nonsense,
356 B.D. Gelb
splice site, and frameshift defects), the burden among CHD cases increased,
attaining an OR of 7.50.
Next, the PCGC investigators asked whether the burden of de novo protein-
altering mutations among the CHD cases preferentially targeted particular biologic
processes [7]. Indeed, they observed a highly significant enrichment of mutation
among genes encoding proteins relevant for chromatin biology, specifically the
production, removal, or reading of methylation of Lys4 of histone 3 (H3K4me)
(Fig. 51.1). The phenotypes of the eight subjects harboring H3K4me de novo
mutations were diverse, both with respect to the form of CHD and the involvement
of extracardiac tissues. In addition, two independent de novo mutations were found
in SMAD2, which encodes a protein with relevance for demethylation of Lys27 of
histone 3 (H3K27me). SMAD2 contributes to the development of the left-right
body axis; both subjects harboring SMAD2 mutations had dextrocardia with unbal-
anced complete atrioventricular canal defects with pulmonic stenosis. While the
contribution of chromatin remodeling to cardiovascular development generally and
Fig. 51.1 De novo mutations in the H3K4 and H3K27 methylation pathways. Nucleosome with
histone octamer and DNA, H3K4 methylation bound by CHD7, and H3K27 methylation and
H2BK120 ubiquitination is shown. Genes mutated in CHD that affect the production, removal, and
reading of these histone modifications are shown; genes with damaging mutations are shown in
red, and those with missense mutations are shown in blue. SMAD2 (2) indicates there are two
patients with a mutation in this gene. Genes whose products are found together in a complex are
enclosed in a box (Reprinted without modification from Ref. [7])
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certain rare genetic syndromes with CHD like Kabuki syndrome had been
recognized previously, this study exposed a far broader role in CHD pathogenesis.
The finding also suggests a fascinating potential link to other birth defects as de
novo chromatin remodeling mutations have also been implicated in autism [8].
51.3 Copy Number Variants
CNVs, which are gains or losses of DNA ranging in size from 1 kb to several Mbs,
affect roughly 10 % of the human genome [9]. CNVs are typically detected on a
genome-wide basis using SNP microarrays or array comparative genomic
hybridization (aCGH). Although differentiating pathogenic CNVs from benign
polymorphic one remains challenging, it has become clear that pathologic CNVs
contribute significantly to the pathogenesis of CHD as rare large CNVs are
observed in 5–15 % of affected individuals [10–14].
To address the issue of how pathogenic CNVs affected outcomes for children with
CHD, Carey and colleagues studied children who had previously been subjects in one
or both of two clinical trials undertaken by the National Heart, Lung, and Blood
Institute-funded Pediatric Heart Network [15]. The two studies were the Infants with
Single Ventricle (ISV) and Single Ventricle Reconstruction (SVR) trials, both focus-
ing primarily on infants with HLHS. Carey et al. used aCGH to identify CNVs in
223 subjects from the ISV and SVR trials for whom genomic DNA was available.
Because the DNA samples were procured late in those trials, subjects who died earlier,
particularly perioperatively, could not be studied. For the CNV work, CNVs were
300 kb and not identified as genetic polymorphisms based on existing databases.
Carey and co-workers observed pathogenic CNVs in 13.9 % of the children,
which was significantly more than the 4.4 % rate in the controls (preexisting data
from blood samples from subjects with solid cancers from The Cancer Genome
Atlas project) [15]. For the CHD cases, there was a roughly 4:1 ratio of duplications
to deletions and the median sizes were 674 kb and 1.5 Mb, respectively. Parental
genomic DNAs were available for 12 of the subjects with pathogenic CNVs;
analysis of those showed that slightly more than have of the pathogenic CNVs
were inherited.
For the ISV and SVR studies, careful assessment of growth (weight-, height- and
head circumference-for-age z-scores) and neurocognitive function (Mental Devel-
opmental Index (MDI) and Psychomotor Developmental Index (PDI) measured
with the Bayley Scales of Infant Development II) were determined at 14 months of
age [15]. Comparison of the CHD subjects harboring pathogenic CNVs to those
who did not revealed that the former were significantly shorter by an average of
0.65 z-score. Subgroup analysis showed that those with deletion CNVs had signifi-
cantly lower PDI scores.
Among the 31 pathogenic CNVs found among the CHD subjects, 13 had
previously been associated with genomic disorders. The children harboring these
known CNVs had the worst outcomes with globally reduced neurocognitive devel-
opment (MDI and PDI) as well as the slowest growth (Table 51.1).
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Finally, Carey and co-workers looked at the sensitivity of clinical examination in
detecting children with CHD and pathogenic CNVs, which was possible for the
subjects from the SVR study [15]. Of 116 children examined, 3.4 % were diagnosed
with a defined genetic syndrome, none associated with a pathogenic CNV, and 25 %
had one or more dysmorphic features and/or extracardiac malformations, which
were not enriched among those with CNVs. Most strikingly, more than 70 % of the
children with CNVs previously associated with genomic disorders had no dysmor-
phic feature or extracardiac anomaly. Taken as a whole, this analysis showed that
clinical examination was relatively insensitive for determining which children with
CHD harbored pathogenic CNVs.
The findings from this study support the routine use of CNV testing in newborns
with single ventricle forms of CHD to enable better prognostication and early
intervention. Similarly, the poorer linear growth associated with all pathogenic
CNVs, the worse neurocognitive outcomes with deletions, and particularly the
globally poor outcomes with CNVs associated with known genomic disorders
could impact clinical trial outcomes depending on the designated endpoints.
51.4 Future Directions
Recent advances in genomics have enabled the elucidation of the architecture of
CHD genetics. As that project proceeds, the next challenge will be translating those
gene discoveries into actionable clinical approaches. Improved prognostication
with respect to the heart disease and extracardiac comorbidities can be used most
immediately. Finding strategies that reduce CHD incidence or alter its natural
Table 51.1 Fourteen-month outcomes for subgroups based on genetic examination
Na MDI PDI Weight Z Length Z HC Z
CNV- Syndrome- Dysmorphic-
Extracardiac-
69 89.1 77.5 0.71 1.13 0.34
(18.0) (20.2) (1.07) (1.32) (1.24)
CNV+ 14 85.4 65.1* 0.94 1.61 0.04
(20.1) (17.6) (0.88) (1.08) (1.38)
CNV+ or syndrome 18 83.2 67.9* 1.19* 1.99* 0.16
(18.7) (19.4) (1.11) (1.73) (1.27)
Dysmorphic/extracardiac 29 89.3 78.1 0.63 1.18 0.10
(18.1) (20.0) (1.25) (1.30) (1.28)
CNV syndrome 98 89.4 77.8 0.73 1.18 0.25
(17.5) (19.8) (1.10) (1.43) (1.32)
All data shown as mean (standard deviation)
MDI mental developmental index, PDI psychomotor developmental index, Weight Z weight-for-
age Z score at 14 months, Length Z length-for-age Z score at 14 months, HC Z head circumference
Z score at 14 months
*p< 0.05 compared to CNV/syndrome/dysmorphic/extracardiac
aSize of each cohort. Incomplete data for outcomes resulted in lower Ns. Reprinted without
modification from Ref. [15]
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history will require the elucidation of pathogeneses, and a careful balancing of
potential benefits with adverse effects as fundamental biological process like
chromatin remodeling will probably predominate.
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Evidence That Deletion of ETS-1, a Gene
in the Jacobsen Syndrome (11q-) Cardiac
Critical Region, Causes Congenital Heart
Defects through Impaired Cardiac Neural
Crest Cell Function
52
Maoqing Ye, Yan Yin, Kazumi Fukatsu, and Paul Grossfeld
Abstract
Jacobsen syndrome (11q-) is a rare chromosomal disorder characterized by
multiple problems including congenital heart defects, behavioral problems,
intellectual disability, dysmorphic features, and bleeding problems. Septal
defects, including double outlet right ventricle (DORV), are among the most
common CHDs that occur in 11q-. One possible mechanism underlying the
CHDs and other problems in 11q- is a defect in neural crest cell function. The
E26 avian leukemia 1, 50 domain (ETS-1) gene is a member of the ETS-domain
transcription factor family. ETS-1 is deleted in every 11q- patient with CHDs,
and gene-targeted deletion of the ETS-1 gene in C57/B6 mice causes DORV
with 100 % penetrance. Normal murine cardiac development requires precisely
regulated specification of the cardiac neural crest cells (cNCCs). To begin to
define the role of ETS-1 in mammalian cardiac development, we have
demonstrated that ETS-1 is strongly expressed in mouse cNCCs during early
heart development. Sox10 is a key regulator for the neural crest cell gene
regulatory network. It is also an early marker for NCCs, and its expression can
facilitate the analysis of cNCC function during embryonic development. We
have demonstrated that loss of ETS-1 causes decreased migrating Sox10-
expressing cells in E10.5 C57/B6 mouse embryos. These results suggest a
NCC migration defect in ETS-1 mutants. Our data support the hypothesis that
ETS-1 is required for specification and migration of cNCCs and for regulating a
cNCC-specific gene regulatory network that is required for normal cardiac
development.
M. Ye, M.D., Ph.D. • Y. Yin, Ph.D. • K. Fukatsu, Ph.D. • P. Grossfeld, M.D. (*)
Division of Pediatric Cardiology, Department of Pediatrics, UCSD School of Medicine, La Jolla,
CA, USA
e-mail: pgrossfeld@ucsd.edu
# The Author(s) 2016




Jacobsen syndrome • Cardiac neural crest • ETS-1 • Double outlet right
ventricle • Genetic modifier
52.1 Introduction
Congenital heart defects (CHDs) are the most common birth defect in live-born
infants, occurring in 0.7 % of the general population. Although there are numerous
genetically engineered mouse models for CHDs, only a small number of these
genes are currently associated with CHDs in humans.
Conotruncal defects (CTDs), including double outlet right ventricle (DORV),
are among the most common CHDs in the general population and usually require
surgical repair to ensure a normal life expectancy. Little is known about the
molecular and cellular mechanisms underlying the development of CTDs in
humans. Normal murine cardiac development requires precisely regulated specifi-
cation of the cardiac neural crest cells (cNCCs) and subsequent migration to the
developing outflow tract. In animal models, impairment of NCCs causes CTDs [1].
The 11q terminal deletion disorder (11q-, Jacobsen syndrome) (OMIM #
1477910) is caused by heterozygous deletions in distal 11q (Fig. 52.1).
Fifty-six percent of patients have CHDs (Table 52.1). Septal defects, including
DORV, account for about half of all CHDs that occur in 11q- patients.
As shown in Fig. 52.2, we have identified a Jacobsen syndrome cardiac “critical”
region in distal 11q containing only five known genes, including the ETS-1
transcription factor.
The ETS-1 gene is a member of the ETS-domain transcription factor family.
ETS factors have important roles in a host of biological functions, including the
regulation of cellular growth and differentiation as well as organ development.
Fig. 52.1 Patient with Jacobsen syndrome. Karyotype demonstrates large terminal deletion
in 11q
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Until recently, nothing was known about the function of ETS-1 in mammalian heart
development or its possible role in causing human congenital heart disease.
Although little is known about the mechanisms underlying ETS-1 in mammalian
heart development, recent studies in the ascidian Ciona intestinalis have
demonstrated that ETS-1 regulates two critical aspects of heart development:
heart progenitor cell migration and heart cell differentiation. Interestingly, loss of
ETS-1 abolishes normal heart cell migration during development, resulting in an
ectopically located heart chamber. Taken together, these results indicate that ETS-1
Table 52.1 CHDs in 11q- Left-sided/flow lesions (two-thirds)







Less common heart defects (one-third)
Secundum atrial septal defect
Aberrant right subclavian artery
Atrioventricular septal canal defect
D-transposition of the great arteries
Dextrocardia
Left-sided superior vena cava
Tricuspid atresia
Type B interruption of the aortic arch/truncus arteriosus




a~10 % born with HLHS; ~1–2 % of all HLHS pts






















Fig. 52.2 Cardiac “critical” region in 11q, defined by region of overlap between smallest terminal
deletion and interstitial deletions in patients with Jacobsen syndrome clinical phenotype, including
congenital heart defects
52 Evidence That Deletion of ETS-1, a Gene in the Jacobsen Syndrome (11q-). . . 363
is required for normal cell migration in heart development, although the mechanism
(s) underlying these cell migration defects remains to be elucidated.
52.2 Evidence for a Role for ETS-1 in the Cardiac Neural Crest
in Mice
52.2.1 Expression of ETS-1 in Cardiac Lineages During Murine Heart
Development
To begin to define the role of ETS-1 in mammalian cardiac development, we have
performed in situ hybridization studies on mouse embryos and have shown that
ETS-1 is strongly expressed in murine cNCCs as well as the endocardium during
early heart development (Fig. 52.3).
52.2.2 ETS-1 Mutant Mice Have a Double Outlet Right Ventricle
(DORV) Phenotype
To determine if loss of ETS-1 causes congenital heart defects, we have analyzed
gene-targeted ETS-1 deletion mice. As shown in Fig. 52.4, ETS-1 homozygous null
mice in a C57/B6 background exhibit DORV with 100 % penetrance, resulting in
perinatal lethality [2].
52.2.3 Lost of ETS-1 Causes Decreased Expression of Sox10
We have previously demonstrated that ETS-1 expression is expressed in cNCCs
and endocardium during murine embryonic development. Sox10 is a key regulator
in the NCC gene regulatory network. It is critical for migration and specification of
NCC fate. To examine the role of ETS-1 in murine cardiac NCC migration, we
examined Sox10 expression in ETS-1/ mutant and control C57/B6 embryos at
E10.5 by using whole-mount in situ hybridization analysis. Expression of Sox10 in
the NCCs in the pharyngeal arch region and dorsal root ganglia was reduced in
ETS-1/ mutant embryos, suggestive of a cNCC migration defect as shown in
Fig. 52.5 (left). The result was confirmed independently by quantitative RT-PCR
analysis (right).
52.3 Establishment of an Explanted cNCC “Ex Vivo” Culture
System
We hypothesized that defects in cNCCs migration should be able to be reproduced
in an “ex vivo” culture system. Toward that end, we have utilized an explanted
culture system to observe cNCCmigration [3]. Mouse embryos were collected from
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C57/B6 background embryos at E8.5, coinciding with the onset of cNCC migration
toward the heart. E8.5 embryos were collected and treated by dispase to dissociate
the tissue gently. After treatment, neural tubes from somite one to three region
(cardiac neural crest) were dissected out and cut into 100 300 um pieces. Each
Fig. 52.3 Expression of ETS-1 in the heart in ED9.5 embryos: in situ hybridizations are shown in
(a) (whole mount) and in sections (b) (anterior coronal section) and (c) (posterior coronal section).
Immunohistochemistry indicating endothelial expression using a PECAM (CD31) antibody is
shown in (d) (whole mount) and in sections (e) (anterior coronal) and (f) (posterior coronal). LacZ
staining of neural crest using a Wnt1-Cre; ROSA26 LacZ indicator strain is shown in (g) (whole
mount), (h) (anterior coronal), and (i) (posterior coronal)
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Fig. 52.4 Gene-targeted knockout of ETS-1 in C57/B6 E16.5 mice, showing double outlet right
ventricle with normally related great arteries. Wild type is shown in (a) and (b); two mutant hearts
are shown in panels (c–f). RA right atrium, LA left atrium, RV right ventricle, LV left ventricle, Pu
pulmonary artery, Ao aorta, VSD ventricular septal defect
Fig. 52.5 Whole mount study demonstrating decreased Sox10 expression in E10.5 ETS-1/
C57/B6 embryos (left, lower panel) compared to wild type (left, upper panel). Real-time quantita-
tive PCR demonstrates decreased Sox10 expression in the body of E10.5 embryos in ETS-1/
embryos, compared to wild type (right)
366 M. Ye et al.
piece was placed on fibronectin-coated glass bottom slides and incubated in culture
media in 5 % CO2 and 21 % O2. After 24 h incubation, we performed DAPI staining
and obtained images of the migrating cells. Representative results from WT and
ETS-1/ mice are shown in Fig. 52.6.
52.3.1 Loss of ETS-1 in C57/B6Mice Causes Decreased NCC Numbers
and Decreased Migration
To analyze the migration distance using our ex vivo system, we counted the number
of migrating cells in each explanted culture. The migration distance was divided
into three distanced from the neural tube edge: 0–150 μm, 150–300 μm, and over
300 μm edge. The total number of cells that had migrated for each distance was
manually counted, and the percentage of the total for each migration distance was
determined. As shown in Fig. 52.6, cNCCs from ETS-1/ C57/B6 embryos were
fewer in number and had decreased migration distance. The percentage of total cells
migrating >300 μm 24 h after explantation in ETS-1/ mutant embryos is
fourfold lower than control. The cell number per embryo was also significantly
decreased in ETS-1/ mutants.
Fig. 52.6 Cardiac neural crest cells migration in explant culture. (A) Schematic of E8.5 embryo.
Blue bar shows the neural tubes somite one to three region. H heart, NT neural tube. (B)
Representative images with DAPI staining of 24 h cultured cardiac neural crest cells in control
(B) and ETS-1/ mutants (C). Scale bar, 300 μm. Both images were taken by an inverted
confocal microscope FV-1000 using a 10 objective lens. (D) Quantification of migration
distances, demonstrating impaired migration ability in ETS-1/ cells compared to wild type
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We then calculated the ratio of 300+ μm over 0–150 μm of cultured migration
cells. As shown in Fig. 52.6, the ratio was significantly reduced in ETS-1/
mutants.
52.4 Cardiac Neural Crest Cell Number and Migration Are
Preserved in ETS-1/ Mice in an FVBN-1 Background
The cardiac phenotype in ETS-1 knockout mice is dependent on the genetic
background. In contrast to C57/B6 mice, ETS-1/ mutant mice in an FVBN-1
background have normal hearts. Consistent with a neural crest cell autonomous
mechanism for causing DORV in the C57/B6 strain, ex vivo studies demonstrate
normal cNCC numbers and migration in ETS-1/ FVBN-1 embryos (data not
shown).
52.5 Summary, Future Directions, and Clinical Implications
Using human and murine genetics systems, we have identified the ETS-1 transcrip-
tion factor gene as the likely causative gene for CHDs in Jacobsen syndrome. Our
expression data implicate an important role for ETS-1 in the cardiac neural crest
during murine heart development. Based on the known function of the ETS-1
homologue in the ascidian Ciona intestinalis and using an ex vivo cell migration
system, we hypothesize that ETS-1 is essential for early cNCC fate determination
and migration in mammalian heart development. Future studies will include
performing in vivo real-time imaging and lineage fate mapping studies in the neural
crest to delineate how loss of ETS-1 causes decreased cNCCs in the developing
heart [4], whether there is a NCC-autonomous mechanism and whether there is a
migration defect. Importantly, loss of ETS-1 in FVBN-1 mice does not cause
congenital heart defects, suggesting the presence of a genetic modifier(s) that can
prevent the development of CHDs in the absence of ETS-1. To address this,
determination of a neural crest cell autonomous mechanism would implicate a
neural crest cell-specific modifier. Identification of such a genetic modifier could
have important implications for the prevention of certain congenital heart defects.
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Notch Signaling in Aortic Valve
Development and Disease 53
Vidu Garg
Abstract
Bicuspid aortic valve (BAV) is the most common type of cardiac malformation
with an estimated prevalence of 1 % in the population. BAV results in significant
morbidity usually during adulthood due to its association with aortic valve
calcification and ascending aortic aneurysms. Mutations in the signaling and
transcriptional regulator, NOTCH1, are a cause of bicuspid aortic valve in
non-syndromic autosomal dominant human pedigrees. The Notch signaling
pathway is critical for multiple cellular processes during both development
and disease and is expressed in the developing and adult aortic valve consistent
with the cardiac phenotypes identified in affected family members. Recent work
has begun to elucidate the molecular mechanisms underlying the link between
Notch1 signaling and the development of BAV and valve calcification. Using
in vitro approaches, loss of Notch signaling has been shown to contribute to
aortic valve calcification via Runx2-, Sox9-, and Bmp2-dependent mechanisms.
In addition, Notch1 signaling has been shown to be responsive to nitric oxide
signaling during this disease process. A new highly penetrant mouse model of
aortic valve disease using Notch1 haploinsufficient mice that are backcrossed in
an endothelial nitric oxide synthase (Nos3)-null background was generated.
Notch1 and Nos3 compound mutant mice (Notch1þ/-;Nos3-/-) display a nearly
100 % incidence of aortic valve malformations, most commonly BAV. The
aortic valves of adult mutant mice are thickened and have associated stenosis
and regurgitation. Based upon the initial discovery of NOTCH1 mutations in
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humans with aortic valve disease, subsequent studies have provided significant
molecular insights into BAV-associated diseases.
Keywords
Congenital heart defect • Bicuspid aortic valve • Aortic valve calcification •
Notch signaling
53.1 Introduction
Congenital heart disease (CHD) is the most common type of birth defect, with an
estimated incidence that ranges from 6 to 19 per 1,000 live births [1]. Even with
recent improvements in the care of children, CHD remains a leading cause of infant
mortality [2]. The etiology for the majority of cases of CHD remains unknown
despite advances in cardiac developmental biology and genetics [3]. While the role
of nongenetic causes, such as infectious agents and teratogens, appears to play a
causative role in a minority of cases CHD, the role of genetic factors in CHD has
become an area of robust investigation. Numerous etiologic genes for CHD have
been identified using conventional linkage or candidate gene sequencing
approaches and more recently using array-based methodologies or whole exome/
genome sequencing [4].
Within CHD, bicuspid aortic valve (BAV) is the most common congenital
cardiac malformation with an estimated prevalence of 1 % in the population.
BAV occurs when the aortic valve has only two cusps instead of the normal three
[5]. BAV is a common cause of adult valve disease as it is often asymptomatic
during childhood. With BAV, the normally thin aortic valve cusps often prema-
turely calcify leading to valvar thickening and stenosis [5]. BAV may also present
with aortic regurgitation and affected individuals are at increased risk for infective
endocarditis. BAV is also associated with ascending aortic dilation/aneurysm and
may result in the development of aortic dissection [5].
Since early case reports described families with multiple members with BAV
nearly four decades ago, several population-based studies have demonstrated a
strong genetic component in BAV. This chapter will review how the identification
of mutations in NOTCH1 in families with inherited BAV have led to an increased
understanding of the role of Notch signaling in aortic valve calcification and the
generation of novel mouse model of BAV with associated valve disease.
53.2 NOTCH1 Mutations and Aortic Valve Disease
We reported a novel genetic etiology of non-syndromic BAV in humans in 2005
[6]. Using a positional cloning approach, a large family with 11 members affected
with autosomal dominant aortic valve disease was studied. The primary cardiac
malformation in affected family members was BAV. Seven members had
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developed calcification of the aortic valve including four who required surgical
valve replacement. The disease locus was mapped to chromosome 9q34, and
subsequent sequencing of a candidate gene, NOTCH1, identified a nonsense muta-
tion in affected family members. In a smaller unrelated family, a NOTCH1 frame-
shift mutation segregated with a similar aortic valve phenotype. Observations of
missense NOTCH1mutations in a subset (~5 %) of individuals with BAV have also
been reported with supporting functional data indicating impaired Notch signaling
[7, 8]. These publications suggested that NOTCH1 haploinsufficiency was a cause
of BAV in humans.
NOTCH1 encodes a single-pass transmembrane receptor and functions in a
highly conserved pathway, which plays critical roles in cell fate determination
during organogenesis. In mammals, there are four NOTCH receptors (NOTCH1-
4), and they interact with two families of ligands (Jagged 1 and 2 and Delta 1, 3, and
4) [9]. Other Notch family members have been linked to human disease as hetero-
zygous mutations in NOTCH3 have been identified in CADASIL syndrome, while
mutations in JAGGED1 and NOTCH2 are found in Alagille syndrome. Targeted
disruption of Notch1 in mice results in embryonic lethality secondary to vascular
defects prior to cardiac valvulogenesis [10]. Each Notch family member has a
distinct expression pattern, and Notch1 is expressed not only in the endocardium
but also the outflow tract cushion mesenchyme during development consistent with
the valve phenotype seen in the affected family members [6, 11]. In addition,
Notch1 mRNA transcripts are found in the adult murine aortic valve. These findings
suggest that Notch1 signaling is important for aortic valve formation and poten-
tially in adult valve diseases.
53.3 Notch1 Signaling and Aortic Valve Calcification
With the increased longevity of human population, calcific valvular disease is
becoming more prevalent. Calcific aortic stenosis affects an estimated 2–3 % of
the population by 65 years of age [12]. Calcification of the normally thin aortic
valve cusps leads to valvular thickening with resultant stenosis/regurgitation that
ultimately requires surgical replacement. Examination of calcified human valves
has demonstrated increased expression of osteogenic markers such as Runx2
[12]. The process of valvular calcification was traditionally proposed to be a
degenerative process that occurred with aging, but increasing evidence suggests
that molecular pathways underlie this complex disease [12]. In addition to clinical
risk factors such as hypertension and hypercholesterolemia, BAV is a major risk
factor for CAVD.
The role of the Notch signaling pathway in the development of CAVD has
becoming increasingly recognized. Our initial studies demonstrated that Notch1
repressed the activity of Runx2, a transcriptional regulator of osteoblast cell fate
[6]. Subsequently our studies focused on the molecular changes that occur with
inhibition of Notch signaling in the aortic valve [11]. Consistent with this hypothe-
sis, diseased human aortic valves have decreased expression of NOTCH1 in areas
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of calcium deposition. To identify downstream mediators of Notch1 during valve
calcification, the gene expression changes that occur with chemical inhibition of
Notch signaling in rat aortic valve interstitial cells (AVICs) were studied.
Downregulation of Sox9 along with several cartilage-specific genes that were direct
targets of this transcription factor was identified. Loss of Sox9 has been published
to be associated with aortic valve calcification in mouse models [13]. Utilizing an
in vitro porcine aortic valve calcification model system, inhibition of Notch activity
resulted in accelerated calcification, while stimulation of Notch signaling
attenuated the calcific process. Overexpression of Sox9 was able to prevent the
calcification of porcine AVICs that occurs with Notch inhibition. These studies
demonstrated that loss of Notch signaling contributes to aortic valve calcification
via a Sox9-dependent mechanism. Additional work by other investigators has
supported these conclusions and have also demonstrated a role for Bmp2 as a
downstream target of Notch1 signaling in this process and found that Notch1
haploinsufficient mice develop aortic valve calcification with aging [14, 15].
Dysfunction of the valvular endothelium is thought to initiate calcification of
neighboring AVICs leading to CAVD. The molecular mechanism by which endo-
thelial cells communicate with AVICs and cause disease is not well understood.
Using a coculture and transwell assays, it was shown that a secreted signal from
endothelial cells inhibits calcification of porcine AVICs [16]. Nitric oxide (NO),
which is secreted by endothelial cells, is critical for numerous physiologic and
pathologic processes and had been implicated in the process of aortic valve calcifi-
cation. In addition, mice lacking Nos3, which encodes for endothelial nitric oxide
synthase, display partially penetrant BAV and making NO a potential candidate for
this secreted signal. NO prevents calcification of AVICs in vitro, similar to the
presence of endothelial cells, while the absence of NO increases calcification.
Overexpression of a constitutively active Notch1 in AVICs prevented calcification
that occurs with NO inhibition linking NO and Notch signaling in this process.
Consistent with this, endothelial-derived NO signaling increases the expression of a
Notch signaling target genes in AVICs and inhibition of NO decreased nuclear
localization of NICD in AVICs. Conversely, increased nuclear localization of
NICD was noted with the addition of NO donor. Lastly, the NOS3 and Notch1
signaling pathways genetically interact in vivo as NOS3;Notch1 compound mutant
mice display a highly penetrant aortic valve disease [16]. These mice have highly
penetrant BAV and develop hemodynamically significant aortic valve stenosis and
regurgitation. These studies suggest that NO signaling in valve endothelial cells
regulates Notch1, Sox9, and Bmp2 in the neighboring AVICs and this pathway may
be critical in the pathogenesis of adult-onset aortic valve calcification (Fig. 53.1).
53.4 Future Directions and Clinical Implications
While mutations in NOTCH1 were identified in a family with a common cardiac
valve malformation, subsequent work has demonstrated a role for Notch1 in aortic
valve calcification. The development of a highly penetrant mouse model of BAV
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will assist in the dissection of the molecular pathways that lead to the development
of this common cardiac malformation. Interestingly, mice deficient for Gata5
display partially penetrant BAV and have reduced expression of Nos3 and Notch
signaling [17]. These mice also offer an opportunity to study the development of
BAV-associated ascending aortic aneurysms. Future investigations into the down-
stream targets of Notch1 signaling may lead to novel therapies for BAV-associated
diseases such as CAVD.
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Fig. 53.1 Role of Notch1 signaling in aortic valve calcification. Endothelial cell dysfunction
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To Detect and Explore Mechanism
of CITED2 Mutation and Methylation
in Children with Congenital Heart Disease
54
Wu Xiaoyun, Xu Min, Yang Xiaofei, Hu Jihua, and Tian Jie
Abstract
In this study we found four CITED2 coding region mutations (c.550G>A,
c.574A>G, c.573–578del6) which led to alterations of amino acid sequence
(p.Gly184Ser, p.Ser192Gly, p.Ser192fs) in 120 children with congenital heart
disease. The CITED2 mutation associated with the dysregulation of HIF-1α,
TFAP2c, and CITED2 methylation accompanied with its decrease in mRNA
expression might be involved in the pathological process of congenital heart
disease.
Keywords
CITED2 • Mutation • Methylation • Congenital heart disease
CITED2 mutation and methylation may be the cause of CHD. The purpose of this
study was (1) to identify CITED2 mutation in children with CHD in China, (2) to
analyze the mechanism of CITED2 mutation in cellular level if CITED2 gene
mutation affects expression of HIF-1α and TFAP2c, and (3) to examine if
CITED2 CpG island methylation exists in children with congenital heart disease.
1. Four CITED2 coding region mutations (c.550G>A one case, c.574A>G one
case, c.573–578del6 two cases) exist in 120 children with congenital heart
disease (Fig. 54.1) [1].
2. CITED2 mutation can inhibit TFAP2c expression. Our study also demonstrated
that CITED2 has negative inhibition for HIF-1α. But this negative mechanism
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will be weakened owing to CITED2 mutation in congenital heart disease;
HIF-1α expression was elevated in CITED2 mutant group.
3. The CITED2 methylation is another mechanism of promoting congenital heart
disease. CITED2 abnormal methylation was found in 26 of 31 congenital heart
diseases. The abnormal methylation leads to decreased CITED2 mRNA
expression [2].
CITED2 mutation and methylation may play an important role for the develop-
ment of congenital heart disease.
Open Access This chapter is distributed under the terms of the Creative Commons Attribution-
Noncommercial 2.5 License (http://creativecommons.org/licenses/by-nc/2.5/) which permits any
noncommercial use, distribution, and reproduction in any medium, provided the original author(s)
and source are credited.
The images or other third party material in this chapter are included in the work’s Creative
Commons license, unless indicated otherwise in the credit line; if such material is not included in
the work’s Creative Commons license and the respective action is not permitted by statutory
regulation, users will need to obtain permission from the license holder to duplicate, adapt or
reproduce the material.
References
1. Yang XF, Wu XY, Li M, et al. Mutation analysis of Cited2 in patients with congenital heart
disease [J]. Zhonghua Er Ke Za Zhi. 2010;48(4):293–6.
2. Xu M, Wu XY, Li YG, et al. Relationship of CpG islands methylation of CITED2 and
congenital heart disease [J]. Third Mil Med Univ. 2013;35(3):245–6.
Fig. 54.1 The sequence of CITED2 mutation
378 W. Xiaoyun et al.
Erratum to: Etiology and Morphogenesis
of Congenital Heart Disease
Toshio Nakanishi, Roger R. Markwald, H. Scott Baldwin,
Bradley B. Keller, Deepak Srivastava, and Hiroyuki Yamagishi
Erratum to:
T. Nakanishi et al. (eds.), Etiology and Morphogenesis
of Congenital Heart Disease,
https://doi.org/10.1007/978-4-431-54628-3
The original online version of this book was inadvertently published with incorrect
affiliation details of the editors. This has now been amended with the correct
affiliation details.
The updated online version of this book can be found at
https://doi.org/10.1007/978-4-431-54628-3
# Springer International Publishing AG, part of Springer Nature 2018





Ageing, 246, 247, 249, 250
Airway clearance, 70, 71, 76
Alk1, 141, 169, 170
Alk3, 139, 164–165
Alternative splicing, 223, 250
Aneurysm, 39, 222, 225, 241, 242, 372, 375
Angiogenesis, 322, 331
Animal model, 15, 20–22, 26, 27, 29, 34, 50,
68, 109, 116, 158, 186, 187, 315, 333,
334, 362
Annulus fibrosis, 13, 16, 163, 165, 166
Aorta, 14, 16, 72, 154, 180, 187, 188, 202, 206,
211, 212, 220, 222–224, 230, 231, 242,
247–250, 255, 259, 322
Aortic valve calcification, 373–375
Aortic valve disease, 372–373
Apoptosis, 22, 29, 96, 141, 155, 246, 249
250, 315
Atherosclerosis, 230, 246, 250, 325
ATP-sensitive potassium channel, 263, 264
Atrioventricular (AV) canal, 105, 146, 155,
162, 171, 270–273, 357
Autophagy, 128
B
Ballooning, 118, 270, 271
Bicuspid aortic valve (BAV), 16, 72, 149, 250,
355, 363, 372–374
BMP-2, 138–142, 164, 171, 172, 271, 273
374, 375
Bmp4, 140, 164
BMPR2, 82, 141, 169
BMP receptors (BMPRs), 139, 140, 164–165
Bone morphogenetic protein (BMP), 15, 27,
35, 82, 87, 138–141, 146, 147, 149,
164–166, 169, 171, 180, 286
C
Cardia bifida, 125
Cardiac assist device, 23
Cardiac cell fate, 5, 6, 8, 194, 315
Cardiac cushions, 138, 154
Cardiac development, 4, 5, 8, 40, 86, 94,
104–108, 110–112, 125, 155, 189, 229,
230, 306–308, 311, 314–316, 322, 326,
362, 364, 372
Cardiac disease, 12, 14–17, 316
Cardiac excitation and conduction system, 270
Cardiac function, 17, 20–22, 26, 29, 40, 55, 96,
282, 300, 315, 330, 333
Cardiac neural crest (CNC), 207, 223,
228–231, 289, 362–368
Cardiac pacemaker cells, 291
Cardiac progenitor cells (CPCs), 22, 34, 85–89,
178–181, 193, 296, 349, 350
Cardiac regeneration, 4, 314–315, 330
345, 346
Cardiac repair and regeneration, 330
Cardiac reprogramming, 6–9, 322, 324
Cardiac stem cell (CSCs), 331, 345, 346
Cardiac tissue, 20, 224, 308, 330–333, 335
Cardiogenic mesoderm, 12
Cardiomyocyte proliferation, 94, 96–99, 110,
141, 142, 314, 315, 349
Cardiomyocytes (CMs), 4, 6, 7, 15, 16
Cardiomyopathy, 15, 21, 22, 106, 110
111, 314
Cardiovascular development, 42, 73, 169, 229,
231, 314, 316, 357
Cavum dorsale, 122
Cell cycle, 6, 94–97, 99, 100, 180, 306
323, 337
Cell sheet, 20–23, 29
Cell sheet engineering, 20–22
Cell signaling, 38, 73
# The Author(s) 2016
T. Nakanishi et al. (eds.), Etiology and Morphogenesis of Congenital Heart Disease,
DOI 10.1007/978-4-431-54628-3
379
Chamber formation, 289, 290
Chick embryo, 16, 118, 129, 205, 228, 230,
282, 290, 333
Cilia, 50, 58–62, 64, 68–73, 75–78
CITED2, 50, 377, 378
c-Jun N-terminal kinase (JNK), 242
c-kit, 16, 345
Clinical study, 20, 22, 72, 76, 326
Compaction, 104, 106, 110–112
Conditional knockout (cKO), 154, 158, 172,
189, 211, 212
Congenital heart defects (CHDs), 34, 178, 184,
187, 188, 193, 296, 306, 356, 358, 359,
362–364, 366, 368
Congenital heart disease (CHD), 4, 16, 34–41,
43, 52, 68–73, 75–78, 85, 136, 137, 159,
197, 198, 202, 211, 215, 250, 256, 264,
272, 301, 302, 321, 322, 324–326, 362,
372, 377, 378
Contractile system, 259, 260
Convergent evolution, 115
Copy number variants (CNVs), 356, 358–359
Coronary artery, 16, 110, 222, 224, 229–231,
241, 242, 334
Cripto, 81, 184–188
Cytolytic necrosis (CN), 246, 248–250
D
3-D, 20, 37
Damaged heart, 6, 20, 21, 349
Development, 4–8
Differentiation, 4, 14, 22, 26, 34, 87, 104, 121,
127, 141, 146, 154, 163, 169, 179, 186,
194, 206, 211, 223, 228, 233, 270, 281,
289, 291, 296, 306, 314, 321, 337, 341,
346, 358, 362
DiI, 116, 118, 120, 196
Dilated cardiomyopathy, 19, 21, 22, 314
Disease modeling, 338
Double outlet right ventricle (DORV), 72, 180,
187–189, 194, 308, 362, 364, 366, 368
Ductus arteriosus (DA), 246, 247, 249, 250,
254–256, 259, 260, 263, 264
E
Ejection fraction (EF), 21, 42, 97, 109
Elastic fiber, 149, 222, 223, 242, 254, 255
Embryo, 5, 16, 50, 58, 68, 87, 104, 116, 129,
140, 146, 154, 169, 172, 178, 184, 194,
205, 212, 216, 223, 228, 234, 237, 282,
290, 296, 307, 314, 330, 364
Embryonic stem cells (ESCs), 22, 26–28, 291,
292, 315, 331
Endocardial cushion, 12, 74, 105, 146, 155,
158, 171, 172, 228, 273
Endocardium, 15, 35, 37, 39, 104, 105,
108–111, 138, 146, 154–157, 159, 169,
230, 364, 373
Endoderm, 26, 87, 125, 126, 180, 186, 188,
205, 206, 229, 286, 321
Endothelial cells (ECs), 4, 15, 17, 110, 118,
119, 154, 157, 234, 248, 249, 322, 323,
374, 375
Endothelin, 15, 229, 263, 289, 290, 324, 325
Endothelium, 15, 87, 110, 154, 156, 163, 169,
180, 233, 246, 349, 374
Engineered cardiac tissues, 21, 330–333, 335
Environmental modification, 215, 216
Epicardial cushion (EC), 117
Epicardial heterogeneity, 12
Epicardium, 12–17, 35, 37, 39, 104, 116–122,
162–164, 166, 349
Epicardium-derived cells (EPDCs), 12–17,
116, 118–121, 163–166
Epigenetic factors, 296, 297, 300–302
ETS-1, 362–364, 366, 368
Evolution and development, 116–122
Exome sequencing, 73, 356
Extracellular matrix (ECM), 5, 20, 138, 141,
146, 149, 157, 222–225, 254, 330, 332




Fate map, 86, 194, 195, 282–285, 287, 350, 368
Fetal reprogramming, 322–324
Fetus, 71, 72, 76, 211, 246, 259, 264
Fibroblasts, 4–8, 12, 13, 17, 26, 34, 39–41, 121,
163, 277, 296, 315, 324, 330, 341, 349
Filamin A, 36–38
First heart field (FHF), 12, 86, 87, 105, 178,
193, 194, 196, 289, 297
Fistulae, 16
Fluid flow, 58–62, 64
Fontan procedure, 51, 53, 54
Forkhead box2 (Foxc2), 211, 212
G
Gap junctions, 5, 20, 41, 333
Gata6, 206, 207, 308
Gene, 5, 12, 34, 50, 61, 70, 81, 87, 94, 106, 129,
139, 147, 154, 169, 178, 184, 203, 212,
216, 222, 229, 233, 246, 259, 270, 282,





Genetics, 4, 6, 16, 28, 30, 34–36, 40–43, 50, 54,
64, 74, 76, 81, 82, 106, 110, 111, 121,
149, 178, 180, 194, 202, 203, 206, 215,
216, 222, 246, 254, 270–271, 283, 306,
308, 314–316, 324, 326, 337, 341, 350,
356, 358, 359, 362, 368, 372, 374
Glenn shunt, 51
Grafting, 17, 20–22, 87, 325
Growth factors, 5, 8, 21, 34, 35, 41, 222, 223,
322, 324, 330, 332
H
Hcn4, 178, 270, 271, 273, 283, 286, 291, 292
Heart, 4, 12, 19, 26, 34, 49, 68, 85, 94, 104,
116, 125, 129, 136, 146, 154, 163, 172,
178, 184, 193, 202, 211, 215, 222, 228,
237, 250, 255, 264, 270, 282, 289, 291,
296, 306, 314, 322, 330, 337, 345, 349,
356, 363, 377
defects, 34, 35, 38, 71, 76, 155, 187, 363
development, 5, 27, 35–39, 85, 86, 96, 104,
105, 129, 164, 178, 189, 194, 229–230,
296, 297, 300, 302, 315, 356, 362–364,
368
field, 5, 86–87, 282, 283, 286, 287
injury, 38, 40, 41, 349
regeneration, 26, 27, 30, 97, 98, 314, 349,
350
surgery, 71, 78, 264
valve, 41, 146–150, 154
Hematopoietic stem cells, 39–41
Heterotaxy, 50–55, 68–73, 76, 81, 82,
186–188, 356
Histone modification, 272, 273, 357
Homology, 37, 110, 121, 122, 158, 368
Human, 4, 16, 26, 34, 50, 57, 70, 81, 109, 116,
146, 154, 166, 169, 178, 187, 216, 246,
254, 276, 296, 306, 313, 322, 330, 341,
356, 362, 372




Hypoplastic left heart syndrome (HLHS), 322,
324, 337, 338, 356, 358, 363
I
Induced pluripotent stem cells (iPSCs), 26,
28–30, 90, 321, 324, 325, 331, 337, 338,
341, 342
Infarction, 16
Inflow tract, 197, 270, 282, 289, 290, 296
Inlet septum, 117–122
Insulin-like growth factor-1 (IGF-1), 346
Interrupted aortic arch (IAA), 72, 202, 211,
212, 215
Intimal thickening, 246, 247, 250, 254–257




Jacobsen syndrome, 362–364, 366, 368
K
Kawasaki disease, 225, 241, 242
Kinases, 35–37, 41, 96, 98, 99, 125, 154–157,
159, 184, 259, 260
L
Lamin A (LMNA), 246
Lamin A/C, 248, 250
Lateral plate mesoderm (LMP), 50, 51, 58, 68,
81, 86, 104, 125, 186, 188, 223, 284,
287, 299, 300, 315
Laterality defects, 70, 71, 73, 74, 76
186–189, 286
Left isomerism, 49, 50, 52
Left ventricular assist devices (LVADs), 19, 22
Left ventricular non-compaction (LVNC), 106,
109–112
Left-right asymmetry, 50–55, 81, 184, 186, 189
Left-right axis, 50, 68, 184
Left-right patterning, 68–73, 75–78, 189
Lefty2, 50, 184
Lentivirus, 41
Lineages, 5, 26, 34, 39–42, 94, 116, 146,
177–180, 196–198, 282, 283, 290, 315,
321–323, 325, 326, 331, 332, 337, 345,
349, 350, 364, 368
Long non-coding RNAs (lncRNAs), 313–316
M
Matricellular proteins, 34, 35, 41, 222
Meis1, 94–97, 99, 100, 274
Methylation, 316, 357, 377, 378
MicroRNAs (miRNAs), 5, 41, 313
Monocilia, 50
Motile cilia, 50, 58–61, 64, 68–70, 73, 76
Mouse model, 73, 111, 146–148, 150, 154,
324, 362, 374
mRNA expression, 96, 323, 378
Index 381
Mutation, 34, 61, 68, 81, 99, 106, 129, 147,
155, 169, 179, 186, 205, 222, 234, 271,
296, 315, 324, 356, 372, 377
Myocardial infarction (MI), 16, 21, 22, 29, 96,
315, 316, 334, 349
Myocardial regeneration, 20, 22, 292





Neural crest (NC), 129, 172, 203, 205, 206,
228, 229, 365, 368
Nkx2-5, 87, 270, 271, 273–275, 283, 284, 286,
287, 300, 306, 307, 338
Nodal
flow, 50, 58, 61–63, 68
signaling, 35–36, 68, 184, 185, 187–189
Notch signaling, 16, 106–108, 111, 142, 233,
234, 271, 374, 375
O
Optical mapping, 282, 283
Organ replacement, 23
Outflow tract (OFT), 86, 87, 105, 121, 122,
138, 142, 146, 172, 177, 179, 193,
195–197, 207, 211, 212, 215, 216, 228,
286, 296, 306, 362, 373
P
Pacemaker, 270–274, 291, 292
Paracrine, 5, 17, 21, 41, 330, 333
Periostin, 35–40, 42, 141
Persistent ductus arteriosus (PDA), 246
Pitx2, 50, 51, 189, 286
Placenta, 237, 238, 246, 263
Pluripotent stem cells (PSCs), 4, 26, 90, 321,
322, 324–326, 331, 337, 338
Podoplanin, 116, 120
Polycomb-group protein, 306
Pompe disease, 341, 342
Postotic, 228–231
Potassium channel openers (KCOs), 263, 264
Preotic, 229–231
Primary ciliary dyskinesia, 68
Primary heart field (PHF), 211, 212, 284
306, 308
Primitive ventricle, 104, 122
Proepicardial organ (PEO), 116, 224
Progerin, 246–250
Prostaglandin E2, 253–257
Protein-losing enteropathy (PLE), 52
Purification, 27
Purkinje fiber, 15, 16, 178, 283
Q
22q11.2 deletion syndrome (22q11DS), 202,
203, 205, 207, 215, 216, 228, 229
Quail–chicken chimera, 14, 116, 118
R
Reentry tachycardias, 16
Regeneration, 4, 17, 40, 55, 86, 90, 94, 96, 222,
223, 314, 330, 345, 349, 350
Regenerative medicine, 4–8, 23, 30
Remodeling, 5, 17, 21, 34, 36, 38, 42, 146,
154–157, 179, 211, 212, 222–225, 241,
242, 254, 256, 298, 300, 301, 306,
314–315, 357, 360
Right isomerism, 49, 51–52
S
Secondary heart field, 211, 212, 284
Second heart field (SHF), 12, 87, 105,
178–181, 193–197, 202, 207, 215, 223,
228, 229, 289, 297, 306
Semilunar valves, 12, 154, 155, 157, 230, 231
Septa, 35, 41, 116, 121, 138
Septal band, 117, 118, 121, 122
Signal transduction, 106
Single-cell transcriptomics, 86, 88–89
Skeletal myoblasts, 20, 21
Smooth muscle cells (SMCs), 14, 87, 121, 163,
180, 222–225, 229–231, 234, 248–250,
254, 259, 260, 349, 350
Somite level, 284
Sphingosine-1-phosphate (S1P), 125







Tbx1, 179, 196, 205, 207, 215, 216, 306
Tbx5 expression, 87, 116, 121, 122, 272
297, 306
Tdgf1, 186
Temperature-responsive culture dishes, 20
Tenascin, 222
Tenascin-C (TNC), 222–224, 241
382 Index
Tertiary heart field, 284
Thyroid hormone receptor, 129, 130, 228
Tie1, 154–157, 159
TMEM100, 169
Trabeculation, 104, 108, 109, 121, 137, 142
Transcription factors, 4–9, 34, 87, 94, 121, 128,
141, 146, 164, 178, 180, 181, 184, 196,
205, 211, 215, 233, 270–275, 283, 286,
295–302, 322, 362, 374
Transcriptional silencing, 306
Transforming growth factor-β (TGF-β), 35, 37,
39, 58, 73, 81, 82, 139, 140, 149, 184,
185, 187, 196, 197, 346
Transplantation, 4, 19, 22, 26, 28–30, 53, 54,
116, 290
Truncus arteriosus, 202, 207, 215, 216, 228
V
Valves, 35, 38, 40, 41, 138, 146, 147, 149, 154,
155, 162–164, 166, 170, 172, 250
273, 373
Valvulogenesis, 139, 148, 155, 373
Valvulopathies, 16
Valvuloseptal morphogenesis, 34, 39, 171
Vascular biology, 246
Vascular development, 169, 222–225, 233,
234, 237, 238
Vascular networks, 20, 234, 349
Vascular pathology, 250
Ventricles, 12, 21, 41, 42, 51, 52, 87, 104, 106,
110, 116, 118, 120–122, 136, 137,
177–180, 187, 193, 194, 196, 197, 211,
233, 270, 271, 290, 296–298, 300, 301,
308, 359
Ventricular arrhythmias, 22
Ventricular septal defect (VSD), 34, 70, 72,
116, 121, 122, 180, 187, 203, 211, 215,
233, 363, 366
Ventricular septum, 15, 116, 117, 122, 138,
172, 187, 206, 289, 297, 298
W
Williams syndrome, 324–325
Wnt signaling, 27, 60, 64, 73, 87, 146, 149,
179–180, 271, 282, 285–287
Z
Zebrafish, 110, 179, 186, 193–197
Index 383
